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Chapter 1 – Introduction, describes medical imaging modalities focussing on 
molecular imaging agents for SPECT and PET, where examples of dual modal imaging 
with either technique or theranostics (simultaneous diagnosis and therapy) are 
highlighted.  Significant examples of imaging probes using technetium and rhenium are 
included with an emphasis on emerging zinc, copper, gallium and indium complexes.  
Development of metal complexes conjugated to agents enabling targeting of receptors is 
described as well as hypoxia and its diagnosis and therapy.  
 
Chapter 2-5 describe the synthesis and characterisation of bis(thiosemicarbazonato) 
ligands (Chapter 2) and zinc & copper (Chapter 3), gallium (Chapter 4) and indium 
(Chapter 5) complexes. An interesting isomerism is explored using Density Functional 
Theory (DFT). The complexes are investigated for their suitability as molecular 
imaging probes, firstly by testing their spectroscopic properties using UV-visible and 
fluorescence spectroscopies. This is followed by assessing their stability, utilising the 
aforementioned techniques with biologically relevant media in solution and in 
biological cells in vitro, using fluorescence lifetime imaging microscopy (FLIM).  Laser 
scanning confocal microscopy is used to investigate cell uptake demonstrating 
localisation within organelles. Furthermore, gallium and indium complexes are 
evaluated for their potential as hypoxia imaging agents, in vitro in addition to the 
investigation of indium complex nuclear and chromosomal uptake. Lastly, copper and 
gallium complexes are studied in nude mice with PC-3 xenografts under normoxic 
conditions (by the Jason Lewis Group, MSKCC, NYC). 
 
Chapter 6. Compounds introduced in chapters 2-5 are studied and compared for their in 
vitro cytotoxicity using MTT and LDH assays.  MTT assay is used to determine a 
quantitative value of toxicity, to enable a direct comparison of all compounds tested and 
in cancerous and non-cancerous cell lines.  LDH assay on the other hand, provides 
insight into the mechanism of molecular action upon the cell membrane, which may 
explain differences obtained using MTT assay in this study and trypan blue experiments, 





Chapter 7 explores methods of attaching a targeting agent, a bombesin analogue, to the 
bis(thiosemicarbazonato) complexes. Novel complexes are characterised and 
subsequently investigated in cells for cytotoxicity and by confocal microscopy and 
FLIM. 
 
Chapter 8 describes a summary of this thesis. 
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Chapter 1. Introduction 
 
1.1.  Perspective 
 
  Cancer accounts for more than a third of deaths in the England and Wales,
1
 (44.3 % 
males and 32.2 % females). Furthermore, current lifetime risk of developing a 
malignant tumour has recently been calculated as high as 40%, and rising, therefore the 
necessity for earlier cancer detection, identification and effective therapy of later cancer 
stages is becoming increasingly important.
2
 Hypoxic tissue develops under low in 
oxygen concentrations and has been correlated to cancer, strokes and heart disease.
3, 4
 
As a tumour grows the intercapillary distance increases until it becomes greater than the 
diffusion range of oxygen (ca. 200 µm) (Figure 1.1). Furthermore, limited perfusion 
and as a result erratic blood supply has also been shown to increase hypoxia. 
 
 
Figure 1.1. Illustration of relative oxygen levels in a tumour, whereby a greater distance from the blood 









 A crucial protein in the development of this process is hypoxia inducible factor-1 (HIF-
1), the mechanism of action of which is beautifully simple: under normal oxygen 
conditions (normoxia) the protein, HIF-1α, is hydroxylated at numerous proline residues 
resulting in ubiquitination and proteasomal degradation; under insufficient oxygen 
conditions, however, HIF-1α translocates to the nucleus and combines with protein HIF-
1β to form the heterodimer, HIF-1 (Figure 1.2). This transcription factor is subsequently 
responsible for the upregulation of up to 100 proteins, in turn altering the cellular 
glucose metabolism, metastasis, cell proliferation, angiogenesis, iron metabolism and 










  Early diagnosis of hypoxia would allow a change in treatment plan and therefore 
improve patient survival chances. Prognosis is often poor at this stage of cancer since 
traditional therapies do not reach hypoxic tissue due to isolation from capillaries. 
Additionally, most therapies target rapidly dividing cells, whereas under hypoxic 
conditions cells grow slowly due to reduced oxygen and nutrient supply. Finally, as 
mentioned above, hypoxia promotes genetic instability, thus increasing the likelihood of 
drug resistance and metastases.
7,8
 As a result there is growing interest in molecular 
imaging as a non-invasive, highly sensitive method capable of both revealing solid 
tumours and enhancing our understanding of the molecular basis of the disease – 





essential for diagnosis, assessing tumour progression and patient prognosis.
9,10
 The aims 
of this project were to develop molecular imaging probes with therapeutic potential to 
be studied both in vivo, by positron emission tomography (PET) or single photon 
emission computed tomography (SPECT) and also in vitro, by fluorescence imaging 
and cytotoxicity assays. 
 
Table 1.1. Summary of the characteristics of medical imaging modalities. OFI = Optical Fluorescence 






Technique Resolution Depth Information Sensitivity/M 
CT 50 µm No limit A, P nwc 
MRI 10 – 100 µm No limit A, P, M 10-3-10-5 
Ultrasound 50 µm 
Frequency 
Dependant 
A, P nwc 
SPECT 1 – 2 mm No limit P, M 10-10-10-11 
PET 
OFI 
1 – 2 mm 

















Figure 1.3. Normal human brain imaged by SPECT 
123
I-liomazenil (left), MRI (middle) and 
11
C-




  Medical imaging techniques can provide anatomical, physiological and even 
molecular information (Table 1.1, Figure 1.3). Traditional imaging modalities such 
as X-ray and computerised tomography (CT) irradiate tissue with harmful radiation 
and provide anatomical information. Anatomical imaging tools have benefited from 
progress in spatial and temporal resolution, but they do not readily recognise 





physiological abnormalities. The capacity of these methods to differentiate cancer is 
therefore reserved for the later stages of disease progression. Consequently there is a 
current trend towards developing more sensitive molecular imaging techniques 
utilising radionuclides for PET or SPECT, which enter diseased tissue selectively. 
Furthermore, healthy tissues remain unharmed due to the low concentrations 
required (ca. 10
11 
M). These modalities give both functional and metabolistic 
information, which not only accelerate understanding of the molecular basis of 
disease, but also enable accurate detection and diagnosis. Metallic radionuclides 
ultimately undergo uptake within cells and, while the distribution of their complexes 
can be determined in vivo at the 1-2 mm range of resolution, little is known of their 
fate once they reach the intercellular environment. This hampers the rational design 
of new diagnostics and therapeutics and ultimately the accurate diagnosis of cancer. 
However, there is growing interest in molecular imaging as a non-invasive, highly 
sensitive tool capable of both early diagnosis and enhancing the understanding of the 




  Intense research is currently underway for the development of new PET and SPECT 
agents for imaging a wide range of disease states, and of new drugs for targeted 
radiotherapy. Radiopharmaceuticals chosen for the purpose of diagnosis are usually 
positron emitters (PET) or gamma emitters (SPECT), whereas therapeutic 
radiopharmaceuticals usually rely upon - emission and the Auger effect causing cell 
death. The choice of radioisotope is also made according to an optimum half-life, which 
at the same time minimises radiation doses whilst giving sufficient time for synthesis 
and accumulation. 
 
  In 2007, this was defined by the Society of Nuclear Medicine defined Molecular 
Imaging as a new interdisciplinary research field, which is at the interface between 
clinical and preclinical research. The rapid development of this key area is 
highlighted by the increasing demand for new imaging probes for specific biological 
targets.
12
 By the end of 2010 more than 3.2 million positron emission tomography 
(PET) studies had been carried out worldwide and this number continues to rise. It is 
widely recognised that optimal disease management can only be achieved by 





monitoring patient status before, during and after therapy. PET agents offer high 
resolution, high sensitivity, non-invasive imaging with provision of invaluable 
diagnosis of biological function at agent concentrations below the pharmacological 
threshold, at which dosage no significant drug effect is observed.  
  
  Since no medical imaging technique is ideal for acquiring all the necessary information, 
the combination of modalities such as SPECT/CT, PET/X-ray, PET/MRI or, most 
frequently PET/CT, allows for better image quality, shorter scanning time and reduced 
costs. Such multimodal imaging results in more efficient use of radiopharmaceuticals 
(i.e. drugs containing a radionuclide) and more facile recognition of abnormalities. A 
combination with optical imaging enables both greater understanding of the probe both 
in cells and in organisms as well as enabling the identification of tumours. The 
advantages of combining the high sensitivity of PET or SPECT, which are not limited 
by tissue penetration with optical imaging presents a very useful marriage of modalities 
with potential to improve both scientific knowledge and patient diagnosis and therapy.  
 
1.2. Single Photon Emission Computed Tomography 
 
  The first tomographic device for medical imaging, Single Photon Emmision 
Computed Tomography, SPECT, was reported by Kuhl and Edwards in 1963.
13
 The 
technique utilises gamma emission, which occurs when a highly energetic nucleus 
relaxes to a ground state. This type of emission can be detected using a gamma 
camera, yielding a 3D image of radionuclide uptake.
14


















Tc, which will be discussed further in section 1.4.  





Table 1.2. Relevant radionuclides for SPECT imaging 
Radionuclide Half-life (t1/2) / 
hours 















Ga 78.281 ec (100) Cyclotron SPECT 
123




Reactor SPECT/ β- 
therapy 
a
 Iodine-131 has a process of six β¯ and fourteen γ-ray emissions 
 
1.3. Positron Emission Tomography 
 
  Compared to SPECT, PET imaging has a crucial advantage in terms of sensitivity 
and resolution (Table 1.1). PET was first reported by Michel Ter-Pogossian in 1972 
and is based on the monitoring of positron-electron annihilation. PET therefore 
relies on the presence of a positron emitting radionuclide where a proton is 
converted into a neutron. A single annihilation causes emission of two gamma rays 
ca. 180
o
 apart, each with a 511 keV energy (Figure 1.4). Detectors are placed around 
the patient so that simultaneous gamma ray detection can be traced to the point of 
annihilation by following the line of response (LOR). These are subsequently 
reconstructed to produce a 3D image of the respective environment and characterise 
any abnormalities.  
 










Use of PET was initially limited by the requirement of an on-site cyclotron, the short 
half-lives of available positron emitting radionuclides, and highly expensive 
equipment. Predominantly a research tool in the beginning, it has now become an 




Table 1.3. Commonly used radionuclides for PET imaging 








C 0.34 h β+ (100) Cyclotron PET 
64



























Y 14.74 h ec + β+ (100) 
β+ (31.9) 
Cyclotron PET 






The choice of radionuclide is dependent on availability, half-life and 
pharmacokinetics. The isotope 
18
F (t1/2 109.8 min) is most widely used for imaging 





FDG) where there are no limitations owing to the availability of a cyclotron 
typically needed for radionuclide generation. 
18
F-FDG, the “gold standard” for PET 
imaging tumours / ischaemic myocardium in clinical practice, lacks selectivity for 
cancer and is not universally applicable for imaging all tumours: for example it does 
not image hypoxic tumors per se.  
 
1.4.  Radionuclides for therapy 
 








Tc, can be followed up by 







provided that the chemical properties of the complex are not significantly changed. 
Therapeutic radionuclides are emitters of either α-particles, β--particles or low energy 
Auger electrons. 
 
Table 1.4. Radionuclides for therapy 
 
 
  Furthermore, a diagnostic agent combined with a therapeutic agent form a 




I 8.02 d β- (100) Nuclear reactor β-therapy 
90
Y 64.00 h β- (100) Gen: 90Sr/90Y β-therapy 
177
Lu 6.647 d β- (100) Nuclear reactor β-therapy 
188
Re 17.00 h β- (100) Gen: 188W/188Re β-therapy 
153
Sm 46.50 h β- (100) Nuclear reactor β-therapy 
213













11.4 d α (100) Gen: 227Ac/227Th/223Ra α-therapy 
67
Cu 2.6 d β-(100) Cyclotron/reactor β-therapy 





‘theranostic pair’. Intrinsically cytotoxic agents can also be radiolabelled while the 
use of nanoparticles filled with a biologically active molecule (BAM)-targeted drug 
may provide a different approach to single theranostic compounds. 
 
1.5. Radiopharmaceuticals and multimodality probe design considerations 
   
  Radiopharmaceuticals are designed to answer a specific medical need and are 
based on the knowledge of molecular biology. The first generation of 
radiopharmaceuticals involved radioactive isotopes aimed at mimicking normal 







which take advantage of upregulated glucose uptake by cancer cells and mimic 
iodine uptake by the thyroid, respectively.
17
 The current trend is moving towards 
‘second generation’ of radiopharmaceuticals, which use a BAM, such as a peptide or 
antibody for specific targeting.  
 
 
Figure 1.5. Chelator structures and targeting groups frequently used with radiopharmaceuticals 
 





  Much of the work makes use of the labelling of standard chelating agents such as 
1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″,-tetraacetic acid (DOTA), 1,4,8,11-
tetraazacyclododecane-1,4,8,11-tetraacetic acid (TETA), 1,4,7-triazacyclononane-
1,4,7-triacetic acid (NOTA), cylam or cyclam variants conjugated to a BAM via a 
linker (Figure 1.5). Reviewed below are recent developments in luminescent zinc, 
copper, gallium, indium metal complexes for in vitro and/or in vivo imaging, 
multimodal imaging, theranostics (combined ‘all-in-one’ diagnostics and 
therapeutics) as well as selected examples from relevant coordination chemistry. 
  
1.6. Technetium and rhenium based imaging probes 
 
99m
Tc is metastable, which means that it does not transmute into another nucleus 
upon emission and was first isolated in 1959 and initially used in 1961 for thyroid 
diagnosis. As previously mentioned, technetium-99m is the most regularly used 
SPECT imaging probe, which is owed largely to its ideal half life of ca. 6 hours and 
its ready availability via a 
99
Mo generator.  
 
 
Figure 1.6. Structures of selected 
99m
Tc complexes in commercial use 
 
There are numerous 
99m
Tc molecular probes in clinical use covering a wide range of 











) and bone (
99m
Tc-MDP). Technetium complexes are 
additionally under development as hypoxia targeting agents, with early attempts  via 
conjugation of chelate derivatives to a nitroimidazole, such as BMS-181321 (Figure 
1.7). 
17, 18
 Nitroimidazoles are promising as hypoxia selective probes, such as 
pimonidazole hydrochloride (Hypoxyprobe
TM
), which is used in 









F-FMISO), which will be 
discussed later. High liver uptake, due to the lipophilicity of the compound however, 
caused it to be unsuitable. Rey et al. however, recently developed a metronidazole 
based technetium complex with a good tumour to muscle ratio and low liver uptake 
(Figure 1.7).
19
   
 
 
Figure 1.7. Structures of compounds developed for hypoxia selectivity 
 
Despite the popularity of this radiometal, it does have its drawbacks. Firstly that 
99m
Tc hinders the binding of organ specific pharmaceuticals, due to its non-
physiological nature and secondly, there is no stable isotope of technetium. 
 
   
Figure 1.8. Rhenium(I) complex (left), which enters the nucleoli of cells (right) 
 
  Isostructural rhenium complexes however, are often used as analogues for in vitro 
luminescence studies, as well as being exciting in vitro imaging agents in their own 
right and with broad applications.
20
 Rhenium(I) polypyridine complexes are of 
particular relevance as sensors, due to good quantum yields, especially since the 
high environmental sensitivity of rhenium(I) polypyridine complexes was 
reported.
21,22
 Rhenium(I) complexes have long luminescent lifetimes and significant 





Stokes shifts, making them highly suitable as in vitro probes. Coogan et al. have 
developed numerous tricarbonyl polypyridyl rhenium(I) complexes for imaging 
cells, 
23, 24, 25
 notably reporting in 2011 a Re(I) complex that can act as a carrier of 
ions such as silver and copper. The unfilled form of the complex does not enter 
cells; however, when filled with Ag
+
 cations it can enter the nucleoli (Figure 1.8).
26
 
Interestingly, dinuclear tricarbonyl rhenium(I) complexes appended to peptide 
nucleic acid showed rapid cell uptake, low cytotoxicity and have the ability to 
discriminate between the nucleus and cytoplasm via different excitation/emission 
properties (Figure 1.9).
27
 Tricarbonyl rhenium complexes have also been developed 
by Lo et al. for in vitro metal ion sensing and displayed increased luminescence 
emission and a longer lifetime upon Zn(II) or Cd(II) binding.
28
 Furthermore, Alberto 
et al. developed  tricarbonyl Re(I) and Tc(I) complexes in 2012 for in vitro and in 
vivo imaging of Altzheimer’s disease. The ligand contained a phenylbenzothiazole, 




   
    a)         b)            c)           d) 
Figure 1.9. A bimetallic Re(I) complex (d) in the nucleus (a) and in the cytoplasm (b), where (c) is an 
overlay of (a) and (b). 27 
 
  Numerous rhenium(I) complexes suitable for bioconjugation and fluorescence 
imaging are currently under development.
30
 Notably, a cytotoxic folic acid-PEG 
derivatised Re(I) complex was investigated in A2780/AD cells, which are a 
multidrug resistant ovarian cancer cell line.
31
 Rhenium(I) complexes with an 
appended –D-glucose were developed with the purpose of monitoring glucose 
uptake, which is increased in cancer and showed mitochondrial uptake as well as 
cytotoxicity that did not depend on cell type.
32
 Polypyridinerhenium(I) bis-biotin 
complexes were observed in HeLa cells by laser scanning confocal microscopy. 
33,34
 










 As mentioned above, isostructural Re/
99m
Tc complexes can be developed for in 
vitro and in vivo investigations respectively. For example, Pelecanou et al. designed 
rhenium and technetium complexes incorporating the [M(CO)3(NNO)] unit 
covalently attached to anticancer agent 2-(4’-aminophenyl)benzothiazole for 
theranostic SPECT applications.
36
 Recently they developed new rhenium and 
technetium complexes of the same family for optical and SPECT imaging 
respectively, which demonstrate greater uptake in cell lines of cancerous origin with 
respect to non-cancerous lines.
37
  
   
 
Figure 1.10. Reaction scheme of “click chemistry” (above, left), folic acid derivatised technetium 
complex by SPECT (below). 
 
The first instance of substituting a well established chelator with a 1,2,3-triazole 
analogue for complexation of Re/
99m
Tc without modifying the biological effects of 
the compound was reported by Mindt et al. in 2008.
38
 The isostructural Re/
99m
Tc 
folic acid analogues were synthesised using a Cu(I) catalysed cycloaddition method, 
known as a “click reaction” that allowed chelation and bioconjugation in one step, 
which the authors named “click-to-chelate” (Figure 1.10). Moreover, Mindt et al. 
designed several new imaging probes for PET, SPECT, Near Infra-red (NIR) or MRI 






Tc agents for 







folate complex has recently been reported as with the capacity to quantify 
macrophage activation (Figure 1.10).
40
 The authors demonstrated that the later 





stages of osteoarthritis can be correlated to reduced macrophage activation, allowing 
monitoring of the disease activity, for which there are no clinical measures at 
present. Furthermore the same group has used click reactions to design tridentate di -
1,2,3-triazole chelator imaging tracers as well as multifunctional 
99m
Tc complexes, 
as a platform for a broad number of potential purposes including multimodal 
imaging probe development.
41, 42
 This efficient and facile synthesis combined with 
uptake in folic acid receptor expressing KB (human epidermoid carcinoma) cells and 
tumour targetting in mice confirms the promise of this procedure. 
 
 Rhenium and technetium complexes have also been designed to enter the nucleus 
and bind to DNA, a significant example of which was published by Santos et al. 
who synthesised tricarbonyl pyrazolyl-diamine rhenium(I) complexes that show 
potential for the development of future targeted radiopharmaceuticals.
43
 
Furthermore, tricarbonyl rhenium and technetium complexes with acridine 
derivatives showed nuclear uptake via fluorescence and activity based studies 
respectively.
44
 Policar et al. designed a tricarbonyl rhenium(I) complex in 2012 to 
selectively enter Golgi apparatus, with its uptake in breast cancer cells followed by 
fluorescence microscopy and IR mapping. Already a dual-modal imaging agent, the 
analagous technetium complex would present potential for a tri-modal imaging.
45
  
Another example of a dual-modal imaging probe under developmentwas reported  
by Faulkner et al. combining a Gd
3+ 
for MRI and a Re fluorophore for luminescence 
investigations.
46
 Furthermore, the first dinuclear rhenium/technetium complex was 






1.7. Copper-based imaging probes 
 








Cu, all of which are 
positron emitters, as well as 
67
Cu, which is a - emitter. Copper-64, with a half-life 
of 12.7 h, decays 41% by electron capture, 40% by - radiation and 19% by + 
radiation,
48
 making this radioisotope highly appropriate for simultaneous diagnosis 
and therapy. A challenge to dual-modal imaging with copper(II) complexes is the 





paramagnetic quenching caused by the d
9
 electronic configuration of the metal 
centre. Despite this, a number of fluorescent copper(II) complexes have been 
reported in the literature, most of which are conjugated to fluorophores such as 
fluorescein, rhodamine or BODIPY as well as BAMs for selectivity (Figure 1.11). 
 
 
Figure 1.11. Commonly used fluorophores 
 
  With possible coordination numbers between four and six and a wide range of 
geometries the 3d
9
, 2+ oxidation state represents the most significant proportion of 
copper complexes developed as radiopharmaceuticals. Thus, there are a large 
number of potential chelators for this metal, which include EDTA, DTPA, NOTA, 
NO2A, DOTA and cyclam derivatives, all of which represent a large proportion of 
copper(II) research.
49
 Research is ongoing to improve chelators for use as 
bifunctional agents, as well as to achieve better yields and very high stability with a 




    Some examples of copper(II) complexes used in conjunction with bifunctional 
chelators are described below. Colorectal cancers often express receptors for the E. coli 
enterotoxin, STh; analogues of these show promise for imaging and therapy. A STh 
analogue was conjugated to DOTA, TETA and NOTA at the N-terminus and labelled 
with 
64
Cu of which the NOTA complex gave the best tumour uptake with respect to 
organs, when investigated by biodistribution and PET studies.
51
 Similarly 4-((8-amino-
3,6,10,13,16,19-hexaazabicyclo [6.6.6] icosane-1-ylamino) methyl) benzoic acid 
(AmBaSar), a cage like bifunctional chelator conjugated to cyclic RGD, was 





 A bombesin analogue conjugated to NO2A 
radiolabelled with 
64
Cu also allowed visualisation of PC-3 xenografts.
53
 Moreover, 




Ga complexes, chelated with 





NODAGA and cross-bridged-TE2A conjugated to somatostatin antagonist p-Cl-
Phecyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2.
54
    
 
Furthermore, dual-modal MRI/PET nanoparticles have been reported by Lee et al. 
involving polyaspartic acid iron oxide nanoparticles conjugated to argenine–




 MRI and PET both indicated selective uptake and offer the 
potential for higher accuracy and earlier detection of cancer. A monoclonal antibody 
for endoglin – an indicator of poor prognosis in cancer – was conjugated to a near 
infrared dye and 
64
Cu via NOTA, by Cai et al. in 2012.
56
 This dual-modal imaging 
agent was capable of rapidly and selectively entering endoglin expressing cells and 
could be useful for assessment of cancer disease progression. Furthermore a multi-
modal imaging agent was developed for MRI, NIRF, and SPECT or PET imaging using 




Cu-DOTA and Gd-DOTA could be 
conjugated to liposome surface, whilst technetium, rhenium or a drug such as 
doxorubicin, could be loaded within. The NIRF dye (IRDye-DSPE) was postinserted 
into the liposomes enabling luminescence imaging. Therefore, this kind of system 
presents the potential advantages of the aforementioned imaging techniques combined 
with therapy especially if combined with a BAM.   
 
  
Figure 1.12. a) Copper bis(thiosemicarbazonato) complex, Cu[ATSM] (left). The following images are 
pretherapy scans of 
18
F-FDG-PET (middle left), 
60
Cu[ATSM]-PET (middle right) and CT scan. The 
arrow indicates lung cancer. The outside of the tumour shows greater 
60
Cu[ATSM] uptake, in contrast to 





   
   A significant complex for molecular imaging, aliphatic copper(II)-diacetyl-bis(N(4)-
methylthiosemicarbazone) (Cu[ATSM]) has been shown to be selective for hypoxic 
tissue and has progressed to phase II clinical trials for cervical cancer diagnosis (Figure 
1.12). 
18
F-FMISO, also in clinical trials, shows promise as a hypoxia selective agent, 





but presents drawbacks such as slow body clearance and low contrast images. 
Cu[ATSM] has shown more rapid uptake in hypoxic cells and greater hypoxic-to-




 The mechanism of Cu[ATSM] selectivity for hypoxic 
cancer cells was originally postulated to be due based on the irreversible reduction of 
Cu(II) to Cu(I) occurring in oxygen-poor environments. 
59
 Dearling et al. however, 
proposed that reduction occurs in both normoxic and hypoxic conditions, but and that 
the compound may undergo re-oxidation in normoxic cells only. As a result, the Cu(II) 
complex can cross the cell membrane, but is trapped within the cell and accumulates in 
the form of an anionic Cu(I) complex (Figure 1.13).  
 
 




  The therapeutic potential of Cu[ATSM] was recently demonstrated by Fujibayashi 
et al., who reported its ability to inhibit tumour growth and malignancy.
61
 The 
mechanism of cell uptake of bis(thiosemicarbazones) can be investigated thanks to 
the weak intrinsic fluorescence of thiosemicarbazones, which can be enhanced by 
binding to a diamagnetic metal such as Zn[ATSM] or by addition of a fluorophore. 
The first in vitro fluorescence study of zinc bis(thiosemicarbazone) complexes in 
human cancer cells was carried out in 2005 by Dilworth et al. using the Zn[ATSM] 
analogue in a number of cell lines.
62
 As Cu[ATSM] is not fluorescent zinc analogues 
have been used as models for Cu[ATSM] in vitro. Since zinc(II) and copper(II) are 
of comparable atomic radii and electronegativity, however there are some limitations 
of this model. Zinc(II) does not possess significant redox potential as does 
copper(II) and therefore can only represent the uptake of the complex under 





normoxic conditions. Recently a series of new fluorescent zinc 
bis(thiosemicarbazonato) complexes were reported showing in vitro uptake in 
cells.
63
 Copper and zinc bis(thiosemicarbazonato) complexes bearing an appended 
fluorescent pyrene tag and reactive styrene with potential for dual modal imaging 
have also been synthesised by Holland et al.
64,65
 Moreover, the better stability 
attributed to copper(II) complexes, indicated by the Irving-Williams series,
66
 allows 
clean synthesis of a copper(II) complex via a zinc(II) complex transmetallation as 
well as by synthesis via a ligand precursor.  
 
Figure 1.14. Bis(thiosemicarbazonato) complexes conjugated to glucose (left) or to a nitroimidazole 
(right) 
 
  There are, however, limitations of Cu[ATSM], including serum instability and high 
liver uptake, due to its lipophilicity. It would therefore be attractive to develop 
similar hypoxic imaging probes, which are biologically stable, with intrinsic 
fluorescence and reduced lipophilicity. As a consequence, current research aims to 
improve upon Cu[ATSM], with recent attempts via  bioconjugation. Glucose, for 
example, was appended to copper bis(thiosemicarbazonato) complexes by Christlieb 
et al., the resultant complex retained hypoxia selectivity yet without the drawback of 





Subsequently, bombesin conjugates were developed displaying binding to PC-3 
cells, which appear suitable for PET applications. Furthermore, Bayly et al. recently 
coupled a nitroimidazole to a copper bis(thiosemicarbazonato) complex (Figure 
1.14).
68
 The conjugates displayed superior hypoxia selectivity and reduced non-
target uptake when compared to propyl derivatives used as controls and CuATSM/A 
derivatives respectively.  
  It is possible to chelate a wide range of metals due to the “soft donor” 
characteristics of the tridentate S,N,N these include zinc and copper (as already 





mentioned above), iron, nickel, rhenium, technetium, gallium, indium, platinum and 
palladium. Therefore, chelation of PET or SPECT radiometals such as gallium or 
indium with a counterion, for example chlorine could be another means of reducing 





Figure 1.15. Structures of thiosemicarbazones found in Refs 
69-72
 
   
  Furthermore, there is a broad scope of biological and medical activity of this family of 
compounds, which includes complexes and their ligand precursors. Uncomplexed 
ligands are active against leukaemia, TB, malaria, viruses (including HIV), bacterial 
cells and superoxide dismutase-like radical scavenger properties with enhanced activity 




 α-N-heterocyclic thiosemicarbazones 
(Figure 1.15), have been shown to possess anti-tumour action via inhibition of the 
ribonucleotide diphosphate reductase (RR) enzyme, which is involved DNA synthesis. 
Since pyridine-2-carboxaldehyde thiosemicarbazone anti-tumour properties were 
observed in 1956, a number of other heterocyclic ring systems have been synthesised 
showing anticancer activity and include isoquinoline-1-carboxaldehyde 
thiosemicarbazone, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) 
and di-2pyrirylketone 4,4-dimethylthiosemicarbazone, which is the most potent (Figure 
Ligand R1 R2 R3 R4 
GTS H H H H 
PTS Me H H H 
PTSM Me H Me Me 
PTSE Me H Et Et 
PTSP Me H Ph Ph 
ATS Me Me H H 
ATSM Me Me Me Me 
CTS Et Me H H 
CTSM Et Me Me Me 
DTS Et Et H H 
DTSM Et Et Me Me 
KTS CH3(EtO)CH H H H 
KTSM CH3(EtO)CH H Me Me 
Table 1.5. Represents a broad range of 
bis(thiosemicarbazonato) complexes 







 Furthermore, Platinum(II) and palladium(II) thiosemicarbazone complexes, 
have shown activity against cancer cells resistant to cis-platin, one of the most 
commonly used anti-tumour drugs.
76
 French and Freelander assayed fifty 
bis(thiosemicarbazonato) ligand precursors and were the first to observe their anti-
tumour properties, with determined KTS and KTSM (Figure 1.15, Table 1.5) as the 
most active. Moreover, it was discovered that their antitumour properties are due to 
their ability to chelate copper(II) ions, which lead to the investigation of chelation of 
other biological metal ion chelation including zinc(II), nickel(II) and iron (II/III).
28
 The 
potential scope therefore, of thiosemicarbazonates is significant in the development of 







 Zinc(II) is a d
10
 metal ion with coordination geometries ranging for example from 
tetrahedral, square pyramidal or trigonal bipyramidal thus giving rise to versatile 
probes for the development of luminescence imaging using transition metal 
complexes: some recent developments will be highlighted hereby.
77
 A series of zinc 
salen complexes (Figure 1.16) were designed by Xu et al. and investigated by single 
and two-photon microscopy in cells displaying colocalisation in the lysosome, 





   
Figure 1.16. Zinc salen complexes and colocalisation in endoplasmic reticulum via single-photon 









 A fluorescent DAQZ@2Zn
2+
 complex, was reported as a sensor in live cells for 
oxalic acid, an inhibitor of lactate dehydrogenase (LDH), presence of which resulted 
in quenching (Figure 1.17).
79
 Cancer cells more frequently undergo anaerobic 
respiration than non-cancer cells, particularly under hypoxia. Therefore oxalic acid 
could provide one method of treating cancer as well as indicating the necessity for 
this type of treatment. Additionally, a binuclear BODIPY-based fluorescent zinc 
complex was developed and investigated in cells by Hamachi et al.
80
 Histological 
studies demonstrated that the complex could distinguish neurofibrillary tangles of 
hyperphosphorylated tau proteins and amyloid plaques in the hippocampus of a 
patient who had Alzheimer’s disease. 
 
 
Figure 1.17. In vitro fluorescence microscopy of a Zn2+ complex of DAQZ ligand 7 in HeLa cells (DIC sown in image a), 




 Keppler et al. studied triapine, which is under investigation as an anticancer agent, 
by fluorescence microscopy. The corresponding zinc complex 
[Zn(Triapine)Cl2].HCl was also synthesised and imaged in colon carcinoma cells to 
show uptake in nucleoli.
81
 The unusual attribute of intrinsic fluorescence of this 
particular anticancer drug may help to facilitate personalised medicine  via 
monitoring the uptake within patient biopsy samples and subsequent morphological 
changes. 
 
  In 2005, trimetallic zinc meso-to-meso ethyne-bridged tris[(porphinato)zinc(II)] 
complexes were designed as NIR fluorophores with potential for in vivo imaging 





showing uptake by fluorescence in murine melanoma cells.
82
 Furthermore, NIR in 
vivo fluorescence imaging of cell death was enabled by the use of a bimetallic 
zinc(II)-dipicolylamine (Zn-DPA) complex, conjugated to a ligand with affinity for 






Figure 1.18. Near-IR fluorescence image of tumour cell death after radiation therapy (a) as a result of 




When compared to Annexin-Vivo 750 (a commercially available NIR fluorescence 
sensor for apoptosis) the complex possessed higher target to non-target ratio on 
account of lower bladder uptake, giving complementary information as two probes 
and good clearance indicating potential for radiolabelling studies due to a resultant 
reduced radiation exposure.
84
 Further, this probe shows promise for the assessment 
of patient response to therapy as well as evaluation of novel anticancer treatments. 
The probe potentially has broader applications and was shown to be capable of 
detecting tissue infected by S. aureus.
85
 The same group developed a series of Zn-
DPA complexes of which the hydrophilic variants are non-toxic to mammalian cells 
yet toxic to S. aureus, including antibiotic resistant strains. Moreover, the uptake of 
a fluorescent analogue was imaged in E. coli and S. aureus.
86
  In 2012 Hnatowich et 
al. combined 
111
In-DOTA-biotin with a fluorophore-conjugated  Zn-DPA analogue 
via a noncovalent linker and investigated the potential of Zn-DPA for assessing 
infection in vivo for the first time. There was notably greater uptake in infected areas 





when compared to induced inflammation indicating that the probe could help with 





Figure 1.19. FRET mechanism of Zn-DPA complexes for sensing of nucleosides (reproduced with 




Hamachi et al. developed another series of Zn-DPA complexes containing four zinc 
nuclei and demonstrated that their D4 tag/Zn-DPATyr pair can successfully label 
proteins.
89
  Moreover, new Zn-DPA complexes were developed by Hamachi et al. 
for the recognition of nucleoside polyphosphates (including ATP), whereby 
fluorescence is activated by the presence of the desired compound via fluorescence 
resonance energy transfer (FRET) yielding a ratiometric response (Figure 1.19).
88
 A 
zinc(II) dipicolylamine complex with ATP sensitivity and conjugated to 
nanoparticles with a silica core was imaged in fixed non-cancerous rat epithelial 
(NRK) cells with potential use in metabolic studies.
90
 Furthermore, targeted cancer 
imaging of oral epithelial cancer was reported by Menon et al. via the conjugation of 






 Gallium is predominantly found in the 3+ oxidation state and has a coordination 
number range of 3-6. A hard acidic cation, Ga(III) strongly binds to multiple anionic 
donor sites including oxygen and thiolates. Gallium is known to bind to chelators 
EDTA, DTPA, DOTA and has promising thermodynamic stability with NOTA 
(including under acidic conditions), DFO and HBED, and show favourable 
characteristics for bifunctional chelators (Figure 1.20).  







Figure 1.20. Useful ligands for chelating Ga(III). 
 
  There are three gallium isotopes of interest for molecular imaging: 
66
Ga (9.5 hour 
half-life) and 
68
Ga (68 minute half-life), which are positron emitters and 
67
Ga (3.26 
days half-life), a gamma emitter.
92
 The PET radioisotope 
68
Ga, has a major 
advantage in that it does not require a nearby cyclotron and is relatively simple to 
obtain via a commercially available 
68
Ge (half-life of 270.8 days) generator. 
Furthermore, 
67
Ga is used as a prognostic of non-Hodgkin’s and Hodgkin’s 
lymphoma as well as to detect bone infection in scintigraphy. 
93-97
  
 There have been a number of bioconjugated gallium complexes with an outlook 
towards theranostics, some examples of which will be presented here. A DOTA-Gly-
Glu-Cyc lactam bridged cyclised -melanocyte stimulating hormone peptide was 
radiolabelled with 
67
Ga to allow the visualisation of primary and metastatic 
melanoma. There is potential for further development of this probe as a theranostic 
agent since the versatility of DOTA could allow chelation of a radiotherapeutic 
metal in the place of gallium.
98
 Furthermore, a DOTA-PEG4-BN(7-14) bombesin 




Lu showed good tumour uptake in PC-3 
xenografted nude mice, where 
67/68







Ga DOTATOC was utilised as a diagnostic and indicated the 
necessity for 
177





  Additionally, a quadruple-modality imaging probe, which can be detected by 
ﬂuorescence, bioluminescence resonance energy transfer (BRET), PET and MRI, 
was reported by Kim et al. (Figure 1 . 2 1 ).
101
 The probe consisted of a cobalt–
ferrite nanoparticle (for MRI), incorporating rhodamine (for ﬂuorescence) and 





conjugated to luciferase (for bioluminescence) and a p-SCN-bn-NOTA chelating 
group that was tagged with 
6 8
Ga (a generator-produced PET radionuclide). 
Each imaging modality displayed dose dependence in vivo. Further 
functionalisation with targeting groups could enhance the potential for effective 
delivery to tumours. 
 
 
Figure 1.21. Quadruple modal imaging: (a) bioluminescence, (b) micro-PET, (c) MRI and (d) 
ﬂuorescence imaging, adapted from Kim et al. 2009. 101 
 
1.10. Indium 
   
  
Indium predominantly exists in the 3+ oxidation state when complexed and can be 
from 3 to 8 coordinate. Despite the possibility of the higher coordination numbers 
indium, like gallium, forms its most stable complexes with hexadentate chelators. In 
contrast to gallium, indium has a higher affinity for softer donors and therefore 
EDTA, DTPA and DOTA bind more securely to indium. There are a number of 






In, however the most commonly 
reported indium radioisotope is
 111
In. Indium-111 is a commercially produced 
radionuclide for SPECT imaging, with a half-life of 2.8 days and photon energies of 
171 and 245 keV. Notable applications to date include tumour-targeted imaging. 
There have been a number of reported peptide/antibody targeted small molecules 
involving indium-111, therefore some selected examples will be reviewed here, in 
a)         b)         c)     d) 
 





particular those pertaining to multimodal imaging or theranostics.  
 
 
Figure 1.22. LLP2A N-[[4-[[[2-ethylphenyl)amino]carbonyl]amino]phenyl]acetyl]-N
ε
-6-[(2E)-1-oxo-3-
(3-pyridinyl-2-propenyl)]-L-lysyl-L-2-aminohexanedioyl-(1-amino-1-cyclohexane)carboxamide (left) and 
linker (right). 
 
  LLP2A coupled to DOTA and PEG was labelled with 
111
In and showed good 
tumour uptake.
102
 The drawback of renal retention however, would require further 
modification. Nevertheless the 
111
In-(LLP2A-DOTA)4-PEG10,000 displayed potential 






Ga DOTATATE enabled the assessment of receptor status as well 
as the imaging of benign insulinomas, which contrary to malignant insulinomas 
often lack somatostatin receptor subtype 2 (sst2) and express GLP-1 receptors.
103
 
DOTATE radiotherapy could be applied to patients with sst2 suppressing tumours.  
 
  Ibritumomab, a monoclonal antibody, was complexed for 
90
Y-ibritumomab 
therapeutic purposes was combined with 
111
In-ibritumomab for pre-therapy scans. 
The 
111
In scans proved capable of predicting disease progression and could be a 
useful tool to tailor therapy towards more aggressive therapeutic 
strategies.
104




Y, reporting high tumour uptake due to specificity for v3 integrin, 
which is present in cancerous melanoma cells, and therefore promise as a theranostic 
pair.
105
 Indium complexes are also currently being developed for multimodal 
imaging. In 2006 Li et al. designed a dual-labelled probe for tumour imaging, 
111
In-
DTPA-Lys(IRDye800)-cyclic(KRGDf), which binds to integrin v3.
106
 Figure 1.23 
shows the uptake of the imaging probe within v3-positive tumours, with no uptake 









In-DTPA-Bz-SA-Lys(IRDye800)-c(KRGDf) in nude mice visualised by (from left to right) 
white light, γ-scintigraphy and NIR. Arrows represent the tumours 106 
 




In for PET 











In DOTA-NT complexes showed 
higher tumour and renal uptake than the DOTA-LB119, with very low background 
in other tissue with exception of the kidneys. Despite the poor affinity of the indium 
DOTA-NT complex for colorectal carcinoma cell line HT29, the respective Yttrium 
complex possessed could bind significantly better, indicating potential for tumour 
targeting as a radiotherapeutic. Tumours were visualised using NIR optical imaging, 
with good resolution and sensitivity, which was complemented by -scintigraphy for 
tissue penetration. Another cyclic peptide c(CGRRAGGSC) was applied for 
combined near infrared fluorescence and SPECT imaging of tumours, allowing 
unambiguous visualisation of the tumour by both modalities.
108
 Moreover, in 2012, 
Hӓfeli et al. designed a trimodal imaging agent for SPECT, MRI  and fluorescence 
imaging.
109
 This consisted of hyperbranched glycerols conjugated to 
111
In-DOTA, 
Gd-DOTA and the fluorescent dye Alexa Fluor. The imaging probe was excreted 
slowly, allowing the image contrast to be significantly enhanced with time. 






Figure 1.24. Trastuzumab-Cy5.5-CHX-A'' (left), investigated using confocal microscopy in cells 
expressing HER2 (top and middle) and cells seldom expressing HER2 (bottom). 
 
 Monoclonal antibodies trastuzamab (binds to HER2 (Human Epidermal Growth 
Factor Receptor 2 expressing cells)) or cetuximab (selective for EGFR Epidermal 
Growth Factor Receptor expressing cells) were conjugated to chelators (CHX-A”) 
for the incorporation of radioisotopes (in this case, 
111
In) (Figure 1.24). The uptake 
of the respective ligands was followed in LS174T, EGFR expressing A431 and two 




 Furthermore, antibodies for 
the targeting of tumours via epidermal growth factor receptors has been utilised by 
Kobayashi et al. allowing discrimination between three types of tumour to be 
(EGFR-1, EGFR-2 and a tumour that did not overexpress HER2).
111
 Using 
cetuximab or trastuzumab conjugated to a linker and to a fluorophore (Rhodamine 
Green, Cy5.5 or Cy7) it was possible to utilise the wavelength of in vivo emission as 
an indication of response to the antibody. For comparative purposes 
111
In-labelled 
antibodies were used in this study – with the fluorescent probes possessing the 
advantages of avoidance of ionising radiation and the potential to discriminate 
between up to three tumour types. Additionally Kobayashi et al. developed a probe, 
which can be labelled with 
111
In and a fluorophore, for antibody-based targeting 
(panitumumab and separately trastuzumab) to enable dual modal optical and SPECT 
imaging.
112
 The fluorescent probes were activated upon internalisation by the cell, 





thus providing a clear visualisation of tumours, which was well complemented by 
the “always on” of nuclear imaging.  
 
 Small molecules containing copper-64 and indium-111 have been targeted using 
peptides/antibodies, allowing for the possibility of both PET and SPECT. Recently 
an 
111
In labelled antibody binding fragment (fab) for c-kit (a proto-oncogene 
significant for many malignancies) was tested for in vitro binding and by cellular 
internalisation assays, whilst 
64
Cu c-kit fab was evaluated in vivo by PET, allowing 
clear tumour visualisation. This makes it a promising tool for enabling an informed 







DOTA-HSA-Z(HER2:342) were also studied by PET and SPECT respectively, both 
displaying high tumour and liver uptake. This ligand is likely to be suitable for 




Lu, which could open the door to 
usage as a theranostic pair.
114
 Moreover, a diabody (a bivalent single-chain antibody 







investigated by biodistribution and 
64
Cu PET in athymic mice, indicating tumour 
uptake and low kidney uptake.
115
 Furthermore, visualisation of the tumour was 








  Medical imaging provides essential diagnosis for a multitude of diseases including 
cancer, whilst nuclear imaging can offer highly sensitive molecular and 
physiological information, enabling rapid detection of early stages of disease. The 
combination of imaging modalities (optical/PET and or SPECT/ MRI) can allow for 
more accurate diagnoses thanks to the specific advantages in terms or resolution and 
sensitivity of each technique, with optical imaging enabling a crucial insight into 
cellular behaviour of a probe under development. One of the crucial research areas is 
that of hypoxia detection, which is a symptom present in numerous diseases and is 
highly significant in the development of cancer. There is currently no clinically 





approved hypoxia imaging probe, therefore the necessity for further development 
remains. Although there has been a recent increase in the development of agents 
capable of both detection and therapy. Thus, the progression of current research 
moves towards a future of personalised medicine and as a result promises an 
improved patient response to therapy. 
 
1.11.1. Aims of thesis 
1. Synthesise copper, gallium and indium acenaphthenequinone 
bis(thiosemicarbazones) with intrinsic fluorescence, which can be rapidly 
and cleanly radiolabelled and have selectivity for cancer cells and hypoxic 
tissue.  
2. Investigate the stability, cell uptake and cytotoxicity of 
bis(thiosemicarbazonato) complexes to allow in vivo studies to commence. 
Usage of computational studies to study electronic configuration and 
thermodynamic stability of these complexes in gas phase and solution 
models.  
3. Explore acenaphthenequinone bis(thiosemicarbazone) complexes for 
selective dual modal imaging and/or enabling of targeted nanomedicines 





Chapter 2. Synthesis, characterisation and spectroscopic investigation 






  The objective of this project was to synthesise new complexes based upon the design 
of Cu[ATSM], but with improved kinetic stability, reduced liver and other non-target 
organ uptake and increased intrinsic fluorescence.  The design was modified by 
introducing a bis(imino)acenaphthene (BIAN) backbone, which is likely to provide 
superior kinetic stability and fluorescence. The BIAN ligand itself possesses redox 
activity, which conceivably could affect the hypoxia selectivity.
116, 117
 Moreover three 
ligands containing an acenaphthyl moiety were recently shown to display greater uptake 
in vitro under hypoxia than normoxia by fluorescence microscopy.
118
 The compounds 
were designed to work on the same principle as many fluorescent hypoxia probes based 
on 2-nitroimidazole, whereby bioreduction of the nitro group under hypoxia results in 
increased fluorescence. This BIAN compound did not contain a nitroimidazole, 
however, and instead was based upon 6-aminoquinoxaline and acenaphtho[1,2-
b]quinoxaline substituted with a nitro group, for bioreduction. Redox properties of the 
BIAN backbone therefore, did not impede the hypoxia selectivity. 
  The aim of this chapter was to synthesise and characterise proligands that could firstly 
act as potential precursors to analogous metal complexes. Secondly, the comparison 
between ligand precursors and their metal complexes is essential for assessing the 
stability of the latter in biologically relevant conditions as well as in vitro. The next 
objective was to investigate these compounds by UV-visible and fluorescence 
spectroscopy, followed by the determination of their fluorescence lifetime in solution 
and in vitro, to allow comparisons with their corresponding metal complexes described 





2.2 Ligand precursor synthesis and characterisation 
 
  Mono(substituted) ligand precursors were synthesised by refluxing one equivalent of 
thiosemicarbazide (incorporating R substituents as peripheral functionalities such as 
methyl, ethyl, phenyl or allyl), with one equivalent of acenaphthenequinone, in presence 
of acid as a catalyst. These mono(thiosemicarbazone) proligands present an opportunity 
to synthesise asymmetric bis(substituted) compounds and will be discussed in Chapter 7. 
To synthesise the bis(thiosemicarbazone) ligand precursors, three or more equivalents 
of thiosemicarbazide were added to the diketone starting material using the same 
procedure, in ethanol with ten drops of concentrated hydrochloric acid (Figure 2.1).  In 




Figure 2.1. Reaction scheme of ligand synthesis method. 
 
Isolated ligand precursors were yellow solids, with the exception of phenyl-substituted 
compound ic which was pale orange. The yields of the mono(substituted) ligand 
precursors ia – id were good (72 - 85 %). Mass spectrometry and NMR spectroscopy 
were used for their characterisation, whereby the mono(substituted) ligand precursor 
m/z resonances were found in agreement with calculated [M + H]
+
 as 292.05, 306.07, 
332.09, and 318.11 (ia, ib, ic and id respectively). All bis(substituted) ligand precursors 
were isolated in moderate to good yields of (64 - 85 %). ESI-MS were confirmed in 
negative ionisation mode as 355.08, 383.12, 479.12 and 407.11, for the bis(substituted) 
ligand precursors iia, iib, iic and iid, respectively. 
 
1
H-NMR spectroscopy indicated the high purity of the ligand precursors and that the 
bis(substituted) compounds showed an asymmetric conformation. Figure 2.2 shows 
1
H-




bis(substituted) proligands is characteristic of an (E,Z) isomerism at the imine 
functionality and has been structurally confirmed using X-ray crystallography (vide 
infra). Moreover, when H2ATSM was optimised by DFT (Density Functional Theory), 




Distinctive nitrogen-bonded protons (referred to as NH) for both mono(substituted) 
and bis(substituted) ligand precursors appear between 8.8 and 12.9 ppm. The (E,Z) NH 
resonances can be assigned accurately for the bis(substituted) ligand precursor, due to 
the characteristic resonances corresponding to the mono(substituted) proligand, which 






H NMR (300 MHz, d6-DMSO) spectroscopy of the aromatic and amino NH shifts of the 
mono-ethyl substituted and bis-ethyl substituted ligand precursors in the 7.5 to 13 pm region. 
 
In the case of compounds iia, iib and iid bis(substituted) proligand resonances 
analogous to the mono(substituted) ligand precursor for between 12.5 and 12.7 ppm are 
representative of the Z hydrazone proton, with shifts between 9.1 and 9.4 ppm 
corresponding to external Z proton. This indicates that shifts of the E nitrogen-bound 












11.3 ppm (hydrazonal) and 8.8 and 9.1 ppm (external). Structural data and DFT 
calculations (vide infra) suggest that the Z hydrazone proton is involved in hydrogen 
bonding to the ketone or the imine of the respective mono(substituted) and 
bis(substituted) ligand precursors. This would likely result in deshielding and the 
observed downfield shift of Z hydrazone proton. When comparing the methyl and ethyl-
substituted proligands (ia to ib or iia to iib) the NH chemical shifts were almost 
identical, as expected from the similar nature of these alkyl substituents. In comparison 
the id and iid allyl-substituted ligand precursor external NH shifts were slightly 
downfield, for example 9.32 ppm and 9.02 ppm for iid and 9.19 ppm and 8.80 ppm for 
iib. This signifies the reduced shielding due to the electron-withdrawing functionality. 
In comparison with other functionalities there was a significant downfield shift 
observed for the two NH resonances of ic (12.79 ppm and 10.93 ppm) and the four NH 
resonances of iic (12.95 ppm, 11.54 ppm, 10.74 ppm and 10.68 ppm).  This can also be 
attributable to the electron-withdrawing nature of the phenyl substituent.  
 
2.3 Structural investigations by X-ray crystallography and DFT modelling 
 
Yellow crystals of bis(thiosemicarbazonato) ligand precursor of iid and of a sulphur-
sulphur dimerised form of iib (iibS-S) suitable for X-ray crystallographic analysis were 
grown from DMSO solutions. The proligands was an (E,Z) isomer, whereby the 
literature reflects a scope of geometries for such compounds. For similar compounds 
such as bis(alklimino)acenaphthene (alkyl-BIAN) ligand precursors the (E,E) geometry 
would be expected, however Cowley et al. reported (E,Z) alkyl-BIAN proligand 
isomers. Authors suggested that the observed geometry was due to the substituents 
steric effects, imino-nitrogen lone pair repulsion and crystal packing.
120
 It would be 
reasonable to consider that the isomerism displayed by compound iid and the iib dimer 
are of similar origins. Structures were reported by Besenyei et al. also reported that 
aryl(BIAN) derivatives may be observed as either (E,E) (major isomer) or (E,Z) isomers 
depending on the solvent.
121
 Furthermore, Dilworth et al. reported a benzil 
bis(phenylthiosemicarbazone) ligand precursor and a benzil 









Figure 2.3. ORTEP representations of allyl-functionalised bis(thiosemicarbazonato) ligand precursor iid 
(above) and dimer of ethyl-substituted bis(thiosemicarbazonato) ligand precursor iib (below).  Ellipsoids 
drawn at 30 %, hydrogen atoms omitted for clarity. 
 
The results of X-ray diffraction experiments are presented in Figure 2.3, with selected 




mono(substituted) thiosemicarbazonato ligand ib. Almost all corresponding bonds of ib, 
iib and iid are similar therefore little discussion structural is possible, but allows for 
later comparisons with analogous metal complexes. The only exception is the carbon-
sulphur bond of iib involved in the sulphur bridge, which is a single bond and therefore 
significantly longer than the corresponding bonds of iid or ib. This may have been 
formed by tautomerisation, followed by deprotonation as illustrated in Figure 2.4. Both 
crystal structures display an (E,Z) geometry, which is consistent with their NMR spectra. 
 
Table 2.1. Selected bond lengths of the ligand precursor crystal structures and optimised structures of iic 
and iic' by B3LYP 6-31++ (d,p) IEFPCM, DMSO, in Angströms. 
 
 




















N-N 1.352(2) 1.391(7) 1.356 1.359 1.367(4) 
  1.392(6) 1.356 1.348 1.361(4) 
C=N or 1.294(2) 1.280(7) 1.293 1.297 1.297(4) 
C=O for ib 1.224(2) 1.311(8) 1.293 1.303 1.306(4) 
C=S 1.6780(19) 1.683(6) 1.691 1.692 1.678(4) 




    
Figure 2.5. Structures of relevant sulphur-bridged thiosemicarbazones by Bermejo et al. (left) and López-




It is notable that a dimerised structure of the ethyl-functionalised bis(substituted) 
ligand precursor has been formed via sulphur-sulphur bridging under aprotic conditions. 
The capacity for DMSO to form disulphide bonds of peptides is well-known. All 
previously reported thiosemicarbazone disulphide-bridged ligand precursors were 
formed by oxidation via a metal-based catalyst. It has been well documented that Cu(II) 
and Fe(III) oxidise organo-thiols to produce sulphur-sulphur bonds.
124
 Cu(II) and Mn(II) 
catalysed thiosemicarbazone sulphur-bridged proligand were reported by López-Torres 
et al. and Bermejo et al. respectively (Figure 2.5).
125
 The S-S bond lengths of these 
published ligand precursors were 2.0335(11) Å and 2.039(1) Å correspondingly, which 
is somewhat shorter than the disulphide bond of the iib dimer, 2.051(2) Å. This suggests 
that the iib dimer bond may be labile and the dimerisation reversible. Literature show 
that the resultant disulphide may be formed intentionally via metal-based catalysis or by 







2.3.1 Density functional theory calculations 
 
To provide insight into the geometry of the bis(imino) ligand-precursor (E,Z) and (E,E) 
isomers were optimised by DFT in the gas phase and in solution. Phenyl-functionalised 
compound optimisations were used as representatives of the bis(imino) ligand-
precursors and were based on available crystal structures.  
 
Figure 2.6. Optimised in solution of asymmetric iic’ by B3LYP 6-31++ (d,p) IEFPCM, DMSO. Where 
grey = carbon, white = hydrogen, blue = nitrogen. 
 
 
Figure 2.7. Optimised in solution structures of symmetric iic by B3LYP 6-31++ (d,p) IEFPCM, DMSO. 





Following the method used by Holland et al.,
119
 the ligand precursors were initially 
optimised in the gas phase using B3LYP 6-31G(d,p), followed by B3LYP 6-31++ (d,p) 
IEFPCM, DMSO to obtain an optimised structure in solution (Figures 2.7 and 2.8). 
Bond lengths of the optimised structures were comparable to crystallographic data 
acquired for compounds iib and iic (Table 2.1). In the gas phase the calculated energy 
difference is 4.17 kJ mol
-1
, indicating that the asymmetric structure iic’ is more stable 
than the symmetric structure iic.  Likewise, when solvent effects were considered  in 
DMSO, the asymmetric structure was more energetically favourable when compared to 
the symmetric by 2.04 kJ mol
-1
, confirming what was observed by NMR spectroscopy 
and X-ray crystallography. The (E,Z) structure iic’ is likely stabilised by internal 
hydrogen-bonding, whilst the (E,E) structure iic may be more favourable for 
complexation as it offers more space for a metal. For example, the alkyl-BIAN ligand 
precursor reported by Cowley et al. as the (E,Z) isomer was metallated to form a zinc 
complex, which possessed the (E,E) geometry.
120
 Likewise, the 1,2-cyclohexanedione 
bis(4-methylthiosemicarbazone) ligand precursor reported in the above study possessed 




Figure 2.8. DFT calculations on H2ATSM by Holland et al.,
119
 which show (E,Z) isomer, 0.0  kJ mol
-1
 
(left) to be more  energetically favourable than the (E,E) isomer, 16.6  kJ mol
-1
 (right). (Numbers to the 




Furthermore, the study by Holland et al. demonstrated that the most stable conformer of 
H2 ATSM is the (E,Z) geometry.
119
 The energy difference between the two conformers 
of H2 ATSM examined was 16.6 kJ mol
-1
. The low energy difference between the (E,Z) 






2.4 Fluorescence Spectroscopy 
 
  Light emitted from a fluorophore is detectable via fluorescence spectroscopy and 
microscopy. These spectroscopic and imaging techniques allow the monitoring of a 
fluorescent compound in solution and in biological cells. The naphthyl backbone of 
ligand precursors above provides electron-rich π-bonds and facilitates fluorescence 
emission.
118
 This bypasses the necessity of conjugating a commercially available 
fluorophore, such as fluorescein or BODIPY which are expensive and may significantly 
affect the biological properties of the compound under investigation. Appropriate 
biological assays and microscopy conditions can be chosen once the fluorescent 
properties of the ligand precursors are understood. Therefore fluorescence scans 
between 200-800 nm were obtained in 100 M DMSO solutions, allowing maxima of 
excitation (ex-max) and emission (em-max), useful information for fluorescence 
microscopy. Furthermore ranges of absorption and emission were assessed using 2D 
contours, which are significant to the choice of cytotoxicity assays and fluorescence 
imaging settings. Since relevant cytotoxicity assays use absorbance readings at 570 nm, 
it is preferable that there should be minimal or no excitation at this wavelength. This 
was confirmed for each ligand precursor making them suitable for later in vitro studies. 
In general the fluorescence of the bis(substituted) ligand precursors was very weak, with 
the overall range of absorption for these compounds approximately between 260 nm 
and 550 nm and an emission range of 450 nm and 680 nm (Table 2.2, Figures 2.9 and 
2.10).   
 
Table 2.2. Fluorescence spectroscopy of bis(thiosemicarbazonato) ligand precursors. 
 
  The wavelengths resulting in maximum excitation (ex-max) were found between 470 to 
490 nm, indicating that compounds would be appropriate for excitation via a standard 
488 nm confocal microscopy laser.  With em-max lying between 545 and 555 nm the 
Compound ex-max / nm Excitation range / nm em-max / nm Emission range / nm 
id 490 240-615 554 454-735 
iia 470 260-610 618 432-800 
iib 490 380-530 550.5 496-663 
iic 490 270-560 545.5 476.5-715 




emission can be expected in a standard green channel of a confocal microscope. The 
notable exception of methyl substituted ligand iia with the λmax of emission at 618 nm 
and a significantly broader emission range of 432 nm to 800 nm is likely to be 
observable in both green and red channels of a standard confocal microscope. The 
mono(substituted) ligand precursor was only weakly fluorescent compared to the 
corresponding bis(substituted) compound. As a representative example the allyl-
substituted mono(substituted) ligand precursor showed broader excitation and emission 
(240 nm to 615 nm and 454 nm to 735 nm respectively).   While ex-max and em-max 
were 490 nm and 554 nm respectively for id, were comparable to the maxima of iid 
(Table 2.2).   
  Considering that the fluorescence of their analogous complexes is likely to be 
significantly greater, due to metal to ligand charge transfer (MLCT) and ligand to metal 
charge transfer (LMCT) this is a positive result. Encouraged by these preliminary 
results a study of the ligand precursors was conducted in vitro, in order to allow 
comparisons with their corresponding metal complexes in later chapters. 
 
Figure 2.9. Excitation/emission map of compound iic. 













































Figure 2.10. Excitation/emission map of compound iid 
 







































2.5 Laser scanning confocal microscopy 
 
  Experiments were carried out to ascertain if the weak fluorescence of the ligand 
precursors was sufficient to be observed in vitro. Cells were cultured using standard 






a)      b) 
  
c)      d) 
Figure 2.11. Single-photon confocal microscopy images of ia in HeLa cells, incubated with lysotracker 
100 μM, 1% DMSO, 20 minutes, at 37°C. a) Differential Interference Contrast (DIC) image. b) 
Micrograph of cells after excitation at 488 nm, green channel, showing localisation of the compound ia. c) 
Micrograph of cells after excitation at 543 nm, red channel, showing localisation of the lysotracker. d) 





Cell viability prior to experiments and over their course was monitored by optical 
microscopy, and validated at the start of the experiments by standard trypan blue tests.  
The compounds were imaged in HeLa (cervical carcinoma), PC-3 (prostate carcinoma), 
MCF-7 (breast cancer) and FEK-4 (non-cancerous fibroblast) cell lines using standard 
confocal fluorescence microscopy with one photon excitation at 488 nm.   
 
 
a)                                                                                b) 
      
c)                                                                                d) 
Figure 2.12. (a – b) Single-photon confocal microscopy of compound iid in FEK-4 at 50 μM, 0.5 %, 
DMSO incubated for 20 minutes, washed then iid was incubated at 100 μM, 1% DMSO and incubated for 
20 minutes, (c – d) iid at 100 μM, 1% DMSO, after 20 minutes in HeLa. (a, c) DIC image. (b, c) 





  The imaging studies were performed using concentrations of 100 µM in a DMSO: 
RPMI (Royal Park Memorial Institute) cell medium 1:99 solvent mix, whereby the final 
DMSO concentration on the imaging plate was lower than 1%.  The fluorescence of the 
compounds was very weak, therefore such high concentrations of the ligand precursors 
were necessary to assess uptake within cells. Compound ia, the methyl substituted 
mono(substituted) thiosemicarbazone ligand was incubated in HeLa cells and was found 
to possess a good colocalisation with lysotracker (Figure 2.11), suggesting that this 
compound is likely to enter the lysosome.  
 
  
a)      b) 
  
c)      d) 
Figure 2.13.  Single-photon confocal microscopy of iic at 100 μM in PC-3, 1% DMSO, incubated for 20 
minutes. a) Micrograph of DIC. b) Red channel, excitation 405 nm. c) Red channel, excitation 488 nm. d) 





Further investigations with colocalisation dyes demonstrated that the ligand precursor 
did not localise in the mitochondria or nucleus (Appendix Figures G.2-3).  Experiments 
showed that bis(substituted) ligand precursor iid possessed weak uptake in HeLa cells, 
which was barely detectable when incubated in FEK-4 cells, under the same conditions 
(Figure 2.12).  The latter result suggests that there could be a preference for the 
compound to enter cancerous cell lines over non-cancerous cells (Figure 2.12 and 
Appendix Figures G.4-8). Optimal imaging conditions were found to be at 405 nm 
rather than at 488 nm excitation and this emission was observed maximally in the green 
channel for methyl, ethyl and allyl substituents (Appendix G). A blue shift in absorbance 
can be expected in a more polar solvent such as water.  A higher level of solvation of a 
lone pair lowers the n-orbital energy, resulting in a larger energy n  * transition and 
thus absorption at a lower wavelength. Absorption of the phenyl bis(substituted) ligand 
precursor was most favourable when using the 405 nm laser, however, the emission was 
maximised in the red channel (Figure 2.13). A comparison between the fluorescence 
observed in the 2D spectra in DMSO solution and within cells shows a blue shift in the 
λex-max from ca. 480 nm to ca. 405 nm, with a redshift in emission. This redshift can be 
understood as a solvent effect, whereby a more polar solvent reduces the energy 
difference between the excited and ground states. The process, known as solvent 
relaxation occurs when solvent molecules stabilise and decrease the excited state energy 
level, therefore resulting in a higher wavelength emission. 
  Rather than being a hindrance, the weak fluorescence of the ligand precursors within 
cells is a significant advantage in being able to assess the stability of their respective 
metal complexes in vitro as will be demonstrated in subsequent chapters. Moreover, 
stability in cells was subsequently investigated using fluorescence lifetime imaging 
microscopy (FLIM), as a quantitative means of stability assessment.  In addition to a 
qualitative evaluation using standard fluorescence microscopy this may provide another 






2.6 Two-photon excitation and fluorescence lifetime imaging microscopy 
 
  Two-photon absorption occurs when the combined energy of two simultaneous 
photons results in molecular excitation.  The first photon to interact generates what is 
known as a virtual state, which has no classical analogue and only exists transiently 
(generally for femtoseconds) in which time a photon can travel ca. 1 μm. Arrival of the 
second photon must occur before the virtual state decays (dephases), which will occur if 
the laser intensity is high and focussed. The probability of single photon absorption is 
proportional to the intensity of light and is in contrast to two-photon absorption, which 
is dependent on both spatial and temporal coincidence (Equations 2.1 and 2.2).
129
 
Therefore, where NAx is the number of photons absorbed per second, I is the intensity, 
σx is the cross-section and x is 1 or 2 photon absorption. 
 
Single-photon absorption:  NA1 = σ1 I     (Equation 2.1) 
Two-photon absorption:  NA2 = σ2 I
2     (Equation 2.2) 
 
 An advantage of two-photon excitation therefore, is that imaging occurs only from the 
focal plane. This is contrasting with single-photon excitation microscopy, in which the 
image is often distorted as it may occur outside the focal plane.
129
  Furthermore, despite 
the requirement of high-powered lasers, two-photon microscopy has been found to 
cause less damage to biological cells than single-photon microscopy, as well as to 
decrease photo-bleaching and augment imaging depth.
130
 
  Two-photon absorption has been used in the development and application of two-
photon fluorescence confocal microscopy since 1990 and provides significantly greater 
control from a clinical perspective, with ongoing research seeking to enable an in-depth 
understanding of biological processes.  In turn this allows for selection of individual 




  Recent advancements have resulted in the design of two-photon fluorescence lifetime 
imaging (FLIM), which combined with highly sensitive single-photon counting lifetime 
measurements poses an attractive method for investigating small molecule fluorescence. 




fluorophores, which possess sufficiently different lifetimes and can also be achieved 
using spectrally resolved microscopy. 
  FLIM is frequently used to separate different portions of the same fluorophore, for 




) or by 
oxygen. Furthermore, this technique can be used to monitor binding of and even 
distance from a fluorophore, with a conformational change is likely to result in a 
different rate of internal non-radiative decay and, therefore, a modification of the 
fluorescence lifetime.
133, 134
 pH effects can also be studied, since protonated and non-
protonated forms of a molecule may possess different lifetimes. In addition 
investigations of aggregation, viscosity, proximity to metal surfaces and nanoparticles 
(due to their long luminescent lifetimes) are carried out.
133
 There has, however, been 





 complexes in vitro, but thus far no reports of use of the stability 
evaluations technique with transition metal complexes. 
  Consequently, if the fluorescence lifetime of the complex is significantly different to 
that of the ligand precursor, FLIM could be utilised to assess the complex stability in 
vitro. Two-photon excitation experiments were performed at the Rutherford Appleton 
Laboratory following the methodology described in Botchway et al. 2008
137
 and in our 
recent publication (Pascu et al. 2011
138
) with assistance of Dr S Botchway, Dr P Burgos, 
Mr A. Mckenzie and Mr A. Henman.  
 
 
a)         b) 
Figure 2.14. Control experiment at 810 nm,  in HeLa cells where a) is the colour image corresponding to 
the two-photon fluorescence lifetime map of the τm (the weighted average fluorescence lifetime), b) is the 
distribution curve of the τm where the colour represents the lifetime of a).  





















a)      b) 
Figure 2.15. Control experiment at 910 nm, two-photon fluorescence lifetime map (τm) in HeLa cells 
showing weak autofluorescence where a) is the colour image corresponding to the two-photon 
fluorescence lifetime map of the τm, b) is the distribution curve of the τm where the colour represents the 
lifetime of a). 
 
  In order to be able to quantify compound fluorescence the background 
autofluorescence of cells had first to be assessed. The 810 nm control possessed the 
fluorescence lifetimes of 0.812 ns (τ1 79 % 0.214 ns FWHM) and 3.140 ns (τ2 21 %, 
0.647 ns FWHM). Figure 2.11b and 2.12b represent the mean lifetime of both 
components in HeLa cells when modelled to two components. Autofluorescence when 
excited at 910 nm, however, was negligible therefore all compounds displaying 
significant fluorescence at 910 nm were tested at the latter wavelength (Figure 2.14).  It 
is in agreement with literature that autofluorescence is less at 900 nm than 800 nm.
139
 
The background fluorescence can be attributable to biological fluorophores; at 910 nm 
these include flavin adenine dinucleotide (FAD) and lipoamide dehydrogenase (LipDH), 
which also absorb at 810 nm.
140
 Biological molecules such as reduced nicotinamide 
adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate 
(NADPH) absorb 810 nm light, but not 910 nm, therefore contributing to the difference 
in autofluorescence intensity observed at the respective wavelengths.
140 
 
  The full width at half maximum (FWHM), calculated from the lifetime distribution 
curve within the focal area was used to assess the error. The percentage of components 
τ1 (major) and τ2 (minor) in cells was from the respective amplitudes a1 and a2 






















calculated using SPCImage software, which models the data for each individual pixel to 
Equation 2.3, where F is fluorescence, a0 is background and t is time: 
 
𝐹(𝑡) =  𝑎0 + 𝑎1𝑒
−𝑡/𝜏1 + 𝑎2𝑒
−𝑡/𝜏2     (Equation 4.3) 
2.6.1 Ligand precursor fluorescence lifetime investigation 
 
For each bis(substituted) ligand precursor tested by Time-Correlated Single Photon 
Counting (TCSPC) two fluorescence lifetime components could be determined in 
DMSO at 10 mM, with the τ1 accounting for at least 94 % in each case. The τ1 values 
were very similar for compounds iia, iib and iic when excited at 810 nm (0.226 ns with 
χ2 of 1.88, 0.183 ns with a χ2 of 1.63 and 0.158 ns with a χ2 of 1.71 respectively). The 
excitation wavelength did not appear to have a significant effect on the fluorescence 
lifetime. For example when iic was excited at 910 the major component was 0.156 ns. 
Similarly the τ1 of iid was comparably shorter (0.020 ns at 810 nm and 0.021 ns at 910 
nm), indicating no observable difference between the lifetimes when exciting at the 
respective wavelengths in DMSO solution. 
  The minor component (τ2) of the fluorescence lifetime of the ligand precursors in 
DMSO at 10 mM did not follow the same pattern. While compounds iia and iic had a τ2 
of ca. 2.5 ns as the minor component for iib was 3.969 ns. By contrast the minor 
component for iid was one order of magnitude longer, with τ2 values of 0.274 ns and 
0.468 ns for excitation with 810 nm and 910 nm respectively. These numbers, however, 
are to be taken with caution as the errors are much larger than for τ1 due to the weakness 
of this second component (< 5%). Excitation at 810 nm produced considerably higher 
quality data than at 910 nm for the ligand precursors in cells (Figures 2.16-2.17), which 






a)      b) 
Figure 2.16. Two-photon mean fluorescence lifetime distribution curve (τm) in HeLa cells of iia, iib, iic 
and iid at 100 µM at a) 810 nm and b) 910 nm. 
 
  The fluorescence lifetime of the compounds were obtained from the FLIM 
distribution curve in cancer cells (HeLa, MCF-7 and PC-3 cells). Standard conditions 
used were 1% DMSO 100 μM, with an incubation time of 20 minutes. The majority of 
cellular studies could be modelled to two fluorescence lifetime components, one of 
which was short (ca. 0.2 ns) with the other being long (ca. 2.5 ns). The solution data 
were within the FWHM, which represents the error for in vitro data and thus confirms 
their comparability. 
 
There were some exceptions however, such as the long components of iib in PC-3 
cells (0.434 ns, 0.209 ns FWHM) and of iid in HeLa and PC-3 cells at 910 nm (0.436 ns, 
0.653 ns FWHM and 0.418 ns, 0.455 ns FWHM, respectively). Other notable 
exceptions were the major components observed for iia and iib when excited at 810 nm, 
with lifetimes of 0.903 ns and 0.868 ns, correspondingly. These are within the FWHM 
of the control, which suggests that most of the fluorescence observed at this wavelength 
for these two compounds is as a result of cellular autofluorescence. This could indicate 
the weakness of the fluorescence of the proligand or simply that the conformation of the 
compound within the cell and in turn the fluorescence lifetime has been significantly 
altered as opposed to in DMSO.  
 














































a)      b) 
Figure 2.17. Two-photon fluorescence lifetime map (τm) of iic a) in PC-3 cells with excitation at 910 nm 
and b) in HeLa cells with excitation at 810 nm. 
 
The minor components nevertheless, could be correlated to the ligand precursor, 
confirming the weak fluorescence of the compound in cells. The fluorescent lifetime 
measurements of the mono(substituted) ligands were similar to their bis(substituted) 
analogues, possessing in general a short, major component of the order of 0.4 ns and a 
long, minor component in the region of 3 ns. Unlike the bis-thiosemicarbazonato 
ligands, this was consistently observed in cells when excited at 910 nm. Different 
molecular orientations would result in a change in fluorescent lifetime, which could 
suggest that the mono(substituted) proligand geometry was less variable than its 
bis(substituted) counterpart.
133
  Interestingly, although consistency of data was observed 
in cells, the respective short, major component is slightly shorter (ca. 0.2 ns), which 
suggests that the complexity of the cellular environment does have impact on the 
lifetime. There appeared to be a more limited effect on the mono(substituted) than the 
bis(substituted) ligand precursor, which displayed greater variation of lifetime within 
cells.  Notably, the fluorescence of the mono(substituted) ligand precursors was very 





2.7 Summary to Chapter 2 
 
Mono(thiosemicarbazonato) and bis(thiosemicarbazonato) ligand precursors were 
successfully synthesised and characterised by ESI-MS and NMR spectroscopy.  
Furthermore their fluorescence properties were analysed, showing weak, but detectable 
emission in solution and in cancerous and non-cancerous cells at 100 μM concentration. 
Fluorescence of respective complexes of these proligands would be expected to be 
higher due to MLCT and LMCT, therefore strong fluorescence at this concentration or 
lower would provide a qualitative indication of complex stability. Furthermore, the 
fluorescence lifetime components of these compounds were determined in solution and 
in cells with characteristic data that proved distinguishable from cellular 
autofluorescence. This means that if a complex decomposes in the cell by deconvoluting 
the various fluorescence lifetime components, provided that these are sufficiently 




Chapter 3. Synthesis, characterisation, spectroscopic, in vitro and in 




 In this Chapter, the transmetallation reactions to generate new copper complexes are 
described. Zinc bis(thiosemicarbazonato) complexes precursors provide a clean means 
of synthesising other metal complexes (such as copper) via transmetallation. The 
fluorescent analogue of the known tracer Cu[ATSM] is its zinc analogue Zn[ATSM]. 
Therefore a means of comparison can be provided by synthesising zinc 
bis(thiosemicarbazonato) complexes containing a acenaphthenequinone based backbone, 
which were first synthesised in the group. 
123, 127, 128
 Subsequently the aims were to 
synthesise zinc and copper bis(thiosemicarbazonato) complexes, acquire and discuss 
new structural data and distinguish, for the first time, their stability in biological cells. 
 
3.2 Zinc complex synthesis 
   
  
Figure 3.1. Synthesis of acenaphthenequinone zinc bis(thiosemicarbazones) 
 
   Earlier studies in the group, showed that acenaphthenequinone zinc 
bis(thiosemicarbazone) complexes can be made in a one-pot synthesis by reflux in 
acetic acid, followed by filtration and washing of the product with diethyl ether. 
Terminal functionalities in this study included methyl, ethyl, phenyl and allyl groups 
(Figure 3.1). 
123, 127, 128
 The complexes were obtained as orange or red solids in 
moderate to good yields of (49% to 68%). The compounds (1a, 1b, novel complex 1c 




C NMR spectroscopy and ES-MS, giving peaks 






3.3. Copper complex synthesis 
 
 
Figure 3.2. Synthesis of acenaphthenequinone copper bis(thiosemicarbazones) via transmetallation 
 
  The zinc compounds (1a-d) act as precursors to the analogous copper complexes in 
transmetallation reactions. One equivalent of the respective zinc complex and two 
equivalents of copper acetate were stirred in methanol at room temperature for 24 hours 
and the product isolated as a brown solid by filtration, after washing with water and 




a)      b) 
Figure 3.3. HPLC of transmetallation from 1c to 2c showing a) the UV trace (blue) and b) the radio trace 
(pink).  
  
  LC-MS was used to characterise these compounds since NMR spectroscopy was not 
informative due to the paramagnetic nature of copper, giving m/z values of 418.01, 
446.04, 542.32 and 470.03, which represent [M + H]
+
. Complexes 2a and 2b were first 
reported in Reference 123 for which the writer of this thesis is a co-author. Furthermore, 
EPR spectroscopy of novel complex 2c gave comparable spectra to 2a, 2b and 2d and 
confirms the presence of a paramagnetic species (Appendix I). Moreover it was possible 




Cu(OAc)2 at Oxford 
Siemens Molecular Imaging Laboratory under the supervision of Dr Phillip A. Waghorn 
and Prof Jon Dilworth. 
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  The partition coefficient log P, which is an indicator of lipophilicity, were calculated 
with 2a, 2b and 2c possessing values of 1.209 ± 0.076, 1.188 ± 0.043 and 1.436 ± 0.062 
respectively.  The 
64
Cu compound was added to a mixture of equal volumes of water 
and octanol, followed by vortexing and centrifugation for 5 minutes. The activity of 
each phase was measured and the log P was calculated as log(octanol [radioactivity] ÷ 
water [radioactivity]), a value above 1 meaning that the compound is lipophilic.
141
  The 
value for Cu[ATSM] under the same conditions was found to be 1.48, which indicates 
that uptake of these copper complexes, in particular for 2c is likely to occur in the liver 




Cyclic voltammetry of complexes 2a and 2b was carried out by Dr Phillip A. Waghorn. 
The compounds were found to possess reduction potentials of -0.517 V and -0.536 V, 
respectively.
123
 Since these are close to the reduction potential of Cu[ATSM] (-0.581 V) 
under comparable conditions it appears that the additional acenaphthene ligand 
backbone has not significantly affected the reduction potentials. Surprisingly, despite 
displaying a log P and reduction potential equivalent to that of Cu[ATSM] a 
preliminary hypoxia study by Dr Waghorn showed that complex 2b did not possess 
hypoxia selectivity within one hour. It can be speculated that longer incubation times 
may be required to observe selectivity. 
 
 
Figure 3.4. Synthesis of acenaphthenequinone copper bis(thiosemicarbazones) via the free ligand 
 
Another method of synthesising the copper complexes was attempted via the free 
ligand by stirring in methanol for 24 h with 3 equivalents of copper acetate (Figure 3.4).  
Despite demonstrating some success, this synthesis method did not prove reliable as 
significant batch-to-batch variations in the product were found, frequently producing a 
black powder, which did not possess the desired spectroscopic properties, as opposed to 




dimerisation observed by X-ray crystallography (Chapter 2.3), which could cause 
formation of a copper-based polymeric compound which proved to be intractable.  
Therefore the transmetallation method was chosen in preference to the free ligand 
process. 
 
3.4 X-ray crystallography 
 
  Crystals suitable for X-ray diffraction were obtained from DMSO or THF:pentane 
solvent mixtures. The crystals were grown slowly by solvent diffusion techniques at 
room temperature. Data will be compared to the previous crystallographic results 
reported in references 123, 127 to 128 and work carried out during this project. The 
bond lengths and angles below of the newly acquired phenyl-substituted crystal 
structures are discussed below. The structures here will be discussed in terms of how 
their structure is affected by functionality, whereby the effect of the metal centre will be 
discussed in Chapter 5.  
 
  It is notable that all of the copper complex crystal structures were determined to be an 
(E,E) the symmetrically bound isomer. Whereas zinc complexes 1a, 1b and 1d were 
found to possess the asymmetric structure. In previous studies in the group, the Zn(II) 
complexes only yielded suitable crystals for X-ray determinations when they were co-
crystallised with DABCO and possessed (E,Z) isomerism. Here, it was possible to 
obtain X-ray crystallographic data for the phenyl-substituted zinc complex without co-
crystallisation. This structure contained a DMSO adduct has been isolated showing that 
ligand may also be bound as the an (E,E) isomer in these Zn(II) complexes (Figures 






Figure 3.5. ORTEP representation of 1c, ellipsoids drawn at 30% probability, hydrogens omitted for 
clarity. 
 
Figure 3.6. ORTEP representation of 2c, ellipsoids drawn at 30% probability, hydrogens omitted for 
clarity. 
 
  For the zinc and the copper complexes there was little variation in the M-N bond 
lengths, however when considering the longest of the two Zn-N bonds it is possible to 
note that phenyl-substituted and the ethyl-substituted zinc complex bond was longer 
than those of the methyl and allyl-substituted bond.  Furthermore, the functionality of 
the copper complex did not appear to greatly affect the bond lengths, whereby the N-N 
bonds were similar as were the C=N bonds, with little differences observed in Cu-S 
bonds where 2b and 2d possessed comparable data, which were longer than for the 
similar Cu-S bond lengths of 2a and 2c.  A greater degree of variation was observed 
when comparing zinc complexes of different functionality (Tables 3.1-3.2).  The length 
of the Zn-S bond pattern was the reverse when compared to those of Zn-N, with 1d the 
longest, followed by 1a and with 1c possessing the shortest (Table 3.1). Meanwhile 
there was little variation in C=N bond lengths according to functionality and N-N bond 





Notably the C-C bonds in both the zinc and copper complexes (here for 1c and 2c this 
bond is C8-C19, (Figures 3.5-3.6) were shortest for the methyl-functionalised 
compounds. The length of this bond was similar for the other substituents in the case of 
the copper complexes, with the methyl substituted zinc complex possessing a shorter C-
C bond than 1b and 1d.  It had previously been noted that the asymmetric (E,Z) zinc 
structures possessed longer C-C bonds than their analogous (E,E) copper and nickel 
structures. Here there was no significant difference between the C-C bond of the zinc 
compound of various functionalities. Indeed a closer look at one (E,E) isomer (the 
phenyl-substituted zinc complex 1c) suggested that the dissimilarity observed was 
caused by the nature of the metal centres employed rather than that of the isomer. This 
hypothesis will be further explored in subsequent chapters.   
 
The bond angles around the zinc atom showed small variations with different 
substituents. For example, the N-M-N angle of complex 1b, 75.5(3)° is smaller than the 
respective angles of the other zinc complexes, of which complex 1d possessed the 
largest N-M-N angle of 88.55(15)°. Conversely the corresponding angles of 1a and 1c 
are comparable, 85.87(17)° and 86.6(1)°. The inverse was observed for the S-M-S angle, 
whereby the largest angle was 118.49(13)°, of complex 1b and the smallest angle of 
110.69(5)° was possessed by compound 1d. Interestingly complex 1b possessed greater 
symmetry in comparison to the other zinc complexes in that the angles around the zinc 
atom within the same molecule were similar (for example the S-M-N angles, 79.7(3)° 
and 79.6(2)°, S-M-A angles, 100.30(19)° and 100.4(2)° and N-M-A angles, 98.4(3)° 
and 98.0(3)°.) Allyl-substituted complex 1d possessed similar S-M-A angles (103.43(9)° 
and 103.16(10)°) and N-M-A angles (107.36(13)° and 107.40(15)°), yet different S-M-
N angles (83.88(10)° and 60.55(12)°). Meanwhile with comparably less symmetry, 
complex 1a had equivalent N-M-A angles (105.16(14)° and 105.13(14)°), with disimilar 
S-M-N (83.47(12)° and 64.89(13)°) and S-M-A angles (102.94(10)° and 99.15(10)°). 
Complex 1c, which was an (E,E) isomer was interestingly found to possess the least 
symmetry whereby its respective S-M-N (83.25(8)° and 80.27(4)°), S-M-A (104.31(4)° 
and 102.01(4)°) and N-M-A (101.11(5)° and 93.77(5)°) angles within the same 






Table 3.1. Selected bond lengths (Å) and bond angles (°) for compounds 1a-1d, determined by X-ray 
diffraction, where A is the adduct atom. 
 
 
  The copper complexes, in comparison showed much greater symmetry with respect to 
the bond angles around the metal centre, for example the equivalent angles of S-M-N of 
2c, which were 83.72(15)° and 83.64(16)° respectively. Little functionality-dependent 
variation was observed for example with similar angles for complexes 2b and 2c for S-
M-S (111.12(4)° and 110.99(7)° respectively) and N-M-N (82.45(14)° and 81.6(2)° 
correspondingly). Interestingly, the S-M-S and N-M-N angles of the 
bis(acenaphthenequinone) copper complexes were significantly larger in comparison 























M-N 2.111(4) 2.132(9) 2.1092(14) 2.082(4) 
 2.022(4) 2.132(8) 2.1603(14) 2.010(4) 
M-S 2.2992(14) 2.378(3) 2.3330(5) 2.829(2) 
 2.6845(19) 2.368(3) 2.3691(5) 2.3063(11) 
C-C 1.495(7) 1.508(13) 1.499(3) 1.508(7) 
N-N 1.316(6) 1.338(11) 1.364(2) 1.365(5) 
 1.363(5) 1.384(10) 1.364(2) 1.375(5) 
C=N 1.315(6) 1.277(12) 1.294(2) 1.303(5) 
 1.284(7) 1.328(13) 1.292(2) 1.314(7) 
S-M-S 113.91(5) 118.49(13) 114.68(3) 110.69(5) 
S-M-N 83.47(12) 79.7(3) 83.25(8) 83.88(10) 
 64.89(13) 79.6(2) 80.27(4) 60.55(12) 
N-M-N 85.87(17) 75.5(3) 86.6(1) 88.55(15) 
S-M-A 102.94(10) 100.30(19) 104.31(4) 103.43(9) 
 99.15(10) 100.4(2) 102.01(4) 103.16(10) 
N-M-A 105.16(14) 98.4(3) 101.11(5) 107.36(13) 


































M-N 1.9590(14) 1.983(4) 1.987(3) 1.967(5) 1.9855(17) 
 1.9616(13) 1.977(4) 1.980(3) 1.976(5) 1.9779(17) 
M-S 2.2462(4) 2.2539(14) 2.2575(11) 2.2508(17) 2.2620(6) 
 2.2367(4) 2.2562(13) 2.2693(11) 2.2598(18) 2.2699(6) 
C-C 1.478(2) 1.470(6) 1.493(5) 1.481(8) 1.476(3) 
N-N 1.3673(18) 1.364(5) 1.359(5) 1.382(6) 1.358(2) 
 1.3697(15) 1.358(5) 1.360(5) 1.384(6) 1.360(2) 
C=N 1.299(2) 1.309(6) 1.289(5) 1.286(7) 1.291(3) 
 1.2961(2) 1.321(6) 1.294(5) 1.293(7) 1.297(2) 
S-M-S 109.234(17) 110.11(5) 111.12(4) 110.99(7) 111.52(2) 
S-M-N 85.20(4) 83.69(12) 82.92(10) 83.72(15) 83.01(5) 
 85.08(4) 83.45(12) 83.51(10) 83.64(16) 83.30(5) 




3.5 Density functional theory calculations 
 
  The crystal structure of the above complexes were first optimised by B3LYP 6-
31G(d,p) and then by B3LYP 6-31++ (d,p) IEFPCM, DMSO, following the method of 
Holland et al.
119
 Whereby an unrestricted spin was used for the optimisation of the 
copper(II) complex due to its paramagnetic nature (Figure 3.7).  
 
  
a)       b) 
 
c)       d) 
Figure 3.7. Optimised in solution structures by B3LYP 6-31++ (d,p) IEFPCM, DMSO, where a) is 
symmetric 1c and b) is asymmetric 1c’, c) is symmetric 2c and d) is asymmetric 2c’. Where grey = 
carbon, white = hydrogen, blue = nitrogen, red = oxygen, green = zinc, orange = copper. 
 
 In the gas phase the asymmetric isomers of the zinc and the copper complexes were 
more energetically favourable with energy differences in energy of 6.18 kJ mol
-1
 for 1c 
and 4.68 kJ mol
-1
 respectively for 2c.  In solution however, the (E,E) symmetric form 
was more stable for each complex with a difference of -0.96 kJ mol
-1
 and -4.37 kJ mol
-1
, 




in Chapter 2.3 that a ligand structure possessing (E,Z) geometry would re-orientate to 
the (E,E) conformation to allow more space for metal chelation. 
 
  
a)      b) 
  
c)      d) 
 
e)      f) 
Figure 3.8. Calculated electronic distribution for the molecular orbitals of complex 2c involved in the 
13
th
 excitation state, in which the most significant absorption occurs, where a) is 137 (HOMO -2), b) is 
139 (HOMO), c) is 140 (LUMO), d) is 137 (HOMO-1), e) 138 (HOMO) and f) is 140 (LUMO +1) 
 
  It is notable that the copper complex symmetric structure was more energetically 
favourable when compared to its corresponding asymmetric structure, in agreement 
with the observation that all the crystal structures of the copper acenaphthenequinone 
bis(thiosemicarbazonato) complexes determined by in the group have been determined 
as the symmetric isomer.  The difference in the energy between the symmetric and the 
asymmetric isomers is relatively low and since the asymmetric has slightly lower 




solution in small proportions.  Subsequently, TD-DFT was calculated for the first 24 
excited states using uB3LYP 6-31++ (d,p) methodology, of which excited state 13 had 
the most significant oscillator strength, f (Figure 3.8, Appendix I). Since the molecular 
orbitals involved the ligand (including the phenyl substituent) and the metal it is very 
likely that both contribute to the fluorescent properties. This could explain the observed 
similarity between the fluorescent lifetimes of complexes in this family of compounds 
as well as the small metal dependency. 
 
3.6 Fluorescence spectroscopy 
 
  Fluorescence spectra were recorded in DMSO for initial scans between 200-800 nm, in 
order to obtain information about intrinsic fluorescence and em-max using solutions of 
100 μM. The ranges of absorption and emission were selected to be of relevance with 
regards to future cytotoxicity assays and fluorescence imaging, were assessed using the 
2D contours as a guideline (Figures 3.9-3.10). Relevant cytotoxicity assays use 
absorbance readings at 570 nm, therefore there should be minimal or no excitation at 
this wavelength, which was true for zinc and copper complexes analysed in this manner, 
with very low absorbance for each.   
 
Figure 3.9. Excitation/emission map of compound 1c. 






































Figure 3.10. Excitation/emission map of compound 2c. 
 
  Initial spectroscopic data for 1a, 1b and 1d and 2a, 2b and 2d have been already 
studied by Pascu et al. 
123, 127, 128
 The spectroscopy of compounds 1c and 2c is described 
below. The absorption range was similar when comparing the zinc and copper 
complexes, however the λmax of absorption was significantly red shifted in the case of 
the copper complex, whilst the emission maxima was slightly lower for 2c, indicating a 
reduction in the Stokes shift.  Interestingly, the range of emission was larger for 2c with 
respect to 1c.  As was expected, 2c possessed significantly reduced fluorescence when 
compared to 1c, which can be explained by paramagnetic quenching.  
 
Table 3.3. Fluorescence measurements of complexes 1c and 2c. 

































Compound em-max / nm Excitation range / nm ex-max / nm Emission range / nm 
1c 440 250-590 581.5 535-723.5 




3.7 Kinetic stability testing 
 
  In vitro assays to determine the stability of complexes for use as medical imaging 
probes is very desirable.  Demetallation could result in non-target tissue uptake and 
poor image contrast in vivo.  Stability is therefore essential for the intended function of 
these complexes and a series of assays with excess of numerous chemicals found in 
biological systems have been carried out up to 24 hours.  These include Glutathione 
(GSH), L-cysteine, L-histidine, L-methionine, citric acid, ethylenediaminetetraacetic 
acid (EDTA), biomimetic eagle’s modified essential media (EMEM) (both with and 
without foetal calf serum) and biologically relevant pH buffers. Indeed, stability of these 
complexes in a range of pHs is significant due to the tendency of cancer cells to be 
slightly more acidic than non-cancerous cells.  UV-visible spectroscopy was utilised 
therefore to assess the kinetic stability of complexes and fluorescence to provide further 
insight whilst in the presence of biological media.  
 
Table 3.4. Summary of estimated complex remaining from UV-visible data at 1:1 DMSO:assay agent at 
15 minutes and 24 h where Citric Acid, EDTA, L-Cys, L-His, L-Met and GSH were in MilliQ water. 
 
  Tests were carried out at room temperature at 100 μM in a 1:1 DMSO: assay solution 
to ensure sufficient solubility and at a concentration providing detectable fluorescence.  
Stability of the allyl-derivatised copper complexes in solution was previously observed 
in solution but only some very preliminary studies were undertaken prior to this 






DMSO 89.1 88.3 
H2O 72.2 63.1 
PBS 80.3 65.3 
5% FCS, MEM 92.1 92.4 
SFM, MEM 67.9 47.3 
Citric Acid 83.2 79.0 
EDTA 69.5 55.9 
L-Cys 82.4 81.9 
L-His 69.2 68.4 
L-Met 61.1 32.7 
GSH 91.0 59.1 






 This investigation utilised both UV-visible absorption (at 10 M and at 100 
M) and fluorescence emission at 100 M, with 1:1 DMSO:challanger to limit 
precipitation.   
 
This allowed a % stability to be estimated via UV-Visible spectroscopy at 15 minutes 
and 24 hours as calculated by (100 % - percentage converted to free ligand) (Table 3.4).  
The first assays carried out in DMSO, water, PBS, 5% FCS EMEM and SFM EMEM 


















 1d, MilliQ water, 15 mins
 1d, MilliQ water, 24 hours
 id, MilliQ water, 15 mins
 iid, MilliQ water, 15 mins



















 1d, in MilliQ water, 15 mins
 1d, in MilliQ water, 24 hours
 id, in MilliQ water, 15 mins
 iid, in MilliQ water,15 mins
 
Figure 3.11. Water assays (50% DMSO, 50% water) for compound 1d at 100 µM, by fluorescence 




    The zinc complex 1d, demonstrated very good stability in each solvent with 88.3 %, 
63.1 %, 65.3 % 92.4 % and 47.3 % estimated complex remaining after 24h in DMSO, 
water, PBS, 5% FCS EMEM and SFM EMEM respectively (Appendix Figures D.1-3).  
Whilst displaying encouraging results in DMSO, water and 5% FCS complex (88.2 %, 
39.6 % and 79.1 % after 24 h respectively) (Figures 3.11 and Appendix Figures D.1-3).  
The stability of the complexes was tested against Eagle’s Minimum Essential Medium 
Serum Free Medium (SFM), which complexes are often incubated in for cell imaging. 
 
  As may be expected a decrease in fluorescence was observed with time, when complex 
1d was assayed with DMSO, and SFM. Conversely, when assayed with FCS and PBS 
the complex showed an increase in fluorescence emission at ca. 450 nm and 460 nm 
(Appendix Figures D.1-9).  This could suggest an interaction with the media perhaps via 
binding to a component of the solvent for example a protein within serum or phosphate 
respectively. Binding of an anion such as a phosphate, however would result in a small 
shift in absorbance, which was not observed in either case.
144
 Nevertheless, the 
fluorescence observed with each solvent (above) was significantly greater than that of 
the proligands, this combined with the presence of the characteristic UV-vis band of the 





3.7.1 Investigation testing stability using biologically relevant agents 
 
  Biologically relevant agents were chosen to provide a better insight into the stability of 
these complexes (Figure 3.12).
145
  For example, L-methionine and L-cysteine can act as 
S-donor models and L-Histidine as a N-donor model.  Furthermore glutathione, a 
tripeptide containing glycine, cysteine and glutamate can function as both an S- and N- 
model.  Moreover, cysteine and GSH via the thiol have potential to reduce the metal, 
which would likely result in decomplexation.  Citric acid can act as a weak organic acid 
in addition to as a chelating agent, with possibility to form salts such as gallium or 
indium citrate.  In addition EDTA, also a chelator was tested for its ability to 
demetallate zinc, gallium and indium complexes. 
 
 
Figure 3.12. Structures of biologically relevant assay agents used hereby. 
 
  Complexes were tested in the presence of 2 equivalents of citric acid, L-methionine, 
Glutathione (GSH), L-cysteine, L-histidine, and EDTA. Zinc complex 1d displayed an 
increase in fluorescence and no significant shift in λmax in each scenario under each of 
these conditions at 100 µM, which is indicative of stability, since the proligands possess 




























 1d, Citric Acid, in MilliQ water, 15 mins
 1d, Citric Acid, in MilliQ water, 24 hours
 id, Citric Acid, in MilliQ water, 15 mins
 iid, Citric Acid, in MilliQ water, 15 mins
 



















 1d, Citric Acid, in MilliQ water, 15 mins
 1d, Citric Acid, in MilliQ water, 24 hours
 id, Citric Acid, in MilliQ water, 15 mins
 iid, Citric Acid, in MilliQ water, 15 mins
 
Figure 3.13. Citric acid assays (50% DMSO, 50% water, 2 eq of citric acid) for compound 1d at 100 µM, 























 1d, EDTA in MilliQ water, 15 mins
 1d, EDTA in MilliQ water, 24 hours
 id, EDTA in MilliQ water,15 mins
 iid, EDTA in MilliQ water, 15 mins
 
 



















 1d, EDTA in MilliQ water, 15 mins
 1d, EDTA in MilliQ water, 24 hours
 id, EDTA in MilliQ water,15 mins
 iid, EDTA in MilliQ water, 15 mins
 
Figure 3.14. EDTA assays (50% DMSO, 50% water, 2 eq of EDTA) for compound 1d at 100 µM, by 
fluorescence spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room 
temperature. 
 
The characteristic spectrum of Compound 1d was observed when assayed with each 
agent with the exception of EDTA, therefore allowing speculation that zinc leaves the 
bis(thiosemicarbazonato) ligand in preference for chelation by EDTA (Figure 3.14). 
Conversely 1d in EDTA solution possessed notable absorbance at 478 nm at 24 h where 




zinc complex can therefore be considered most likely stable under these conditions 
tested. 
3.7.2 pH stability estimation 
 The stability of complexes at biologically relevant pH is an important factor in this 
study.  Cancer cells are slightly more acidic than non-cancerous cells, therefore it is 
important that the molecular probes are stable at lower pH.
146
  All fluorescence scans 
were carried out with an excitation wavelength of 400 nm and at a concentration of 100 
μM, with a 1:1 DMSO:buffer solution.146 The stability of complexes at biologically 
relevant pH is an important factor in this study.  
Following the above preliminary study allyl-substituted compounds were selected 
as a representative of the other functionality to assess the stability of newly 
synthesised gallium and indium complexes using UV-visible and fluorescence 
spectroscopy both at 15 minutes and 24 hours, with 1:1 DMSO:buffer solution. The 
pH of the samples was measured and found to have no significant difference to the 
blank, however with a notable variance from that of the original pH solution in each 
case (Appendix Table D.1.).   
 
 
Figure 3.15. Fluorescence spectroscopy buffer assay 1c pH study where: pH 2 > pH 3 > pH 5 > pH 9 ≥ 
pH 7 > pH 9.4 ≥ pH 10 ≥ pH 1.1 
 
Complex 1d displayed the best stability in neutral solutions, with dissociation more 
likely under acidic conditions, which is consistent with data acquired in the MChem 
thesis of Brett Kennedy
6

































complex, however showed the most intense fluorescence using weakly acid buffers 
of pH 5 and pH 3 (Figure 3.16). 
 
 
Figure 3.16. Fluorescence spectroscopy buffer assay 2c pH study where: pH 5 > pH 3 > pH 7 ≥ pH 9 > 
pH 9.4 > pH 1.1 ≥ pH 2 > pH 10. 
  
  In a pH 1.1 and pH 2.0 buffer the UV-visible and fluorescence spectra of complex 1d 
closely resembled that of iid, indicating that most of the complex had decomposed to 
form the proligand (Figure 3.17, Appendix Figures D.50 and D.51).  After 24 hours 
however, the complex appeared to have decomposed entirely since the absorption 
spectra resemble neither iid nor id. Within the pH 3 buffer the absorbance and emission 
of 1d decreased with a blueshift ca. 5 nm in the fluorescence spectrum after 24 h, 
suggesting some conversion to the bis-substituted ligand, yet with a significant 
proportion of the complex remaining. 
 
When assayed with a Sodium phosphate Monobasic / Sodium phosphate Dibasic based 
pH 7 buffer, the UV-visible spectrum of 1d at both 15 minutes and 24 hours was similar 
to that of iid implying that most of the complex has formed the ligand precursor (Figure 
3.17).  Conversely 1d displayed significantly higher fluorescence than iid, suggesting 
that some complex was still remaining.  Furthermore it is unlikely that the complex has 
poor stability at this pH due to the data acquired for SFM (pH 7.0 – 7.4) and PBS (pH 
7.4).  It therefore is more probable that the apparent decomposition of 1d was due to 

































Figure 3.17. Buffer assays (50% DMSO, 50% water, pH 1.1 buffer, blank measured pH 1.6) for 
compound 1d at 100 µM by fluorescence spectroscopy (above)  and UV/Vis (below) monitored at 15 
minutes at room temperature.  
 
  Meanwhile, in buffers of pH 5, pH 9 and pH 10 complex 1d showed an increase in 
fluorescence intensity after 24 h incubation, with a decrease in absorbance, but no shift 
in either absorption or emission spectra indicating good stability of this complex in 
these buffers.  It can therefore be considered from this study that zinc complex 1d is 
stable within the range of pH 4.4 and pH 12.7 (the measured pH of buffer:DMSO 1:1 
for buffers of pH 3.0 and pH 10.0). This indicates that the complex is stable over a very 
broad range of pHs in a biological capacity, with complex presence as long as after 24 h 






















 1d, pH 1.1 buffer, 15 mins
 1d, pH 2.0 buffer, 15 mins
 1d, pH 3.0 buffer, 15 mins
 1d, pH 5.0 buffer, 15 mins
 1d, pH 7.0 buffer, 15 mins
 1d, pH 9.0 buffer, 15 mins
 1d, pH 10.0 buffer, 15 mins





















 1d, pH 1.1 buffer, 15 mins
 1d, pH 2.0 buffer, 15 mins
 1d, pH 3.0 buffer, 15 mins
 1d, pH 5.0 buffer, 15 mins
 1d, pH 7.0 buffer, 15 mins
 1d, pH 9.0 buffer, 15 mins




3.7.3 Two-photon fluorescence lifetime investigations 
 
The two-photon investigations were first introduced in Chapter 2 and all studies were 
performed at the Rutherford Appleton Laboratory under the supervision of Dr S. 
Botchway. Zinc complexes 1b-d were tested in both DMSO and in cells.  In solution, 
1b was found to possess a fluorescence lifetime with 2 components, at 810 nm the 
lifetime of the major component was 0.261 ns and representative of 98.2% of the 
lifetime, with the minor component 0.597 ns at 10 mM (χ2 = 1.52). This was highly 
comparable to the single exponential decay with the excitation wavelength of 910 nm, 
0.275 ns, with a χ2 of 1.25.  Furthermore, at 910 nm the phenyl- and allyl-substituted 
complexes possessed similar major component lifetimes of 0.30 ns and 0.28 ns 
respectively in solution. 
 
  If the complex were to demetallate within cells there could potentially be four 
components, two corresponding to the free ligand and two representing the complex.  
The long component (ca. 2.5 ns) of the bis(substituted) proligands which was often 
observed in HeLa and PC-3 cells is significantly different to the short major component 
and long minor component of the zinc complexes and would therefore allow facile 
resolution.  Moreover, the amount of data necessary to enable resolution of the short 
components (in solution ca. 0.2 ns and 0.28 ns for ligand and complex respectively) to 
be sufficiently spaced would require acquisition times of many minutes.  It would be 
possible however, to evaluate dissociation modelling the analysis to up to two decays 
only, compiling the longer and shorter components, with the longer providing insight 





a)   
b)  
Figure 3.18. a) Two-photon fluorescence lifetime map (τm) of compound 1b incubated in HeLa cells b) is 
the distribution curve of the τm where the colour represents the lifetime of a). 
 
When 1b was incubated in cancer cells (Figure 3.18a) the lifetime observed at 910 nm 
was 0.217 ns, 0.098 ns FWHM (major component) and 0.505 ns, 0.821 ns (minor 
component), which was very close to and within the FWHM of what was observed in 
solution. When excited at 810 nm, the lifetimes were 0.152 ns, 0.093 ns FWHM and 
0.433 ns, 0.625 ns FWHM major and minor components respectively.  This indicates 
that in cells the lifetime was not significantly different (within the FWHM) when 





















excited by the two respective wavelengths.  Moreover the lifetimes observed in cells at 
910 nm and 810 nm closely matched data acquired for compound 1b at 10 mM, 810 nm 
excitation, importantly so in the case of the minor component of ca. 0.5 ns.  
Furthermore, the lifetimes in solution of 1c and 1d, for example 0.302 ns and 0.283 ns 
for the corresponding compound, were similar to those observed in cells 0.284 ns (0.087 
ns FWHM) and 0.266 ns (0.146 ns FWHM) respectively. 
 
  In cells the major components of these zinc complexes were all short (in the region of 
0.15 to 0.28) and their respective long components were either less than 1.5 ns or not 
present, this is highly indicative that no significant portion of the zinc complexes have 
dissociated to free ligand for which the long component would be far in excess of this 
value (1.5 ns).  These data, therefore are in strong support of the stability of this family 
of zinc complexes, especially due to the high correlation between the lifetime in 
solution and in cells, including the second component, which not comparable with the 
very long component observed for the free ligand. 
 
  Copper complexes tested in solution and in cells (50 μM, 0.5 % DMSO, 3 h incubation) 
showed very similar τ1 values confirming their stability under these conditions (Figure 
3.19).  The major component observed both in DMSO solution and in cells was in the 
region of 0.3 ns for 2c and 2d was a minor component that was not observable within 
the cell, of ca. 1 – 1.9 ns, perhaps suggesting a preference for the major conformation 
within the cell.  As was discussed regarding the zinc complex data, the presence of a 




a)    
 
b)  
Figure 3.19. a) Two-photon fluorescence lifetime map (τm) of 2c in HeLa cells with excitation at 910 nm 
b) is the distribution curve of the τm where the colour represents the lifetime of a). 
 
Therefore, since there was no presence of a long component in any significant 
proportion when complex 2c was incubated in cells it can be considered that little 
demetallation has occurred. Furthermore, due to the high correlation between solution 
and cell data these investigations signify that the copper complexes are stable within 
cells and the timeframe of these experiments. 




















3.8 Laser scanning confocal microscopy 
  
 Cells were cultured using standard protocols, analogous with earlier investigations of 
fluorescent thiosemicarbazones. Cell viability prior to experiments and over the course 
of experiments was monitored by optical microscopy, and validated at the start of the 
experiments by standard trypan blue tests and MTT assays.
127, 128
 Complexes were 
imaged in HeLa (cervical carcinoma), PC-3 (prostate carcinoma), MCF-7 (breast cancer) 
and FEK-4 (non-cancerous fibroblast) cell lines, cultured as described in the 
Experimental section by confocal fluorescence microscopy using one photon excitation 
at 488 nm with the emission long-pass filtered at 515 nm.  
 
  The imaging studies were performed using concentrations of 50 µM compound in a 
DMSO: RPMI 0.5:99.5 cell medium solvent mix, (RPMI = Royal Park Memorial 
Institute), whereby the final DMSO concentration on the imaging plate was lower than 
1%. It was found that complexes 1b-1d yielded near-identical results to each other 
under analogous conditions yet displayed significantly different uptake to Zn[ATSM], 
which had notable uptake in the nucleoli.
62
 The consistently higher fluorescence 
intensity of the zinc complexes 1b-1d allowed the procedure to be optimised for better 
comparisons with the respective free ligand and indication of stability. It was found that 
concentrations of 50 μM and incubation times of 20 minutes could be used, which had 
previously been predominantly 100 μM, with longer incubations. An interesting effect 
was observed when incubating HeLa cells with complex 1c, a significant phototoxicity 
could be observed with cell health visibly diminishing after 15 minutes and was not 





a)      b) 
 
c)      d) 
Figure 3.20. Single-photon laser scanning confocal microscopy of 1c, 50 μM, 0.5% in HeLa cells before 
irradiation (a – b) and after 15 minutes of irradiation (c – d). Where (a) and (c) are the DIC channel land 
(b) and (d) are the fluorescence micrograph of with excitation at 488 nm. 
 
  Copper complexes were initially incubated for longer periods of time of 2 hours to 
ensure uptake. To investigate the mechanism of uptake copper complex 2b, the 




C, whereby if uptake was 
only observed at 37
 o
C it would be highly suggestive that the complex enters the cell by 
an active means (Figure 3.21).
147
 The experiment showed that uptake occurred under 
both conditions and it can therefore be considered as entering by passive diffusion.  The 
fluorescence was slightly less intense at 4 
o
C, which could be explained by a lower rate 






a)    b)            c)     
 
d)    f)            g) 
Figure 3.21. Confocal microscopy of HeLa cells incubated with 2b at 100 μM for 3h.  (a - c) represents 
an incubation at 37 ˚C and (d – g) at 4 ˚C, where (a, d) is an overlay of (b, e) the DIC image and of (c, f) 
the micrograph with excitation at 488 nm. 
 
3.9 In vivo imaging 
 
  Normoxic PC-3 xenografts were grown on the right shoulder of nude mice in 
Memorial Sloan-Kettering Cancer Center (MSKCC), New York by Dr Brian Zeglis. M 
= 64Cu, R = Et and Ph were labelled from their respective precursor in ethanol achieving 
high radiochemical yield by a 5 minute microwave-assisted reaction, followed by semi-
preparative HPLC purification. MicroPET and biodistribution data collection were 
carried out for 64Cu these complexes at MSKCC by Zeglis and Pascu. Welsh et al. 
investigated the biodistribution of 64Cu [ATSM] in 1998. After 40 minutes, Welsh and 
co-workers found significant radioactivity in non-target organs of the lungs, liver, 
spleen, kidney and intestines, with uptake in the hypoxic tumour (4.17 %ID/g ± 1.03 




2b and 2c were 0.34 %ID/g ± 0.04 SD and 0.44 %ID/g ± 0.18 SD respectively (Figures 
3.22 and 3.23). It is desirable that retention within normoxic tumours is low, since it 
would allow a hypoxic tumour to be distinguished more readily.  
 
 
Figure 3.22. Biodistribution study in nude mice, of 2b. 
 
 
a)      b)         c)            d)   e) 
Figure 3.23. MicroPET images of in nude mice, 2b, where (a), (b), (c) (d) and (e) are at timepoints  1h, 
3h, 6h, 12 h and 24 h respectively.   
 
  Furthermore, non-target organ uptake of compounds 2b and 2c was lower when 
compared to 64Cu[ATSM] in the liver, kidneys, brain, heart, intestines, bone and in the 
blood. Retention levels in the lung were comparable (19.17 %ID/g ± 6.55 SD, 23.33 
%ID/g ± 7.73 SD, respectively) and biodistribution of compound 2b was similar to that 
of Cu[ATSM] in the spleen.  Spleen uptake levels of phenyl-substituted copper-64 
labelled complex were the only non-target organ with significantly higher uptake than 












64Cu Biodistribution of R = Et complex













64Cu Biodistribution of R = Et complex




clearance was observed, therefore the reduced uptake within vital organs combined with 
limited retention in the normoxic tumour represents promising results for probes 
designed for hypoxia selectivity  
 
3.10 Summary to Chapter 3 
 
  Zinc and copper bis(thiosemicarbazonato) complexes were synthesised and 
characterised in this study.  New crystallographic and computational data were acquired 
for the phenyl-substituted complexes, with X-ray diffraction results compared to those 
of different functionality, showing interesting differences in structure.  Furthermore, 
DFT calculations allowed insight into the isomeric exchange observed in solution by 
NMR spectroscopy for 1c, as well as for paramagnetic 2c, each indicating that in 
solution the symmetric isomer was more stable. The kinetic stability of these complexes 
was demonstrated in solution and importantly in cells.  Moreover complexes 2b and 2c 
were radiolabelled with 
64
Cu and assessed in vivo displaying limited tumour uptake in 
nude mice under normoxic conditions, indicating that a thorough study of hypoxic 
selectivity of these complexes could prove useful.  If significantly better uptake is 
observable in hypoxic cells, the copper complexes possess potential as PET molecular 




Chapter 4. Synthesis, characterisation, spectroscopic, in vitro and in 
vivo analysis of gallium bis(thiosemicarbazonato) complexes  
 
  Despite the majority of copper bis(thiosemicarbazonato) complex studies focussing on 
their hypoxia selectivity these complexes are receiving growing interest as bifunctional 
chelators (discussed in greater detail in Chapters 1 and 2).  However, there remains high 
liver uptake of the copper complex in vivo, with attempts to lower uptake by introducing 
hydrophilic groups on the exocyclic structure having some, yet limited success.
67
  
Therefore, another method of reducing liver accumulation is by way of using 
gallium(III) and indium(III) (vide infra, Chapter 5) complexes. Gallium complexes hold 
potential for the development of new molecular imaging probes largely due to the 
readily available 
68
Ga positron emitting radioisotope that is generated from 
68
Ge and 
therefore does not require a nearby cyclotron.  Therefore the aim of this chapter was to 
synthesise new intrinsically fluorescent gallium complexes that could act as agents 
capable of detecting cancer, whilst understanding their physical and chemical properties 
in solution, in vitro and in vivo.    
 
4.1. Gallium complex synthesis 
 
 
Figure 4.1. Synthesis of acenaphthenequinone gallium bis(thiosemicarbazones) 
 
  Transmetallation served as a reliable, rapid and clean means of synthesising the 
gallium complex by the following method. The acenaphthenequinone gallium(III) 
chloride bis(thiosemicarbazone) complexes was successfully synthesised by reflux in 
methanol in excess of GaCl3 for 20 minutes, with 5 equivalents of GaCl3 sufficient 
when refluxed for 6 hours (Figure 4.1).  Methyl, ethyl, phenyl and allyl analogues were 
prepared using this method and isolated by filtration after reaching room temperature as 
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orange-red powders in moderate yield (36% to 67%).  Characterisation proceeded by 
NMR spectroscopy, ES-MS and X-ray crystallography. Crystals suitable for X-ray 
crystallography for each of these compounds were grown by vapour diffusion method 
of THF:Hexane and the molecular structure proved the connectivity of ligand to the [Ga 




 at m/z = 
458.96, 484.99 and 580.99, 502.94 and 508.99 for 3a, 3b, 3c, 3d respectively, all values 
being within 0.1% error of those calculated.   
 
4.1.1 NMR spectroscopy 
  Studies in the group had indicated that the 1d complex displays a dynamic    
equilibrium between a symmetric and an asymmetric isomer in solution.
127, 128
 This is 
strongly shifted towards an asymmetric conformation when wet DMSO was bound, or 
in the presence of DABCO or bipy. 
1
H NMR spectroscopy of 3a-d showed similar 
splitting of proton resonances between an asymmetric and a symmetric form. 
Proportions of the different isomers were calculated by comparing the integrations of 
the H-3 or H-1 resonances for both isomers, which appear as two distinct (1H) doublets 
for the asymmetric version and a single (2H) doublet for the symmetric isomer (Figure 
4.2) and (Table 4.1).  
 
Table 4.1. Proportions of symmetric and asymmetric isomers in the gallium complexes. 























Figure 4.2 shows the splitting of 
1
H resonances in the aromatic region for the 3a 







Figure 4.2. The proton numbering of complex 3a (above), 
1
H NMR spectroscopy of complex 3a, where 
green indicates the (E,E) isomer and red indicates the (E,Z) isomer (below). 
 
The methyl signals around 3.10-3.16 ppm, displayed interesting feature. The groups are 
represented as doublets due to the proximity of exocyclic NHs, therefore, if there were a 
mixture of symmetric and asymmetric only three doublets would be expected rather 
than the four that appear in this spectrum.  Furthermore, using the approximate ratio of 
the number of expected protons of 1.9:2.5 a total integration of 13.5 would be expected 
for these methyl groups. Yet, an integral of 14.5 is observed, therefore it is possible that 
there are in fact 3 species: 2 symmetric and 1 asymmetric, where the abnormal 





 (Figures 4.3 and 4.4). The isomerism was investigated 
further by VT-NMR spectroscopy to identify possible isomers and their equilibrium 


















H NMR spectroscopy of 3a complex δ 3-3.3 ppm. In red, the asymmetric shifts, in green the 
symmetric resonances and in blue the third possible isomer. 
 
 ~ 52 %                   ~ 43 %                   ~ 5% 
Figure 4.4. Proposed isomeric exchange for the gallium methyl complex 
 
3b presented proportions of the symmetric and asymmetric isomer that were calculated 
as 49% and 51% respectively.  The calculated integral for the CH3(Et) groups would be 
ca. 12.2H and for the CH2(Et) groups ca. 8.1H, which is close to the actual integrals of 
12.1H and 8.4H respectively. The resonances overlap significantly and are likely due to 
the expected 3 overlapping triplets for the CH3 and 3 doublets of doublets. 
 
For 3c, the proportions of asymmetric isomer appeared low, as demonstrated by the 
features observed in the 
1
H NMR spectroscopy (Figure 4.5). It was however difficult to 
estimate the actual proportion, which is about 25% of asymmetric isomer. This was due 
to overlapping and poor resolution of the asymmetric signals, only those corresponding 











H NMR (300 MHz, d6-DMSO) spectroscopy of  complex 3c.  
 
  Moreover, complex 3d  displayed both the asymetric and symetric isomers with a  
ratio of  2:1 asymmetric:symmetric.Interestingly, the integral of the CH2 group is 6H, 
which is what would be expected as calibrated below, appears as two overlapping 





H NMR (300 MHz, d6-DMSO) spectroscopy of  complex 3c.(expansion: δ 4.0-4.5 ppm). 
 


















  Zinc precursors and free ligand were radiolabelled under the supervison of Prof Eric 
Aboagye by Frazer Twyman at Hammersmith Hospital, London (Figure 4.7 and 
Appendix Figures B.6-8).  A 
68
Ga generator was used to elute 10 mL of 0.1 M HCl, ca. 
6 mCi of 
68
Ga, which was trapped on a 30 mg/1 mL Strata X-C cartridge and eluted 
with 700 µL of 0.02 M HCl (98% acetone). This was subsequently dried for 15 minutes 
under a nitrogen stream at 110°C. Next the of bis(thiosemicarbazonato) compound was 
added in dry DMSO (2 mg/mL) and 2 mL of injectable ethanol. This was heated at 90
 
o
C for 30 minutes and injected into a radio-HPLC. Conversion to the respective gallium 
complex occurred rapidly (within 30 minutes), however with remaining 
68
GaCl3 
indicating that radiolabelling had not gone to completion. 
  
 
Figure 4.7. Overlay of UV-HPLC trace (black) of aromatic zinc bis(thiosemicarbazonato) precursor 1d 
(R = allyl) with the radio-HPLC trace (blue) of aromatic 
68
GaCl bis(thiosemicarbazonato) complex.  
 
  Radiolabelling with the zinc complex via transmetallation was successful showing 
highly comparable data when considering the UV-HPLC spectrum of the ‘cold’ gallium 
compound and the Radio-HPLC of the ‘hot’ Ga-68 complex. The process was made 
more efficient using microwave-assisted reactivity with the Lewis group in the 
Memorial Sloan-Kettering Cancer Center, New York, for the radiolabelling of 3b with 
the achievement of >95% radiochemical yield in ethanol. 








































4.3 Structural studies 
4.3.1 Crystallographic analyses  
  Crystal structures of 3a-d have been obtained and were grown in THF:hexane or 
THF:pentane either by standard liquid diffusion or gas diffusion methods, with the 
crystals of 3d grown by Dr. Phillip A. Waghorn (Figures 4.8-10).  In agreement with 
the NMR spectroscopy 3c was solved as a symmetric structure, whereas 3b and 3d were 
asymmetric, interestingly 3a displayed the symmetric and asymmetric form within the 
same asymmetric unit. It is noticeable that all symmetric compounds possess a plane of 
symmetry across the backbone and symmetric binding to the metal, yet the terminal 
functionalities (Me, Ph and Allyl) are not symmetric.  All complexes display a distorted 
square pyramidal structure around the metal centre with the Cl in the axial position with 




Figure 4.8. Ellipsoids drawn at 30% probability. Hydrogens omitted for clarity. For 3a two molecules 
(left) 3a and (right) 3a' were present in the asymmetric unit, only one is represented here.  
 
  It was notable in Reference 127 that
 
the C-C bond (C3-C14 of 3a, C1-C2 of 3b, C8-
C19 of 3c and C2-C3 of 3d) of asymmetric zinc compounds are longer than for 
symmetric nickel complexes.  However, there was no significant difference in bond 
length when varying the substituent group indicating that the previously observed 
pattern is most likely metal-dependant rather than isomer-based. Furthermore, the 
fortuitous occurrence of 3a demonstrating both the symmetric and the asymmetric 
isomer in the same asymmetric unit allow for more facile comparisons between the 
isomers to be made. 
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Table 4.2. Selected bond lengths (Å) and bond angles (°) for compounds 3a-3d, determined by X-ray 
diffraction.  
 
  The M-S(1) and M-S(2) bond lengths are different for all asymmetric complexes 
whereas, for symmetric 3c both M-S bonds are similar.  Furthermore, where the bond 
angles for S-M-N are dissimilar for asymmetric complexes they are similar for all 
symmetric complexes. It is also noticeable that both Ga-(N) bonds are shorter for the 
asymmetric 3a than for both other symmetric gallium compound.  Interestingly, the N-
M-Cl bond angle of the (E,Z) isomer of complex 3a, 106.5(4)°, is larger than that of the 
(E,E) isomer, 102.2(7)°. Moreover the same angle of the 3a (E,Z) isomer is equivalent 
to that of the (E,Z) isomers of 3b and 3d, indicating that the increase in this angle is 



























M-Cl 2.415(5) 2.2121(19) 2.2121(19) 2.230(3) 2.2096(14) 2.237(6) 
M-N 2.0538(15) 2.004(6) 2.004(6) 2.028(11) 2.069(4) 2.033(15) 
 2.0638(15) 1.924(11) 2.13(3) 1.947(11) 2.075(4) 1.926(16) 
M-S 2.3009(5) 2.302(2) 2.302(2) 2.282(3) 2.3130(16) 2.262(6) 
 2.3065(5) 2.17(2) 2.537(9) 2.474(4) 2.3171(15) 2.528(6) 
C-C 1.483(2) 1.468(12) 1.468(12) 1.469(18) 1.488(6) 1.480(2) 
N-N 1.363(2) 1.332(9) 1.332(9) 1.278(14) 1.372(5) 1.360(2) 
 1.367(2) 1.32(5) 1.39(3) 1.340(15) 1.371(5) 1.380(2) 
C=N 1.300(2) 1.356(9) 1.356(9) 1.394(16) 1.383(7) 1.30(2) 
 1.292(2) 1.30(3) 1.37(2) 1.307(16) 1.369(7) 1.30(2) 
S-M-S 105.25(5) 107.1(3) 103.96(19) 106.38(13) 105.11(5) 104.8(2) 
S-M-N 82.47(4) 83.5(2) 83.5(2) 84.4(3) 81.42(12) 84.9(5) 
 82.19(5) 84.0(8) 67.2(5) 68.0(3) 81.43(11) 68.1(1) 
N-M-N 76.09(6) 94.1(7) 67.2(4) 88.4(5) 77.33(15) 68.0(5) 
S-M-Cl 105.13(2) 108.34(8) 108.34(8) 106.7(1) 108.56(6) 109.06(5) 
 108.891(19) 111.0(5) 101.1(2) 102.6(1) 108.38(6) 102.14(6) 
N-M-Cl 99.31(5) 99.3(2) 99.3(2) 98.8(3) 99.7(1) 101.72(14) 
 101.45(4) 102.2(7) 106.5(4) 107.1(4) 98.4(1) 106.84(14) 
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identified an asymmetric binding mode of the ligand compared to the structures 
obtained for the aliphatic compound.  
 
 
Figure 4.9. ORTEP representation of 3b, ellipsoids drawn at 30% probability. Hydrogen atoms were 
omitted for clarity.  
 
 
Figure 4.10. ORTEP representation of 3c, ellipsoids drawn at 30% probability. Hydrogens were omitted 
for clarity. For 3c two molecules were present in the asymmetric unit, only one is represented here. 
 
  For 3a, X-ray structure determination further showed that both symmetric and 
asymmetric binding modes were possible for this class of Ga(III) compounds supporting 
NMR spectroscopy analyses. All bond lengths and angles of 3a - 3d are within the 
range expected for this class of compounds, and close to those determined for their 
reported Zn(II) precursors.
127, 128
 It is likely that that the rigid backbone and tight control 
of the ligand bite angles by the presence of the aromatic naphthyl substituents in 
complexes 3a – 3d may account for the significantly higher kinetic stability of aromatic 
gallium complexes with respect to aliphatic analogues. This trend is consistent with 





4.3.2 DFT optimisations 
  To provide insight into isomeric exchange of the gallium complexes with the phenyl 
functionality the were optimised from their crystal structures, following the method 
used by Holland et al.
119
 Initially the compounds were optimised in the gas phase using 
B3LYP 6-31G(d,p), followed by B3LYP 6-31++ (d,p) IEFPCM, DMSO to obtain an 
optimised structure in solution (Figure 4.11). In the gas phase the calculated energy 
difference is 4.99 kJ mol
-1
, indicating that the asymmetric structure 3c’ is more stable 
than the symmetric structure 3c.  Likewise, when solvent effects were considered in 
DMSO, the symmetric structure was more energetically favourable when compared to 
the asymmetric (the energy difference is -4.34 kJ mol
-1
), which is in agreement with 
1
H-




Figure 4.11. Optimised in solution structures by B3LYP 6-31++ (d,p) IEFPCM, DMSO, where (above) is 
symmetric 3c and (below) is asymmetric 3c’. Where grey = carbon, white = hydrogen, blue = nitrogen, 




4.3.3 Variable temperature NMR spectroscopy  
 
  To investigate the isomerism further 3a was studied in d8-THF, by Variable 
Temperature -NMR spectroscopy (400 MHz) (Figures 4.12-13). Change in enthalpy, 
entropy and Gibbs free energy were calculated from the VT-NMR spectroscopy data 
using Van’t Hoff analysis and the equation: 
 








  Complex 3a displayed some observable fluxional behaviour in solution. Considering 
Figure 4.12, k is ratio of symmetric / asymmetric isomer at each temperature, i.e. the 
equilibrium from asymmetric to symmetric isomer. H was calculated to be -3626.65 
J/mol, whilst S equals -12.0412 J/K/mol, with G at 298 K calculated as -38.3824 




Figure 4.12. Proposed isomeric exchange for the aromatic bis(thiosemicarbazone) complexes studies 
hereby where M = Zn, Cu, Ga or In, R = Me, Et, Ph or allyl, X = DMSO, THF, DABCO, bipy, and K is 




     
Figure 4.13. 
1
H NMR spectroscopy showing resonances corresponding to 3a at 232.1 K, 245.3 K, 258.8 





Fluorescence spectroscopy was performed on DMSO solutions, using initial scans for 
excitation wavelengths between 200-800 nm. This provided information about the 
intrinsic fluorescence of the complexes and the corresponding em-max using solutions of 
100 M. Ranges of absorption and emission, which are important with regards to 
cytotoxicity assays and fluorescence imaging, were also assessed using the 2D contours 
as a guideline. Relevant cytotoxicity assays use absorbance readings at 570 nm, 
therefore there should be minimal or no excitation at this wavelength, which was true 
for all complexes except 3c (Figure 4.14b).   
 
Compounds generally emitted between 520 and 675 nm, whereas excitation mainly 
occurred between 250 and 570 nm (Table 4.3, Figure 4.14 and Appendix Figure C.2.  
All compounds displayed intrinsic fluorescence. em-max was found to vary for gallium 
complexes depending on the functionalities: 510 nm, 400 nm, 450 nm and 520 nm for 



















 232.1  245.3  258.8  299.9
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3a, 3b, 3c and 3d complexes respectively. Quantum yields were calculated using the 




Where Φ = quantum yield, D = integrated area under emission band, S = sample, A = 
absorbance of solution at excitation wavelength, R = reference, η = refractive index of 
solvent, I = maximum intensity of excitation band [Ru(bipy)3][PF6]2 in water was used 
as a reference, with a quantum yield of 0.042. Importantly, the quantum yields indicate 
sufficient fluorescence imaging in biological cells, with similar values for each gallium 
compound. 
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Compound ex-max / nm Excitation range / nm em-max / nm Emission range / nm Quantum Yield 
3a 410 250-560 551 495-685 0.11 
3b 500 250-570 556 500-685 0.19 
3c 450 250-610 599 550-740 0.08 






Figure 4.14. Excitation/emission map at 100 μM in DMSO of compound 3b (above) compound 3c 
(below) 
  















































































4.5 Kinetic stability testing in an aqueous environment 
 
  Gallium complexes 3a and 3c (Figures 4.15-4.16) had an unexpected intensity 
increase with time up to 8h.  The compounds remained fluorescent at 24h, but at a lower 
intensity than at 8h.  Preliminary assays with media in the absence of serum displayed a 
gradual decrease in fluorescence with time, which is consistent with the zinc complexes 
1d in serum and serum free media.  The difference between these two assay types is 
protein content, indicating that the gallium compounds likely interact with the protein.  
Interestingly, compound 3c showed that the fluorescence band maxima shifts from ca. 
590 nm at t = 0 h to ca. 530 nm at t = 2 h, indicating that the complex may bind to a 
component of the serum (Figure 4.16).   
 
  
Figure 4.15.  FCS stability assay by fluorescence spectroscopy for compound 3a in FCS: DMSO, 1: 1 
ratio 



















 t = 0
 t = 15 min
 t = 30 min
 t = 45 min
 t = 1 h
 t = 2 h
 t = 3 h
 t = 4 h
 t = 5 h
 t = 6 h
 t = 7 h
 t = 8 h




Figure 4.16. Fluorescence spectroscopy - FCS stability assay 3c FCS: DMSO 1: 1  
 
  Due to the significantly greater fluorescence of the gallium complexes in comparison 
to its respective proligand, fluorescence intensity observed is indicative of complex 
stability.  However, since the free ligand does possess some fluorescence, it is important 
to consider the UV-Visible spectra of complexes to confirm stability under these 
conditions.  In conjunction with a study allowing comparisons with [GaCl(ATSM)], 
which was found to form the corresponding ligand precursor within 5 minutes in 99% 
FCS, 1% DMSO, the gallium complex 3d was tested under analogous conditions 
(Figure 4.17).  
 
  Whilst changes in the UV/Vis spectra for the gallium complex 3d were observed 
over an incubation of 24 h in serum (Figure 4.17), it is apparent that the product of 
the assay has not completely converted to free ligand iid. UV/Vis spectroscopy 
studies on 3d suggested that little decomposition occurs up to 3 h although some 
deteriation of the gallium species is evident after 18 h with LCMS analysis at this 
time suggesting the presence of both the parent chloride complex and some of the 
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Figure 4.17. Serum assay (99% FCS, 1% DMSO) by UV/Vis for compounds 3d at 100 µM, monitored at 
time intervals up to 24h at room temperature and filtered using a 0.45 µm PTFE microfilter, Compound 




  This investigation utilised both UV-visible absorption (at 10 M and at 100 M) and 
fluorescence emission at 100 M, with 1:1 DMSO:[assay agent] to limit precipitation.  
This allowed a % stability to be estimated via UV-Visible spectroscopy at 15 minutes  
and 24 hours as calculated by (100 % - percentage converted to free ligand) (Table 4.4).  
The first assays carried out in DMSO, water, PBS, 5% FCS EMEM and SFM EMEM  
enabled complex stability to be understood in media likely to be encountered in a cell 
biology experiment.  UV-visible spectroscopy data for each of the above assays are 
described first, followed by the analysis of their corresponding fluorescence studies, 
which were carried out in parallel. 
 
  By UV-vis complex 3d displayed encouraging results in DMSO, water and 5% FCS 
(88.2 %, 39.6 % and 79.1 % after 24 h respectively) (Figures 4.17 and 4.20) complex 
3d was not stable during a 24 h incubation in PBS (Figure 4.18) or in SFM (Figure 4.19) 
and showed contrastingly high stability in SFM after 15 minutes (64.3 %) and limited 























 3d, 15 mins FCS
 3d, 1h FCS
 3d, 3 h FCS
 3d, 6h FCS
 3d, 24h FCS
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remaining complex in PBS (10.9% after 15 minutes.)  Moreover, 3d demonstrated 75.3 % 
estimated stability in DMSO:water 1:1 after 15 minutes, but with a significant decrease 
in absorbance representing 39.6 % remaining complex after 24 h. 
 
Table 4.4. Summary of estimated complex remaining from UV-visible data at 1:1 DMSO:biologically 
relevant agent at 15 minutes and 24 h where Citric Acid, EDTA, L-Cys, L-His, L-Met and GSH were in 
MilliQ water. 
 
  For the fluorescence spectra, there was no significant change in intensity of complex 
3d in DMSO over a period of 24 h, which had showed a small decrease in fluorescence 
for the zinc complex 1d (Appendix Figures D.11-15 and Chapter 3). Subsequently 
complexes were tested and compared to the ligand precursor iid in a 1:1 MilliQ 
water:DMSO solution over a period of 24 h (Figure 4.17).  Under these conditions the 
gallium complex displayed a significant decrease in fluorescence after 1 day of 
incubation and a blue shift in fluorescence maxima of 13 nm after 24 h from 559.5 nm 
at 15 mins, indicative of some conversion to free ligand (a λmax of 542 nm at 15 mins) 
(Figure 4.8).    The fluorescence intensity observed was sufficient to indicate the 
presence of some remaining gallium complex after 1 day, in agreement with UV-visible 
data.   






DMSO 92.1 88.2 
H2O 75.3 39.6 
PBS 10.9 NS 
5% FCS, MEM 75.4 79.1 
SFM, MEM 64.3 NS 
Citric Acid 80.0 NS 
EDTA 87.1 51.6 
L-Cys 80.0 51.1 
L-His 44.6 28.1 
L-Met 58.1 45.1 
GSH 52.8 7.7 






























 3d, MilliQ water, 15 mins
 3d, MilliQ water, 24 hours
 id, MilliQ water, 15 mins
 iid, MilliQ water, 15 mins
 




















 3d, in MilliQ water, 15 mins
 3d, in MilliQ water, 24 hours
 id, in MilliQ water, 15 mins
 iid, in MilliQ water,15 mins
 
Figure 4.18. Water assay (50% DMSO, 50% water) for compound 3d at 100 µM, by fluorescence 
spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room temperature. 
 
Fluorescence data in PBS were significantly weaker than in water, in combination with 
a blue shift in absorbance is indicative of decomposition into bis-substituted free ligand 
(Figures 4.17-4.18).  Most of the gallium complex appears to have become ligand 
within 15 minutes as confirmed by the estimated 10.9 % remaining complex calculated 
using UV-visible measurements and possessed very similar λmax of 537.5 nm for 3d at 





















 3d, PBS 15 mins
 3d, PBS 24 hours
 id, PBS 15 mins
 iid, PBS 15 mins


















 3d, PBS 15 mins
 3d, PBS 24 hours
 id, PBS 15 mins
 iid, PBS 15 mins
 
Figure 4.19. PBS assay (50% DMSO, 50% PBS) for compound 3d at 100 µM, by fluorescence 
spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room temperature. 
 
  The stability of the complexes was tested against Eagle’s Minimum Essential Medium 
Serum Free Medium (SFM), which complexes are often incubated in for cell imaging.  
The fluorescence of each complex decreases over the time period studied at the λmax, 
however complexes 1d and 3d interestingly show an increase in fluorescence at ca. 450 
nm and 460 nm (Figures 4.20-4.21).  This could suggest that a new species is being 
formed or interaction with the media perhaps via binding to a component of the solvent 
for example amino acids or glucose. The λmax of iid under these conditions is 531 nm 
indicating that the new band does not correspond to free ligand, however the λmax of id 























 3d SFM, 15 mins
 3d SFM, 24 hours
 id SFM, 15 mins
 iid SFM, 15 mins


















 3d SFM, 15 mins
 3d SFM, 24 hours
 id SFM, 15 mins
 iid SFM, 15 mins
 
Figure 4.20. EMEM SFM assay (50% DMSO, 50% SFM) for compound 3d at 100 µM, by fluorescence 
spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room temperature. 
 
  With λmax of 3d 536 and 537 nm at 15 minutes and 24 h respectively it is likely that a 
significant proportion of complex has rapidly become free ligand. An augmentation of 
absorbance and fluorescence was also observed in the case of complex 3d after 
incubation of 24 h and retaining a band in the UV-visible spectrum at ca. 500 nm not 
























 3d 5% FCS, 15 mins
 3d 5% FCS, 24 hours
 id 5% FCS, 15 mins
 iid 5% FCS, 15 mins



















 3d 5% FCS , 15 mins
 3d 5% FCS , 24 hours
 id 5% FCS, 15 mins
 iid 5% FCS, 15 mins
 
Figure 4.21. FCS assay (50% DMSO, 45% EMEM, 5% FCS) for compound 3d at 100 µM, by 
fluorescence spectroscopy (left) UV/Vis (right) monitored at time intervals up to 24h at room temperature. 
 
  This is not surprising since FCS is known to increase background absorbance; 
interestingly, there was no fluorescence increase at ca. 450 nm or 460 nm as was 
observed in the absence of serum. This shows that presence of FCS is significant with 
regards to interaction of media and likely causes formation of the zinc and gallium 




4.5.1 Stability assays to estimate kinetic stability against common 
biologically-relevant agents 
  Biologically relevant agents were chosen to provide a better insight into the stability of 
these complexes,
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 as were introduced in (Chapter 3).  Complexes were tested in 
presence of 2 equivalents of citric acid, L-methionine, Glutathione (GSH), L-cysteine, 
L-histidine, and EDTA. Complex 3d, however displayed less promising stability. In 
citric acid 3d demonstrated significantly reduced fluorescence and absorbance in milliQ 
water whereby the complex appears stable at 15 minutes, at 24 h both fluorescence and 
UV-visible spectra were not characteristic of the allyl functionalised gallium complex 
(Appendix Figure D.11).  When incubated in PBS and citric acid rapid conversion to 
free ligand was observable due to similarity of the 3d spectrum to distinctive absorption 
spectrum of iid under the same conditions (Figure 4.22).  
 
  Conversely it is apparent that the 3d UV-vis spectrum is not identical to iid at 15 
minutes, with significantly greater fluorescence at this timepoint showing that some 
gallium complex is remaining in PBS with citric acid.  It is likely that 3d has almost 
completely converted to iid after 24 h of incubation attributable to the comparable 
spectra.  In aqueous solutions of  L-methionine, L-cysteine, L-histidine, or EDTA, 3d 
displayed similar properties, each with the characteristic 3d absorbance spectrum at 15 
minutes followed by a significant decrease in absorbance at ca. 480 nm, but not the 
formation of data corresponding to that of the iid free ligand (Figures 4.23-4.24 and 



















 3d, Citric Acid, in PBS, 15 mins
 3d, Citric Acid, in PBS, 24 hours
 id, Citric Acid, in PBS, 15 mins
 iid, Citric Acid, in PBS, 15 mins






















 3d, Citric Acid, in PBS, 15 mins
 3d, Citric Acid, in PBS, 24 hours
 id, Citric Acid, in PBS, 15 mins
 iid, Citric Acid, in PBS, 15 mins
 
Figure 4.22. Citric acid assays (50% DMSO, 50% PBS, 2 eq of citric acid) for compound 3d at 100 µM, 
by fluorescence spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room 
temperature. 
 
  This combined with the greater fluorescence of 3d after 24 h incubation as compared 
with iid at 15 minutes is indicative that not all of the complex has formed free ligand.  
The 24 h spectrum of 3d in GSH is very similar to that of iid at 15 minutes, displaying a 
very similar absorbance spectrum, indicating that most of 3d has been converted to 




























 3d, EDTA in MilliQ water, 15 mins
 3d, EDTA in MilliQ water, 24 hours
 id, EDTA in MilliQ water,15 mins
 iid, EDTA in MilliQ water, 15 mins























 3d, EDTA in MilliQ water, 15 mins
 3d, EDTA in MilliQ water, 24 hours
 id, EDTA in MilliQ water,15 mins
 iid, EDTA in MilliQ water, 15 mins
 
Figure 4.23. EDTA assays (50% DMSO, 50% water, 2 eq of EDTA) for compound 3d at 100 µM, by 
fluorescence spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room 
temperature. 
 
  It can be observed that there is a much higher fluorescence intensity for 3d at 24h than 
for iid at 15 minutes, indicating that although most complex may have converted to free 
ligand, it is likely that not all of the complex has. In contrast to the data acquired for L-
cysteine, L-methionine and L-histidine, in which 3d appeared much more stable, it can 
be speculated that this combination of three peptides, containing both N- and S- groups 





















 3d, GSH challenge in MilliQ water, 15 mins
 3d, GSH challenge in MilliQ water, 24 hours
 id, GSH challenge in MilliQ water,15 mins
 iid, GSH challenge in MilliQ water, 15 mins


























 3d, GSH challenge in MilliQ water, 15 mins
 3d, GSH challenge in MilliQ water, 24 hours
 id, GSH challenge in MilliQ water,15 mins
 iid, GSH challenge in MilliQ water, 15 mins
 
Figure 4.24. Glutathione assays (50% DMSO, 50% water, 2 eq of Glutathione) for compound 3d at 100 
µM, by fluorescence spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room 
temperature. 
 
4.5.2 pH study 
 
  The stability of complexes at biologically relevant pH is an important factor in this 
study.  Cancer cells are slightly more acid than non-cancerous cells it is important that 
the molecular probes are stable at lower pH.
146
  All fluorescent scans were carried out 
with an excitation wavelength of 400 nm and at a concentration of 100 M, with a 1:1 
DMSO:buffer solution. An initial preliminary study was carried out using fluorescence 


































Figure 4.25. Fluorescence spectroscopy buffer assay 3b pH study (above). Where pH 2 >> pH 1.1 > pH 
9 > pH 7 > pH 3 ≥ pH 5> pH 10 > pH 9.4 and 3c pH study (below) Where pH 2 >> pH1.1 > pH 10 > pH 
3 > pH 9.4 > pH 9 > pH 5 ≥ pH 7  
 
  The gallium compounds all displayed maximum fluorescence at pH 2, with 
particularly intense fluorescence for 3a and 3b at this pH.  It is interesting to notice that 
3a and 3b are very fluorescent at pH 2, but very little fluorescent at pH 3.  This could be 
explained by the nature of the species involved in the buffer.  Buffer pH 2 contained 
HCl and KCl, whereas the pH 3, pH 5 and pH 7 buffers contained citric acid.  Holland 
et al. have recently shown that citric acid can be used to remove zinc from zinc 
bis(thiosemicarbazonato) complexes,
 148
 which may have happened in the preliminary 





























Table 4.5. Summary of UV-visible data at 50: 50 DMSO: pH buffer at 15 minutes and 24 h, where NS = 
not stable. 
 
Therefore an intial study where citric acid was used was carried out (prior to the assays 
described above) followed by another investigation that did not include citric acid as 
part of the buffer systems, a means to monitor if the nature of the buffer had a 
significant effect.  These gallium complexes are therefore very pH sensitive, for 
example, 3c is fluorescent at pH 1 and pH 2, indicating that it can readily  be protonated, 
but shows little fluorescence under more alkaline conditions (Figure 4.25). 
 
  Following the above preliminary study, the allyl-substituted compounds were selected 
as a representative of the other functionalities to assess the stability of newly 
synthesised gallium and indium complexes using UV-visible and fluorescence 
spectroscopy both at 15 minutes and 24 hours, with 1:1 DMSO:buffer solution with the 
assistance of Johan Stojanoviḉ, technician student from ESCOM, France. The pH of the 
samples was measured and found to have no significant difference to the blank, 
however with a notable variance from that of the original pH solution in each case 
(Table 4.5).   
 
  3d, 100 µM 
Buffer Measured pH % stability at 15 mins % stability at 24 h 
pH 1.1 1.6 68.6 NS 
pH 2 2.5 85.5 53.9 
pH 3 4.4 86.9 NS 
pH 5 6.9 73.7 51.7 
pH 7 9.4 5.0 NS 
pH 9 9.35 6.2 NS 




Figure 4.26. All buffer assays (50% DMSO, 50% water) for compound 3d at 100 µM by fluorescence 
spectroscopy (above)  and UV/Vis (below) monitored at 24 hours at room temperature. 
 
  Furthermore all gallium complexes (Figure 4.26 and Appendix Figures D.16, D.20-27) 
appeared most stable at either pH 2 or pH 3 after 15 minutes or less, which is also in 
agreement with data acquired where citric acid was a component of the buffer solutions.  
By UV-visible spectrometry compound 3d seems to decompose completely after 24 
hours when incubated in a pH 1.1 buffer, yet appears to remain intact at 15 minutes, as 
its spectrum has formed the shape characteristic of iid in this time, fluorescence 
however appears to be fully quenched at 15 minutes (proligand iid buffer study 
Appendix Figures D.50 and D.51).  It is likely that stability of the gallium complex is 
poor at this pH. In pH buffers 2.0, 3.0 and 5.0 there is complex presence indicated by 



















 3d, pH 1.1 buffer, 24 hours
 3d, pH 2.0 buffer, 24 hours
 3d, pH 3.0 buffer, 24 hours
 3d, pH 5.0 buffer, 24 hours
 3d, pH 7.0 buffer, 24 hours
 3d, pH 9.0 buffer, 24 hours
 3d, pH 10.0 buffer, 24 hours





















 3d, pH 1.1 buffer, 24 hours
 3d, pH 2.0 buffer, 24 hours
 3d, pH 3.0 buffer, 24 hours
 3d, pH 5.0 buffer, 24 hours
 3d, pH 7.0 buffer, 24 hours
 3d, pH 9.0 buffer, 24 hours
 3d, pH 10.0 buffer, 24 hours
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fluorescence intensity and absorbance including a blue shift for pH 3.0 and pH 5.0 
buffers are indicative of instability of this compound at longer incubations.   
 
  As was observed with 1d, 3d spectra closely resembled those of compound iid when 
incubated with a pH 7.0 buffer, however due to the high stability observed in the 5% 
FCS assay the apparent lack of stability could be explained by interaction with the 
components of the buffer rather than the pH itself.  When considering the measured pH 
of the pH 7.0 buffer blanks 1:1 DMSO:buffer is 9.4 (a Sodium phosphate Monobasic / 
Sodium phosphate Dibasic based buffer), as was the measured pH when incubating 
with the pH 9.0 buffer was pH 9.35 (a glycine / sodium hydroxide based buffer) and 
that spectra were comparable the most likely outcome is in fact that the complex has 
poor stability under alkaline conditions, which are seldom observed in a biological 
environment. 
 
  Whilst spectroscopic (fluorescence and UV-vis) data acquired with the pH 7.0 and pH 
9.0 buffers were similar, in both cases it was observable that conversion to iid was not 
complete, indicating a small proportion of complex remaining.  UV-visible and 
Fluorescence spectra of 3d when incubated with a pH 10.0 buffer (measured pH with 
blank pH 12.7) displayed spectra more closely resembling the free ligand iid, indicating 
that the stability was poorer under more alkaline conditions.  The range of good stability 
of this complex when considering the measured pH with the blank is pH 2.5 to pH 6.9, 
however under no conditions tested using the pH buffers was complete conversion to iid 
after 15 minutes, indicating that short-term experiments in biological environments are 
valid with this compound, especially with the stability observed after 24 h in 99% FCS 
for this complex, with a blank pH of 7.35. In summary the spectra acquired support the 
legitimacy carrying out cell uptake experiments, where incubations would be less than 




4.3 Two-photon fluorescence lifetime study 
 
  The two-photon investigations were first introduced in Chapter 2 and all studies were 
performed at the Rutherford Appleton Laboratory under the supervision of Dr S 
Botchway. Gallium complexes possessed two components in solution with 1 
comparable to the 1 of the ligand precursor under the same conditions, yet slightly 
longer for each complex.  The τ2, on the other hand was significantly lower at ca. 1 – 
1.5 ns (Appendix Figure E.3., Table E.5).  This combined with the stability study in 
solution using UV-vis and fluorescence signifies that this similarity is most likely due to 
the ligand-dependant nature of the fluorescence (Chapter 3) according to TD-DFT 
calculations carried out for the copper complex 2c, rather than decomposition to free 
ligand in solution.  The presence, therefore of a long component by FLIM in vitro of 
more than 2 ns may thus be the best indication of complex becoming proligand using 
this technique.   
 
  In cells when exciting at 910 nm results were similar to those observed within solution 
for all major components, and most minor components under standard conditions.  
Gallium complexes were incubated at 50 μM, 0.5% DMSO, for 20 minutes, unless 
stated otherwise in the text. The 2 (minor component) are highly comparable to the 
lifetimes observed for the free ligand 3a HeLa (0.588 ns, 0.406 ns FWHM), 3b PC-3 
(0.475 ns, 0.094 ns, FWHM) and 3c MCF-7 (0.567ns, 0.228 ns FWHM), for example 
the major component of iic at 910 nm was 0.531 ns, 0.508 ns FWHM.  Equally, this 
could signify some conversion to free ligand 4%, 8% and 20% respectively) or that the 
gallium complex forms similar interactions for the cell as its ligand counterpart.  
 
  Further investigations, using excitation of 810 nm showed that τ2 was higher than 
expected for the complex in HeLa cells 3b and 3c (2.026 ns 0.865 ns FWHM and 2.523 
ns, 1.562 ns FWHM respectively), therefore making some ligand formation the more 
probable of the two above mentioned outcomes. These minor components respectively 
accounted for 11% and 16 %, thus indicating that most of the complexes are stable 
within cells under standard conditions. In each case (at 810 nm or 910 nm) the 
fluorescence intensity was significantly greater than observed for the proligand, 
indicating complex stability, with FLIM providing quantitative means of evaluating 
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stability and demetallation. The combined use therefore of UV-Visible spectroscopy, 
fluorescence spectroscopy and FLIM offer a powerful method of investigating small 
molecule stability in both solution and in cells and confirm the stability of these 
complexes. 
 
    
a)      b)         c) 
Figure 4.27. Two- photon FLIM (m) at 910 nm in HeLa cells after 20 minutes of incubation of a) iib at 
100 µM, 1% DMSO, b) 3b at 50 µM, 0.5% DMSO c) 4b at 50 µM, 0.5% DMSO 
 
4.6 Laser scanning confocal microscopy 
 
  Cells were cultured using standard protocols, analogous with earlier investigations on 
ﬂuorescent thiosemicarbazones. Cell viability prior to experiments and over the course 
of experiments was monitored by optical microscopy, and validated at the start of the 
experiments by standard trypan blue tests and MTT assays.
127, 128
 Complexes 3a-3d 
were imaged in HeLa (cervical carcinoma), PC-3 (prostate carcinoma), MCF-7 (breast 
cancer) and FEK-4 (non-cancerous fibroblast) cell lines, cultured as described in the 
Experimental section by confocal ﬂuorescence microscopy using one photon excitation 
at 488 nm with the emission long pass ﬁltered at 515 nm. 
 
 The imaging studies were performed using concentrations of 50 µM compound in a 
DMSO: RPMI 0.5:99.5 cell medium solvent mix, whereby the ﬁnal DMSO 
concentration on the imaging plate was lower than 1%. The solutions were left to 
incubate with the adherent cancer cell lines for 20 or 60 min, with preliminary 
investigations incubating up to 3 hours and at concentrations of 100 μM, at 4 °C or 
37 °C. The cells were carefully washed with Phosphate Buffered Saline (PBS) pre-
warmed to 37°C, which was replaced by FCS-free medium to remove the non-
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internalised ﬂuorescent dispersion prior to ﬂuorescence imaging. As before, the imaging 
work was carried out in the presence of minimum amount of serum to avoid potential 




   
a)                 b) 
   
c)           d) 
Figure 4.28. Single-photon confocal microscopy images of 3a PC-3 cells, 50 μM, 0.5% DMSO, 20 
minutes, at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) excitation at 405 nm, 
emission 420-480 nm (d)  is an overlay of (a), (b) and (c). Scalebar: 20 μm. 
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a)          b) 
   
c)       d) 
Figure 4.29. Complex 3b, 50 μM, 0.5% DMSO, 20 minutes, at 37°C irradiation experiment at 488 nm in 
MCF-7 cells: (a – e) before irradiation and (f – j) after irradiation for ca. 10 minutes, where DIC image (a, 
f), micrograph of cells after excitation at 405 nm (b, g), micrograph of cells after excitation at 488 nm (c, 
h, compound, green channel), micrograph of cells after excitation at 543 nm (d, i, compound, red channel). 
Image (e) is an overlay of (a), (b) and (c) images, whereas (j) is an overlay of images (f – i). Scalebar: 20 
μm. 
 
  The necessity to use concentrations as high as 50 μM in these studies was a result of 
the rather weak ﬂuorescence emissions (by comparison with organic, commercial dyes). 
Control experiments prior to incubation of cells with the compounds of interest were 
obtained by ﬂuorescence imaging (Appendix G) to ensure that the cell morphology 
remains unaltered prior to the imaging experiments. No signiﬁcant changes in cell 
morphology were observed by optical microscopy after 20 min incubation with respect 
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to control. After 60 min incubation at 37 
◦
C with compounds 3a–3d the cell morphology 
gave evidence of stress thus suggesting that these metal complexes are toxic at the 1 h 
timepoint. The following figures below depict representative confocal ﬂuorescence 
microscopy images in HeLa and PC-3 cells for these complexes. 
 
  
a)             b)             c) 
Figure 4.30. 2- photon FLIM (tm) of 3b in MCF-7 a) before irradiation, b) after irradiation for 9 minutes 
at 488 nm, c) fluorescence lifetime distribution curve (tm) at 910 nm before and after irradiation. 
 
  Co-localisation dyes and cells are shown and were recorded a minimum incubation of 
20 minutes and a maximum of up to 3 hours. The observation of ﬂuorescence in these 
images suggests that substantial amounts of these complexes remain intact inside the 
cell. Within the ﬁrst 20 minutes there is widespread distribution of the gallium 
complexes within the cell cytoplasm (Figure 4.28).  
 
Co-localisation with commercially available dyes (e.g. Mitotracker Red and Green, 
Hoechst, Lysotracker Red and Green) were used to identify regional uptake within the 
cell, investigating whether the gallium complexes enter the mitochondria, lysosomes, 
the nucleus and lipid-rich regions of the cell, which may in turn shed light upon the 
nature of compound activity. 
 
  Additionally, complex 3b displayed interesting photoinduced changes in intracellular 
localisation within cells and was studied in MCF-7 and PC-3 cells, showing comparable 
data in each cell line (Figure 4.29 and Appendix Figure G.12).  After irradiation with 
488 nm light the green fluorescence was less evenly distributed within the cell with a 
more punctuated appearance.  It was noticeable that the cell morphology was 
dramatically altered resulting in rounder and larger cells indicating occurrence of 
blebbing, which occurs during the process of apoptosis (programmed cell death).  This 




















 3b pre irradiation
 3b post irradiation
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signifies that the photoactivity of the complex results in greater cytotoxicity implying a 
potential for photodynamic therapy using these compounds.  The effect of light on the 
complex was further investigated in solution by NMR spectroscopy, using LEDs 
producing light broadly around 500 nm with the assistance of Mr Christopher Woodall. 
 
  Interestingly, after irradiation for 9 minutes a significant change in fluorescent lifetime 
was observed when incubating 3b in MCF-7 cells (Figure 4.30), resulting in a 
fluorescence lifetime of 2.001 ns, 1.118 ns FWHM. It can be speculated that the 
metabolism of this particular cell line has caused formation of free ligand, since no 




4.6.1 1H NMR spectroscopy investigation 
  The study was carried out using a 400 MHz NMR spectroscopy and 5 mg of 3b in 0.5 
mg/mL of d6-DMSO at room temperature.  An initial control was carried out keeping 
the solution in the dark at room temperature for 6 hours measuring a NMR spectrum 
before and after the required time to investigate if the spectrum changed without 
irradiation.  The spectra were identical, indicating that there is no significant change 




Figure 4.31. 1H NMR spectroscopy (400 MHz at 10 mg/mL in d6-DMSO) of 3b where blue line shows 
the spectrum of a freshly made solution, red is after 6 hours in solution protected from light, green is the 
same solution irradiated with LEDs producing light of ca. 500 nm for 14 hours and lilac/top is the same 
solution stored in the dark at room temperature for 10 hours. 
 
  Moreover, the solution was irradiated using LEDs that produce light broadly around 
500 nm for 5 minutes. This resulted in the appearance of new resonances at 9.38 ppm, 
8.10 ppm and 7.71 ppm. The solution was then irradiated a further 14 hours, a spectrum 
taken and subsequently protected from light followed by spectra taken after an 
additional 45 minutes and another 10 hours (Table 4.6).  The ratio of the first 
asymmetric N(H) proton at 9.60 ppm (which will be referred to as ‘resonance 1’) to the 
new resonance at 9.38 ppm (‘resonance 2’) was measured for each of these spectra 
integrating between 9.662 - 9.501 ppm and 9.418 and 9.350 respectively allowing direct 
comparisons to be made.  The ratio was also calculated for the spectrum before 
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irradiation to give an indication of a ‘background’ in which there was no visible triplet 
resonance, which accounted for 2.21%. It is apparent that a new species is formed upon 
irradiation, which is produced rapidly after just 5 minutes with resonance 2 
representing 10.6 % of a resonance 1.  Further irradiation did not increase this ratio 
(with the slight decrease to 9.79 % after a further 14 hours of irradiating indicating that 
the new species) signifying that the species very quickly reaches its maximum 
proportion whilst using these LEDs.   
 
Table 4.6. ‘Resonance 2’ integral percentage of ‘Resonance 1’ integral. ‘Resonance 1’ was integrated 
between 9.662 - 9.501 ppm and ‘Resonance 2’ 9.418 - 9.350 ppm. 
Irradiation details of 3b in d6-DMSO 9.38 ppm resonance % integral of 9.60 resonance 
Before irradiation 2.21 
< 5 min after irradiation for 5 minutes 10.6 
< 5 min after irradiation for 14 h 9.79 
45 min after irradiation 9.7 
10 h after irradiation 5.95 
 
  This implies that more highly powered light producing instruments, such as lasers may 
be able to produce a more significant fraction of this species and should be investigated 
using high-powered lasers. Despite the fast production of the new species, conversion 
back to produce the original spectrum was not as rapid since after 45 minutes in the 
dark the proportion was 9.7 %.   
 
After a further 10 hours protected from light the percentage was reduced to 5.95 % 
indicating that the process is slowly reversible.  One possibility is that the new species 
is the alternative symmetric isomer as discussed above for complex 3a (Section 4.1.1).  
This is plausible since two of the new resonances are triplets, one in the region expected 
for nitrogen bound protons and the other in the aromatic region. If this is correct each of 
the new resonances represent two protons of the alternate symmetric isomer as 
compared to the one proton of the asymmetric isomer and so meaning that there is ca. 5% 




   
a)               b) 
   
c)               d)  
Figure 4.32. Complex 3b, 50 μM, 0.5% DMSO, 20 minutes at 37°C and Nile Red in MCF-7 cells after ca. 
5 minutes of irradiation: DIC image (a), micrograph of cells after excitation at 488 nm (b, compound, 
green channel), micrograph of cells after excitation at 543 nm (c, Nile Red, red channel). Image (d) is an 
overlay of (a), (b) and (c) images suggesting localisation with lipid rich regions of the cell. Scalebar: 20 
μm 
 
  Currently, it can be hypothesised that high power lasers would be required to achieve 
the difference observed within cells. Another possibility however, is that the new 
species can enter different organelle(s) more rapidly than its other respective isomers, 
which upon entry begin to convert back to its more usual forms, which are thus 
effectively trapped within the cell.  Likewise as the alternate symmetric isomer outside 
the organelle is produced it is removed from the cytoplasm, forcing the uptake of the 
complex to appear as a punctuated shape.  To explore the nature of organelle in question 
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MCF-7 cells were incubated with Nile Red dye, which is a marker for lipid-rich regions 
of the cell, which showed very strong correlation as to that of the uptake of 3b after 
irradiation (Figure 4.32). 
 
   
a)                                                                               b)  
Figure 4.33. Single-photon confocal fluorescence imaging: Complex 3d, 50 μM, 0.5% DMSO, at 37°C 
in HeLa cells incubated for 1 hour: (a – b) the cells were irradiated with 488 nm light for less than 5 
minutes, where DIC image is represented by (a) and micrograph of cells after excitation at 488 nm by (b, 
compound, green channel). Scalebar: 20 μm. 
 
  Interestingly, complex 3d when incubated for 60 minutes, punctuation was also 
observed during the process of finding a representative area to image, indicating that 
the effect is also rapid with the allyl functionality (Figure 4.33). A further study was 
carried out incubating HeLa cells with 3d for 3 hours at 100 µM, 1% DMSO to 
determine if this effect occurs without irradiation when incubation is longer and more 
compound is present. This effect was not observable in absence of irradiation 
indicating that this process does not occur with time alone. Additionally, the study was 
carried out at 37°C and 4°C, to investigate if the uptake occurred by passive diffusion 
alone, since mechanisms such as endocytosis do not occur at low temperatures (Figure 
4.34). 3d entered cells both at 4 ºC and 37 ºC, implying that cell uptake occurs by 
passive diffusion alone in fixed cells with the nucleus stained with DAPI. Nuclear 
uptake was observed at 37 ºC, but not at 4 ºC, signifying that the process did not occur 




    
a)                                                                               b) 
   
c)                                                                               d) 
Figure 4.34.  Single-photon confocal microscopy images of complex 3d and DAPI in HeLa (fixed cells), 
incubated for 3h, 100 µM, 1% DMSO where (a) – (b) at 37 oC and (c) – (d) at 4 oC; (a) and (c) represent 
the micrograph with excitation at 488 nm, emission >505 nm, (b) and (f) represent an overlay of the 
micrograph of excitation at 405 nm, emission 420-480 nm (a) and (c) respectively and the DIC image. 
 
  The study was further carried out with 3b with more standard incubation times of 20 
minutes and 50 µM 0.5% DMSO, to determine if the same effect is observed for shorter 
incubations and lower concentrations, which indicated no nuclear uptake at 4ºC and 
very little complex within the nucleus at 37°C signifying that entry to the nucleus is 
only significantly achieved at longer time-points as above.  Interestingly it appears that 





     
a)                                                                               b) 
   
c)                                                                               d) 
Figure 4.35. Single-photon confocal microscopy images of (a-d) Complex 3b, 50 μM, 0.5% DMSO, 20 
minutes and Hoechst (nuclear stain) in HeLa cells at 37°C: DIC image (a), micrograph of cells after 
excitation at 488 nm (b, compound, green channel), micrograph of cells after excitation at 543 nm (c, 
compound, red channel). Image (d) is an overlay of (a), (b), (c) and the micrograph from excitation at 405 
nm. (e-h) 3b, 50 μM, 0.5% DMSO, 20 minutes in HeLa cells incubated at 4 oC, (e) DIC image, (f) 
excitation at 488 nm, emission >505 nm, (g) after excitation at 543 nm and (h) is an overlay of (e), (f) and 
(g). Scalebar: 20 μm. 
 
 
  Complex 3d was additionally incubated in FEK-4 cells, a non-cancer cell line, which 
displayed similar properties as to in the cancer cell lines tested with the majority of 
uptake in the cytoplasm and little in the nucleus.  Likewise, longer incubation times of 3 






a)                                                                               b) 
 
c)                                                                               d) 
Figure 4.36. (a-b) Complex 3d in FEK-4 cells, 50 μM, 0.5% DMSO, 20 minutes: (a) is micrograph of 
cells after excitation at 488 nm (compound, green channel). Image (b) is an overlay of (a), the DIC image 
and micrograph of cells after excitation at 405 nm. Figure (c-d) Complex 3d irradiation experiment at 488 
nm in FEK-4 cells, 100 μM, 1 % DMSO, ca. 3 hours images, fixed cells stained with DAPI, scalebar: 20 
μm, (c) is micrograph of cells after excitation at 488 nm, (d) is an overlay of (c), the DIC image and 
micrograph of cells after excitation at 405 nm. 
 
  Moreover, strong red emission with weak green emission was also observed for 3c 
when incubated at 37°C. This is in agreement with the fluorescence data in solution 
described above.  Thus, imaging is suggesting that this complex unsuitable for 
investigation via green and red colocalisation dyes, however staining with Hoechst 
Chapter 4 
 145 
demonstrated that this complex does not enter the nucleus within 20 minutes at 50 µM 
(Figure 4.37). 
 
   
a)                                                                               b) 
Figure 4.37. Complex 3c, 50 μM, 0.5% DMSO, 20 minutes at 37°C in HeLa cells incubated with 
Hoechst dye, where DIC image (a), micrograph of cells after excitation at 405 nm (b), micrograph of cells 
after excitation at 488 nm (c, compound, green channel), micrograph of cells after excitation at 543 nm (d, 
i, compound, red channel). Image (e) is an overlay of (a), (b) and (c) images. Scalebar: 20 μm. 
 
  Initial tests on the co-localisation of 3a and 3d with the mitochondrial stains 
Mitotracker Red and lysosome stain Lysotracker Red(Invitrogen) were carried out and 
results show mitochondrial (Figure 4.39 and Appendix Figures G.16) and lysosomal 
colocalisation in line with earlier observations for their Zn(II) precursors
127, 128
 Data 
were highly comparable for 3a and 3d in both HeLa and PC-3 cells. (Figure 4.39 and 
Appendix Figures G.17-18) 
 
  In summary, this family of gallium complexes enter both cancer and non-cancer cells.  
Localisation appears to occur in many organelles and indicates that, if cytotoxic these 
compounds may have many modes of action. Long incubations saw the complex 3d 
enter the nucleus indicating a possibility DNA damage during prolonged exposure, 
whereas rapid uptake was observable in the lysosome and the mitochondria, meaning 
that these complexes may possess potential to disrupt these organelles. Data suggest that 
the complex can enter cells by passive diffusion, yet enters the nucleus via other means. 
Moreover, the photoactivity of 3b presents a prospect of photodynamic therapy, with 
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the evolution of a new species in a reversible process as well as localisation in lipid-rich 
regions of the cell. 
 
   
a)                                                                               b) 
   
c)                                                                               d) 
Figure 4.38. (a – b) Complex 3a, 50 μM, 0.5% DMSO, 20 minutes at 37°C and Mitotracker in PC-3 cells: 
(a) micrograph of cells after excitation at 488 nm, (b) is an overlay of (a), DIC image and micrograph of 
cells after excitation at 543 nm. Images (c-d). Complex 3d, 50 μM, 0.5% DMSO, 20 minutes at 37°C and 
Lysotracker in HeLa cells, (c) micrograph of cells after excitation at 488 nm, (d) is an overlay of (c), DIC 
image and micrograph of cells after excitation at 543 nm. Scalebar: 20 μm 
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4.7 Preliminary In vivo imaging 
 
  Normoxic PC-3 xenografts were grown on the right shoulder of nude mice in 
Memorial Sloan-Kettering Cancer Center, New York by Dr Sofia I. Pascu and Dr Brian 
Zeglis. MicroPET was carried out for 
68
Ga complex 3b, good renal clearance was 
observed, indicating suitability of these probes (Figure 4.39).  Furthermore, no tumour 
uptake under these normoxic conditions was observed for all cases, with some limited 
uptake in the lungs, liver and spleen and clear bladder localisation/excretion. This 
represents a promising result for probes designed for hypoxia selectivity, signifying that 
it would be beneficial for an in vitro hypoxia study to be carried out data processing is 
in process reveal the exact biodistribution. 
 
 
a)     b)      c)       d) 
Figure 4.39. MicroPET images of in nude mice, M = 68-Ga, R = Et, where a, b, c and d are at timepoints 
30 mins, 1h, 2h and 4h respectively.   
 
4.8 Hypoxia selectivity testing 
 
  An investigation to assess the hypoxia selectivity of these complexes was carried out 
by the collaborating group of Professor Eric Aboagye (Dr Israt S. Alam) in EMT6 
(murine breast carcinoma) and PC-3 cells, grown under standard conditions described in 
Experimental Section. 
 
  Compound 3d was incubated in cells at 50 µM, 4% DMSO, with normoxic conditions 
of 20.7% O2 and 5% CO2 at 37 C, with hypoxic samples pre-incubated for 20 minutes 
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at 1% O2, 5% CO2 at 37
 C before complex addition.  Following addition of the 
compound cells were incubated for a further 20 minutes and subsequently washed three 





Figure 4.40. Confocal micrographs of 3d in FEK-4 (top) and EMT6 (bottom) cells under normoxic (left) 
and hypoxic (right) conditions. 
 
  Using confocal imaging the compound preference for hypoxia was not easily 
deducible (Figure 4.40), however, flow cytometry and radioactive cell uptake studies, 
provided quantitative means to assess the selectivity (conditions used are within the 













































Figure 4.41. Flow cytometry studies under normoxia and hypoxia of 3d (a) in EMT6 and (b) in PC-3 
cells. 
 
  Median fluorescence intensities (MFU) obtained using flow cytometry under hypoxic 
conditions were lower than those of the normoxic cells (12% lower for EMT6 (*P<0.05) 
and 21 % lower in PC-3 cells (***P<0.001)) (Figure 4.41). Although this decrease in 
fluorescence may be understood as lower uptake, it is more likely that incubation under 
hypoxic conditions causes reduction of the complex, which would result in 
demetallation and therefore loss of fluorescence. It consequently is difficult using this 
technique alone to determine if the lower fluorescence is due to less uptake, conversion 
to ligand and lower uptake or conversion to ligand and increased uptake.  
 
allyl-68Ga-BTSC uptake in EMT6 (%Total tracer/mg of protein)





























Figure 4.42. Radioactive cell uptake studies under normoxia and hypoxia of 3d in EMT6 cells. 
 
  To investigate this issue a preliminary radioactive cell uptake experiment was carried 
out, showing that 
68
Ga uptake was greater in hypoxic cells than normoxic cells (64% 
and 49% higher at 30 and 60 minutes respectively) (Figure 4.42). This therefore 
indicates that the most likely cause of the reduction in fluorescence is due to the 
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combination of increase in uptake as well as conversion to free ligand, signifying that 
the gallium complexes possesses selectivity for cells under hypoxic conditions. 
 
4.9 Summary to Chapter 4 
 
  New intrinsically fluorescent gallium complexes were synthesised and characterised 
using ES-MS, NMR spectroscopy and X-ray crystallography.  The complexes displayed 
a symmetric and an asymmetric isomer in solution, which were further explored using 
VT-NMR spectroscopy and DFT for complexes 3a and 3c respectively each indicating 
a small preference towards formation of the symmetric isomer.  Laser scanning confocal 
microscopy studies showed that the gallium complexes enter cancer and non-cancerous 
cells and rapidly localise in the lysosome and mitochondria, whilst nuclear uptake 
occurs more gradually.  Entry to cells occurred at 4°C, indicating the process occurs by 
passive diffusion, however penetration into the nucleus was only achieved at 37°C 
meaning that that this did not occur by passive diffusion alone. 
 
  Complex 3b demonstrated photoactivity and appears to form a new species upon 
irradiation with light around 500 nm, causing a change in localisation in the cell and 
initiation of cell death via apoptosis.  In vivo experiments demonstrated suitability for 
3b in that there was good renal clearance and seldom any uptake in the tumour under 
normoxic conditions – an essential feature of a hypoxia imaging agent.  Furthermore, an 
investigation to discover the hypoxia selectivity of these complexes has been carried out 
indicating a preference for hypoxic cells of ca. 20%.  Further experiments should be 
carried out to ascertain if complex uptake occurs under hypoxic conditions in vivo, 








Chapter 5. Synthesis, characterisation, spectroscopic, in vitro and in 
vivo analysis of indium(III) bis(thiosemicarbazonato) complexes 
 
  Indium complexes were designed and synthesised since they present an alternative 
method of reducing liver uptake of bis(thiosemicarbazonato) complexes, with the 
radioactive isotope In-111 an attractive agent for SPECT, by way of its gamma decay 
and for radiotherapeutics due to its auger electron emission. Aromatic indium 
bis(thiosemicarbazonato) complexes are likely to be sufficiently intrinsically fluorescent, 
due to metal to ligand charge transfer, to enable their progress to be monitored in vitro 
and potentially for dual-modal imaging. The main objective of this chapter was 
therefore to develop new indium(III) bis(thiosemicarbazonato) complexes that would be 
highly stable in biological media, rapidly and cleanly radiolabelled and capable of 
entering cancer cells. 
 
5.1 Indium complex synthesis 
 
 
Figure 5.1. Synthesis of acenaphthenequinone indium bis(thiosemicarbazones) 
 
  As was found with the gallium complexes transmetallation provided a clean means of 
obtaining the indium complexes. Indium(III) compounds 4a, 4b, 4c and 4d were 
successfully synthesised in methanol under reflux for 6 hours, via the zinc precursor and 
vast excess of InCl3 (Figure 5.1).
138
 Following filtration and washing with diethyl ether 
the product was isolated as the solid as a red coloured powder for 4a, 4b, and 4d, with 
4c isolated from the filtrate, which was rotary evaporated and subsequently washed with 
diethyl ether. NMR spectroscopy and ES-MS were used for characterisation, with 






THF:Hexane. Mass spectrometry (ESI) gave peaks for [M-H]
-
 at m/z =502.94, 530.97, 
556.98 and 626.97 4a, 4b, 4c and 4d respectively, all values being within 0.1% error of 
those calculated.   
 
Unlike the gallium complexes discussed in the previous chapter the indium complexes 
did not display the same kind of isomeric mixture, with only the symmetric isomer 














5.2 Density functional theory calculations 
 
 The isomerism was investigated further for the indium complexes with the phenyl 
substituent in an analogous study to the previous chapter by Density Functional Theory, 
following the method used by Holland et al.
119
.  An initial optimisation was carried out 
where the basis set was 6-31G(d,p) for S, Cl, C, N, H and SDD for In in the gas phase, 
with a final optimisation of with a basis set of B3LYP 6-31++ (d,p) IEFPCM, DMSO 




Figure 5.3. Second level optimisations where (above) is symmetric 4c and (below) is asymmetric 4c’. 
Where grey = carbon, white = hydrogen, blue = nitrogen, red = oxygen, green = chlorine, deep pink = 
indium. 
 
In the gas phase the calculated energy difference is -3.53 kJ mol
-1
, indicating that the 






when solvent effects were considered in DMSO, the symmetric structure was more 
energetically favourable when compared to the asymmetric, with an energy difference 
of -7.69 kJ mol
-1
. This was the largest for any of the complexes in strong agreement 
with NMR spectroscopy and crystallographic data, both of which show a strong 
preference for the symmetric isomer. 
 
5.3 Radiochemistry experiments 
 
  A major goal of this Chapter was to establish whether the indium complexes could be 
readily radiolabelled, as this would render them useful as new SPECT molecular 
imaging probes.  These experiments were carried out at the Oxford Siemens Laboratory, 
University of Oxford under the supervision of Dr Phillip A. Waghorn and Prof Jon 
Dilworth.  
 
Figure 5.4. Overlay of UV-HPLC trace (black) of aromatic zinc bis(thiosemicarbazonato) precursor with 
the radio-HPLC trace (blue) of aromatic 
111
InCl bis(thiosemicarbazonato) complex with compound 1b. 
 
In a typical experiment, a 1 mg/mL stock solution of the complex was prepared in 
DMSO, from which 10 µL was added to 100 µL of ethanol and was further diluted with 
100 µL of water. Subsequently 10 µL of InCl3 (ca. 10 MBq) was added to the solution 
and was heated at 60°C. After 15 minutes, an aliquot of 30 µL was removed from the 
solution and analysed using HPLC with a C18 column and a mobile phase of 0.1 % (v/v) 
TFA in acetonitrile/water. Figure 5.4 shows an overlay of the UV-HPLC trace of the zinc 





































precursor and the indium-111 complex for 1b.  Data show that  could be made rapidly 
and cleanly for these complexes by transmetallation despite the UV traces indicating 
that 1c contained a mixture of symmetric and asymmetric isomers as shown by the two 
slightly differing retention times (Figure 5.5).   
 
 
Figure 5.5. Overlay of UV-HPLC trace (black) of aromatic zinc bis(thiosemicarbazonato) precursor with 
the radio-HPLC trace (blue) of aromatic 
111
InCl bis(thiosemicarbazonato) complex with compound 1c. 
 
  Due to the importance of lipophillicity and liver uptake the partition coefficient (log P) 
was calculated for these complexes with values of 1.19 ± 0.09, 1.07 ± 0.03, 0.94 ± 0.13 
and 1.20 ± 0.11 for compounds 4a, 4b, 4c and 4d respectively.  The log P values were 
comparable to yet slightly lower than their analogous copper complexes, importantly 
they are significantly less lipophilic than Cu[ATSM], with a log P of ca. 1.48, 





5.2 Single crystal X-ray crystallography  
  
  Crystals were grown in THF:Hexane by a standard liquid or gas phase diffusion 
method for complexes 4a, 4b, 4c and 4d. X-ray structure determinations showed that, in 
agreement with NMR spectroscopy and DFT calculations, there is a strong preference 
for the symmetric isomer formation, and this was observed in the crystal structures of 













































all compounds studied here. As was observed with symmetric gallium compounds, each 
indium complex possessed a plane of symmetry across the backbone and symmetric 
binding to the metal, yet the terminal functionalities (Et, Ph and Allyl) are asymmetric 
(Figures 5.6 and 5.7).  
 
Table 5.1: Selected bond lengths (Å) and bond angles (°) for compounds 4a-d, determined by X-ray 
diffraction 
  
  A distorted square pyramidal around the metal centre was also notable and was 
likewise comparable to the gallium complexes with the Cl in the axial position with the 
base formed by the two nitrogens and two sulphurs.  The bond distance of M-Cl is 
similar for 4a and 4b (2.434(4) Å and 2.4180(16) Å correspondingly) and 4b and 4d 
(2.4180(16) Å and 2.4157(8) Å respectively) (Table 5.1), but is smaller for 4c 
















M-Cl 2.434(4) 2.4180(16) 2.3960(15) 2.4157(8) 
M-N 2.260(13) 2.244(4) 2.281(4) 2.257(2) 
 2.305(14) 2.250(4) 2.278(4) 2.270(2) 
M-S 2.474(5) 2.4602(14) 2.4638(14) 2.4784(7) 
 2.472(5) 2.4658(14) 2.4998(14) 2.4693(8) 
C-C 1.492(2) 1.487(7) 1.478(7) 1.492(4) 
N-N 1.349(18) 1.360(6) 1.349(6) 1.364(3) 
 1.381(19) 1.343(6) 1.359(6) 1.354(3) 
C=N 1.320(19) 1.294(6) 1.297(7) 1.292(4) 
 1.306(19) 1.299(6) 1.292(7) 1.299(4) 
S-M-S 123.19(15) 117.93(5) 120.54(5) 120.15(3) 
S-M-N 76.8(4) 77.39(11) 75.46(11) 76.72(6) 
 74.2(4) 77.47(11) 76.44(11) 77.03(6) 
N-M-N 72.2(4) 73.17(15) 71.55(15) 72.56(8) 
S-M-Cl 109.5(2) 106.42(5) 106.72(5) 105.63(3) 
 108.2(2) 107.14(5) 106.41(5) 104.52(3) 
N-M-Cl 91.0(4) 98.8(1) 102.2(1) 102.16(7) 






(73.17(15)°) and 4d (72.56(8)°) (whereby the N-M-N of 4a (72.2(4)°) was similar to 
each of the respective indium complexes.)  Moreover, the S-M-S angle of 4b 
(117.93(5)°) was shorter than those of 4c (120.54(5)°) and 4d (120.15(3)°), which were 
similar, whilst 4a (123.19(15)°) was notably larger than those of the other indium 
complexes of this family.  Notably, the N-M-Cl angle appeared to increase the larger the 
functionality (91.0(4)° for methyl-substituted indium complex 4a and 102.2(1)° for 
phenyl-functionalised indium complex 4c) with the opposite observed for the S-M-Cl 
angle (e.g. 109.5(2)° in 4a and 106.72(5)° in 4c). The other bond lengths and angles of 
these indium compounds were comparable indicating that despite the functionality at 
the exocyclic nitrogen atoms having some effect on the rest of the structure, this effect 




Figure 5.6. Molecular structures of compounds 4a (above) and 4b (below), ellipsoids drawn at 30% 
probability, hydrogens omitted for clarity. 
 
  Since the phenyl-substituted complex crystal structures were acquired during this 
study, each possessing the symmetric conformation their comparison can shed light 
upon the effect of the metal centre on the structure and will be considered below (Table 






were longest for the indium complex, followed by the zinc and the gallium, with the 
copper complex possessing the shortest metal bonds. Interstingly, the C-C bond is 
similar for each metal complex, therefore it can be speculated that the difference in this 
bond length reported previously in the group between (E,Z) isomer of the zinc complex 
1d and the (E,E) isomer of the copper complex may be due to crystal packing forces 
rather than an isomeric or metal-dependant effect.
127 
 
Table 5.2. Selected bond lengths (Å) and bond angles (°) for compounds 1c-4c, determined by X-ray 
diffraction, where A is adduct atom. 
 
  Interestingly, the C=N of the gallium complex is significantly longer than that of the 
















M-Cl/M-O *2.0642(12)  2.2096(14) 2.3960(15) 
M-N 2.1092(14) 1.967(5) 2.069(4) 2.281(4) 
 2.1603(14) 1.976(5) 2.075(4) 2.278(4) 
M-S 2.3330(5) 2.2508(17) 2.3130(16) 2.4638(14) 
 2.3691(5) 2.2598(18) 2.3171(15) 2.4998(14) 
C-C 1.499(3) 1.481(8) 1.488(6) 1.478(7) 
N-N 1.364(2) 1.382(6) 1.372(5) 1.349(6) 
 1.364(2) 1.384(6) 1.371(5) 1.359(6) 
C=N 1.294(2) 1.286(7) 1.383(7) 1.297(7) 
 1.292(2) 1.293(7) 1.369(7) 1.292(7) 
S-M-S 115.636(19) 110.99(7) 105.11(5) 120.54(5) 
S-M-N 80.27(4) 83.64(16) 81.42(12) 75.46(11) 
 78.96(4) 83.72(15) 81.43(11) 76.44(11) 
N-M-N 76.65(5) 81.6(2) 77.33(15) 71.55(15) 
S-M-A 104.31(4) n/a 108.56(6) 106.72(5) 
 102.01(4) n/a 108.38(6) 106.41(5) 
N-M-A 101.11(5) n/a 99.7(1) 102.2(1) 
 93.77(5) n/a 98.4(1) 100.1(1) 






was largest for gallium compound 3c (108.56(6))° and smallest for zinc complex 1c 
(104.31(4)°), with the N-M-A largest for indium complex 4c (102.2(1)°). The angles S-
M-N and N-M-N are largest with the copper metal centre (83.64(16)° and 81.6(2)° 
respectively), followed by with a gallium atom (81.42(12)° and 77.33(15)° 
correspondingly), whereby for the indium complex these angles are the smallest 
(75.46(11)° and 71.55(15)° respectively).  The opposite trend is true (with the gallium 
the smallest angle rather than the copper) for S-M-S angle indicating that whilst the 
sulphur atoms are closer in comparison to each other, the nitrogen atoms are further 
away from each other around the metal centre for the indium complexes, when 




          
Figure 5.7. Crystal structures of 4c (above) and 4d (below), ellipsoids drawn at 30% probability, 




  Fluorescence spectra were obtained in DMSO for initial scans between 200-800 nm, in 






100 M. Ranges of absorption and emission, which are important with regards to 
cytotoxicity assays and fluorescence imaging, were also assessed using the 2D contours 
as a guideline (Figure 5.8). Relevant cytotoxicity assays use absorbance readings at 570 
nm, therefore there should be minimal or no excitation at this wavelength, which was 




Figure 5.8. Excitation/emission map at 100 μM in DMSO of compound 4b (above) and 4c (below) 
 
  Complexes 4a, 4b and 4d displayed very similar absorption (ca. 250 – 570 nm) and 
emissions (ca. 515 – 685 nm), each with λmax of emission ca. 560 nm (Table 5.3). Each 
compound had a λmax of 400 nm, with 4c possessing a much broader range of excitation 













































































and emission than the other functionalities, as well as a higher λmax of emission of 590 
nm. 
 





Quantum yields were calculated using the standard solution of [Ru(bipy)3](PF6) in water 
as a reference and utilising the equation above. Where Φ = quantum yield, D = 
integrated area under emission band, S = sample, A = absorbance of solution at 
excitation wavelength, R = reference, η = refractive index of solvent, I = maximum 
intensity of excitation band [Ru(bipy)3][PF6]2 in water was used as a reference, with a 
quantum yield of 0.042. The quantum yields of the indium compounds higher than their 
respective gallium complexes and were sufficient to proceed to fluorescence imaging in 
biological cells. 
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Compound ex-max / nm Excitation range / nm em-max / nm Emission range / nm Quantum Yield 
4a 400 250-570 556 520-680 0.31 
4b 400 250-570 556 515-685 0.19 
4c 400 250-610 590 540-740 0.15 






5.5 Kinetic stability tests 
 
  In vitro assays were carried out to determine the stability of complexes for use as 
medical imaging probes.  Demetallation could result in non-target tissue uptake and 
poor image contrast in vivo.  Stability is therefore essential for the intended function of 
these complexes and a series of assays with excess of a numerous biologically relevant 
chemicals have been carried out up to 24 hours.  These include Glutathione (GSH), L-
cysteine, L-histidine, L-methionine, citric acid, ethylenediaminetetraacetic acid (EDTA), 
biomimetic eagle’s modified essential media (EMEM) (both with and without foetal 
calf serum) and biologically relevant pH buffers. Indeed, stability of these complexes in 
a range of pHs is significant due to the tendency of cancer cells to be slightly more 
acidic than non-cancerous cells. 
 
  UV-visible spectroscopy was utilised therefore to assess the kinetic stability of 
complexes and fluorescence to provide further insight whilst in the presence of 
biological media. Tests were carried out at room temperature at 100 M in a 1:1 DMSO: 
assay agent solution to ensure sufficient solubility and at a concentration providing 
detectable fluorescence, with the assistance of Johan Stojanoviḉ, technician student 
from ESCOM, France.   
 




















 t = 0            t = 7 h
 t = 15 min   t = 8 h
 t = 30 min   t = 9 h
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 t = 1 h         t = 11 h
 t = 2 h         t = 12 h
 t = 3 h         t = 13 h
 t = 4 h         t = 14 h
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Figure 5.10. Fluorescence spectroscopy of compound 4c: FCS stability assay (100 µM FCS: DMSO, 1: 
1).  
 
  Preliminary fluorescence studies focussing on EMEM containing 10% Foetal Calf 
Serum (FCS) demonstrated a general decreased intensity with time for all indium 
compounds, with the most significant reduction within the first hour, followed by 
equilibration after ca. 6h (Figures 5.9-5.10, Appendix Figures D.31-34, D.46).  There 
was only a very limited a shift in the fluorescence maxima implying that no new species 
evolved. Spectra are almost identical for 4a, 4b and 4d, whereas 4c had a much lower 
initial fluorescence, but also a much lower rate of decline, indeed 4c displayed notable 
fluorescence even after 24 h.  Due to the significantly greater fluorescence of the indium 
complexes in comparison with the free ligand, fluorescence intensity observed is 
indicative of complex stability (as was also observed with the gallium complexes).  
However, since the free ligand does possess some fluorescence, it is important to 





















 t = 0
 t = 15 min
 t = 30 min
 t = 45 min
 t = 1 h
 t = 2 h
 t = 3 h
 t = 4 h
 t = 5 h
 t = 6 h








Figure 5.11. Serum assays (99% FCS, 1% DMSO) by UV/Vis (below) for compound 4d, at 100 µM, 
monitored at time intervals up to 24h at room temperature and filtered using a 0.45 µm PTFE microfilter. 
(above) The structure of [GaCl(ATSM)] is also shown. This compound which was found not to be stable 
under comparable conditions. 
 
  In conjunction with a study comparing [In-Cl(ATSM)], which was found to form 
the corresponding to free ligand within 5 minutes in 99% FCS, 1% DMSO, with 
indium complex 4d tested under analogous conditions (Figure 5.11). Whilst changes 
in the UV/Vis spectra for the indium complex 4d were observed over an incubation 
of 24 h in serum, it is apparent that the product of the challenge has not completely 
converted to free ligand iid.  
 




























 4d, 15 mins FCS
 4d, 1h FCS
 4d, 3 h FCS
 4d, 6h FCS






Table 5.4. Summary of estimated complex remaining from UV-visible data at 1:1 DMSO:biologically 
relevant agent at 15 minutes and 24 h where Citric Acid, EDTA, L-Cys, L-His, L-Met and GSH were in 
MilliQ water. 
 
  Following initial stability tests in pH buffers, in EMEM and in FCS a more in-depth 
study focussing on the indium allyl derivative as a representative example of this class 
of compounds.  Indium complex 4d, however  exhibited good stability in each media 
with no significant change in absorbance between 15 minutes and 24 hours room 
temperature incubation in DMSO and high percentage remaining complex after 24 h 
incubation in each of the above solvents (94.4 %, 61.5 %, 69.4 %, 76.9 % respectively). 
 
  This investigation utilised both UV-visible absorption (at 10 M and at 100 M) and 
fluorescence emission at 100 M, with 1:1 DMSO:challanger to limit precipitation.  
This allowed a % stability to be estimated via UV-Visible spectroscopy at 15 minutes 
and 24 hours as calculated by (100 % - percentage converted to free ligand) (Table 5.4).   
The first assays carried out in DMSO, water, PBS, 5% FCS EMEM and SFM EMEM 
enabled complex stability to be understood in media likely to be encountered in a cell 
biology experiment.   
 






DMSO 86.6 86.6 
H2O 94.8 94.4 
PBS 66.8 61.5 
5% FCS, MEM 77.9 69.4 
SFM, MEM 81.4 76.9 
Citric Acid 85.2 87.8 
EDTA 94.2 90.4 
L-Cys 94.3 94.0 
L-His 80.8 79.6 
L-Met 77.6 77.5 

























 4d, H2O MQ 15 mins
 4d, H2O MQ 24 hours
 id, H2O MQ 15 mins 
 iid, H2O MQ 15 mins 



















 4d, in MilliQ water, 15 mins
 4d, in MilliQ water, 24 hours
 id, in MilliQ water, 15 mins
 iid, in MilliQ water,15 mins
 
Figure 5.12. Fluorescence (above) and UV/Vis (below) spectroscopy in aqueous media monitored at time 
intervals up to 24h at room temperature, (50% DMSO, 50% water, for compound 4d at 100 µM)  
 
  Indium complex 4d, contrary to the gallium complex 3d exhibited good stability in 
each media with no significant change in absorbance between 15 minutes and 24 hours 
in DMSO and high percentage remaining complex after 24 h incubation in each of the 
aforementioned solvents (86.6, 94.4 %, 61.5 %, 69.4 %, 76.9 % respectivly) (Figures 
5.12-15, Appendix Figures D.31, D.46). The fluorescence study was carried out in 
parallel largely confirming the UV-visible spectroscopy data. There was no significant 
change in fluorescence intensity of the indium complex in DMSO over a period of 24 h. 
 
  As was observed for the gallium complex, the fluorescence intensity for the indium 






absorbance is indicative of some decomposition into bis-substituted free ligand (Figure 
5.13).  The absorbance of the indium complex remained yet reduced at 500 nm after 24 
h, in contrast characteristic bands of the gallium complex (Chapter 4.5) were no longer 
present and displayed the form of the bis-substituted free ligand as investigated using 
















 4d, PBS 15 mins
 4d, PBS 24 hours
 id, PBS 15 mins
 iid, PBS 15 mins
 




















 4d, PBS 15 mins
 4d, PBS 24 hours
 id, PBS 15 mins
 iid, PBS 15 mins
 
Figure 5.13. PBS assays (50% DMSO, 50% PBS) for compound 4d at 100 µM, by fluorescence 
spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room temperature. 
 
This suggests that in the case of the indium complex a significant proportion of the 
complex has remains intact over the observation period. This was in contrast to the 
finding for the gallium complex, which appeared to have converted into the ligand 






higher affinity of the indium complex for soft donor ligands, such as a 
bis(thiosemicarbazone). 



























 4d SFM, 15 mins
 4d SFM, 24 hours
 id SFM, 15 mins
 iid SFM, 15 mins
 


















 4d SFM, 15 mins
 4d SFM, 24 hours
 id SFM, 15 mins
 iid SFM, 15 mins
 
Figure 5.14. EMEM SFM assays (50% DMSO, 50% SFM) for compound 4d at 100 µM, by 
Fluorescence(above) UV/Vis (below) spectroscopies monitored at time intervals up to 24h at room 
temperature. 
 
  Interestingly, the zinc complex 1d displayed little change in fluorescence and 
maintained its characteristic absorption spectrum (Chapter 3.7), signifying better 
stability than that of the gallium and indium complex in PBS.  The stability of the 
complex 4d was tested against Eagle’s Minimum Essential Medium Serum Free 




























 4d 5% FCS, 15 mins
 4d 5% FCS, 24 hours
 id 5% FCS, 15 mins
 iid 5% FCS, 15 mins



















 4d 5% FCS , 15 mins
 4d 5% FCS , 24 hours
 id 5% FCS, 15 mins
 iid 5% FCS, 15 mins
 
Figure 5.15. FCS assay (50% DMSO, 45% EMEM, 5% FCS) for compound 4d at 100 µM, by 
fluorescence spectroscopy (above) UV/Vis (below) monitored at time intervals up to 24h at room 
temperature. 
 
  The fluorescence emission of each of the complex decreases over the time period 
studied at the λmax. Compound 4d showed a very significant decrease in fluorescence 
over 24 h (to 17 % of the original), coupled with a small red shift from 551.5 nm to 
556.5 nm. Since the free ligand formation would be accompanied by a blue shift 
(approaching λmax 531 nm) presumably the shift and intensity decrease are due to 
quenching, which may be caused by the interaction with the media, protonation or 







  Moreover, these data suggest that it is likely that the complex remains intact under the 
conditions investigated hereby.  When incubated in FCS EMEM, indium complex 4d 
displayed a significant reduction in fluorescence and an increase in absorbance at 468 
nm, this could either indicate conversion to Compound iid (λmax 412 nm) or interaction 
with protein molecules present in serum and quenching.  It is apparent, however, that 4d 
did not fully convert into the corresponding free ligand iid, confirming stability of this 
complex up to 24 hours (Figure 5.15). 
  The complex 4d was therefore found to be intact for all five of the above media 
(DMSO, water, PBS, SFM and 5% FCS EMEM).  It was thus appropriate to explore 








5.5.1 Assays with biologically relevant agents 
  Biologically relevant agents were chosen to provide a better insight into the stability of 
these complexes, as were introduced in (Chapter 3).
145
  Complexes were tested in 
presence of 2 equivalents of citric acid, L-methionine, Glutathione (GSH), L-cysteine, 
L-histidine, and EDTA. Indium complex 4d displayed very similar properties in citric 
acid, and sulphur containing L-Met and L-Cys in water in that there was little 
observable change in the spectral properties between 15 minutes and 24 h (Figure 5.16 
and Appendix Figure D.34). The characteristic absorbance spectrum for Compound 4d 
was observable indicating very good stability of this complex up to 24 h in these 



















 4d, L-Cys, in MilliQ water, 15 mins
 4d, L-Cys, in MilliQ water, 24 hours
 id, L-Cys, in MilliQ water, 15 mins
 iid, L-Cys, in MilliQ water, 15 mins
 




















 4d, L-Cys, in MilliQ water, 15 mins
 4d, L-Cys, in MilliQ water, 24 hours
 id, L-Cys, in MilliQ water, 15 mins
 iid, L-Cys, in MilliQ water, 15 mins
 
Figure 5.16. L-cysteine spectroscopic stability assays (50% DMSO, 50% water, 2 eq of L-cysteine) for 
compound 4d at 100 µM, by fluorescence spectroscopy (above)  UV/Vis (below) spectra monitored at 



























 4d, L-His in MilliQ water, 15 mins
 4d, L-His in MilliQ water, 24 hours
 id, L-His in MilliQ water, 15 mins
 iid, L-His in MilliQ water, 15 mins
 





















 4d, L-His in MilliQ water, 15 mins
 4d, L-His in MilliQ water, 24 hours
 id, L-His in MilliQ water, 15 mins
 iid, L-His in MilliQ water, 15 mins
 
Figure 5.17. L-histidine challenge by spectroscopic assays (50% DMSO, 50% water, 2 eq of L- histidine) 
for compound 4d at 100 µM, by fluorescence spectroscopy (above)  UV/Vis (below) monitored at time 
intervals up to 24h at room temperature. 
 
The fluorescence spectroscopy assay involving the addition of N-donating L-His to 
solutions of Compound 4d resulted in a significant increase in fluorescence emission 
(505 nm). UV-Visible Spectroscopy showed that the mixture possessed spectral 
characteristics typical of 4d. The absorbance band decreased slightly, but remained 
notable (Figure 5.17). This therefore suggests that whilst some of the indium complex 






  When  GSH was added to compound 4d  a notable increase in fluorescence emission 
and a slight increase in absorbance band (in the UV-Vis spectrum at both 10 µM and 
100 µM concentrations) with the distinctive 4d spectrum were observable up to 24 h. 



















 4d, GSH challenge in MilliQ water, 15 mins
 4d, GSH challenge in MilliQ water, 24 hours
 id, GSH challenge in MilliQ water,15 mins
 iid, GSH challenge in MilliQ water, 15 mins
 




















 4d, GSH challenge in MilliQ water, 15 mins
 4d, GSH challenge in MilliQ water, 24 hours
 id, GSH challenge in MilliQ water,15 mins
 iid, GSH challenge in MilliQ water, 15 mins
 
Figure 5.18. Glutathione challenge by spectroscopic assays (50% DMSO, 50% water, 2 eq of Glutathione) 
for compound 4d at 100 µM, by fluorescence spectroscopy (above)  UV/Vis (below) monitored at time 
intervals up to 24h at room temperature. 
 
  When compound 4d was assayed with 2 equivalents of EDTA, in aqueous media, 
fluorescence spectroscopies showed a notable decrease in fluorescence emission (12% 
of original) and blue shift of 64 nm. A decrease in absorbance band was observed in 






demonstrates some stability of this complex up to 24 h, indicative of the high stability 





















 4d, L-Met, in PBS, 15 mins
 4d, L-Met, in PBS, 24 hours
 id, L-Met, in PBS, 15 mins
 iid, L-Met, in PBS, 15 mins
 


















 4d, L-Met, in PBS, 15 mins
 4d, L-Met, in PBS, 24 hours
 id, L-Met, in PBS, 15 mins
 iid, L-Met, in PBS, 15 mins
 
Figure 5.19. L-methionine spectroscopic assays (50% DMSO, 50% PBS, 2 eq of L-methionine) for 
compound 4d at 100 µM, by fluorescence spectroscopy (above)  UV/Vis (below) spectra were monitored 
at time intervals up to 24h at room temperature. 
 
Additionally, the kinetic stability of compound 4d was evaluated in aqueous solutions 
of PBS (phosphate buffered saline, which contains NaCl, KCl, Na2O4HP and KO4H2P). 
Unlike similar assays with L-Met or citric acid carried out without PBS (which all 






absorbance at 460 nm and the decrease of the band at ca. 505 nm was observed agents 
tested, suggesting that complex had demetallated and therefore that PBS reduces the 





























 4d, EDTA in MilliQ water, 15 mins
 4d, EDTA in MilliQ water, 24 hours
 id, EDTA in MilliQ water,15 mins
 iid, EDTA in MilliQ water, 15 mins
 























 4d, EDTA in MilliQ water, 15 mins
 4d, EDTA in MilliQ water, 24 hours
 id, EDTA in MilliQ water,15 mins
 iid, EDTA in MilliQ water, 15 mins
 
Figure 5.20. EDTA assays (50% DMSO, 50% water, 2 eq of EDTA) for compound 4d at 100 µM, by 
fluorescence spectroscopy (above)  UV/Vis (below) monitored at time intervals up to 24h at room 
temperature. 
 
Overall these tests provide strong evidence that 4d is stable in the presence of 
biologically relevant agents in water, whereby challenger assays did not reveal a 







5.5.2 pH buffer stability tests 
The stability of complexes at biologically relevant pH is an important factor in this 
study.  Cancer cells are slightly more acid than non-cancerous cells it is important that 
the molecular probes are stable at lower pH.
146
  All fluorescent scans were carried out 
with an excitation wavelength of 400 nm and at a concentration of 100 M, with a 1:1 
DMSO:buffer solution. An initial preliminary study was carried out using fluorescence 
spectroscopy for gallium and indium complexes.  There is a clear trend in the behaviour 
of the indium complexes in these buffers.  All displayed fluorescence between pH 2 and 
pH 9, indicating that compounds have good stability at normal physiological pH and 
reflecting their potential for protonation and deprotonation (Figure 5.21).  Under more 
alkaline conditions the emission bands are slightly blueshifted, which indicates that a 
different species may be present, perhaps OH
-








Following the above preliminary study allyl substituted compounds were selected as 
representative of the other functionality to assess the stability of newly synthesised 
gallium and indium complexes using UV-visible and fluorescence spectroscopy both at 
15 minutes and 24 hours, with 1:1 DMSO:buffer solution. The pH of the samples was 
  4d, 100 µM 
Buffer Measured pH % stability at 15 mins % stability at 24 h 
pH 1.1 1.6 76.1 NS 
pH 2 2.5 99.0 NS 
pH 3 4.4 95.1 95.0 
pH 5 6.9 93.3 93.0 
pH 7 9.4 86.4 37.3 
pH 9 9.35 83.9 81.4 






measured and found to have no significant difference to the blank, however with a 




Figure 5.21. Fluorescence spectroscopy buffer assay  4a pH study (above). Where pH 3  > pH 2 > pH 7 > 
pH 9 > pH 5 > pH 1.1 ≥ pH 9.4 ≥ pH 10, 4b pH study (below). Where pH 2 > pH 3 >> pH 5 > pH 9 > pH 
7 > pH 9.4 ≥ pH 10 ≥ pH 1.1.  
 
      Furthermore complex 4d (Figures 5.22-5.23 and Appendix Figure D.39-45) 
appeared most stable at either pH 2 or pH 3 after 15 minutes or less, which is also in 
agreement with data acquired where citric acid was a component of the buffer solutions.  
When incubated in pH 1.1 buffer the absorption spectrum of 4d maintained some of its 
original characteristic shape, suggesting some yet poor stability especially when 
comparing its fluorescence spectrum, which was almost identical to that of iid 






























































both 1d and 3d after 24 h fluorescence and absorption of 4d diminished signifying 
complete decomposition and instability of these complexes under the harsh conditions 
of a pH 1.1 buffer. Interestingly, despite complex 4d displaying very high stability by 
both fluorescence and UV-visible after 15 minutes, after 24 h absorbance has decreased 
and no longer possessed the characteristic 4d complex absorption spectrum in pH 2 
buffer.  It is most likely, however that some complex does remain since the fluorescence 
intensity is significantly greater than that of free ligand iid and the UV-visible spectrum 
of 4d after the 24 h incubation does not resemble that of the free ligand.   
 
  Incubations in pH 3.0 and pH 5.0 buffers demonstrated very strong stability, with 
almost identical spectra by both UV-visible and fluorescence spectroscopy after 15 
mintes and 24 hours, each displaying the typical 4d complex absorption spectrum. 
When challenged with a pH 7.0 and pH 9.0 buffer highly comparable results were 
found in that good fluorescence and characteristic UV-visible spectra were 
observable after 15 minutes. This was followed by a blue shift in absorbance and a 
considerable decrease in fluorescence indicating that a large proportion of the 
complex has likely formed the free ligand Compound iid, yet with a significant 
proportion of the indium complex 4d remaining intact under the conditions tested. 
 
    Similar to observations made with regards to the zinc and gallium complexes, 
stability appeared poorer when incubated with a pH 10.0 buffer than with a pH 9.0 
or pH 7.0 buffer, here with the blue shift observable after 15 minutes when 
compared to the characteristic shape of the absorption spectrum of 4d and a similar 
reduction in fluorescence after 24 h that was observed with the previously discussed 
pH 7.0 and pH 9.0 buffers.  Interstingly, the UV-visible spectrum after 15 minutes 
was identical to that after 24 hours signifying that the loss of fluorescence intensity 









Figure 5.22. Buffer stability assays (50% DMSO, 50% water) for compound 4d at 100 µM by 
fluorescence spectroscopy (above)  and UV/Vis (below) monitored at 15 minutes at room temperature. 
 
Therefore the stability of this indium complex 4d, representative of the other indium 
complexes of this family, can be considered to be very broad with significant stability 
for all buffers in exception of pH 1.1 after 15 minutes, thus displaying fluorescence 
within a range of pH 2.5 and pH 12.7 for short-term incubations.  Longer-term 
incubations demonstrated fluorescence between pH 2.5 and pH 6.9, with stability 























 4d, pH 1.1 buffer, 15 mins
 4d, pH 2.0 buffer, 15 mins
 4d, pH 3.0 buffer, 15 mins
 4d, pH 5.0 buffer, 15 mins
 4d, pH 7.0 buffer, 15 mins
 4d, pH 9.0 buffer, 15 mins
 4d, pH 10.0 buffer, 15 mins





















 4d, pH 1.1 buffer, 15 mins
 4d, pH 2.0 buffer, 15 mins
 4d, pH 3.0 buffer, 15 mins
 4d, pH 5.0 buffer, 15 mins
 4d, pH 7.0 buffer, 15 mins
 4d, pH 9.0 buffer, 15 mins






is well within the requirements of biological experiments in strong support of in vitro 
experiments carried out on the indium complexes. 
 
Figure 5.23. Buffer stability assays (50% DMSO, 50% water) for compound 4d at 100 µM by 
fluorescence spectroscopy (left)  and UV/Vis (right) monitored at 24 hours at room temperature. 
 
  In summary, all complexes tested possess good stability in biological media within  15 
minutes incubation, with the indium complexes appearing kinetically stable after 24 h 
when assayed with 5% FCS, SFM, Citric Acid, EDTA, L-Cys, L-His, L-Met, GSH and 
pH 3.0 to pH 10.0 buffers. It was notable that the gallium complex was considerably 
less kinetically stable than the indium complex under the conditions tested, which could 























 4d, pH 1.1 buffer, 24 hours
 4d, pH 2.0 buffer, 24 hours
 4d, pH 3.0 buffer, 24 hours
 4d, pH 5.0 buffer, 24 hours
 4d, pH 7.0 buffer, 24 hours
 4d, pH 9.0 buffer, 24 hours
 4d, pH 10.0 buffer, 24 hours





















 4d, pH 1.1 buffer, 24 hours
 4d, pH 2.0 buffer, 24 hours
 4d, pH 3.0 buffer, 24 hours
 4d, pH 5.0 buffer, 24 hours
 4d, pH 7.0 buffer, 24 hours
 4d, pH 9.0 buffer, 24 hours






bis(thiosemicarbazonates) resulting in lower lability in aqueous media.
150
 These assays 
are a good indicator of strong biological stibility, indicating that experiments could 
proceed to testing in vitro.   
 
5.6 Two-photon fluorescence lifetime study 
 
  The two-photon investigation was introduced in Chapter 2 and was performed at the 
Rutherford Appleton Laboratory under the supervision of Dr S Botchway. Indium 
complexes were incubated at 50 μM, 0.5% DMSO, for 20 minutes, unless stated 
otherwise in the text. The fluorescence lifetime components τ1, of the indium complexes 
in solution were ca. 0.45 ns for 4a, ca. 0.4 ns for 4b, ca. 0.2 ns for 4c and ca. 3.5 ns for 
4d (Table 5.6).  TCSPC using either 810 nm or 910 nm gave highly similar results 
under the same conditions.  
 
Table 5.6. Two-photon Time Correlated Single Photon Counting data of solutions in DMSO of indium 
bis(thiosemicarbazonato)complexes. 
 4a 4b 4c 4d 
ex  = 810 nm χ
2
 = 1.06 
0.454 ns 100% 
χ2 =  1.19 
0.454 ns 100% 
χ2 = 1.24 
0.174 ns 54.4% 
0.391 ns 45.6% 
χ2 = 1.11 
0.458 ns 100% 
ex  = 910 nm χ
2
 = 1.42 
0.466 ns 100 % 
χ2 = 1.32 
0.453  ns 100% 
χ2 = 1.42 
0.182 ns 58.9% 
0.375 ns 41.1% 
χ2 = 1.43 
0.442  ns 100% 
 
 
Table 5.7. Two-photon fluorescence lifetime imaging data in HeLa cells of indium 
bis(thiosemicarbazonato) complexes, ex  = 810 nm. 
Compound 4b 4c 
χ2 1.33 1.26 
τ1 % 92 83 
τ1 / ns 0.262 0.278 
FWHM / ns 0.066 0.412 
τ2 % 8 17 
τ2 / ns 1.314 2.265 







Figure 5.24. Two-photon fluorescence lifetime map (τm) at 910 nm in HeLa cells after 20 minutes of 
incubation of iib (left) at 100 µM, 1% DMSO, 4b at 50 µM, 0.5% DMSO (right) 
 
  There were small differences between the τ1 values of the indium complexes in cancer 
cells and in solution, but this can largely be attributable to the interaction with cellular 
components or biological media. As was the case with the gallium complexes when 
excited with 810 nm or 910 nm in vitro, the minor component was longer than expected 
according to the solution data (Appendix Table F.8).  A long component of ca. 2 ns for 
4b and 4c was observable as a minor component using ex  = 810 nm indicating that a 
small proportion of the complex may convert to free ligand within the cell during the 
time course of this experiment. This could mean in both cases the presence of 
autofluorescence or of ligand precursor, however for the purposes of these experiments 
is not significant since the longer minor component was proportionally quite small 
(between 8 and 17 %) and therefore most of the complex is stable under these 
conditions (Table 5.7). Additionally, the indium compounds were considerably more 
fluorescent than their corresponding proligand at 910 nm, therefore the better intensity 
obtained at lower concentrations for the complexes is also indicative of stability (Figure 
5.24). 
 
  Fluorescence lifetime imaging was therefore used to provide evidence that the newly 






combined use of UV-Visible spectroscopy, fluorescence spectroscopy and FLIM offer a 
powerful method of investigating small molecule stability in both solution and in cells. 
 
5.7 Laser scanning confocal microscopy 
 
Cells were cultured using standard protocols, analogous to earlier investigations on 
ﬂuorescent thiosemicarbazones, as described in Chapter 4.5. Imaging conditions for 
complexes 4a-4d were standardised in an identical manner to the gallium complexes, 
with standard incubations of 0.5 % DMSO, 50 µM for 20 minutes. Cells were washed 
three times with PBS, which was replaced with serum free medium.  As was observed 
with complexes 3a-3d, compounds 4a-4d caused significant changes in cell 
morphology after 60 minutes and therefore 20 minute incubation times were used, 
which showed little cytotoxicity.   
 
    
a)                  b)         c) 
  
d)            e) 
Figure 5.25. Single-photon confocal microscopy images of 4c in MCF-7 cells, 20 minute incubation, 50 
µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) excitation at 
488 nm, emission >505 nm, (d) micrograph of cells after excitation at 543 nm and (e)  is an overlay of (a), 







Initial experiments were carried out with the complex incubated alone, whereby each 
compound displayed significant fluorescence within cells when excited at 488 nm, with 
a long pass filer of 515 nm (Figure 5.26).  With the exception of 4b, each complex 
showed sufficiently weak fluorescence when excited at 543 nm, using a long pass filter 
at 606 nm enabling experiments with red colocalisation dyes to proceed (Figure 5.27).   
  There was seldom any fluorescence in the blue channel when exciting at 405 nm at 
37°C for all of the indium complexes an example of which is included (Figures 5.26, 
5.27 and Appendix G).  
 
   
a)               b)         c)    
   
e)               f)         g)        
Figure 5.26. Single-photon confocal microscopy images of 4b at 50 µM 0.5% DMSO in HeLa cells, 20 
minute incubation, at 37°C (b) excitation at 488 nm (c) micrograph of cells after excitation at 543 nm and 
(d)  is an overlay of fluorescence micrographs excitation at 405 nm and (a -b) and (e), (e), (f) and (g) are 
the DIC image from excitation at 405, 488 and 543 nm, respectively. Scalebar: 20 μm. 
 
At 4°C red-shifted fluorescence emission was observed an effect that was also displayed 
for the analogous gallium complex (Appendix Figure G.20). Interestingly, rapid 






when HeLa cells were incubated with 4b (Figure 5.27), which occurred in the time 
taken to acquire the image.  Such an intense photoactivity was not observed for any 
other complex of this class, with the ethyl-substituted complex therefore possessing 
interesting photosensitive properties. 
  Furthermore, Figures 5.27 e-g shows blebbing occurring within the cell, however no 
changes in localisation were observed as with complex 3b (Section 4.5). Uptake was 
observed at both 37°C and 4°C, which indicates that entry to cells can occur by passive 
diffusion alone. Interestingly, emission in the green channel was much weaker at 4°C 
(Appendix Figure G.25), with increased fluorescence in the blue channel (λex = 405) and 
in the red channel (λex = 543). However, complex 4c was irradiated for ca. 10 minutes 
with 488 nm and did not result in a significant change in cell morphology or size 
indicating that this compound was not phototoxic under the conditions tested, 
confirming the significance of functionality to this study (Appendix Figures G.26-27). 
 
  
Figure 5.27. Single-photon Epi-fluorescence microscopy images of 4d in FEK-4 cells, excitation with 
light 400-500 nm, emission >505 nm 3 hour incubation, 100 μM, 1% DMSO at 37 °C (left) and at 4°C  









Figure 5.28. Single-photon confocal microscopy images with Hoechst stain of 4a at 50 µM 0.5% DMSO 
at 37°C, and in HeLa cells after 20 minutes. (a) Micrographs of cells after excitation at 488 nm. b) 
Overlays of respectively, of the corresponding DIC image and the micrograph after excitation at 405 nm.  
Scalebar: 20 μm 
 
  
a)      b) 
Figure 5.29. Single-photon confocal microscopy images with Hoechst stain and 4c at 50 µM 0.5% 
DMSO at 37°C, 6 hour incubation in PC-3 cells (c-d). (a) Micrograph of cells after excitation at 488 nm. 
b) Overlay of (a), of the corresponding DIC image and the micrograph after excitation at 405 nm, 
emission 420-480 nm (a), (b) and (c).  Scalebar: 20 μm 
 
  Incubations of 4b and 4d in FEK-4 cells over 3 hours (with concentrations as high as 
100 µM) followed by Epi-Fluorescence microscopy showed that compounds entered 






enters the nucleus under both conditions (Figures 5.28). Additionally cellular 
morphology was not visibly affected on the timescale of this experiment, with highly 
comparable data acquired for 4b and 4d. This contrasts with the results observed at the 
incubation of these compounds (50 µM) in HeLa and PC-3 cells, which showed 
morphological changes even after 60 minutes at either 4°C and 37°C.   
  This suggests that these compounds may be more cytotoxic towards cancer cell lines 
than non-cancer cells and are explored in Chapter 6.  To obtain further confirmation of 
the nuclear uptake, cells were co-stained with Hoechst (nuclear stains from Invitrogen) 
as well as the compounds. Cells were incubated with 50 µM of the compound using 0.5% 
DMSO for 20 minutes, 60 minutes and up to 6 hours. Complexes 4a, 4b and 4d entered 
the nucleus of cancer cells within 60 minutes, with low levels of uptake after 20 minutes 
(Figure 5.29 and Appendix Figures G.35-45). Compound 4c, however did not co-
localise with Hoechst after 6 hours confirming that the compound does not enter the 
nucleus (Figure 5.30 and Appendix Figure G.45).  Intact cellular morphologies were 
observed after 20 minute incubations suggesting that uptake does not compromise the 
nuclear membrane as a result of complex toxicity.  
 
5.7.1 Fluorescence images of the nucleus and chromosomes 
  Due to the observed nuclear uptake a preliminary investigation was carried out at the 
Rutherford Appleton Laboratory with Dr Yusuf Mohammed and Ms Ana Estandarte to 
assess whether the complexes bind to chromosomes. Non-cancerous lung cell line 
CCD37-LU was cultured in DMEM containing 10% foetal bovine serum (FBS) and 1% 
L-Glutamine at 37°C in a 5% CO2 incubator.  Chromosomes were isolated via a 
Colcemid (Gibco BRL) treatment before cells were trypsinised and subsequently 
resuspended in pre-warmed KCl hypotonic solution (0.075M) at 37°C for 12 minutes.  
This was followed by fixing in a 3:1 methanol/acetic acid solution, which was added 
onto a glass microscope slide, to which 100 µL of Compound 4d (100 µM) was 








a)                 b) 
Figure 5.30. Epi-fluorescence images of 4d in (a) Isolated Cellular nucleus b) Isolated chromosomes 
 
  Finally images were acquired using a Zeiss Axio Imager 2 microscope, which showed 
uptake of the complex in both the nucleus and in chromosomes.  The entry to the 
nucleus was expected and is in agreement with the Hoechst study above and with 
apparent uniform binding to chromosomes (Figure 5.30). Further work could be carried 
out to assess if band patterns observed with this complex 4d is different for cancer and 





  As discussed above, 4c did not enter the nucleus and therefore behaves differently 
when compared to other indium compounds. It was subsequently was found to localise 
within the endoplasmic reticulum, which is involved in protein and lipid synthesis 
(Figure 5.31a). It can be hypothesised that the aromatic functionality enables different 
binding modes within the cell when compared to the other substituent groups. Moreover 
compounds 4a, 4c and 4d appeared to localise in the lysosome and the mitochondria 







     
a)                             b) 
   
c)                       d) 
Figure 5.31. Single-photon confocal microscopy images 20 minute incubation, 50 µM 0.5% DMSO at 
37°C of a) 4c and ER tracker in PC-3 cells, b) 4c and Mitotracker in PC-3 cells, c) and d) 4a and 
Lysotracker Red in HeLa cells. Where a), b) and d) are overlays of images of DIC, a micrograph of 
excitation at 488 nm, emission >505 nm and a micrograph of cells after excitation at 543 nm, (c) is a 
micrograph of cells after excitation at 543 nm. 
 
  In summary uptake of indium complexes was similar to that of the gallium complexes 
in that localisation was observed in the mitochondria and the lysosome, long-term 
experiments more than 20 minutes caused cytotoxicity and photoactivity was observed 
for the ethyl-substituted complex. Interestingly localisation did not change when 
irradiated with light. Another notable difference was that indium complexes entered the 






showing that complex 4d uniformly binds to the chromosomes of a non-cancer cell line, 
CCD37-LU.  Tests in cancer cells can evaluate if a difference can be observed, which 
could assess the potential of the compound as a clinical diagnostic. 
 
5.8 In vitro hypoxia selectivity testing 
 
  An analogous study to the one carried out using the gallium complexes in EMT6 
(murine breast carcinoma) and PC-3 cells, was carried out under the supervision of Prof 
Eric Aboagye (by Dr Israt S. Alam) at Hammersmith Hospital, Imperial College 
London. Compounds 4c and 4d were incubated in cells at 50 µM, 4% DMSO, with 
normoxic conditions of 20.7% O2 and 5% CO2 at 37
ᵒ
C, with hypoxic samples pre-
incubated for 20 minutes at 1% O2, 5% COᵒ2 at 37
ᵒ
C before complex addition.  
Following addition of the compound, cells were incubated for a further 20 minutes and 
subsequently washed three times with PBS before being returned to serum free media 
and imaged immediately.   
 
  
Figure 5.32. Confocal micrographs of 4d in FEK-4 cells under normoxic (left) and hypoxic (right) 
conditions. 
 
An initial confocal study was carried out within which significant differences in 
fluorescence were biologically relevant to determine (Figure 5.32).  Therefore a flow 
cytometry study was carried out, which as was observed in the gallium complex, 
fluorescence was lower under hypoxic conditions than normoxic conditions.  For the 
allyl-substituted indium complex, the fluorescence was lower by 25.4% (*P<0.01) in 






emission under hypoxic conditions for complex 4c seems lower by 22% (*P<0.05) in 
EMT6 cells and by 8% (*P<0.05) in PC-3 cells (Figure 5.33).  
 
 
Figure 5.33. Flow cytometry studies under normoxia and hypoxia of 4d in EMT6 (above) and in PC-3 
cells (below). 
 
  The level of hypoxia selectivity is therefore similar for 4c and 4d, with the selectivity 
of 4d slightly greater than that of 4c.  It is likely as was observed with the gallium 
complex that under hypoxia and the resultant reduction of the metal centre the complex 
demetallated causing a loss of fluorescence.  A future study using radiochemical 






5.9 Summary to Chapter 5 
 
  New indium bis(thiosemicarbazonato) complexes have been synthesised and 
characterised by NMR spectroscopy, ES-MS and X-ray crystallography.  Data show a 
strong preference towards the symmetric isomer, with only this isomer assignable by 
NMR  X-ray crystallography and DFT calculations are in agreement with this, with the 
optimised symmetric complex more stable than the asymmetric complex in the gas 
phase and in solution (a finding not observed for the respective zinc, copper or gallium 
complex).  Furthermore complexes were cleanly and rapidly radiolabelled in addition to 
possessing sufficient fluorescence to continue the study with an in vitro cell uptake 
study.  Complexes were found to possess excellent stability via tests in solution 
biomimetic media, biologically relevant agents and possessed stability over a broad pH 
range (pH 4.4 to pH 12.7 by UV-visible spectroscopy and pH 2.5 to pH 12.7 by 
fluorescence spectroscopy).  Furthermore, two-photon fluorescence lifetime imaging 
microscopy confirmed the stability of these complexes in cancer cells. Additionally, 
indium compounds of this type localised in the mitochondria and lysosome, with the 
phenyl-substituted complex entering the endoplasmic reticulum. 
 
  Moreover, the indium complex with an ethyl functionality displayed phototoxicity, as 
did the corresponding gallium complex, yet without a change in localisation within the 
cell.  Interestingly the indium complexes (with the exception of the phenyl-substituted 
complex) localised within the nucleus and were found to bind to chromosomes in a 
preliminary study. Furthermore hypoxia selectivity was observed for complexes 4c and 
4d in EMT6 and PC-3 cells by way of a reduction of fluorescence monitored by flow 
cytometry.  In summary, these complexes show potential in diagnostics either as 









Chapter 6. Cellular investigations  of new bis(thiosemicarbazonato) 
complexes by cytotoxicity assays 
 
In this chapter pharmacological assays were performed in order to understand the 
cellular toxicity of the newly synthesised compounds. Standard MTT and LDH assays 
were adapted and used hereby. Cell viability and cytotoxicity assays cause a 
colorimetric response, which allow a chosen biological characteristic or process to be 
monitored. An increase in absorbance can either be the result of living cells retaining 
normal functions and/or morphology (cell viability assay) or alternatively the result of 
cellular disruption (cytotoxicity assay). 
  Various assays monitor different functions and do not always give the same result.  
Therefore it is beneficial to carry out more than one.  On one hand, the Lactate 
Dehydrogenase (LDH) assay is informative on cell membrane lysis over short periods 
of time, but instead indicates overall toxicity for longer periods of time, such as 24 h.  
Methyl Tetrazolium (MTT) assay on the contrary is indicative of the number of live 
cells and therefore the overall toxicity of a particular drug. Mitochondria of live cells 
convert MTT into formazan, which absorbs broadly around 500 nm; increased toxicity 
therefore results in low absorbance, with all MTT assays carried out at 570 nm. The 
mitochondria of any non-viable cell will not be functional; therefore this assay is not 
informative per se on action on the mitochondria. 
 
6.1 Time series assays by MTT 
 
  A preliminary study was carried out in FEK-4, a non-cancer fibroblast cell line at 10 
μM at 1 hour, 3 hours, 6 hours and 24 hours to assess the effect of the complexes and 
Cu[ATSM] on cells with time by MTT assay.  The allyl substituted complexes were 
chosen as representatives of the other functionalities to allow the effect of the metal on 
cytotoxicity to be considered, whilst the indium complexes were selected for the 







  The analogous allyl compounds and Cu[ATSM] enabled an initial comparison 
between metal centre, the addition of the acenaphthenequinone backbone and allyl 
functionality to be investigated for the first time. Zinc and copper, metals of biological 
significance represented the acenaphthenequinone complexes of highest and lowest 
cytotoxicity respectively.  The gallium and indium compounds displayed very similar, 
gradual toxicity, which indicates that the mechanism of action may be due to their 












































Figure 6.1. MTT assays at 10 μM in FEK-4 in SFM EMEM of allyl complexes (above), indium 
complexes (below). 
 
  In contrast 1d and Cu[ATSM] demonstrated more rapid activity upon cells each with 
ca. 60% viability after 3 hr, with 2d, 3d and 4d ca. 80% viability after incubation at this 
timepoint.  The comparison between Cu[ATSM] and 2d implies that the addition of the 






attribute for a potential diagnostic.  This could perhaps be due to the greater stability 
and subsequently lower reactivity of 2d with respect to Cu[ATSM].   
 
  The absorbances of 4a, 4b and 4c were comparable, indicating that the effect of the 
functionality may be less significant than that of the metal centre. 4d is an exception, 
with somewhat higher cytotoxicity displayed here and may be due to the greater 
reactivity of this substituent compared to the relatively unreactive methyl, ethyl or 
phenyl groups.  
 
6.2 MI50 determinations by MTT 
 
  To explore this further and to obtain quantitative measures of the cytotoxicity of this 
family of compounds the MI50, the concentration at which metabolism is reduced to 
50%, were calculated using MTT assay for a 48 h incubation with the compound, 1% 
DMSO. The value corresponding to 50% cells was corrected for background absorbance, 
which corresponded to the point at which all cells of a sample were dead. 
 Previous studies in the group using trypan blue and an incubation time of 48 hours 
found that zinc complex 1d and copper complex 2d possessed LD50 values of ca. 15 µM 
and 25 µM respectively in MCF-7 cells,
127
 with zinc complexes 1a, 1b and 1c 
cytotoxicity estimations of 15 µM.
128
 Similarly, 2b had LD50 values of ca. 12.5 µM in 
IGROV (ovarian cancer) cells and ca. 50 µM in MCF-7 (breast cancer) cells.
123
 This 
hence indicates that the zinc complexes may be marginally more cytotoxic than the 
copper compounds.  (Since quantitative data from trypan blue is achieved by the 
counting of cells, of which the dye stains the membrane of intact cells, metabolism is 
not measured and therefore was referred to as LD50, here defined as the concentration to 
kill 50% of cells.)  Cis-Platin (CP), in comparison was estimated to possess LD50 values 
of ca. 4.0 µM in IGROV cells and ca. 12.0 µM for MCF-7, meaning that whilst the zinc 
and copper complexes appeared to possess comparable cytotoxicity to CP, however 







6.2.1 Cell viability assays in HeLa cells 
  MTT assay was chosen as an alternative to the more time consuming and less sensitive 
trypan blue. Control experiments were used to determine a MI50 of CP and was 
calculated to be 27 µM ± 5 µM under comparable conditions and in agreement with the 
literature
152
, whilst Cu[ATSM] was found to be 0.55 µM ± 0.03 µM in HeLa cells, a 
cervical cancer cell line.  By crystal violet method Cu[ATSM] had previously been 
estimated to have a value of ca. 18.6 µM in HeLa indicating a stark difference in nature 
of the cytotoxicity tests, whereby crystal violet stains DNA as opposed to MTT assay 
which is dependent on metabolism of mitochondria.
153
 Considering Table 6.1, which 
includes the MI50 data gathered on all compounds tested in HeLa, each with at least 3 
repeat experiments allowed this family of molecules to be compared in terms of their 
cytotoxicity.   
 
Table 6.1. MI50 data of compounds in HeLa cells, where N/A = no significant cytotoxicity and nd = not 
done.




 a b c d 
i 0.105 µM ± 0.006 µM 6.5 µM ± 0.7 µM 6.4 µM ± 1.8 µM 0.18 µM ± 0.04 µM 
ii N/A 28 µM ± 13 µM† 5.2 µM ± 0.8 µM N/A 
1 nd 3.0 µM ± 0.2 µM 3.0 µM ± 0.6 µM nd 
2 nd 17 µM ± 4 µM 19 µM ± 1µM nd 
3 0.49 µM ± 0.03 µM 1.6 µM ± 0.2 µM 3.6 µM ± 0.8 µM 0.91 µM ± 0.03 
4 0.37 µM ± 0.10 µM 1.0 µM ± 0.2 µM 0.38 µM ± 0.07 µM 0.44 µM ± 0.16 µM 
 
                                                 
*







Figure 6.2. Scatter graph representing MI50 in HeLa cells a) of id b) of 4b 
 
General patterns were observable that the indium complexes possessed greater 
cytotoxicity than the gallium complexes, which in turn were more active than the zinc 
complexes (Appendix Figures H.1-H.9).  Of the complexes copper was the least 
cytotoxic, with comparable potency to CP.  Proligands iib demonstrated low levels of 
cytotoxicity, with compound iia and iid showing little cytotoxicity in preliminary 
experiments, indicating that chelation improves the activity of bis(thiosemicarbazones).  
Much greater cytotoxicity, however, was expressed by iic at 5.2 µM ± 0.8 µM, yet this 
was less toxic than its corresponding complexes, with the exception of the 
comparatively lower activity of the copper compound 2c. Mono-substituted free ligands 
displayed the most variable properties with ia the most potent compound tested and ib 
with similar cytotoxicity to 2b in HeLa cells. Interestingly compounds 1b and 1c 
possess significantly lower MI50 values by MTT assay when compared to trypan blue 
studies. Trypan blue experiments are dependent on cell membrane integrity therefore if 







































































it were that this family of complexes cause little membrane damage including after 
longer incubation times it could explain why the estimations differ, this is explored in 
section 6.3. 
6.2.2 Non-cancerous cells assays by MTT – investigations in FEK-4 cells 
  To prepare cancer diagnosing or treating agents, action against non-cancer cells is 
important to explore.  In FEK-4 cells these data were greatly contrasted by ia causing 
limited cell death compared with in HeLa, with a MI50 of 9 µM ± 3 µM, with id also 
possessing a MI50 of much higher than in HeLa cells (Appendix Figures H.10-12).  The 
MI50 of the gallium and indium complexes tested were comparable, yet possessing 
notably lower toxicity against the non-cancer cell line.  This data therefore provides 
strong evidence that these compounds possess selectivity towards cancer over non-
cancer.  Exhaustive studies in numerous cell lines (both cancer and non-cancer) could 
confirm if this effect is general for cancer. 
 
Table 6.2. MI50 data of compounds in FEK-4 cells 
 a d 
i 9 µM ± 3µM 5 µM ± 2 µM 
3 1.25 µM ± 0.07 µM 3 µM ± 2 µM 
4 0.95 µM ±  0.06 µM 0.82 µM ±  0.08 µM 
 
6.3 In vitro investigation to provide insight into the complex mode of action 
 
  Bis(thiosemicarbazonato) complexes had previously been tested for cytotoxicity by 
Pascu et al.,
127, 128
 and Ackerman et al.
153
.  Compounds generally showed low to 
medium toxicity, theorised to be mediated via initial the mitochondria followed by entry 
into the nucleus.
128
  To allow pharmacological comparison of the new compounds 
presented in Chapters 2-4 with known complexes such as Cu[ATSM], Zn[ATSM] as 
well as 1d, 3d and 2b a study of cytotoxicity and cell uptake was carried out using 
lactate dehydrogenase (LDH) assays in HeLa (cervical cancer cells), MCF-7 (breast 







  LDH assay indicates potential cell membrane action as a mechanism of toxicity when 
cells are incubated with the drug for short periods of time (up to ca. 6 h).  LDH 
catalyses the conversion of lactate into pyruvate, which reacts with tetrazolium salt INT 
to produce formazan.  High absorbance therefore indicates high LDH activity and a high 
amount of cell lysis.  For longer periods of time (e.g. 24 hours) this assay is 
representative of overall toxicity rather than action by membrane lysis. All LDH assays 
were carried out at 570 nm. 
 
 
a)    b)    c) 
Figure 6.3. Published fluorescence images of Zn[ATSM] in MCF-7 (a), IGROV (b) and  PC-3 (c) (breast, 




As illustrated in Figure 6.3 (Dilworth et al. 2005)
62
 one compound can behave 
differently according to the cell line it is in.  It was therefore important to investigate the 
effect of each compound in this study on a number of various cell types.  Cu[ATSM] is 
currently under clinical trials as a PET hypoxia molecular imaging probe for cancer and 
has so far been tested mainly in cancer lines.  Because of its therapeutic potential, 
however, it may be more important to test its cytotoxicity on non-cancerous cells.  In 
this study FEK-4 cells, which are non-cancerous were used for comparative purposes of 
anti-cancer selectivity.  HeLa (cervical cancer) and MCF-7 (breast cancer) were the 
cancerous cell lines chosen to investigate this compound class. Each dataset is a repeat 


































Figure 6.4. MTT assay (above) and LDH assay (below) of HeLa cells, where black is medium control, 
containing Foetal Calf Serum (FCS), dark grey is the serum free medium (SFM) control, light grey is the 
DMSO control (99:1, SFM:DMSO), orange is 3d, dark green is 1d, light green is Zn[ATSM], dark blue is 
2b. Compounds were incubated in 99:1, SFM:DMSO at 10 μM concentration. 
 
Both assays were in agreement that the (M = Zn and Cu) [ATSM] compounds showed 
greater overall toxicity and that the remaining compounds were of relatively equal 
toxicity in this cell line. Zn[ATSM] was the only compound with fast-acting 
cytotoxicity (Figure 6.4). 2b showed most of its toxicity within the first 3 hours, which 
















































Figure 6.5. MTT assay (above) and (below) LDH assay of MCF-7 cells, where black is medium control, 
containing FCS, dark grey is the SFM control, light grey is the DMSO control (99:1, SFM:DMSO), 
orange is 3d, dark green is 1d, light green is Zn[ATSM], dark blue is 2b. Compounds were incubated in 
99:1, SFM:DMSO at 10 μM concentration. 
 
LDH leakage was higher than for controls in the first 3 hours for the (M = Zn and Cu) 
[ATSM] complexes and 2b, indicating that they cause cell membrane lysis and possibly 
explaining why there was such a strong correlation between the MI50 and the LD50 
values obtained for 2b. The 1d and 3d, however, did not appear to act on the cell 






This could clarify the discrepancy of lower cytotoxicity observed for the zinc complexes 















































Figure 6.6. MTT assay (above) and LDH assay (below) of FEK-4 cells, where black is medium control, 
containing FCS, dark grey is the SFM control, light grey is the DMSO control (99:1, SFM:DMSO), 
orange is 3d, dark green is 1d, light green is Zn[ATSM], dark blue is 2b. Compounds were incubated in 
99:1, SFM:DMSO at 10 μM concentration. 
 
  All (M = Zn and Cu) [ATSM] and 1d and 3d displayed a significant toxicity from 3 






effect during the first hour for Zn[ATSM] (Figure 6.5). 2b, in comparison showed little 
toxicity until 24 hours. The LDH assays indicated that some membrane activity was 
displayed by (M = Zn and Cu) [ATSM] compounds and 3d. 
 
With exception of Zn[ATSM] all compounds displayed little toxicity until 3 hours. 
From 6 hours onwards, however, all compounds, excluding 2b showed high toxicity.  
The LDH assays indicate significant cell membrane lysis by the (M = Zn and Cu) 
[ATSM] complexes and 2b and slight lysis by both 1d and 3d compounds.  After 
discussing these compounds in the respective cell lines it was next possible to consider 
them per compound. 
 
6.3.1 Discussion of trends emerging from in vitro cytotoxicity 
investigations 
 
6.3.1.1 Compounds: 1d and 3d  
 
  1d and 3d displayed rapid moderate toxicity, showing significant difference from the 
controls at 3 h for FeK4 (non-cancer) and MCF-7 and at 6 h for HeLa and a gradual 
decrease in cell viability for all cell lines (MTT assays, Figures 6.4-6.6a). 1d showed 
significantly greater LDH leakage after 24h in MCF-7 and FEK-4 cells, rendering 
membrane activity very unlikely for this compound.   
 
  For 3d the LDH assays showed a considerable leakage in MCF-7 and slight leakage in 
FEK-4 at 6 h, but there was no significant difference between the leakage of controls in 
HeLa cells. It is therefore possible that for 3d cell membrane lysis is a mechanism of 
action in MCF-7, whereas it is more likely to be another mechanism, perhaps DNA 
damage for HeLa cells. This is a possibility due to the gradual nuclear uptake of 1d 
(previously carried out by the group) and 3d observed in this study by fluorescence 
microscopy (Chapter 4.5).  Furthermore, a long-term LDH assay showed less LDH 
leakage for 1d and 3d than controls, which could be indicative of DNA repair by Poly-












Figure 6.7. long-term LDH assay in HeLa cells (above), where black is medium control, containing FCS, 
dark grey is the SFM control, light grey is the DMSO control (99:1, SFM:DMSO), orange is 3d, dark 
green is 1d, light green is Zn[ATSM], dark blue is 2b. Compounds were incubated in 99:1, SFM:DMSO 
at 10 μM concentration. A comparison between the pathways of PARP and LDH, indicating that DNA 
repair in cancer cells could be the cause of reduced absorbance in an LDH assay (below). 
 
6.3.1.2 Known compound: Zn[ATSM]  
 
  Zn[ATSM] displayed rapid toxicity on all cell types, resulting in significantly less cell 
viability after only 1h incubation and was therefore the most toxic of the compounds 
tested.  Microscopy by Dilworth et al. (Figure 6.3) showed nuclear uptake by MCF-7, 
PC-3 and IGROV (however most of the localisation for IGROV was in the lysosome), 
















































































































observed after 3h in all cell lines tested pointing to cell membrane damage as a likely 
cytotoxicity mechanism (Figures 6.4-6.6b), which is supported by the work of Dilworth 





6.3.1.3 Known Compound: Cu[ATSM]  
 
The known compound  Cu[ATSM] displayed medium toxicity to the cancer cell lines 
tested and there was significantly less toxicity to non-cancerous FEK-4 cells.  This is a 
promising result since 
64
Cu[ATSM] is currently in clinical trials as an in vitro PET 
molecular imaging probe, indicating that cytotoxicity is negligible at concentrations 
required for nuclear imaging.  The data show that this compound is likely to cause cell 
membrane damage in FEK-4 and HeLa cells, and may also in MCF-7 cells, since LDH 
leakage was observed up to 6h incubation with the complex. Zn[ATSM] is used as a 
model for the cell uptake of Cu[ATSM], which is not fluorescent due to quenching by 
the Cu(II) (3d
9
).  Therefore in consideration that Zn[ATSM] enters the nucleus it is 
reasonable to expect Cu[ATSM] to do likewise indicating DNA damage as another 
possible mechanism.   
 
6.3.1.4 Compound: 2b 
 
  Cell viability observed in MCF-7 and FEK-4 when incubated with 2b showed little 
variation with controls, making it the least toxic of the compounds tested in this study.  
The compound, however, showed medium toxicity towards cervical cancer cells, 
indicating that investigations with further cell lines are necessary to fully understand the 
cytotoxicity of 2b. The LDH study indicated significant cell leakage from 1h in HeLa 
and FEK-4 cells, which decreased with time for HeLa cells.  This could indicate that the 
mechanism of cytotoxicity is by a non-linear mechanism of cell membrane lysis.  The 
microscopy study indicated localisation in the cell membrane, which is suggestive of 







6.4 Summary to Chapter 6 
 
  The cytotoxicity of this family of compounds have been investigated in three cell lines 
allowing comparisons to be made between metal centre, functionality, relative speed of 
and mode of action on cancerous and non-cancerous cells. It was possible to make 
general conclusions such as:  (a) the metal complexes were more toxic than their bis-
substituted free ligands, (b) copper complexes were the least cytotoxic of the metal 
compounds tested, (c) for all compounds tested so far more activity was observed 
against cancerous cells than non-cancerous cells indicating a possibility of selectivity. 
  Further experiments however, in numerous cell lines are needed to fully elucidate if 
this is a universal prospect for future cancer treatment and diagnosis. The phototoxic 
effect of these compounds discovered in previous Chapters could be explored as it was 
not investigated using cell viability or cytotoxicity assays. Whilst there was some 
exposure to light as the compounds were added to cells, all samples were incubated in 
absence of light.  
  The comprehensive localisation of these compounds in a number of organelles 
observed in previous Chapters indicate that numerous modes of action are plausible, 
many of which could be investigated further in another study. However the activity on 
the cell membrane observed in this project suggest that this is a plausible mode of action 
for the copper complexes, Cu[ATSM] and 2b, with the lack of membrane activity by 
the zinc complexes indicative of the different results obtained here by MTT assay and 





Chapter 7. Investigations towards the syntheses of a peptide-targeted     
bis(thiosemicarbazonato) complex, spectroscopic and in vitro imaging 
 
7.1 Introduction to Chapter 7 
 
Receptors of many peptides are overexpressed in a large number of cancers and 
therefore form a means of targeting cancer. Furthermore peptides have an advantage 
in that they enable fast uptake into tissue of interest and more efficient body 
clearance when compared to antibodies.
155
 Imaging of tumours using peptides was 
first achieved in 1989 as Krenning et al. detected radiolabelled somatostatin using a 
gamma counter.
156
 Each peptide facilitates the targeting of its own unique selection 
of receptors and tumours, for example somatostatin analogues provide a means of 
targeting neuroendocrine tumours. 
 
   
 
a)     b) 
Figure 7.1.  A rhenium tricarbonyl complex conjugated to a bombesin analogue and an intercalator, 
(right), visualised in fixed PC-3 cells by fluorescence microscopy (left), where green represents the 




Furthermore bombesin analogues target  numerous tumours notably prostate, 
breast, gastrointestinal and lung cancer, making it an attractive peptide as a 
component of a molecular imaging agent. Bombesin is a 14-amino acid peptide 
isolated from amphibian skin, is an analogue of the gastrin-releasing peptide found 
in mammalians and possesses strong affinity for a G protein-coupled receptor known 
Chapter 7 
208 
as GRPR.  
 
The first in vivo investigation of bombesin analoges was carried out by Van de 
Wiele et al. showing targeting of breast and prostate cancer patients in 2000.   More 
recently tricarbonyl rhenium and technetium complexes with acridine derivatives 
showed nuclear uptake via fluorescence and activity based studies respectively.
44
 
Alberto et al. developed rhenium and technetium complexes comprising of a DNA 
interchelator for nuclear targeting, a biologically active molecule (here a bombesin 
analogue) and a linker, cleavable upon cell entry displaying uptake in both the 




In addition to bombesin-targeted copper thiosemicarbazonato complexes mentioned 
in the Introduction, copper and gallium bombesin-conjugates have been synthesised 
paving the way for further investigations with this peptide. For example, a  bombesin 
analogue conjugated to NO2A radiolabelled with 
64
Cu allowed visualisation of PC-3 
xenografts, with preliminary in vitro studies recently carried out on a new cyclam 
bombesin derivative.
53, 159





Lu, showing good tumour uptake in PC-3 xenografted 
nude mice, where 
67/68
Ga can act as a diagnostic radionuclide and 
177





Conjugation of a bombesin analogue to the acenaphthenequinone 
bis(thiosemicarbazonato) complex could result in the development of dual-modal 
fluorescent and PET or SPECT imaging probes with potential for simultaneous 
therapy due to their cytotoxicity. Furthermore, cell studies under normoxic 
conditions have shown that all compounds have toxicity towards non-cancerous as 
well as cancerous cells (Chapter 6).  Therefore, it would be beneficial to add a 
targeting group such as bombesin onto the compounds for added cancer selectivity.   
For complexes that are found not to be hypoxia selective, this would provide a 
means of targeting cancer and thus the aim of this chapter was to synthesise an 
acenaphtenequinone bis(thiosemicarbazonato) complex conjugated to bombesin.  
The first objective was to synthesise a stable and intrinsically fluorescent precursor, 
which via a linker could be attached to the peptide, followed by its spectroscopy and 
in vitro characterisation.  Finally the goal of this Chapter was to investigate the 
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possibility to couple the complex to the peptide and analyse it by the same means as 
the precursor. 
 
7.2 Attempted ligand synthesis 
 
A free ligand mono(thiosemicarbazonato) ligand was attempted by my mixing 1 
equivalent of thiocarbohydrazide with an equivalent of acenaphthenequinone in 150 mL 
of ethanol (Figure 7.2).  Upon reflux 4 drops of glacial acetic acid were added and after 
3 hours the suspension was filtered whilst hot yielding a yellow solid, which was 
analysed by mass spectrometry and NMR spectroscopy. 
Following this, the reaction was repeated with an excess of thiocarbohydrazide, in 30 
mL of ethanol and with 4 drops of acetic acid as before. After three hours the reaction 
was filtered, producing a similarly coloured powder.  Furthermore, from the filtrate 
crystals suitable for X-ray diffraction formed overnight (Figure 7.3).   
 
 
Figure 7.2. Synthesis attempt to make a free ligand suitable for peptide conjugation 
 
 
Figure 7.3. ORTEP representation of the free ligand produced by the reaction described above. 
 
  The NMR spectra were identical for the solid and the crystals from this reaction as 
well as the solid from the reaction using one equivalent of thiocarbohydrazide, 
indicating that the same product had been formed.  The crystal structure (below) as well 
as a mass spectrum of 289.074 confirmed that the desired product of a 
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thiosemicarbazonato free ligand analogous to those of previous chapters as well as 
suitable for addition of a targeting group had not been formed and that another route 
should be pursued (the calculated value was 289.075). 
 
7.3 Initial attempts via protecting group chemistries 
7.3.1 Synthesis of the mono-substituted t-Boc protected amine 
thiosemicarbazide 
 
A zinc precursor complex with t-Boc protected amines which could be de-protected 
under acidic conditions to a mono-substituted t-Boc protected amine thiosemicarbazide 
was therefore desirable. Prior to the synthesis of the complex DFT calculations were 
carried out, which confirmed the theoretical thermodynamic stability of the complex 
(Figure 7.4).   
 
 
Figure 7.4. DFT optimisation of the symmetric isomer of a zinc bis(thiosemicarbazonato complex with a 
7 amino acid bombesin analogue as one substituent and a t-Boc protected amine as the other in the gas 
phase by B3LYP 6-31G(d,p). Where grey = carbon, white = hydrogen, blue = nitrogen, red = oxygen, 




  Firstly 500 mg of thiocarbohydrazide was stirred in 5 mL DMSO for 20 minutes, 
followed by dropwise addition of an equivalent of Boc anhydride (1030 mg).  After 
stirring at room temperature for 2 hours the reaction was quenched by adding 5 mL of 
water dropwise.  The solution was frozen using dry ice and acetone, which lead to the 
precipitation of a white solid.  Mass spectrometry and NMR spectroscopy showed that 
the resultant product was a mixture of a mono-substituted and a bis-substituted 
thiocarbohydrazide.  TLC plates showed that both compounds formed long tails for a 
broad range of concentrations tested and therefore would not be readily isolated by a 
separation column.  Purifications and extractions based upon solubility were also found 
to be unsuccessful and since the zinc complex synthesis described in Chapter 3 requires 




Figure 7.5. Synthesis of mono-substituted and bis-substituted thiocarbohydrazide  
 
  The reaction conditions were therefore modified. Firstly using more dilute conditions 
resulted in very little precipitation; secondly using four equivalents of 
thiocarbohydrazide yielded a mixture of thiocarbohydrazide as well as the other two 
aforementioned products. This was confirmed by mass spectrometry m/z values of 
129.02 for thiocarbohydrazide, 229.07 for mono-substituted thiocarbohydrazide and  




7.3.2 Attempt to synthesise a Zinc(II) complex incorporated a t-Boc 
protected thiosemicarbazide 
 
  Using the assumption that the bis-substituted t-Boc protected thiocarbohydrazide 
would not react with diketone acenaphthenequinone and would possess significantly 
different solubility to the resultant zinc complex a synthesis was attempted using a 
mixture that did not include thiocarbohydrazide. An initial trial using a 50 mg mass of 
acenaphthenequinone was undertaken under analogous conditions as were used for the 
synthesis of the zinc bis(thiosemicarbazonato) complexes in 2 mL of glacial acetic acid.  
This method was not successful, producing a black solid, which was likely a polymer. 
 
  Next, these conditions were modified to be carried out in 50 mL of 1,4-dioxane with 1 
mL of acetic acid, over molecular sieves (Figure 7.6). After 30 hours the reaction was 
filtered whilst hot, which gave a white solid corresponding to crushed sieves.  The 
filtrate was allowed to cool to room temperature resulting in the precipitation of an 
orange solid, in which mass spectrometry confirmed the presence of the desired 
compound, whilst NMR spectroscopy showed that the product was impure.  The 
temperature of the filtrate was reduced, which resulted in further precipitation, with the 
orange solid produced giving similar results as described above. Therefore, the filtrate 
was rotary evaporated and washed with 50 mL of diethyl ether providing the desired 
product that by NMR spectroscopy showed significantly better purity, which was 
confirmed by LC-MS, and gave 34% yield and was successful on only one occasion. 
 
 





Figure 7.7. Chromatogram of 1e from HLPC, showing a single major peak at 2.4 minutes 
 





at 619.09 and 1243.18 respectively with a single LC trace at 2.4 minutes and was 
investigated by 
1
H NMR spectroscopy (Figure 7.7). 
 












































Figure 7.9. Selected resonances from the 
1
H NMR spectroscopy of 1e in the region of  7.5-9.6 ppm. 
 
Due to exchange with deuterated solvent NH protons appear as broad singlets.  The 
spectra show two sets of doublets and one triplet as would be expected from an aromatic 
backbone (Figures 7.8 and 7.9).  This is indicative of a predominantly symmetric 
structure, however small peaks such as at 8.46 signify that there may be a small 
proportion of asymmetric isomers present, which would be consistent with previous 
studies by the group 
31
.  A singlet would be expected of the tert-butyl groups and since 
this is not a clean signal and a greater integral than would be expected is observed, it 
may also indicate some asymmetric isomer presence. 
 
7.3.3 Spectroscopic investigations in solution 
 
  An initial 200-800 nm 2D scan in DMSO at 100 M was used in order to assess 
intrinsic fluorescence of 1e, the excitation wavelength of maximum emission and the 
range of excitation and emission (Figure 7.10).  The compound has a broad excitation 
and emission of 260-660 nm and 480-755 nm respectively, with the excitation 
wavelength resulting in maximum emission at 510 nm at 572.5 nm.  It may be possible 
that interchange with the dimeric form of the compound may reduce fluorescence 
9.6 9.3 9.0 8.7 8.4 8.1 7.8 7.5
Ppm
H-1 H-2 




emission. Compound 1e has been shown to be weakly fluorescent and therefore has 
potential for fluorescence imaging.   
 
 
Figure 7.10. 2D fluorescence scan of the 1e in DMSO at 100 M. 
 
  Quantum yield is the proportion of absorbed and emitted photons and has been 
estimated in DMSO at 100 M as 0.007 by:  
 
 
Where Φ = quantum yield, D = integrated area under emission band, S = sample, A = 
absorbance of solution at excitation wavelength, R = reference, η = refractive index of 
solvent, I = maximum intensity of excitation band [Ru(bipy)3][PF6]2 in water was used as 
a reference, with a quantum yield of 0.042. The quantum yield result confirms that the 
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7.3.5 Synthesis of t-Boc protected amine copper(II) 
bis(thiosemicarbazonato) complex 
 
The analogous copper complex (2e) was synthesised by stirring with 2 equivalents of 
copper acetate with 1e in methanol for 72 h, following isolation of a black solid by 
rotary evaporation in 40% yield. 
 
 




Figure 7.12. HPLC trace of compound 2e. 
 
7.3.6 Radiolabelling experiments 
 
7.3.6.1 Radiolabelling with Copper-64 
 
1











































Cu(OAc)2 as the starting material. 
After 2 h stirring at room temperature the desired 
64
Cu complex had not been cleanly 
made; however after 24 h the radio-trace appeared quite clean (Figure 7.13), indicating 
that the complex can be radiolabelled cleanly despite it not being a rapid process.  It is 
possible that some of these peaks represent the mono-deprotected, di-deprotected, a 
dimeric form of the compound and asymmetric isomers.  
 
(a)      
 
(b)     
Figure 7.13. Transmetallation of 1e to 2e with Cu-64 (a) after ca. 2 hours and (b) after ca. 24 hours 
 
















 1e + Cu-64 after 2h














 1e + Cu-64 after 20 h
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7.3.6.2 Radiolabelling with Indium-111 
 
 
Figure 7.14. Synthesis of acenaphthenequinone t-Boc protected amine indium(III)chloride 
bis(thiosemicarbazone) (4e) 
 
1e was further radiolabelled with indium-111 yielding two major peaks, one indicative 
of 
111
InCl3 at 3.8 minutes and the other at 7.6 minutes could be due to the indium(III) 
tert-butyl carbamate (4e) substituted bis(thiosemicarbazonato) complex (Figure 7.15). 
There was sufficient 1e for radiolabelling, however there was not enough to make 4e to 
enable spectroscopic characterisation. Peak-splitting observed in the Radio channel 
could be explained by formation of a mixture of symmetrical and unsymmetrical 
isomers, or could be explained by de-protection of the tert-butyl groups resulting in the 
formation of two species of similar size and polarity. NMR spectroscopy studies of 4e 
once it is synthesised in sufficient quantities would determine the proportion of the 
respective isomers. Unfortunately the reproducibility of the mono-substituted t-Boc 
protected thiocarbohydrazide synthesis was poor and other synthetic routes were 
investigated. 
 
Figure 7.15. 1e complex radiolabelled with In-111 
 

































7.4 Synthesis of an asymmetric zinc complex precursor 
 
  As an alternative synthetic means of developing a peptide-targeted 
bis(thiosemicarbazonato) complex, an equivalent of mono-substituted 
thiosemicarbazone, i.e. ia-id, was added to three equivalents of zinc acetate.  To this a 
vast excess of thiocarbohydrazide was added, with the mixture refluxed in acetic acid 
for 30 h.  The suspension was filtered whilst hot and washed with 100 mL of diethyl 
ether giving a yellow solid for 1aN and 1bN, a dark red solid for 1cN and a brown solid 
for 1dN.  Successful synthesis was confirmed by ES-MS, with m/z values of 420.00, 
434.02, 482.02 and 446.02 for 1aN, 1bN, 1cN and 1dN respectively and by 
1
H-NMR 
spectroscopy (Figures 7.17-7.19). 
 
 
Figure 7.16. Reaction scheme for amine-functionalised zinc bis(thiosemicarbazonato) complexes. 
 
  Interestingly, the 
1
H NMR spectroscopy or 1cN clearly shows the presence of one 
isomer, with H-1 present as one doublet representing 2 protons, which would be 
otherwise non-equivalent for the asymmetric isomer.  The H-2 and H-2’ resonances 
were non-equivalent, but overlapping, indicating that the amine group does have a small 
effect on the symmetry of the complex. The exchange observed in previous chapters 
would in fact cause two isomers to be formed as below, which would display up to six 















H-NMR spectroscopy of 1bN in d6-DMSO, 300 MHz. 
 
  Furthermore in order to synthesise a gallium complex the asymmetric ethyl and amine-
substituted 50 mg of zinc 1bN was heated into 2.5 mL of DMSO, to which an excess of 
gallium chloride was added and 30 mL of MeOH.  This was refluxed under an 
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atmosphere of nitrogen for 6 hours and was filtered after cooling to room temperature.   
The solution was removed in vacuo and the resultant material washed with 10 mL of 
ethyl acetate, followed by two times 10 mL of diethyl ether. This yielded an orange 
solid of 45 mg, which was confirmed as 3bN by m/z of 438.01 by mass spectrometry 
and 
1





H-NMR spectroscopy of 3bN in d6-DMSO, 300 MHz. 
 
7.4.1 Fluorescence spectroscopy 
  Fluorescence spectra were obtained in DMSO for initial scans between 200-800 nm, in 
order to obtain information about intrinsic fluorescence and em-max using solutions of 
100 M. Ranges of absorption and emission, which are important with regards to 
cytotoxicity assays and fluorescence imaging, were also assessed using the 2D contours 
as a guideline (Figures 7.21-7.22 and Table 7.1). Relevant cytotoxicity assays use 
absorbance readings at 570 nm, therefore there should be minimal or no excitation at 
this wavelength, which was true for each complex.  Fluorescence emission 
corresponding to the amine-substituted zinc and gallium complexes was notably weaker 
than previously characterised symmetric zinc complexes and gallium complexes. 
Interestingly the λmax of emission was blue shifted, yet with λmax of excitation being 
brought to 470 nm.  Furthermore, the excitation and emission maxima of gallium 
complex 3bN (340 nm, 526 nm) were significantly lower than that of 3b (500 nm, 556 
nm), indicating a large Stoke’s shift for this complex. The excitation range of 3bN was 
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lower than 3b; however the range of emission was broader.  The amine group therefore 
has a considerable influence on the spectroscopic properties of these complexes. 
 
a)      b) 
Figure 7.21. 2D fluorescence scan in DMSO at 100 M a) of 1d, b) of 1dN 
 
a)      b) 
Figure 7.22. Fluorescence mapping: 2D fluorescence scan in DMSO at 100 M a) of 3b, b) of 3bN 
 
Table 7.1. Fluorescence spectroscopy of zinc and gallium bis(thiosemicarbazonato) complexes 
 






























































































































































Compound ex-max / nm  Excitation range / nm λ em-max / nm  Emission range / nm 
1c 440 250-590 581.5 535-723.5 
1d 520 250-570 551 490-695 
1cN 470 250-650 553 496-734 
1dN 470 260-570 539 480-738 
3b 500 250-570 556 500-685 
3bN 340 250-530 526 459.5-684.5 
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7.4.2 In vitro cellular imaging 
 
7.4.2.1 Laser scanning confocal microscopy and fluorescence lifetime imaging study 
 
  Cells were cultured using standard protocols, analogous with earlier investigations on 
ﬂuorescent thiosemicarbazones and following the same method as described in previous 
chapters. As was observed above, fluorescence was weak, however emission 
significantly greater than autofluorescence was measured within the cell when incubated 
in cancer cells at 100 μM. In agreement with the study on symmetric 
bis(thiosemicarbazonato) complexes of this family of compounds, uptake appeared to 
be well dispersed within the cytoplasm of the cell.  The uptake of the zinc 
bis(thiosemicarbazonato) complexes (1bN, 1cN and 1dN) with an amine functionality 
displayed comparable uptake to each other when comparing the different substituent 
complexes (Figure 7.23).   
 
 
a)          b)                c) 
 
e)            f)    g) 
Figure 7.23. Two-photon fluorescence imaging of complex 1bN, 100 M,  1% DMSO,  λex = 910 nm, 
incubated in MCF-7 cells for 20 minutes. a) DIC micrograph. b) Micrograph of green channel with 
excitation at 488 nm. c) Overlay of a) and b). e) Fluorescence intensity profile. f) Fluorescence lifetime 
map (τm). g) The corresponding lifetime distribution plot in ns. 
















Fluorescence lifetime / ns
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The TCSPC in DMSO at 10 mM of these zinc complexes were similar each with a 
major component of ca. 0.05 ns, with a minor component at ca. 0.2 ns.  The minor 
component observed in solution closely resembled the major component acquired in 
cancer cells at both wavelengths for all cell lines that these compounds were tested in 
indicating stability and a conformational change in presence of cells. Furthermore, the 
asymmetric gallium complex, 3bN, with slightly stronger fluorescence was observable 
in HeLa and PC-3 cells at 50 μM, displayed similar uptake as was displayed by the 
analogous zinc complex (Figure 7.24).  The fluorescence lifetime (TCSPC) of 3bN in 
DMSO, 10 mM possessed two components, which when excited by 810 nm and 910 nm 
gave comparable results of ca. 0.65 ns and 2.4 ns, each of almost equal weighting. 
 
  The same components for complex 3bN were observed in HeLa and PC-3 cells, with 
the shorter component of 0.465 ns, 0.266 ns FWHM and 0.442 ns, 0.274 respectively 
accounting for 86 % of the fluorescence lifetime indicating a difference in molecular 
conformation in the cellular environment.  In the same way, these data and the 
agreement in solution and in cells provide strong evidence that this complex remains 
intact in vitro. Interestingly this shows a large difference in fluorescence lifetime when 
changing the metal, which was much more significant when comparing the lifetimes of 
the symmetric bis(thiosemicarbazonato) complexes. 
 
 
a)    b)    c) 
Figure 7.24. Single-photon confocal microscopy images of 3bN in PC-3 cells, 50 μM, 0.5% DMSO, 20 
minutes, at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c)  is an overlay of (a) and 





7.4.3 In vitro cytotoxicity investigations 
After demonstrating that these novel complexes enter cells it was possible to estimate 
their cytotoxicity, using the same method as described in Chapter 6 to obtain MI50 
values. These were determined in HeLa cells as 8 µM ± 2µM for 1aN, 38 µM ± 8 µM 
for 1bN, 0.68 µM ± 0.08 µM for 1cN and 16 µM ± 1 µM for 1dN.  It is interesting and 
surprising that symmetric zinc complexes 1b and 1c possessed comparable cytotoxicity, 
yet the modification of functionality to include an amine group resulted in a decrease in 
cytotoxicity for 1bN and an increase in cytotoxicity for 1cN.  Furthermore 3bN did not 
cause 100% cell death indicating its low cytotoxicity. The MI50 value was therefore 
determined to be of greater than 47 µM ± 6 µM, which is significantly less toxic than 3b 
(1.6 µM ± 0.2 µM), since 3b and 3bN possess similar solubility. This indicates a 
notable difference in cellular activity followed by this molecular alteration, but also 
greater suitability as a diagnostic, which requires low cytotoxicity.  
  
7.4.4 Derivatisation of a targeting peptide model 
 
  These complexes possessing an amine group were designed to allow a targeting group 
such as a peptide to be added and due to the suitability observed it was appropriate to 
continue and attempt to couple these complexes. A seven amino acid peptide, bombesin 
analogue was synthesised by Jennifer Williams and Fatima Merzoug via solid state 
synthesis and purified using semi-preparative HPLC by the author. Prior to peptide 
coupling it was necessary to derivatise the peptide with a linker, for which purpose 
pyruvic acid was utilised.  An equivalent of pyruvic acid was added to coupling agents 
EDC (1-ethyl-3-(3’-dimethylaminopropyl) carbodiimide) and HOBt 
(hydroxybenzotriazole) on ice in DMF.  After 45 minutes 5 mg, (1 equivalent) of 
bombesin was added followed by dropwise addition of DIPEA (N,N’-
diisopropylethylamine) until pH 8 was reached.  This was allowed to react for 2 hours 
and was subsequently extracted from DMF and purified using a solid phase extraction 




7.4.5 Peptide coupling to a zinc(II) complex 
 
  Following this 5 mg of derivatised bombesin analogue (4.55 mols) was added to 2.0 
mg (4.55 mols) of zinc complex, compound 1bN or compound 1dN in 400 L of 
DMSO, for the purpose of synthesising compound 1bB (ethyl derivative) or 1dB (allyl 
derivative) (Figure 7.25). To this mixture 10 mL of HPLC grade methanol was added 
followed by 1 drop of concentrated HCl (32%), resulting in an instant colour change 
from dark orange to yellow.  After stirring at 30C for ca. 16 hours, the solution became 
pale orange and was freeze-dried in vacuo. Reaction mixtures of complexes 1bB and 
1dB were then purified using semi-preparative HPLC as below, λabs = 400 nm (Figures 
7.32-7.33, Figures B.4-5).  Preliminary imaging in three cancer cell lines has been 
carried out, demonstrating characteristics significantly different from other 
bis(thiosemicarbazonato) complexes previously observed.  Attempts have been made to 
ionise the new complex for analysis by mass spectrometry, but have so far been 




Compound 1bN Compound 1bB 
Figure 7.25. Molecular diagrams of zinc bis(thiosemicarbazonato) complexes (left) the amine 





Figure 7.26. HPLC of compound 1bB reaction mixture (λabs = 400 nm), reference peaks to note under 
the same conditions – compound 1bN Rt = 9.2 minutes and derivatised bombesin analogue Rt = 4.8 
minutes (HPLC method E).  
 

















































Due to limited access to facilities, initial in vitro experiments were carried out on a 
reaction mixture of compound 1bB. This was analysed using HPLC and showed a 
single major peak that did not correspond to starting materials and was rotary 
evaporated and freeze-dried overnight (Figure 7.28 and 7.29). 
 
 
Figure 7.28.  HPLC traces of the derivatised bombesin (red), the zinc complex 1bN starting material 
(black) and the reaction mixture (blue) with the derivatised bombesin analogue (red), at 400 nm, HPLC 
method B. 
 

















 1bN 1 mg/mL
 Derivatised bombesin analogue 1 mg/mL
















 Reaction mixture ca. 0.25 mg/mL
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7.4.6 Initial solution study, cell uptake study, laser scanning confocal 
microscopy and two-photon fluorescence lifetime study 
 
7.4.6.1 Solution and HeLa cell study 
 
  The fluorescence lifetime of the reaction mixture of complex 1bB in solution (10 mM 
in DMSO) was found to contain 3 components, the first at 0.030 ns (77.2%), the second 
at 0.670 ns (21.3%) and the third at 2.307 ns (1.5%), χ2 = 1.28. Complex 1bN in 
solution (10 mM in DMSO) was found to contain 2 components, the first at 0.045 ns 
(92.7%) and the second at 0.236 ns (7.3%), which displayed precipitation (χ2 = 3.28). 
The bombesin-conjugated complex reaction mixture, displayed uptake in all three cell 
lines tested HeLa (cervical cancer), PC-3 (prostate cancer) and MCF-7 (breast cancer) 
cells. Interestingly the characteristics and uptake demonstrated by the complex was very 
cell line dependent, which is unprecedented for this family of complexes. In HeLa, the 
conjugated complex 1bB was modelled to two component fluorescence lifetimes with χ2 
= 1.20, τ1 = 0.689 ns, 0.406 ns FWHM, 80%; τ2 = 3.333 ns, 1.450 FWHM, 20%, which 
is similar to the lifetimes to the minor components observed in solution and indicates 
stability as well as interaction with cells or cellular media (Figure 7.30). 
   
 
a)    b)    c) 
Figure 7.30. (a – c) Microscopy of complex 1bB, 100 M, 1% DMSO, incubated in HeLa cells for 20 
minutes where a) single-photon confocal overlay of DIC channel and with excitation at 488 nm Scalebar 
= 20 m, b) and c) two-photon fluorescence imaging where b) the fluorescence lifetime map of τm and c) 
is the corresponding lifetime distribution plot in ns of τm. 
 
















Fluorescence Lifetime / ns
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7.4.5.2 PC-3, prostate cancer cell line 
 
  The data obtained in PC-3 cells was particularly interesting in that the complex 
appeared to greatly damage the plasma membrane, almost instantly after addition of the 
complex, which was monitored by plasma membrane colocalisation with Alexa Fluor 
dye (Figure 7.32). This is an effect that had not previously been observed for this family 
of compounds.  Further work could be to carry out lactate dehydrogenase (LDH) assays 
to test for cell membrane damage. The fluorescence lifetime was modelled to 2 
components, which were χ2 = 1.25, τ1 = 0.660 ns, 0.329 ns, 80% and τ2 = 3.515 ns, 
2.570 ns, 20%, again displaying highly comparable data to the minor components in 
solution as was observed in solution indicating that the complex is most likely stable 
and interacts with cells and/or cellular media (Figure 7.31). 
 
 
a)           b)    c) 
Figure 7.31. (a – c) Microscopy of complex 1bB, 100 M, 1% DMSO, incubated in PC-3 cells for 20 
minutes where a) single-photon confocal overlay of DIC channel and with excitation at 488 nm Scalebar 
= 20 m, b) and c) two-photon fluorescence imaging where b) the fluorescence lifetime map of τm and c) 
is the corresponding lifetime distribution plot in ns of τm. 
 
  























      a)      b) 
  
      c)      d) 
Figure 7.32. PC-3 cells stained with Alexa fluor plasma membrane dye after addition of complex 1bB, 
final concentration within 5 minutes of addition at 100 M, 1% DMSO, final concentration a) represents 
the DIC channel, (b) corresponds to excitation at 405 nm, (c) excitation at 488 nm and (d) are an overlay 
of the three channels were acquired addition. (Precipitation was observable since no cell washing 
occurred to enable the image to be taken as soon as the compound was added.) Scalebar: 20 m. 
 
7.4.6.3 MCF-7, breast cancer cell line  
 
  Complex 1bB reaction mixture primarily entered the plasma membrane of MCF-7, but 
slowly entered the cytoplasm, where it possessed a lower fluorescence lifetime indicated 
by the orange colour as opposed to the green observed in the membrane itself (Figure 
7.32), displaying a very large contrast when compared to the uptake of complex 1bN in 
the same cell line under identical conditions (Figure 7.23).  As was observed in HeLa 
and PC-3 cells the fluorescence lifetime possessed two components (χ2 = 1.21, τ1 = 
1.299 ns, 0.523 ns FWHM 75%, τ2 = 5.170 ns, 2.007 ns FWHM, 25%) whereby the 
lifetimes were longer in comparison to those acquired in solution, which is attributable 
to the larger lifetime observed in the cell membrane of MCF-7 cells. Plasma membrane 
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uptake was confirmed by plasma membrane colocalisation with Alexa Fluor dye 
(Appendix Figures G.58-59).  
 
 
a)    b)    c) 
Figure 7.33. (a – c) Microscopy of complex 1bB, 100 M, 1% DMSO, incubated in MCF-7 cells for 20 
minutes where a) single-photon confocal overlay of DIC channel and with excitation at 488 nm. Scalebar 
= 20 m, b) and c) two-photon fluorescence imaging where b) the fluorescence lifetime map of τm and c) 
is the corresponding lifetime distribution plot in ns of m. 
 
7.4.7 In vitro experiments performed on the purified complexes 
  Following purification, the complexes 1bB and 1dB were added to cells (Figure 7.34 
and Appendix Figures G.61-64). Complex 1dB did not display good FLIM data in cells, 
which could be attributed to optimal emission with λex = 543 nm (Appendix Figure 
G.62).  Compound 1bB demonstrated presence of 3 components in the fluorescence 
lifetime, when excited by 810 nm and by 910 nm, whereby at 810 nm τ1 was 0.050 ns 
(83.6%), τ2 was 0.728 ns (11.0%) and τ3 was 3.508 ns (5.3%), χ
2
 = 2.72. At 910 nm the 
first component was 0.050 ns (corresponding to 74.0%), with a second component of 
0.855 ns (22.9%) and third component of 7.232 ns (3.1%), χ2 = 1.06.  
 
  These values are different from those acquired from the reaction mixture, in that τ1 is 
slightly lower and τ2 is greater, which could be indicative of removal of impurities. The 
allyl-substituted complex possessed similar data to the ethyl functionalised-complex 
with slightly higher fluorescence lifetimes observed when exciting at 910 nm (χ2 = 1.21), 
for example τ2 at 810 nm was 0.832 ns (8.3%) and was 0.830 ns (13.1%) at 910 nm and 
τ3 was 4.422 ns (2.5%) at 810 nm and 9.302 ns (2.2%) at 910 nm. The major 
components where comparable at 0.048 ns (89.2%) and 0.049 ns (79.3%) respectively. 



















  When incubated in cells complex 1bB possessed similar behaviour as before in that 
most of the uptake was observed in the cell membrane and the cytoplasm, giving 
comparable results as were seen before purification in HeLa and PC-3 cells (Figure 
7.34). In MCF-7 distribution of the compound within the cell appeared similar to the 
other cell lines, therefore not giving an identical result as before, nevertheless minor 
components of the solution data closely match the fluorescence lifetimes observed in 
cells for the major component of 0.690 ns, 0.615 ns FWHM.  Likewise in HeLa and PC-
3 cell data were similar to the second component measured in solution whereby in HeLa 
at 810 nm the data were modelled to one component, which was 0.872 ns ± 0.490 ns 
FWHM, with the two components present when incubated in PC-3 at 810 nm were 
0.889 ns ± 0.418 ns FWHM (first component) and 3.682 ns, 1.596 ns FWHM (second 
component). This is indicative of the likely stability of the complex and its interaction 
with cells/cellular media. Attempts were made to ionise the compound by MALDI-TOF 
mass spectrometry, which were unsuccessful. These experiments however, present 




a)    b)      c) 
Figure 7.34. Compound 1bB, 1% 100 μM in PC-3 a) FLIM colour map where χ2 = 1.27, lifetime is 0.889 
ns ± 0.418 ns FWHM, range of FLIM image is 0 to 5 ns, where λex = 810 nm and b) is an overlay of DIC 
image and λex = 488 nm, scalebar = 20 µm. τ1 = 0.804 ns, 0.720 ns FWHM 79%, τ2 = 3.682 ns, 1.596 ns 
FWHM, 19%. 
  


















Fluorescence Lifetime / ns
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7.5 Summary to Chapter 7 
 
  A number of approaches for the development of a targeted intrinsically fluorescent 
bis(thiosemicarbazonato) complex were attempted.  Amine-functionalised zinc 
complexes and a gallium complex were synthesised and characterised displaying 
suitable properties as molecular imaging probes, showing uptake and stability within 
cells.  A seven amino-acid analogue of bombesin was derivatised with pyruvic acid and 
a coupling reaction with zinc complexes was attempted.  HPLC data were promising, 
however it could not confirm the presence of the desired peptide-conjugated complex. 
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Chapter 8. Conclusions and further work 
 
  The synthesis and characterisation of a number of intrinsically fluorescent 
acenaphthenequinone zinc(II), copper(II), gallium(III) and indium(III) 







successfully used for clean and rapid radiolabelling by transmetallation from the zinc 
precursors. Biomimetic stability tests were performed using UV-Visible and 
fluorescence spectroscopy, which found the complexes to possess suitable properties for 
in vitro kinetic stability assays, cytotoxicity assays and cell uptake experiments. 
 
  The kinetic stability of the complexes was assayed with water, DMSO and PBS as well 
as Glutathione (GSH), L-cysteine, L-histidine, L-methionine, citric acid, 
ethylenediaminetetraacetic acid (EDTA) and biomimetic Eagle’s modified essential 
media (EMEM) (both with and without foetal calf serum). These tests indicated 
excellent kinetic stability for the zinc and indium complexes, and appropriate stability 
for the gallium complexes for cellular experiments. Moreover, the complexes were 
tested with biologically relevant pH buffers and media, which indicated that the gallium 
complexes possessed sufficient stability between pH 2.5 and 7.35 within the timeframe 
of a cellular assay. The zinc and indium complexes, furthermore demonstrated kinetic 
stability within the range of pH 4.4 to 12.7 for up to 24 hours. 
 
  Subsequent fluorescence lifetime imaging experiments confirmed the stability of the 
bis(thiosemicarbazonato) complexes in solution and in biological cells. To the best of 
the author’s knowledge this was the first report in the literature of the use of this 
technique to assess the stability of a transition metal complex in biological cells.  
 
  As a consequence, a range of novel bis(thiosemicarbazonato) complexes, as well as 
previously synthesised compounds, were studied in vitro, all showing cell uptake and 
varying degrees of cytotoxicity.  Colocalisation stains were used to evaluate the uptake 
in numerous organelles, including the nucleus, cell membrane, lysosome, mitochondria 
and endoplasmic reticulum. The gallium and indium complexes displayed nuclear 
uptake, while many of the complexes were seen to enter the lysosome and mitochondria. 
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Furthermore the phenyl-substituted derivatives localised mainly in the endoplasmic 
reticulum. 
 
 These findings provide some insight into possible mechanisms of action. Further 
studies would be required to confirm these hypotheses using biological assays.  
Interestingly, photoactivity was observed for some of the compounds. The ethyl-
functionalised acenaphthenequinone gallium(III) bis(thiosemicarbazonato) complex, in 
particular, displayed a significant change of uptake to form a punctuated appearance 
upon irradiation at 488 nm wavelength.  Exclusively under these conditions cells were 
also observed to undergo blebbing, indicating cell death. This seems to indicate that 
these compounds could have potential for photodynamic therapy. A preliminary study 
was carried out to determine structural changes after irradiation using LEDs. NMR 
spectroscopy showed the presence of a new species, which, however, was not in 
sufficient proportions to allow assignment. Future work should investigate the structural 
changes initiated by light using high-powered lasers, in addition to by MI50 cytotoxicity 
experiments carried out under light irradiation. 
 
  The cytotoxicity of these complexes was evaluated with cells incubated in the dark 
using MTT and LDH assays. Results showed that a lower concentration was required to 
cause cell death in the cancerous cell line, HeLa, compared to the healthy cell line, 
FEK-4.  Since some degree of toxicity was observed in non-cancerous cells, new zinc 
precursors and a gallium precursor featuring an amine group were synthesised to enable 
more selective targeting of cancer cells.  Attempts to attach a targeting peptide via 
standard coupling reactions with a bombesin analogue were carried out. The product of 
which was purified by HPLC, with attempts to obtain a mass spectrum unsuccessful. 
Future work should explore different methods for coupling the precursor complexes to 
peptides and ionisation of the desired product. The crude and purified zinc complex 
reacted with a bombesin analogue were investigated for cell uptake. Each entered cells 
and possessed a comparable major fluorescence lifetime component with minor 
component solution data, which was different from the analogous amine-derivatised 
zinc complex. This therefore represents an advance towards attaching targeting these 








Ga and biodistribution of 
64
Cu with a normoxic PC-3 Xenografted tumour 
(by collaborators in the Jason Lewis Group, MSKCC, NYC).  These experiments 
showed very little uptake in the normoxic tumour combined with low non-target organ 
uptake compared to Cu[ATSM]. This may be seen as a promising result for an intended 
hypoxic selective probe. Furthermore, in vitro studies (carried out by collaborator Dr 
Israt S. Alam, Imperial College London) showed hypoxia selectivity in the case of 
gallium and indium complexes 3d, 4c and 4d. Future work should therefore include an 
investigation of hypoxic selectivity in nude mice to enable comparisons with the 
normoxic study. Moreover, the mechanism of hypoxic selectivity should be tested by 
cyclic voltammetry.   
 
  Finally, if some of the compounds synthesised during the course of this PhD are found 
to possess hypoxia selectivity in vivo, the major goal of developing and testing an 
intrinsically fluorescent, kinetically stable, hypoxic selective – and potentially 
therapeutic – molecular agent will have been achieved.  
 




Chapter 9. Experimental 
 
9.1 General Information 
 
Mass spectrometry data was acquired on a Bruker Daltonics ESI-TOF and NMR 




H: 300 MHz, 
13
C: 75.5 MHz).  Mass 
spectrometry was carried out in HPLC-grade methanol or distilled water, in some cases 
with 1% DMSO. NMR spectroscopy solvents, acenaphthenequinone, Zinc acetate, 
copper acetate, gallium trichloride and indium trichloride were obtained commercially 
and used as received.  Gallium trichloride and indium trichloride were weighed out in 
an MBraun glovebox at O2, H2O > 0.3 ppm. 
 
Continuous wave electron paramagnetic resonance (cwEPR) spectra at the X-band 
(9.450 GHz) were measured at 1mM in DMF at 60 K with a Bruker EMX spectrometer 
by Dr M. W. Jones, University of Oxford.  
 
Elemental analyses were carried out by Mr Alan Carver, University of Bath, in parallel 
with A. Rosie Chhatwal (for compounds iia-iid and 2a-2d.) 
 
Crystal structure determination by X-ray diffraction 
Single crystal X-ray diffraction data were obtained by Dr Gabriele Kociok-Köhn, Dr 
Sofia I. Pascu or Dr Simon K. Brayshaw for compounds iibs-s, iid, LB, 1c, 2c, 3a, 3b, 3c, 
4a, 4b, 4c and 4d. Crystals were selected using the oil drop technique, in 
perfluoropolyether oil and mounted at 150(2) K with an Oxford Cryostream N2 open-
flow cooling device. Intensity data for 2c, 3a, 3c, 4a – 4d were collected on an Nonius 
Kappa CCD single crystal diffractometer using graphite monochromated Mo-Kα 
radiation (λ = 0.71073 Å). Data were processed using the Nonius Software.160 For LB, 
1c and 3b data were collected on an Oxford Diffraction Gemini single crystal 
diffractometer at 150 K. Data were processed using the Oxford Diffraction software 
package (CrysAlisPro Version 1.171.33.55). Data for iibS-S and iid were collected at 
Diamond using Synchrotron radiation (λ = 0.68890 Å) on a CrystalLogic Kappa (3 
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circle), Rigaku Saturn724 at 100K. Data were processed using the Rikagu software 
package (CrystalClear-SM Expert 2.0 r5). 
For most structures a symmetry-related (multi-scan) absorption correction had been 
applied. Crystal parameters and details on data collection, solution and refinement for 
the complexes are provided in Tables A.1, A.2 and A.3. 












the WINGX-1.80 suite of programmes throughout.  Additional 





 and ORTEP 3 for windows. Hydrogen atoms were placed 
onto calculated positions and isotropically refined using a riding model.  
 
HPLC characterisation was carried out by one of the following methods 
 
HPLC method A was carried out using a Symmetry® C-18 column (4.6 x 260 mm) 
with UV/visible detection measured at obs = 200 nm, 300 nm, 400 nm, 450 nm, 500 nm, 
600 nm, 700 nm and 800 nm. The gradient elution was 1.1 mL/minute, with 0.1% TFA 
MilliQ water as solvent A and 0.1% TFA MeCN as solvent B. Start 95 % A reverse 
gradient until 5% A at 7.5 minutes, isocratic until 15 minutes, reverse gradient until 
17.5 minutes 95% A, then hold to 18 minutes. 
 
HPLC method B was carried out using a Symmetry® C-18 column (4.6 x 260 mm) 
with UV/visible detection measured at eight wavelengths from obs = 200 nm, 220 nm, 
280 nm, 300 nm, 400 nm, 450 nm, 500 nm, 600 nm, 700 nm and 800 nm. The gradient 
elution was 0.8 mL/minute, with 0.1% TFA MilliQ water as solvent A and 0.1% TFA 
MeCN as solvent B. Start 95 % A reverse gradient until 5% A at 7.5 minutes, isocratic 
until 15 minutes, reverse gradient until 17.5 minutes 95% A, then hold to 18 minutes. 
 
HPLC method C was carried out using a Acclaim® 120 C-18 column (4.6 x 150 mm) 
with UV/visible detection measured at up to four obs = 214 nm, 220 nm, 254 nm, 280 
nm, 300 nm and 400 nm. The gradient elution was 1.0 mL/minute, with 0.1% TFA 
MilliQ water as solvent A and 0.1% TFA MeCN as solvent B. Start 95 % A reverse 
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gradient until 5% A at 7.5 minutes, isocratic until 15 minutes, reverse gradient from 
15.1 minutes 95% A, then hold to 18 minutes.  
 
HPLC method D was carried out using a Waters C-18 column (4.6 x 250 mm) with 
UV/visible detection measured at up to four obs = 254 nm. The gradient elution was 1.0 
mL/minute, with 0.1% TFA MilliQ water as solvent A and 0.1% TFA MeCN as solvent 
B. Start 95 % A reverse gradient until 5% A at 12 minutes, isocratic until 15 minutes, 
reverse gradient from 15.1 minutes 95% A, then hold until  21 minutes.  
 
HPLC method E was carried out using a Acclaim® 120 C-18 column (4.6 x 150 mm) 
with UV/visible detection measured at up to four obs = 214 nm, 220 nm, 254 nm, 280 
nm, 300 nm and 400 nm. The gradient elution was 1.0 mL/minute, with 0.1% TFA 
MilliQ water as solvent A and 0.1% TFA MeCN as solvent B. Start 95 % A reverse 
gradient until 5% A at 10 minutes, isocratic until 15 minutes, reverse gradient from 15.1 
minutes 95% A, then hold to 18 minutes.  
 
HPLC method F was carried out using a Waters C-18 column (4.6 x 250 mm) with 
UV/visible detection measured at obs = 254 nm. The gradient elution was 1.0 
mL/minute, with 0.1% TFA MilliQ water as solvent A and 0.1% TFA MeCN as solvent 
B. Start 95 % A, reverse gradient until 5% A at 10 minutes, isocratic until 12 minutes, 
reverse gradient until 95% A at 14 minutes, then hold to 15 minutes at 95% A. 
 
HPLC method G was carried out using a Waters C-18 column (4.6 x 250 mm) with 
UV/visible detection measured at up to four obs = 214 nm, 220 nm, 254 nm, 280 nm, 
300 nm and 400 nm. The gradient elution was 1.0 mL/minute, with 0.1% TFA MilliQ 
water as solvent A and 0.1% TFA MeCN as solvent B. Start 95 % A reverse gradient 
until 5% A at 15 minutes, isocratic until 22.5 minutes, reverse gradient from 22.6 
minutes 95% A, then hold to 25.5 minutes.  
 
HPLC method H was carried out using an Eclipse C-18 column (2 x 50 mm) with 
UV/visible detection measured at up to four obs = 214 nm, 220 nm, 254 nm, 280 nm, 
300 nm and 400 nm. The gradient elution was 1.0 mL/minute, with 0.1% TFA MilliQ 
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water as solvent A and 0.1% TFA MeOH as solvent B. Start 95 % A reverse gradient 
until 5% A at 8 minutes, hold until 10 minutes. 
 
HPLC method I was carried out using a Phenomenex Ultracarb C-18 column (4.6 x 
150 mm) with UV/visible detection measured at up to four obs = 254 nm. The gradient 
elution was 1.0 mL/minute, with 0.1% TFA MilliQ water as solvent A and 0.1% TFA 
MeOH as solvent B. Start 95 % A reverse gradient until 5% A at 12 minutes, hold until 
15 minutes. 
 
Semi-Preparative HPLC was carried out using a Phenomenex® Gemini C-18 column 
(10 x 250 mm) with UV/visible detection measured at up to four obs = 214 nm, 220 nm, 
254 nm, 280 nm, 300 nm and 400 nm. The gradient elution was 1.0 mL/minute, with 
0.1% TFA MilliQ water as solvent A and 0.1% TFA MeCN as solvent B. Start 95 % A 
reverse gradient until 5% A at 15 minutes, isocratic until 22.5 minutes, reverse gradient 
from 22.6 minutes 95% A, then hold to 25.5 minutes.  
 
General Radiochemistry Procedures 
Copper and indium experiments were carried out at either University of Oxford or 
University of Cambridge under the supervision of Prof Jonathan R. Dilworth or Dr 
Franklin I. Aigbirhio respectively. The zinc complex was prepared as either 1 mg/mL or 









 using an ion exchange column. An aqueous 
64
CuCl2 solution was acquired 
in 0.1 mol.dm
-3
 HCl, which was diluted with 0.2 mL 
64
CuCl2 in 0.1 mol.dm
-3
 
Na(CH3CO2).  200 μL of < 10 MBq 
64
Cu(CH3CO2)2 was added to 100 μL of 1 mg/mL 
zinc complex in DMSO and 400 μL water in a 2 mL reaction vial. After stirring at room 
temperature 25 μL of this solution was entered into the HPLC, which was combined 
with both a UV tracer detecting at 254 nm and NI scintillation crystal detection with 
approximately a 10s delay.  For indium 50 μL of the zinc complex in DMSO at a 
concentration of 1 mg/mL was added to 150 μL of MeOH and 2.5 μL 111InCl3, < 10 
MBq per experiment.  The solutions were stirred at 60 
o
C and entered into the HPLC 
after ca. 1h.  Gallium experiments were carried out by Mr Frazer Twyman, 
Hammersmith Hospital, Imperial College London, whereby 10 mL of 0.1M HCl was 
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 from the generator and was subsequently trapped on a 
30 mg/mL Strata X-C cartridge.  This was eluted with 700 μL of 0.02M HCL / 98% 
acetone and dried for 15 minutes under a stream of nitrogen at 110
oC. Next, 25 μL of 2 
mg/mL zinc complex in DMSO and 2 mL of HPLC-grade ethanol. The solution was 
heated for 30 minutes at 90 
o
C. HPLC methods F, G, H and I were used in all cases. 
 




In (ca. 0.5 MBq) in 0.5 mL de-ionized water was added to 0.5 mL of  octanol 
in an Eppendorf tube. The tube was vigorously vortexed for 5 min and centrifuged at 
5000×g for 5 min. Aliquots (50 μL)  of both aqueous and octanol layers were collected 
in triplicate and the associated activity counted using a gamma counter (Triathler,  
Hidex). Log P values were then calculated and compared with that of Cu[ATSM] 
standard, using the formula: 
log P = log(counts(octanol))/counts(H2O)) 
 
Animal Xenograft Models 
All experiments were carried out following an Institutional Animal Care and Use 
Committee-approved protocol, Memorial Sloan-Kettering Cancer Center, New York by 
Dr Brian Zeglis. Athymic mice aging six to eight weeks were obtained from Taconic 
Farms Incorporated (Hudson, NY). The animals were given ca. 1 week prior to 
treatment to acclimatise in ventilated cages and were provided with food and water ad 
libitum. Xenografts were induced on the right shoulder by subcutaneous injection of 100 
L of 3 x 106 PC-3 cells.  
 
Small-animal PET imaging 
Small-animal PET imaging was performed at MSKCC, New York, on a micro-PET R4 
rodent scanner (Concorde Microsystems) by Dr Brian Zeglis. Mice were injected with 
complex radiolabelled with Cu-64 or Ga-68 of 10-15 MBq and anesthetised by 
inhalation of 2% isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen gas mixture. The 
animal was positioned on the scanner bed with anesthesia maintained by a 1% 
isoflurane/gas mixture. Measurements for each mouse were recorded using static scans 
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at time points between 30 minutes and 24 hours. Each scan occurred for between 10 and 
45 minutes and contained at least 20 million coincident events. The energy window 
used was 350-700 keV, with a coincidence timing window of 6 ns. Data were arranged 
into 2D histograms by Fourier rebinning, and transverse images were reconstructed by 
filtered back-projection into a 128 x 128 x 63 (0.72 x 0.72 x 1.3 mm
3
) matrix. Images 
were normalised to correct for non-uniformity of response of the PET, dead-time count 
losses, positron branching ratio, and physical decay to the time of injection but no 
attenuation, scatter, or partial-volume averaging correction was applied. The counting 
rates of the reconstructed images were converted to activity concentrations (percentage 
of injected dose [%ID] per gram of tissue) using a calibration factor based on the image 
of a mouse-sized water-equivalent phantom containing either Cu-64 or Ga-68. ASIPro 
VM
TM
 software (Concorde Microsystems) was used to analyse the data.  
Biodistribution study 
Biodistribution experiments were carried out at MSKCC, New York, by Dr Brian Zeglis, 
with mice bearing PC-3 tumour grafts as described above and randomised prior to the 
study. Prior to intravenous tail injection with Cu-64 radiolabelled 2b and 2c (0.5 – 1.0 
MBq) the mice were gently warmed with a heat lamp for 5 minutes. Mice were 
euthanised by CO2 gas asphyxiation at 1h, 2h, 6h, 12h and 24h, after which organs 
(including the tumour) were removed, rinsed with water, dried in air, weighed and 
counted using a Cu-64 calibrated gamma counter. Count data were converted to activity 
concentrations (percentage of injected dose [%ID] per gram of tissue).” 
 
UV-visible spectra were obtained using a Perkin-Elmer Spectrometer, Lamda 650 in 
DMSO and processed using UV Winlab 3 software.  The orientation of the 1.00 cm 
quartz cuvette was the same for each experiment for consistency. 
 
Fluorescence spectra were measured in a 1.00 cm quartz cuvette using a Perkin-Elmer 
LS55 luminescence spectrophotometer. A scan from 200-800nm with increments of 
10nm was initially carried out to discover excitation wavelength of maximum emission 
(λex-max) and wavelength of maximum emission (λem-max). Quantum yields were 
estimated by reference to [Ru(bipy)3](PF6)2 in water (ΦR = 0.042 in water at 420 nm) 
using the equation: 
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Φ is the quantum yield, D is the integrated area of the emission band, A is the 
absorption of the solution at the excitation wavelength, I is the maximum intensity of 
the excitation band and η is the refractive index of the solvent. S is the sample and R is 
the reference [Ru(bipy)3](PF6)2. 
Fluorescence pH and biomimetic media studies 
Buffers from pH 1.1 to pH 10 were made using a Fisher brand Hydrus 600 pH meter in 
order to investigate the stability of compounds by fluorescence spectroscopy.  The 
following buffer systems were used, following the procedure described in “Buffers: A 





pH Buffer systems 
1.1KCl/HCl 
2.0 KCl/HCl 
3.0 Citric acid/Sodium citrate dehydrate OR Glycine / HCl 
5.0 Citric acid/Sodium citrate dehydrate OR Acetic Acid / Sodium acetate 
7.0 Citric acid/Dibasic Sodium phosphate OR Sodium phosphate Monobasic / Sodium 
phosphate Dibasic 
9.0 Glycine/Sodium Hydroxide 
10.0 Sodium Carbonate Anhydrous/Sodium Hydrogen Carbonate 
 
A 4 mL solution of twice the final concentration was added to 4 mL of the buffer 
system or biomimetic media and then scanned for fluorescence between 200-800nm 
with an excitation wavelength of λmax.  If precipitation was observed samples were 
filtered using a Millex
TM
 0.22 μm filter prior to scanning.  Eagle’s Minimum Essential 
Medium containing 0.5% penicillin/streptomycin and 1% glutamine was used to assess 
the stability of the compounds in biomimetic media and also in relevance to the cell 
studies. Two equivalents of biologically relevant agents glutathione (GSH), L-cysteine, 
L-histidine, L-methionine or citric acid or chelator ethylenediaminetetraacetic acid 
(EDTA) were used.  
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Cell culturing and cell plate preparation.  
Cells were cultured at 37 
◦
C in a humidified atmosphere in air and diluted once 
confluence had been reached. Culture occurred in Eagle’s Minimum Essential Medium 
(EMEM) for HeLa (cervical cancer cells) and FEK-4 (epithelial fibroblast cells), 
Dulbecco’s Modified Eagle’s Medium (DMEM) for MCF-7, RPMI 1640 for PC3 
(prostate cancer cells) and Weymouth’s medium for EMT6 (murine breast carcinoma).  
The media contained foetal calf serum (FCS) (10% for HeLa, PC-3, EMT6 and MCF-7 





and 200 mM L-Glutamine (5 mL). All steps were performed in absence of phenol red. 
Surplus supernatant containing dead cell matter and excess protein was aspirated.  The 
live adherent cells were then washed with 2 x 10 mL aliquots of phosphate buffer saline 
(PBS) solution to remove any remaining media containing FCS, which inactivates 
trypsin. Cells were resuspended in solution by incubation in 3 mL of trypsin–PBS 
solution (0.25% trypsin) for 5 min at 37 
◦
C. After trypsinisation, 5 mL of medium 
containing 10% serum was added to inactivate the trypsin and the solution was 
centrifuged for 5 min (1000 rpm, 25 ºC) to remove any remaining dead cell matter. The 
supernatant liquid was aspirated and 5 mL of cell medium (10% or 15% FCS) was 
added to the cell matter left behind. Cells were counted using a haemocytometer and 
then seeded as appropriate. 
 




) and left for 48 h 
to adhere fully. All steps were carried out in the absence of phenol red. (a) For MI50 
estimations by MTT assays, cells were incubated with each compound tested for 48 h at 
37 ˚C. Concentrations used were 1 nM, 100 nM, 1 µM, 10 µM, 50 µM, 100 µM and 250 
µM( 1% DMSO, 99% Eagle’s Modified Essential Medium containing FCS at standard 
concentration of the cell line). Subsequently, cells were washed three times with PBS 
and 100 mL of MTT was added (0.5 mg mL
-1
, 10% PBS: SFM) followed by a 2 h 
incubation. Following aspiration, 100 mL of DMSO was added and 96 well plates were 
read at an ELISA plate reader, Molecular Devices Versa Max (BN02877). Data were 
obtained from five consistent results and MI50 was calculated using Origin 8 as half the 
height of the fitted curve for each compound and for each individual experiment. Due to 
background absorbance, 100% cell death would not correspond to zero absorbance, 
therefore the height of the curve was calculated as the highest absorbance of the fit plot 
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minus the minimum absorbance of the curve, at which point death of all cells has been 
achieved. Where 100% cell death had not been attained, in the case of compounds iib 
and 3bN, the MI50 was calculated using the same method in that the minimum 
absorbance of the fitted curve was subtracted. This value therefore indicates the 
minimum MI50 for this compound and is stated in the text/figure legend. The mean MI50 
was calculated from the average of the five MI50 values obtained from five consistent 
experiments. The error reported was the standard error of the mean and shown as ± 
S.E.M. 
 
(b) Time lapse studies by MTT assays were carried out in HeLa, MCF-7 and FEK-4 
cells by an analogous method to that described at (a) above, but under serum free 
EMEM conditions aiming to link directly cytotoxicity tests to fluorescence imaging 
experiments. Concentrations used were 10 µM and 50 µM in 1% DMSO, 99% Eagle’s 
Modified Essential Medium. Conclusions were reached following observations of cells’ 
viability within 1 h incubation (37 °C) interval. 
 
LDH assay 
The medium containing serum was aspirated and the compounds were added in serum 
free medium (SFM).  After drug treatment, the supernatant was removed and added to a 
separate 96 well plate. To the remaining cells 100 μL SFM containing SDS was added.  
A preliminary study showed that the optimum percentage of SDS for FEK-4 and MCF-
7 cells was 0.015% and for HeLa cells 0.1 %.  These were mixed by pipette and 20 μL 
of LDH reaction kit, Roche Scientific ® (1:40 catalyst:dye) was added to each well.  
After 20 min the 96 well plates were read by Molecular Devices Versa Max (BN02877) 
at 570 nm.  % LDH leakage was calculated by supernatant OD divided by (supernatant 
OD + cell OD). 
 
Fluorescence microscopy. At Bath fluorescence microscopy experiments were carried 
out on a Nikon eclipse TE2000 epi-fluorescence or a Zeiss LSM510META microscope, 
whereas at the Rutherford Appleton Laboratory a modified Nikon TE2000-U 
microscope was used. For all fluorescence microscopy experiments, cells were cultured 
as above and plated in glass-bottomed dishes as 1.5 x 10
5
 cells per dish (ca. 60% 
coverage) and incubated for 12 h for HeLa, EMT-6 and FEK-4, 48 h for MCF-7 and 72 
h for PC-3 cells. All steps were carried out in the absence of phenol red. This timing 
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was found to be minimum necessary for the two different cell lines to adhere to the 
glass bottomed Petri dishes used for imaging. Prior to compound addition, cells were 
washed 3 times with PBS, before adding serum free medium (2 mL). Subsequently, a 
small volume of medium was removed (10 mL) and compound in DMSO was added to 
obtain a final volume of 1 mL and the desired concentration. The final concentration of 
compounds on the cell plate was 50 mM in medium, containing 0.5% DMSO or 1% 
DMSO, depending on the compound solubility. After 20 min or 1 h incubation with the 
compound cells were washed 3 times with PBS and fresh serum free medium was added 
(1 mL) and images were recorded immediately. 
 
Co-localisation studies. Cells were cultured using standard protocols, as described 
above, in RPMI-1640 (PC-3). Prior to addition of any commercial co-localisation dye, 
cells were washed 5 times with PBS. Protocols adapted from Invitrogen were used 
throughout.  
 
(a) Hoechst A stock solution of 100 mg mL
-1
 Hoechst 33342 (Invitrogen) was prepared 
in sterile MilliQ water. To 10 L of the stock solution, a volume of 990 L was added 
giving a final concentration of 1 mg mL
-1
. After cells were incubated with this solution 
for 30 min a further 5 washings with PBS were carried out, before the addition of 1 mL 
of SFM. Subsequently, a small volume of serum free medium (SFM) was removed (e.g. 
10 µL) and compound in DMSO was added in equal volume to what was removed, to 
obtain a final volume of 1 mL and the desired concentration (50 mM in cell medium 
containing 0.5% DMSO). After 20 min or 1 h incubation with the compound cells were 
washed 3 times with PBS and fresh serum free medium was added (1 mL) and images 
were recorded immediately. 
 
(b) Mitotracker A stock solution of 20 M Mitotracker® Red FM (Invitrogen) was 
prepared in DMSO. To 10 L of stock solution, 990 L was added giving a final 
concentration of 200 nM. After cells were incubated with this solution for 30 min a 
further 5 washings with PBS were carried out, before the addition of 1 mL of SFM. 
Subsequently, a small volume of SFM was removed (e.g. 10 µL) and compound in 
DMSO was added in equal volume to what was removed, to obtain a final volume of 
2mL and the desired concentration (50 mM in cell medium containing 0.5% DMSO). 
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After 20 min or 1 h incubation with the compound cells were washed 3 times with PBS 
and fresh serum free medium was added (1 mL) and images were recorded immediately. 
 
(c) Lysotracker A stock solution of 20 M Lysotracker® Red DND-99 (Invitrogen) was 
prepared in DMSO. To 10 L of stock solution, 990 L was added giving a final 
concentration of 200 nM. After cells were incubated with this solution for 60 min a 
further 3 washings with PBS were carried out, before the addition of 1 mL of SFM. 
Subsequently, a small volume of SFM was removed (e.g. 10 µL) and compound in 
DMSO was added in equal volume to that which was removed to obtain a final volume 
of 1 mL and the desired concentration (50 mM in cell medium containing 0.5% 
DMSO). After 20 min or 1 h incubation with the compound cells were washed 3 times 
with PBS and fresh serum free medium was added (1 mL) and images were recorded 
immediately. 
 
(d) ER tracker  
A stock solution of 100 M ER-tracker® Red (Invitrogen) was prepared in DMSO. To 
10 L of stock solution, 990 L was added giving a final concentration of 100 M. 
After cells were incubated with this solution for 20 min a further 3 washings with HBSS 
were carried out, before the addition of 1 mL of SFM. Subsequently, a small volume of 
SFM was removed (e.g. 10 µL) and compound in DMSO was added in equal volume to 
that which was removed to obtain a final volume of 1 mL and the desired concentration 
(e.g. 50 mM in cell medium containing 0.5% DMSO). After 20 min or 1 h incubation 
with the compound cells were washed 3 times with PBS and fresh serum free medium 
was added (1 mL) and images were recorded immediately. 
 
 (e) Nile Red 
A stock solution of 10 g/mL Nile Red (Invitrogen) was prepared in DMSO. To 10 L 
of stock solution, 990 L was added giving a final concentration of 100 ng/mL. After 
cells were incubated with this solution for 10 min a further 3 washings with HBSS were 
carried out, before the addition of 1 mL of SFM. Subsequently, a small volume of SFM 
was removed (e.g. 10 µL) and compound in DMSO was added in equal volume to that 
which was removed to obtain a final volume of 1 mL and the desired concentration (e.g. 
50 mM in cell medium containing 0.5% DMSO). After 20 min or 1 h incubation with 
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the compound cells were washed 3 times with PBS and fresh serum free medium was 
added (1 mL) and images were recorded immediately. 
 
(f) Alexa Fluor 
A stock solution of 50 g/mL Alexa fluor® 350 conjugate (Invitrogen) was prepared in 
HBSS (Hank’s Buffered Salt Solution). To 10 L of stock solution, 990 L was added 
giving a final concentration of 100 M. After cells were incubated with this solution for 
10 min a further 3 washings with HBSS were carried out, before the addition of 1 mL of 
SFM. Subsequently, a small volume of SFM was removed (e.g. 10 µL) and compound 
in DMSO was added in equal volume to that which was removed to obtain a final 
volume of 1 mL and the desired concentration (e.g. 50 mM in cell medium containing 
0.5% DMSO). After 20 min or 1 h incubation with the compound cells were washed 3 
times with PBS and fresh serum free medium was added (1 mL) and images were 
recorded immediately. 
Fixed cell imaging 
Cells were plated in a Petri dish containing a glass cover slip. Before fluorescence 
imaging, the serum containing medium was replaced with SFM. After the drug 
treatment cells were fixed by inverting the coverslip placing it onto 50 μL of 
paraformaldehyde-PBS (4% paraformaldehyde).  After 15 min, the coverslip was 
mounted to a slide using Vectashield®, hard set mounting medium with DAPI (Vector 
Laboratories, Inc.) 
 
Two-photon excitation experiments were performed at the Rutherford Appleton 
Laboratory following the methodology described in Botchway et al. 2008
137
 and in our 
recent publication (Pascu et al. 2011
138
) with assistance of Dr S Botchway, Dr P Burgos, 
Mr A. Mckenzie and Mr A. Henman. An optical parametric oscillator was pumped by a 
mode locked Mira titanium sapphire laser (Coherent Lasers Ltd), generating 180 fs 
pulses at 75 MHz and emitting light at a wavelength of 580-630nm nm. The laser was 
pumped by a solid state continuous wave 532 nm laser (Verdi V18, Coherent Laser 
Ltd), with the oscillator fundamental output of 915 ± 2 nm or 810 ± 2 nm. The laser 
beam was focused to a diffraction limited spot through a water immersion ultraviolet 
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corrected objective (Nikon VC x60, NA1.2) and specimens illuminated at the 
microscope stage of a modified Nikon TE2000-U with UV transmitting optics.  
  The focused laser spot was raster scanned using an XY galvanometer (GSI Lumonics). 
Fluorescence emission was collected without de-scanning, bypassing the scanning 
system and passed through a coloured glass (BG39) filter. The scan was operated in 
normal mode and line, frame and pixel clock signals were generated and synchronised 
with an external fast microchannel plate photomultiplier tube used as the detector 
(R3809-U, Hamamatsu, Japan). These were linked via a Time-Correlated Single Photon 
Counting (TCSPC)PCmodule SPC830. Lifetime calculations were obtained using 
SPCImage analysis software (Becker and Hickl, Germany) or Edinburgh Instruments 
F900 TCSPC analysis software. Preliminary single-photon FLIM investigations were 
conducted using the Becker and HicklDCS120 system with a 40 ps 473 nm diode laser.  
 
Fluorescence imaging of the nucleus and chromosomes  
Due to the observed nuclear uptake a preliminary investigation was carried out at the 
Rutherford Appleton Laboratory with Dr Yusuf Mohammed and Ms Ana Estandarte to 
assess whether the complexes bind to chromosomes. Non-cancerous lung cell line 
CCD37-LU was cultured in DMEM containing 10% foetal bovine serum (FBS) and 1% 
L-Glutamine at 37°C in a 5% CO2 incubator.  Chromosomes were isolated via a 
Colcemid (Gibco BRL) treatment before cells were trypsinised and subsequently 
resuspended in pre-warmed KCl hypotonic solution (0.075M) at 37°C for 12 minutes.  
This was followed by fixing in a 3:1 methanol/acetic acid solution, which was added 
onto a glass microscope slide, to which 100 µL of Compound 4d (100 µM) was 
aliquoted and was washed with DMSO after 15 minutes. Finally images were acquired 
using a Zeiss Axio Imager 2 microscope, which showed uptake of the complex in both 
the nucleus and in chromosomes.   
 
In vitro hypoxia testing study 
Cells were cultured as described above with the final concentration on the cell plate 50 
µM, containing 4% DMSO for 20 minutes with the hypoxia investigation carried out by 
Dr Israt S. Alam, Imperial College London. Normoxic conditions were 20.7% O2 and 5% 




 C before complex addition.  Cells were washed 3 times with PBS, which was 
replaced with 2mL of serum free media, with images recorded immediately. 
 
Flow cytometry studies 
Cells were seeded as 3 x10
5
 cells per well in a 6 well plate and incubated for ca. 12 h. 
The cells were subsequently washed twice with PBS, with the media replaced with 
serum free medium and compound of 50 M 4%, DMSO final concentration. This was 
incubated for 20 minutes at 20.7% O2 and 5% CO2 at 37

C for the normoxic sample. 
Hypoxic conditions were obtained by pre-incubating the cells for 20 minutes at 1% O2 
and 5% CO2 at 37

C, followed by incubation of a further 20 minutes under the same 
conditions with the compound. Following this cells were washed three times with PBS, 
trypsinised and centrifuged at 600g for three minutes. The precipitate was washed with 
PBS, resuspended in 1 mL of serum free medium, kept on ice and analysed in an LSRII 
cytometer (BD Biosciences, Rockville, MD USA), with 10 000 cells counted per event. 
Each experiment was carried out at least three times, with data analysis performed using 
FlowJo software (TreeStar, USA). 
 
Radioactive cell uptake investigation 
Cells were seeded as 3 x10
5
 cells per well in a 6 well plate and incubated for ca. 12 h. 
The cell medium was aspirated and replaced with serum free medium containing the 
Ga-68 radiolabelled complex (following the radiochemical procedure above). This was 
incubated at 20.7% O2 and 5% CO2 at 37

C for the normoxic sample. Hypoxic 
conditions were obtained by pre-incubating the cells for 20 minutes at 1% O2 and 5% 
CO2 at 37

C, followed by incubation under the same conditions with the compound for 
the time course of the study. Cell plates were put on ice, washed 3 times with ice-cold 
PBS and lysed using 0.2 mL RIPA buffer for 10 minutes (Thermo Fisher Scientific Inc., 
Rockford, IL, USA). PBS (0.5 mL) was added to each well and cell lysates were 
transferred to counting tubes, with measurements of decay-corrected radioactivity 
performed using a gamma counter (Cobra II Auto-Gamma counter, Packard Biosciences 
Co, Pangbourne, UK). Aliquots were snap-frozen and subsequently protein 
determination was carried out using a BCA 96-well plate assay (Thermo Fisher 
Scientific Inc., Rockford, IL, USA).  Decay corrected counts were corrected to protein 





Data were expressed as mean ± standard error of the mean (SEM), unless stated in the 
text. Student's t test (Prism v5.0 software for windows, GraphPad Software, San Diego, 
CA, USA) was used to assess the significance of comparison between two data sets. If P 






Mono(substituted) 4-methyl-3-thiosemicarbazone acenaphthenequinone (ia)  
 
For Compound ia, acenaphthenequinone (0.50 g, 2.74 mmol) and 4-methyl-3- 
thiosemicarbazide (0.29 g, 2.80 mmol) were added in absolute ethanol (15 mL) and 
refluxed for 2 hours. 10 drops of conc. HCl were added upon reflux. The solid was 
isolated by filtration whilst hot, resuspended in hot methanol (10 mL) and stirred for 15 
minutes before filtering and washing with further methanol. The resultant yellow solid 
(0.60 g, 2.25 mmol, 82%), compound ia, was dried in vacuo. 
1
H NMR (300 MHz, d6–DMSO, 25 °C): δ 12.65 (s, 1H, N-NH), 9.38 (m, 1H, NHMe), 
8.38 (d, 1H, H-3, J = 8.3 Hz), 8.14 (d, 1H, H-3', J = 8.3 Hz), 8.10 (d, 1H, H-1, J = 7.1 
Hz), 7.98 (d, 1H, H-1', J = 6.9 Hz), 7.88 (overlapping t, 2H, H-2), 7.85 (overlapping t, 
2H, H-2'), 3.13 (d, 3H, (CH3)). 
13
C NMR (75.5 MHz, d6–DMSO, 25°C): δ 188.6, 178.0, 
139.1, 137.2, 132.9, 130.5, 130.1, 130.0, 129.0, 128.7, 127.2, 122.6, 118.3, 31.5. Mass 




 292.0515, found m/z = 292.0494.  
 
Mono(substituted) 4-ethyl-3-thiosemicarbazone acenaphthenequinone (ib)  
 
For Compound ib, acenaphthenequinone (0.50 g, 2.74 mmol) and 4-ethyl-3-
thiosemicarbazide (0.36 g, 3.00 mmol) were added in absolute ethanol (15 mL) and 
refluxed for 2 hours. 10 drops of conc. HCl were added upon reflux. The solid was 
isolated by filtration whilst hot, resuspended in hot methanol (10mL) and stirred for 15 
minutes before filtering and washing with further methanol. The resultant yellow solid 




H NMR (300 MHz, d6–DMSO, 25°C): δ 12.60 (s, 1H, N-NH), 9.42 (t, 1H,NHEt, J = 
5.9 Hz), 8.38 (d, 1H, H-3, J = 8.2 Hz), 8.14 (d, 1H, H-3’, J = 8.3 Hz), 8.10 (d, 1H, H-1, 
J = 7.0 Hz), 8.01 (d, 1H, H-1’, J = 6.9 Hz), 7.88 (t+t,2H, H-2 and H-2’), 3.68 (m, 2H, 
(CH2)CH3), 1.23 (t, 3H, CH2CH3, J = 7.2 Hz). 
13
C NMR (75.5 MHz, d6 –DMSO, 25 
C): δ 188.5, 176.9, 139.1, 137.2, 132.8, 130.5, 130.1, 129.9, 128.9, 128.6, 127.1, 122.5, 





found 306.0667.  
 
Mono(substituted) 4-phenyl-3-thiosemicarbazone acenaphthenequinone (ic)  
 
For Compound ic, acenaphthenequinone (0.5136 g, 2.81 mmol) was added to 1.1 
equivalents of 4-phenyl-3-thiosemicarbazide (0.5116 g, 3.05 mmol) were added in 
absolute ethanol (15mL) and refluxed for 2 hours. 10 drops of conc. HCl were added 
upon reflux. The solid was isolated by filtration whilst hot, resuspended in hot methanol 
(10mL) and stirred for 15 minutes before filtering and washing with further methanol. 
The resultant light orange solid (0.800 g, 2.41 mmol, 85%), compound ic, was dried in 
vacuo. 
1
H-NMR (300 MHz, d6-DMSO, 25°C): δ 12.79 (s, 1H, N-NH), 10.93 (s, 1H, NHPh), 
8.36 (d, 1H, H-3, J = 8.1 Hz), 8.13 (d, 1H, H-3’, J = 8.3 Hz), 8.10 (d, 1H, H-1, J = 6.9 
Hz), 8.08 (d, 1H, H-1’, J = 7.0 Hz), 7.86 (overlapping t, 1H, H-2), 7.82 (overlapping t, 
1H, H-2’), 7.65 (obscured d, 2H, o-H), 7.45 (t, 2H, m-H, J = 7.6 Hz, 8.3 Hz), 7.29 (m, 
1H, o-H). 
13
C-NMR (75.5 MHz, d6-DMSO, 25
o
C): δ 188.6, 176.6, 139.4, 138.5, 137.7, 
132.8, 130.4, 129.99, 129.93, 128.9, 128.6, 128.4, 127.2, 125.8, 122.5, 120.9, 118.8. 




 332.0858, found 332.0861. 
Elem. Anal.: Found: C; 68.10 %, H; 3.96 %, N; 13.10 %, Calc.: C; 68.86 %, H; 3.95 %, 





Mono(substituted) 4-allyl-3-thiosemicarbazone acenaphthenequinone (id)  
 
For Compound id, acenaphthenequinone (0.500 g, 2.745 mmol) and 4-allyl-3-
thiosemicarbazide (0.393 g, 3.293 mmol) were added in absolute ethanol (15mL) and 
refluxed for 2 hours. 10 drops of conc. HCl were added upon reflux. The solid was 
isolated by filtration whilst hot, resuspended in hot methanol (10mL) and stirred for 15 
minutes before filtering and washing with further methanol. The resultant yellow solid 
(0.595 g, 1.723 mmol, 63%), compound id, was dried in vacuo. 
1
H NMR (d6-DMSO, 25 °C): δ 12.61 (s, 1H, N-NH’), 9.57 (t, 1H, NHAllyl, J = 6.0 Hz), 
8.34 (d, 1H, H-3, J = 8.2 Hz), 8.11 (d, 1H, H-3’, J = 8.3 Hz), 8.06 (d, 1H, H-1’, J = 7.0 
Hz), 7.96 (d, 1H, H-1, J = 6.9 Hz), 7.85 (overlapping t, 1H, H-2 or H-2’), 7.81 
(overlapping t, 1H, H-2 or H-2’), 5.95 (m, 1H, -CH2CHCH2), 5.27 + 5.21 (q, 1H, Htrans, 
J = 17.3 Hz), 5.19 + 5.15 (q, 1H, Hcis, J = 10.3 Hz), 4.30 (ddt, 2H, -CH2CHCH2). 
13
C 
NMR (d6-DMSO, 25 ◦C): δ 188.5, 177.5, 139.1, 137.3, 134.0, 132.8, 130.4, 130.0, 





, found 318.0665. Elem. Anal.: Found: C; 65.09 %, 
H; 4.43 %, N; 14.21 %, Calc.: C; 65.06 %, H; 4.44 %, N; 14.23 %. 
 
Bis(substituted) 4-methyl-3-thiosemicarbazone acenaphthenequinone (iia)  
 
Acenaphthenequinone (0.25g, 0.137 mmol) and methyl thiosemicarbazide (0.43 g, 
0.411 mmol) were suspended in 40mL ethanol and refluxed for 4 hours. 10 drops of 
conc. HCl were added upon reflux. The solid was isolated by filtration whilst hot, 
resuspended in hot methanol (10 mL) and stirred for 15 minutes before filtering and 
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washing with further methanol. The resultant yellow solid (266.6 mg, 54 %), compound 
iia, was dried in vacuo.  
1
H NMR- (300 MHz, d6-DMSO, 25ºC) δ 12.60 (s, 1H, N-NH’), 11.29 (s, 1H, N-NH), 
9.15 (m, 1H, NH’CH3), 8.86 (m, 1H, NHCH3), 8.20 (d 1H, H-1, J = 7.3 Hz), 8.13 (d, 1H, 
H-3’, J = 8.3 Hz), 8.07 (d, 1H, H-1’, J = 7.0 Hz), 8.03 (d, 1H, H-3, J = 8.3 Hz), 7.79 (m, 
2H, H-2 and H-2’), 3.11 (m, 6H, overlapping CH3 groups).
13
C NMR- (75.5 MHz, d6-
DMSO, 25ºC) δ 178.42, 138, 136.45, 133.23, 130.25, 129.20, 128.20, 128.18, 127.03, 





found 355.0804 Elem. Anal.: Found C; 53.7 %, H, 4.51 %, N; 23.4 %, Calc.: C; 
53.91 %, H; 4.52 %, N; 23.58 %. 
 
Bis(substituted) 4-ethyl-3-thiosemicarbazone acenaphthenequinone (iib)  
 
Acenenaphthenequinone (0.25 g, 0.137 mmol) and 4-ethyl-3thiosemicarbazide (0.48 g, 
0.411 mmol) were suspended in 40 mL ethanol and refluxed. 10 drops of conc. HCl 
were added upon reflux. The solid was isolated by filtration whilst hot, resuspended in 
hot methanol (10 mL) and stirred for 15 minutes before filtering and washing with 
further methanol. The resultant yellow solid (446.7mg, 85%), compound iib, was dried 
in vacuo.  
1
H NMR- (300 MHz, d6-DMSO, 25ºC)  12.55 (s, 1H, N-NH’), 11.21 (s, 1H, N-NH), 
9.19 (t, 1H, NH’Et, J = 6.0 Hz), 8.80 (t, 1H, NHEt, J = 5.5 Hz),  8.19 (d, 1H, H-1, J = 
7.2 Hz), 8.13 (d, 1H, H-3’, J = 8.3 Hz), 8.09 (d, 1H, H-1’, J = 7.0 Hz), 8.03 (d, 1H, H-3, 
J = 8.3 Hz), 7.79 (overlapping t, 2H, H-2 and H-2’), 3.66 (m, 4H, CH2CH3), 1.24 (m, 
6H, CH2CH3). 
13
C NMR- (75.5 MHz, d6-DMSO, 25ºC) δ 178.77, 176.92, 139.25, 
139.16, 136.66, 133.06, 130.04, 128.69, 128.58, 128.12, 128.35, 126.17, 124.64, 119.60, 
31.05 Mass spectrum ESI-MS calcd for C18H19N6S2 [M-H]
-
 383.1113, found 383.1155. 
Elem. Anal.: Found C; 56.1 %, H, 5.23 %, N; 21.8 %. Calc.: C; 56.22 %, H; 5.24 %, N; 





Bis(substituted) 4-phenyl-3-thiosemicarbazone acenaphthenequinone (iic)  
 
Acenaphthenequinone (0.25g, 0.137mmol) and 4-phenyl-3thiosemicarbazide (0.68g, 
0.411mmol) were suspended in 40mL ethanol and refluxed 4hours. 10 drops of conc. 
HCl were added upon reflux. The solid was isolated by filtration whilst hot, 
resuspended in hot methanol (10 mL) and stirred for 15 minutes before filtering and 
washing with further methanol. The resultant yellow solid (549 mg, 83%), compound 
iic, was dried in vacuo.  
1
H NMR: (300 MHz, d6-DMSO, 25ºC), δ 12.95 (s, 1H,N-N(H’)), 11.54 (s, 1H, N-NH), 
10.74 (s, 1H, NHPh or N-NH’), 10.67 (s, 1H, NHPh or N-NH’), 8.30 (overlapping d, 
2H, H-1 and H-1’, J = 7.6 Hz and 7.4 Hz), 8.18 (d, 1H, H-3 or H-3’, J = 8.4 Hz), 8.07 (d, 
1H, H-3 or H-3’, J = 8.3 Hz), 7.84 (m, 4H, H-2 and H-2’, o-H’), 7.68 (d, 2H, o-H’, J = 
8.1 Hz), 7.43 (m, 4H, m-H and m-H’), 7.25 (overlapping t, 2H, p-H and p-H’). 13C 
NMR: (75.5 MHz, d6-DMSO, 25ºC) δ 178.41, 176.55, 138.89, 138.81, 132.70, 130.0, 





 479.1118, found 479.1194. Elem. Anal.: Found C; 64.75 %, H, 




Bis(substituted) 4-allyl-3-thiosemicarbazone acenaphthenequinone (iid)  
 
Acenaphthenequinone (0.25g, 0.137mmol) and 4- allyl 3-thiosemicarbazide (0.54 g, 
0.411 mmol) were suspended in 40mL ethanol and were refluxed. 10 drops of conc. 
HCl were added upon reflux. The solid was isolated by filtration whilst hot, 
resuspended in hot methanol (10 mL) and stirred for 15 minutes before filtering and 
washing with further methanol. The resultant yellow solid (415 mg, 74%), compound 
iid, was dried in vacuo.  
1
H NMR: (300 MHz, d6-DMSO, 25ºC) δ 12.63 (s,1H, N-NH’), 11.27 (s,1H, N-NH), 
9.32 (t, 1H, NHAllyl, J = 6.0 Hz), 9.02 (t, 1H, NH’Allyl, J = 5.7 Hz), 8.21 (d, 1H, H-1 
or H-1’, J = 7.2 Hz), 8.11 (overlapping d, 2H, H-3 and H-3’), 8.01 (d, 1H, H-1 or H-1’, 
J = 7.1 Hz), 7.80 (overlapping t, 1H, H-2 or H-2’), 7.78 (overlapping t, 1H, H-2 or H-
2’), 5.95 (m, 2H, CH2CHCH2) 5.35 + 529 (ddt, 2H, H trans, J = 17.4 Hz), 5.25 + 5.18 
(ddt, 2H, Htrans, J = 17.4 Hz), 5.17 + 5.14 (m, 2H, Hcis, J = 10.6 Hz),  4.31 (m, 4H, 
CH2CHCH2), . 
13
C NMR: (75.5 MHz, d6-DMSO, 25ºC) δ 182.52, 178.14, 138.23, 
136.45, 134.86, 134.40, 133.21, 130.32, 129.28, 128.88, 128.55, 128.18, 127.09, 124.93, 





407.1113, found 407.1106. Elem. Anal.: Found C; 58.9 %, H; 4.94 %, N; 20.5 %. 
C20H20N6S2. Calc.: C; 58.80 %, H, 4.93 %, N; 20.57 %. 
 
Zinc(II) bis(4-methyl-3-thiosemicarbazone) acenaphthenequinone (1a)  
 
Zinc complex 1a was prepared by suspending 1 equivalent of acenaphthenequinone 
(502 mg, 2.76 mmols) and 3 equivalents of zinc acetate (1.82 g, 8.29 mmols) in acetic 
acid at 60 
o
C.  Vast excess 4-methyl-3-thiosemicarbazide (2.95 g, 28.04 mmols) was 
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added, the temperature increased to 120 
o
C and refluxed for 30h.  Isolation was 
achieved by hot filtration, followed by washing with 100 mL diethyl ether, yielding an 
orange powder of 601 mg, 1.43 mmols, 52%. Comparison of 
1
H NMR spectra of these 
products with literature data, as well as mass spectroscopy, confirmed the desired 
structures.  
1
H NMR (d6-DMSO, 25 
o
C): δ 8.19 (d, 2H, H-1, J = 6.8 Hz), 7.99 (d, 2H, H-3, J = 8.3 
Hz), 7.85 (m, 2H,  N-H), 7.76 (apparent t, 2H, H-2, J = 7.9 and 7.4 Hz), 3.04 (d, 6H, 
CH3, J = 3.9Hz), 1.91 (3H, CH3, acetic acid) 
13
C NMR (300 MHz, d6–DMSO, 25°C): δ 
179.2, 140.0, 138.1, 130.6, 128.6, 128.2, 126.9, 123.1, 29.4. Mass spectrum ESI-MS 
calcd for C16H15N6S2Zn
+
 [M + H]
+
 419.0086, found 419.0101. HPLC (Method H): Rt = 
2.0 mins.  
 
Zinc(II) bis(4-ethyl-3-thiosemicarbazone) acenaphthenequinone (1b)  
 
Zinc complex 1b was prepared by suspending 1 equivalent of acenaphthenequinone 
(498 mg, 2.73 mmols) and 3 equivalents of zinc acetate (1.763 g, 8.03 mmols) in acetic 
acid at 60 
o
C.  Vast excess of 4-ethyl-3-thiosemicarbazide (3.229 g, 27.09 mmols) was 
added, the temperature increased to 120 
o
C and was refluxed for 30h.  Isolation was 
achieved by hot filtration, followed by washing with 100 mL diethyl ether, yielding an 
orange powder of 603 mg, 1.35 mmols, 49%. Comparison of 
1
H NMR spectra of these 
products with literature data, as well as mass spectroscopy, confirmed the desired 
structures.  
1
H NMR (d6-DMSO, 25 
oC): δ 8.17 (d, 2H, H-1, J = 7.0 Hz), 7.98 (d, 2H, H-3, J = 8.1 
Hz), 7.91 (m, 2H, NHEt), 7.75 (t, 2H, H-2, J = 7.7 Hz), 3.57 (q, 4H, CH2CH3, J = 3.4 
Hz and 3.6 Hz), 1.23 (t, 6H, CH2CH3, J = 7.2 Hz).
13
C NMR (300 MHz, d6–DMSO, 
25°C ): δ 178.8, 140.0, 138.3, 130.9, 129.0, 128.6, 127.2, 123.1, 37.5, 14.8. Mass 
spectrum ESI-MS calcd for C18H19N6S2Zn
+
 [M + H]
+





Zinc(II) bis(4-phenyl-3-thiosemicarbazone) acenaphthenequinone (1c)  
 
Zinc complex 1c was prepared by suspending 1 equivalent of acenaphthenequinone 
(0.504 g, 2.77 mmols) and 3 equivalents of zinc acetate (1.81 g, 8.25 mmols) in acetic 
acid at 60 
o
C.  4-phenyl-3-thiosemicarbazide was added, the temperature increased to 
120 
o
C and was refluxed for 30h.  Isolation was achieved by hot filtration, followed by 
washing with 100 mL diethyl ether, yielding a red powder of 1.020 g, 1.88 mmols, 68%. 
Comparison of 
1
H NMR spectra of these products with literature data, as well as mass 
spectroscopy, confirmed the desired structures.  
1
H NMR (d6-DMSO, 25 
o
C): δ  10.03 (s, 2H NHPh), 8.25 (d, 2H, H-1, J = 7.0 Hz), 8.10 
(d, 2H, H-3, J = 8.2 Hz), 7.93 (d, 4H, o-H, J = 7.7 Hz), 7.85 (t, 2H, H-2, J = 7.1 Hz), 
7.42 (t, 4H, m-H and m-H’, J = 7.9 Hz), 7.08 (t, 2H, p-H and p-H’, J = 7.3Hz). 13C 
NMR (300 MHz, d6–DMSO, 25 ˚C): δ 177.2, 142.3, 140.5, 138.6, 130.7, 128.6, 128.3, 





 543.0399, found 543.0348. 
 
Zinc(II) bis(4-allyl-3-thiosemicarbazone) acenaphthenequinone (1d)  
 
Zinc complex 1d was prepared by suspending 1 equivalent of acenaphthenequinone 
(0.502 mg, 2.76 mmols) and 3 equivalents of zinc acetate (1.815 g, 8.27 mmols) in 
acetic acid at 60 
o
C.  Vast excess of 4-allyl -3-thiosemicarbazide was added the 
temperature increased to 120 
o
C and refluxed for 30h.  Isolation was achieved by hot 
filtration, followed by washing with 100 mL diethyl ether, yielding an orange powder of 
62%. Comparison of 
1
H NMR spectra of these products with literature data, as well as 




H NMR (d6-DMSO, 25 
oC): δ 8.18 (d, 2H, H-1, J = 6.8 Hz), 7.95 (t, 2H, NH), 7.89 (d, 
2H, H-3, J = 8.1 Hz), 7.68 (apparent t, 2H, H-2, J = 8.1 Hz and 7.2 Hz), 6.00 (m, 2H, -
CH2CHCH2), 5.27 (dd, 2H, Htrans), 5.15 (dd, 2H, Hcis), 4.18, (bm, 4H, -CH2CHCH2). 
13
C NMR (300 MHz, d6-DMSO, 25 °C): δ 175.3, 155.4, 146.3, 135.3, 130.5, 129.9, 





 471.0396,  found 471.0404.  
 
Zinc(II) bis(t-Boc-protected amine thiosemicarbazone) acenaphthenequinone (1e)  
 
Acenaphthenequinone (50 mg, 0.274 mmols) and zinc acetate (183 mg, 0.833 mmols) 
in 2:98 acetic acid:dioxane were added in the presence of activated molecular sieves 
was heated to 60°C. A mixture of Monoboc thiosemicarbazide (tert-butyl-2-
hydrazinecarbonothioyl)hydrazinecarboxylate) and the di-substituted-boc, was added in 
excess to a suspension and the temperature raised to 110 °C. This was refluxed for 30 h 
and by filtrated whilst hot. The filtrate was dried in vacuo, washed with 50 mL diethyl 
ether and dried once more in vacuo. The product was obtained as an orange solid (58 
mg, 0.093 mmols, 34%). Elemental analysis indicated that this complex could not be 
isolated in high purity. 
1
H NMR (d6-DMSO, 25 
o
C): δ 9.39 (s, 2H, NH), 8.92 (s, 2H, NH), 8.30 (d, 2H, H-1, J 
= 7.1 Hz), 8.06 (d, 2H, H-3, J = 8.2 Hz), 7.76 (t, 2H, H-2, J = 7.6 Hz), 3.50 (d, 1H, 





 619.0913, found 619.0893. Elem. Anal.: Found C; 35.3 %, 
H; 4.42 %, N; 18.05 %. Calc. C; 46.34 %; H; 4.54 %; N; 18.01 %. HPLC (Method H): 




Copper(II) bis(4-methyl-3-thiosemicarbazone) acenaphthenequinone (2a)  
 
Synthesised from the proligand: 1 equivalent compound iia (0.1g, 0.028 mmol) and 3 
equivalents copper acetate (0.152g, 0.0842mmol) were stirred at rt in 50 mL methanol 
for 24 hours. This was filtered and washed with water and diethyl ether yielding a 
brown solid 82.9 mg, 70.5%. Synthesis via zinc complex: 1a (50 mg, 0.119 mmols) was 
added to two equivalents of copper acetate (49.2 mg, 0.247 mmols) in methanol and 
stirred at room temperature for 24h, filtered and washed with diethyl ether. This yielded 
36 mg (0.086 mmols, 72%) of brown solid. Mass spectrum ESI-MS calcd for 
C16H15CuN6S2
+
 [M + H]
+
, 418.0090, found 418.0092. Elem. Anal.: Found: C; 45.6 %, 
H; 3.85 %, N; 18.8 %. Calc.: C; 45.97 %, H; 3.38 %, N; 20.11 %. HPLC (Method A): 
Rt = 11.3 mins, (Method H): Rt = 8.1 mins.  
 
Copper(II) bis(4-ethyl-3-thiosemicarbazone) acenaphthenequinone (2b)  
 
Synthesis from proligand: 1 equivalent bis ethyl thiosemicarbazone ligand (0.15g, 0.390 
mmol) and 3 equivalents copper acetate (0.254g, 1.10 mmol) were stirred at rt in 50 mL 
methanol for 24 hours. This was filtered and washed with water and diethyl ether giving 
a brown solid, yielding 67.8 mg, 0.152 mmols, 39%. Synthesis from the zinc complex: 
1b (50 mg, 0.112 m mols) was added to two equivalents of copper acetate (44.5 mg, 
0.223 mmol) in methanol. This was stirred at rt in 50 mL methanol for 24 hours. It was 
filtered and washed with water and diethyl ether yielding a brown solid of 26.6 mg, 
0.060 mmols, 53%. Mass spectrum ESI-MS calcd for C18H19CuN6S2
+
 [M + H]
+
 
446.0403, found 446.0400. Elem. Anal.: Found: C; 47.9 %, H; 4.05 %, N; 17.60 %. 
Calc.: C; 47.73 %, H; 4.64%, N; 17.58%. HPLC (Method H): Rt = 9.3 mins.  
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Copper(II) bis(4-phenyl-3-thiosemicarbazone) acenaphthenequinone (2c)  
 
Synthesis from zinc bis phenyl thiosemicarbazone: The zinc complex 1c, (101 mg, 
0.186 mmols) added to two equivalents of copper acetate (77 mg, 0.386 mmols) in 
methanol and stirred at room temperature for 24h. The product (67 mg, 0.124 mmols, 
66%) was isolated by filtration and washing with water and diethyl ether.  




 540.0258, found 540.0237. 
Elem. Anal.: Found: C; 55.8 %, H, 3.50 %; N; 14.60 %. Calc. (+MeOH): C; 56.48 %, 
H, 3.86 %, N; 14.64 %. HPLC (Method D): Rt = 14.9 mins. 
 
Copper(II) bis(4-allyl-3-thiosemicarbazone) acenaphthenequinone (2d)  
 
Synthesis from the ligand: 1 equivalent bis allyl thiosemicarbazone (0.2g, 0.049 mmol) 
and 3 equivalents copper acetate (0.32g, 0.147 mmol) were stirred at rt in 50 mL 
methanol for 24 hours. This was filtered and washed with water and diethyl ether 
yielding a brown solid of 95mg, 41%. Synthesis from zinc complex: 1d, (52 mg, 0.110 
mmols) added to two equivalents of copper acetate (44 mg, 0.223 mmols) in methanol 
and stirred at room temperature for 24h. The product (33 mg, 0.070 mmols, 64%) was 





 468.0258, found 468.0260. Elemental Analysis: 
Found: C; 49.85 %, H, 3.82 %, N; 17.0 %. Calc.: C; 51.10 %, H,3.86 %, N; 17.88 %. 





Copper(II) bis(t-Boc-protected amine thiosemicarbazone) acenaphthenequinone 
(2e)  
 
The zinc complex 1e, (20 mg, 0.032 mmols) was added to two equivalents of copper 
acetate in methanol and stirred at room temperature for 24h.  The product was isolated 
by rotary evaporation yielding 8 mg of very dark brown solid (0.013 mmols, 40%). 




 618.0898, found 618.0761. 
HPLC (Method H): Rt = 8.5 mins. 
 
 
Gallium(III) chloride bis(4-methyl-3-thiosemicarbazone) acenaphthenequinone (3a)  
 
A suspension of zinc bis(4-methyl-3-thiosemicarbazide) acenaphthenequinone (0.101 g, 
0. 242 mmol) in MeOH (50 mL) was added to GaCl3 (0.193 g, 1.11 mmol). The 
resulting suspension was heated at reflux for 6 h. The red solid that precipitated on 
cooling to room temperature was then isolated by filtration, washed with Et2O and dried 
under vacuum (0.0395 g, 0.086 mmol, 36%). The (E,E) and (E,Z) isomers were found to 
be present in the integral ratio of 57:43 (favouring the (E,E) isomer) in d6-DMSO by 
1
H 
NMR analysis.  
(E,E) isomer (57% relative abundance) 
1
H NMR (d6-DMSO, 25 °C): δ 8.81 (broad s, 
2H, NH), 8.29 (d, 2H, H-1, J = 6.8 Hz), 8.19 (d, 2H, H-3, J = 8.3 Hz), 7.88 (t, 2H, H-2, 
J = 4.5 Hz), 3.11 (d, 6H, CH3). (E,Z) isomer (43% relative abundance) 
1
H NMR (d6-
DMSO, 25 °C): δ 9.53 (apparent d, 1H, NH, J = 4.1 Hz), 8.90 (apparent d, 1H, N(H’), J 
= 4.5 Hz), 8.58 (d, 1H, H-1 or H-1, J = 7.0Hz ‘), 8.16 (obscured d, 1H, H-1 or H-1’), 
8.07 (d, 1H, H-3 or H-3’, J = 8.2Hz), 7.94 (d, 1H, H-3 or H-3’, J = 6.9 Hz), 7.84 (t, 1H, 
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H-2 or H-2’, J = 7.7Hz), 7.80 (t, 1H, H-2 or H-2’, J = 7.6Hz), 3.16 (d, 3H, CH3 or CH3’, 
J = 4.4 Hz), 3.12 (obscured d, 3H, CH3 or CH3’). 
13
C NMR (d6-DMSO, 25 °C): δ 178.7, 
174.7, 170.7, 147.5, 142.4, 138.9, 138.8, 136.0, 132.3, 130.4, 129.7, 129.4, 129.1, 
129.04, 128.95, 128.90, 128.6, 127.4, 126.2, 124.6, 118.4,  33.2, 30.2 29.4, 27.1. Mass 




 456.9587, found 458.9605. 
Elemental analysis: Calc.: C; 41.81 %, H; 3.07 %, N; 18.28 %, Found: C; 41.8 %, H; 
3.04 %, N; 18.0 %. 
 
Gallium(III) chloride bis(4-ethyl-3-thiosemicarbazone) acenaphthenequinone (3b)  
 
A suspension of zinc bis(4-ethyl-3-thiosemicarbazide) acenaphthenequinone (0.216 g, 
0.482 mmol) in MeOH (50 mL) was added to GaCl3 (0.420 g, 1.478 mmol). The 
resulting suspension was heated at reflux for 6 h. The red solid that precipitated on 
cooling to room temperature was then isolated by filtration, washed with Et2O and dried 
under vacuum (0.146 g, 0.299 mmols, 62%). 
 The (E,E) and (E,Z) isomers were found to be present in the integral ratio of 
approximately 1:1 in d6-DMSO by 
1





C): δ 9.58 (t, 1H, NH), 8.87 (t, 1H, NH’), 8.50 (d, 1H, H-1, J = 7.0 Hz), 
8.11 (d, 1H, H-3’, J = 8.3 Hz), 8.03 (d, 1H, H-3, J = 8.1 Hz), 7.93 (d, 1H, H-1’, J = 6.9 
Hz), 7.83 (apparent t, 1H, H-2), 7.76 (apparent t, 1H, H-2’), 3.61 + 3.56 (m, 4H, CH2), 
1.26 + 1.25 (two t, 6H, CH3, J = 7.2 Hz). (E,E) isomer (49%): δ 8.79 (broad t, 2H, NH), 
8.16 (d, 2H, H-1, J = 7.0 Hz), 8.09 (d, 2H, H-3, J = 8.3 Hz), 7.75 (apparent t, 2H, H-2), 
3.59 (m, 4H, CH2), 1.25 (t, 6H, CH3, J = 7.2 Hz). 
13
C NMR (d6-DMSO, 25 °C):  
177.56, 173.20, 169.93, 138.72, 138.50, 135.84, 132.28, 130.25, 129.65, 129.31, 128.92, 
128.47, 127.00, 126.83, 126.06, 124.23, 118.39, 114.13, 41.87, 38.34, 37.57, 14.60, 
14.07, 13.67. Mass spectrum ESI-MS calcd for C18H17ClGaN6S2 [M-H]
-






Gallium(III) chloride bis(4-phenyl-3-thiosemicarbazone) acenaphthenequinone (3c)  
 
A suspension of zinc bis(4-phenyl-3-thiosemicarbazide) acenaphthenequinone (0.100 g, 
0.184 mmol) in MeOH (50 mL) was added to GaCl3 (0.1567 g, 0.551 mmol). The 
resulting suspension was heated at reflux for 6 h. The red solid that precipitated on 
cooling to room temperature was then isolated by filtration, washed with Et2O and dried 
under vacuum (72.4 mg, 0.124 mmols, 67%). The (E,E) and (E,Z) isomers were found 
to be present in the integral ratio of approximately 1:1 in d6-DMSO by 
1
H NMR 
analysis. (E,Z):(E,E) 27:73%.  NMR data of the (E,Z) isomer was not assigned due to 
major overlapping with (E,E) peaks and poorly defined signals.  
(E,E) isomer (73%). 
1
H NMR (d6-DMSO, 25 °C
 ): δ 10.81 (s, 2H, NH), 8.28 (two 
overlapping d, 4H, H-3 + H-1), 7.97 (apparent t, 2H, H-2), 7.87 (d, 4H,  o-H, J = 8.0 
Hz), 7.50 (apparent t, 4H, m-H), 7.20 (t, 2H, p-H, J = 7.3 Hz). 
13
C NMR (75.5 MHz, 
d6-DMSO, 25 °C): weak due to poor solubility  








Gallium(III) chloride bis(4-allyl-3-thiosemicarbazone) acenaphthenequinone (3d)  
 
A suspension of zinc bis(4-allyl-3-thiosemicarbazide) acenaphthenequinone (0.050 g, 
0.106 mmol) in MeOH (50 mL) was added to GaCl3 (0.284 g, 1.635 mmol). The 
resulting suspension was heated at reflux for 6 h. After allowing cooling a red solid was 
then isolated by filtration, washed with Et2O and dried under vacuum (0.029 g, 0.057 
mmol, 54%). (E,Z) isomer (62% relative abundance) 
1
H NMR (300 MHz, d6-DMSO, 
25 °C): δ 9.78 (m, 1H, NH), 9.08 (m, 1H, NH´), 8.52 (d, 1H, H-1, J = 7.2 Hz), 8.12 
(overlapping d, 1H, H-1), 8.05 (d, 1H, H-3, J = 8.3 Hz), 7.94 (d, 1H, H-1, J = 7.0 Hz), 
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7.79 (overlapping t, 1H, H-2 or H-2), 7.77 (overlapping t, 1H, H-2 or H-2), 5.87–6.09 
(m, 2H, CH2CHCH2, 5.30 (two overlapping dd, 2H, Htrans), 5.17 (two overlapping dd, 
2H Hcis), 4.23 (m, 2H, CH2CHCH2), 4.17 (m, 2H, CH2CHCH2). (E,E) isomer (38% 
relative abundance) 
1
H NMR (300 MHz, d6-DMSO, 25 ◦C): δ 9.02 NH, 8.21 (d, H-3, J 
= 7.2 Hz), 8.15 H-1, 7.84 H-2, 5.87-6.09 (m, CH2CHCH2), 5.28 (dd, Htrans), 5.21 (dd, 
Hcis.), 4.23 (m, 2H, CH2CHCH2). 
13
C NMR (d6-DMSO, 25 ◦C): δ 178.5, 170.3, 147.6, 
142.6, 138.8, 135.9, 134.2, 133.7, 133.3, 132.2, 129.7, 129.6, 129.5, 128.9, 128.7, 128.5, 
127.1, 127.0, 125.9, 124.4, 118.5, 117.3, 116.6, 116.5, 48.9, 45.7, 45.0. Mass spectrum 
ESI-MS calcd for C20H17ClGaN6S2
-
 [M - H]
-
 508.9900, found 508.9911. Elem. Anal.: 
Found C; 45.7%, H; 3.45 %, N; 15.6 %. Calc. (for 3·MeOH): C; 46.39 %, H; 4.08 %, N; 
15.46 %,  
 
Indium(III) chloride bis(4-methyl-3-thiosemicarbazone) acenaphthenequinone (4a)  
 
A suspension of zinc bis(4-methyl-3-thiosemicarbazide) acenaphthenequinone (0.155 g, 
0. 370 mmol) in MeOH (50 mL) was added to InCl3 (0.365 g, 1.652 mmol). The 
resulting suspension was heated at reflux for 6 h. The red solid that precipitated on 
cooling to room temperature was then isolated by filtration, washed with Et2O and 
dried under vacuum (0.116 g, 0.230 mmol, 62%). 
1
H NMR (d6-DMSO, 25 °C): δ 8.42 (d, 2H, H-1, J = 6.6 Hz), 8.09 (d, 2H, H-3, J = 8.1 
Hz), 7.98 (m, 2H, NH), 7.75 (apparent t, 2H, H-2, J = 7.4 Hz and 7.9 Hz), 3.11 (d, 6H, 
CH3, J = 4.7 Hz). 
13
C NMR (d6-DMSO, 25 °C): δ 176.2, 139.9, 137.2, 130.3, 128.7, 
128.6, 127.3, 124.2, 29.2. Mass spectrum ESI-MS calcd for C16H13ClInN6S2
-
 [M - H]
-
 
502.9370, found 502.9375. Elem. Anal.: Calc.: C; 38.07 %, H; 2.80 %, N; 16.65 %, 





Indium(III) chloride bis(4-ethyl-3-thiosemicarbazone) acenaphthenequinone (4b)  
 
A suspension of zinc bis(4-ethyl-3-thiosemicarbazide) acenaphthenequinone (0.155 g, 0. 
370 mmol) in MeOH (50 mL) was added to InCl3 (0.365 g, 1.652 mmol). The resulting 
suspension was heated at reflux for 6 h. The red solid that precipitated on cooling to 
room temperature was then isolated by filtration, washed with Et2O and dried under 
vacuum (0.116 g, 0.230 mmol, 62%). 
1
H NMR (d8-THF, 25 
o
C): δ 8.29 (d, 2H, H-1, J = 6.9 Hz), 7.92 (d, 2H, H-3, J = 8.3 
Hz), 7.68 (m, 4H, NH + H-2), 3.72 (m, 4H, CH2), 1.34 (t, 6H, CH3, J = 7.3 Hz). 
13
C NMR (d8-THF, 25 
o
C):  175.3, 142.4, 139.7, 131.8, 129.3, 129.2, 128.9, 125.5, 




 530.9683, found 
530.9679. Elem. Anal.: Found: C; 38.80 %, H; 3.42 %, N; 14.60 %. Calc. (for 
1·MeOH): C; 40.40 %, H; 3.93 %, N; 14.88 %. 
 
Indium(III) chloride bis(4-phenyl-3-thiosemicarbazone) acenaphthenequinone (4c)  
 
A suspension of zinc bis(4-phenyl-3-thiosemicarbazide) acenaphthenequinone (0.100 g, 
0. 1838 mmol) in MeOH (50 mL) was added to InCl3 (0.365 g, 1.652 mmol). The 
resulting suspension was heated at reflux for 6 h. 4c was isolated from the filtrate, 
which was dried under vacuum and subsequently washed with water and diethyl ether 
(49.9 mg, 0.079 mmol, 43%). 
1
H NMR (d8-THF, 25 
o
C): δ 9.60 (s,2H,NHPh), 8.40 (d, 2H, H-3, J = 7.0 Hz),  8.04 (d, 
2H, H-1, J = 8.2 Hz), 7.85 (d, 4H, o-H, J = 7.6 Hz), 7.73 (apparent t, 2H, H-2,), 7.42 (t, 
4H, m-H, J = 7.9 Hz), 7.13 (t, 2H, p-H, J = 7.4 Hz). 
13
C NMR (d8-THF, 25 
o
C):  174.2, 
144.5, 141.0, 136.9, 132.0, 129.8, 129.6, 129.5, 128.7, 125.4, 124.7, 123.0.  Mass 
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 626.9683, found 626.9716. Elem. 
Anal.:. Found C; 45.90 %, H; 3.27 %, N; 12.10 %. Calc. (for 2·H2O):  C; 46.97 %, H; 
3.34 %, N; 12.64 % 
 
Indium(III) chloride bis(4-allyl-3-thiosemicarbazone) acenaphthenequinone (4d)  
 
A suspension of zinc bis(4-allyl-3-thiosemicarbazide) acenaphthenequinone (0.100 g, 0. 
212 mmol) in MeOH (50 mL) was added to InCl3 (0.209 g, 0.946 mmol). The resulting 
suspension was heated at reflux for 6 h. The red solid that precipitated on cooling to 
room temperature was then isolated by filtration, washed with Et2O and dried under 
vacuum (0.031 g, 0.056 mmol, 27%). 
1
H NMR (300 MHz, d6-DMSO, 25 °C):  8.35 
(br s, 2H, H-1), 8.18 (s, 2H, NH), 8.04 (d, 2H, H-3, J = 8.2 Hz), 7.79 (t, 2H, H-2, J = 7.6 
Hz), 6.01 (m, 2H, CH2CHCH2), 5.29 (dd, 2H, Htrans, J = 17.1 Hz), 5.14 (dd, 2H, Hcis, J = 
10.3 Hz), 4.19 (s, 4H, CH2CHCH2). 
13
C NMR (75.5 MHz, d6-DMSO, 25 °C):  176.0, 





 554.9683, found 554.9683 Elem. Anal.:. Found C; 
42.40 %, H; 3.24 %, N; 14.8 %. Calc. (for 1·MeOH):  C; 42.83 %, H; 3.77 %, N; 14.27 % 
 
Bis-acenaphthenequinone bridged thiosemicarbazonato proligand (LB)  
 
Excess of thiocarbohydrazide (1.43 g, 13.47 mmol) with an equivalent of 
acenaphthenequinone (0.5 g, 2.74 mmols) in 30 mL of ethanol (Figure 7.2).  Upon 
reflux four drops of glacial acetic acid were added and after 3 hours the suspension was 
filtered whilst hot yielding a yellow solid (247.9 mg, 0.86 mmols). Crystals precipitated 
(372.9 mg, 1.29 mmols) from the filtrate and possessed identical spectral properties as 




H NMR (300 MHz, d6-DMSO, 25 °C):  7.88 (overlapping d, 2H, H-3, J = 8.1 Hz), 
7.73 (overlapping d, 2H, H-1, J = 6.9 Hz), 7.63 (overlapping t, 2H, H-2), 6.98 (s, 2H, 
OH), 4.61 (s, 4H, NH2). 
13
C NMR (75.5 MHz, d6-DMSO, 25 °C):  180.2, 139.2, 134.7, 
130.4, 128.1, 125.2, 121.1, 95.5. Mass spectrum ESI-MS calcd for C13H13N4O2S
+
 
289.0754, found 289.0741. 
 
Zinc(II) 4-methyl-3-thiosemicarbazone-thiocarbohydrazide acenaphthenequinone 
(1aN)  
 
Zinc complex 1aN was prepared by suspending 1 equivalent of compound ia (0.1044g, 
0.38 mmol) and 3 equivalents of zinc acetate (0.2486, 1.13 mmol) in 10 mL of acetic 
acid at 60 
o
C. 3 equivalents of thiocarbohydrazide (0.1196g, 1.12 mmol) was added, the 
temperature increased to 120 
o
C and refluxed for 30h.  Isolation was achieved by hot 
filtration, followed by washing with 5 mL of THF and 100 mL diethyl ether, yielding 
yellow powder of 0.1215 g, 0.28 mmol, 74%.  
1
H NMR (300 MHz, d6-DMSO, 25 
o
C): All peaks: δ 9.96 (very broad, 1.3H, NH, (E,E)), 
8.95 (broad, 0.3H, NH, (E,Z)), 8.77 (broad, 0.3H, NH, (E,Z)), 8.15-8.75 (m, 2H, Ar-H-
1/3) 7.80-8.05 (m, 2H, Ar-H-1/3), 6.71 (broad, 0.46H, NH2, (E,Z)), 6.60 (broad, 1.04H, 
NH2, (E,E)), 3.01-3.14 (m, 3H, CH3). 
13
C NMR (75.5 MHz, d6-DMSO, 25 °C): δ 
178.08, 175.59, 145.85, 135.09, 130.59, 129.51, 128.42, 127.81, 127.36, 127.11, 126.39, 









 417.9887, found 417.9911. HPLC 





Zinc(II) 4-ethyl-3-thiosemicarbazone-thiocarbohydrazide acenaphthenequinone  
(1bN)  
 
A suspension of compound ib (250.6 mg, 0.885 mmols) was added to three equivalents 
of zinc acetate (587.3 mg, 2.68 mmols) was heated to 60°C in 10 mL of acetic acid. 
Three equivalents of thiocarbohydrazide (285.6 mg, 2.69 mmols) were added and the 
temperature increased to 120°C. This was refluxed for 28 h and then filtered whilst hot, 
washed with 5 mL of THF, 100 mL of diethyl ether, and dried under vacuum, yielding a 
yellow powder of 221.6 mg, 0.510 mmols, 58 %. 
1
H NMR: (300 MHz, d6-DMSO, 25 °C) All peaks: δ 9.87 (1H, very broad peak, NH 
[E,E,]), 8.98 (0.39 H, NH, (E,Z)), 8.75 (0.36 H, NH’, (E,Z)), 8.15-8.63 (m, 2H, Ar-H-
1/3), 7.68 (overlapping t, 2H, H-2 and H-2’), 6.64 (0.7H, NH2’), 6.54 (1H, NH2), 3.60 (t, 
2H, CH2), 1.28 (t, 3H, CH3). 
13
C NMR (75.5 MHz, d6-DMSO, 25 °C):  177.48, 175.67, 
135.01, 130.67, 129.52, 128.35, 127.35, 125.76, 120.12, 37.96, 22.76, 14.18. Mass 
spectrum ESI-MS calcd for C16H16N7S2Zn
+
 [M + H]
+
 434.0200, found 434.0211. 
HPLC (Method B): Rt = 10.5 mins, (Method E): Rt = 9.2 mins. 
 
Zinc(II) 4-phenyl-3-thiosemicarbazone-thiocarbohydrazide acenaphthenequinone 
(1cN)  
 
A suspension of compound ic (0.1025 g, 0.31 mmol) was added to three equivalents of 
zinc acetate (0.2048 g, 0.93 mmols) using was heated to 60°C in 10 mL of acetic acid. 
Three equivalents of (0.0998g, 0.94 mmol) thiocarbohydrazide were added and the 
temperature increased to 120°C. This was refluxed for 28 h and then filtered whilst hot, 
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washed with 5 mL of THF, 100 mL of diethyl ether, and dried under vacuum, yielding a 
dark red powder of 0.0982 g, 0.20 mmol, 65%. 
1
H-NMR (300 MHz, d6-DMSO, 25 °C):  9.92 2H (s, NH and NH’  overlapping), 8.67 
(broad d, 1H, H-3 or H-3’), 8.07 (broad, 1H, H-3 or H-3’), 7.95 1H (d, H1 or H1’, J = 
8.29 Hz) and 7.89 1H (d, H-1 or H-1’), 7.71 (d, 2H,o-H), 7.62 (d, 1H, H-2 or H-2’), 
7.51 (t, 1H, H-2 or H-2’), 7.40 (t, 2H, m-H), 7.16 (t, 1H, p-H), 6.55 (s, 2H, NH2). 
13
C NMR (75.5 MHz, d6-DMSO, 25 °C):  140.15, 135.02, 130.30, 128.54, 128.01, 





482.0200, found 482.0200. 
 
Zinc(II) 4-allyl-3-thiosemicarbazone-thiocarbohydrazide acenaphthenequinone 
(1dN)  
 
A suspension of compound id (0.1034g, 0.35 mmol)was added to three equivalents of 
zinc acetate (0.2228g, 1.01 mmol) using was heated to 60°C in 10 mL of acetic acid. 
Three equivalents of thiocarbohydrazide (0.1091, 1.02 mmol) were added and the 
temperature increased to 120°C. This was refluxed for 28 h and then filtered whilst hot, 
washed with 5 mL of THF, 100 mL of diethyl ether, and dried under vacuum, yielding a 
light brown powder of 0.0787g, 0.17 mmol, 48%. 
(E,E) isomer, 67 % 
1
H NMR (300 MHz, d6-DMSO, 25 
o
C): δ 9.82 (s, 1H, NH), 8.99 (s, 
1H, NH’), 8.60 (d, 1H, H-1), 8.38 (broad, 1H, H-1’), 7.98 (d+d, 2H, H-3, J = 7.9 Hz), 
7.68 (d+d, 2H, H-2), 6.59 (d, 2H, NH2), 6.01 (m, 1H, CH2CHCH2), 5.28 (dd, 1H, Htrans), 
5.14 (dd, 1H, Hcis), 4.18 (bm, 2H, CH2CHCH2). (E,Z) isomer contained many 
overlapping peaks and was not assignable. 
13
C NMR (75.5 MHz, d6-DMSO, 25 °C): 
(Weak data due to poor solubility)  129.54, 115.75, 128.27, 127.26, 125.92, 115.75, 











acenaphthenequinone (3bN)  
 
 
50 mg, 0.115 mmols of zinc 1bN was solubilised in 2.5 mL of DMSO, to which an 
excess of gallium chloride was added and 30 mL of MeOH.  This was refluxed under an 
atmosphere of nitrogen for 6 hours and was filtered after cooling to room temperature.   
The solution was removed in vacuo and the resultant material washed with 10 mL of 
ethyl acetate, followed by two times 10 mL of diethyl ether. This yielded an orange 
solid of 45 mg, 0.095 mmols, 82.6% (E,E) isomer. 
1
H NMR (300 MHz, d6-DMSO, 25 
o
C):  10.25 (s, 1H, NH), 8.60 (t, 1H, NH, J = 6.41 Hz), 8.15 (d, 1H, H-3, J = 8.3 Hz), 
7.98 (m, 1H, H-3', J = 8.2 Hz), 7.85 (m, 2H, H-1/1') 7.75 (m, 2H, H-2/2'), 7.61 (s, 2H, 
NH2), 4.12 (broad, 2H, CH2), 1.30 (t, 3H, CH3, J = 7.3 Hz). 
13
C NMR (75.5 MHz, d6-
DMSO, 25 °C): δ 129.81, 129.38, 128.27, 126.96, 125.78, 117.81, 37.96, 13.88. Mass 
spectrum ESI-MS calcd for C20H16N7S2GaCl
-
 471.9696, found 471.9729. HPLC 





Bombesin analogue  
 
Fmoc-protected rink amide resin (1g, 0.5 mmols) was swelled in a peptide vessel 
for 20 min with DCM. This was subsequently deprotected using a solution of 20% 
piperidine in DMF, with deprotection confirmed by Kaiser-test. For the first step, 
three equivalents of the amino-acid (Fmoc-Leu-OH, 530 mg, 1.5 mmols) of HOBt 
(203 mg, 1.5 mmols) and of base N,N′-Diisopropylcarbodiimide (235 µL, 1.5 mmols) 
in DMF was added to the resin. This was to react for 90 minutes, followed by 
deprotection using 20% piperidine in DMF as confirmed by the Kaiser-test. 
Subsequent steps used three equivalents of amino acids, 1.9 equivalents of HOBt 
(360 mg) and 6 equivalents of N,N′-Diisopropylcarbodiimide and were followed by 
deprotection as described above. The amino acids were Fmoc-His(Trt)-OH (619.7 mg), 
Fmoc-Gly-OH (446 mg), Fmoc-Val-OH (509.1 mg),Fmoc-Ala-OH (467 mg), Fmoc-
Trp(Boc)-OH (790 mg), Fmoc-Gln(Trt)-OH (916.05 mg), respectively. Finally the 
peptide was t-boc deprotected by stirring for three hours with a cocktail of 95% TFA, 
2.5% TIS and 2.5% H2O, with resin beads filtered and the solution collected. This was 
freeze-dried in vacuo and purified using semi-preparative HPLC yielding 60 mg of 
peptide. 
Mass spectrum ESI-MS calcd for C38H57N12O8
+
 807.4417, found 807.4403. HPLC 





Derivatised bombesin analogue 
 
An equivalent of pyruvic acid (0.4 mg, 4.55 µmols) was added to coupling agents EDC 
(1-ethyl-3-(3’-dimethylaminopropyl) carbodiimide) (0.9 mg, 5.80 µmols) and HOBt 
(hydroxybenzotriazole) (0.86 mg, 6.37 µmols) on ice in DMF, which was achieved 
using 10x stock solutions in DMF.  After 45 minutes 5 mg, (1 equivalent, 4.55 µmols) 
of bombesin was added followed by dropwise addition of DIPEA (N,N’-
diisopropylethylamine) until pH 8 was reached.  This was allowed to react for 2 hours 
and was subsequently extracted from DMF and purified using a solid phase extraction 
cartridge. Mass spectrum ESI-MS calcd for C41H57N12O10
- 
877.4321, found 877.4377. 
HPLC (Method E): Rt = 4.8 mins. 
 
Ethyl-bombesin derivatised zinc complex, 1bB 
 
Following this 5 mg of derivatised bombesin analogue (4.55 mols) was added to 2.0 
mg (4.55 mols) of zinc complex, compound 1bN in 400 L of DMSO, for the purpose 
of synthesising compound 1bB. To this mixture 10 mL of HPLC grade methanol was 
added followed by 1 drop of concentrated HCl (32%), resulting in an instant colour 
change from dark orange to yellow.  After stirring at 30C for ca. 16 hours, the solution 




Allyl-bombesin derivatised zinc complex, 1dB 
 
Following this 5 mg of derivatised bombesin analogue (4.55 mols) was added to 2.0 
mg (4.55 mols) of zinc complex, compound 1dN in 400 L of DMSO, for the purpose 
of synthesising compound 1dB. To this mixture 10 mL of HPLC grade methanol was 
added followed by 1 drop of concentrated HCl (32%), resulting in an instant colour 
change from dark orange to yellow.  After stirring at 30C for ca. 16 hours, the solution 
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Appendix A. X-ray crystallography data 
 
Table A.1. X-ray crystallography data of iibS-S, iid, LB and 1c. 
 
Sulfur-bridged 
dimer, iibS-S  
iid LB 1c 
Empirical formula C36H38N12S4 C20H20N6S2 C13H12N4O2S C32H36N6O3S5Zn 
Formula weight / 
g mol
-1 
767.02 408.54 288.33 778.34 
Crystal system Orthorhombic Triclinic Triclinic Monoclinic 
Space group P 21 21 21 P 1 P 1 P 21/n 
a (Å) 8.535(2) 7.859(7) 10.1253(4) 17.6908(13) 
b (Å) 19.120(5) 11.040(9) 10.5869(4) 7.7955(6) 
c (Å) 22.172(6) 12.049(9) 12.7786(5) 25.4735(18) 
α (deg) 90 90.546(6) 110.818(4) 90 
β (deg) 90 95.3880(10) 90.107(3) 96.074(7) 
γ (deg) 90 110.304(13) 95.659(4) 90 
V (Å
3
) 3618.2(16) 975.1(14) 1273.14(9) 3493.3(4) 
Z 4 2 4 4 
µ (mm
-1
) 0.310 0.292 0.262 1.045 
ρ (g cm-3) 1.408 1.391 1.504 1.480 
θ range (°) 2.06 to 24.99 2.58 to 24.35 2.85 to 32.53 2.94 to 28.23 
Measured/independent 
reflections/ Rint 
28222 / 6895 / 
0.2717 
6825 / 3176 / 
0.0509 
17266 / 8480 / 
0.0162 




 wR2 [I > 2σ(I)]
b
 0.0993, 0.2568 0.0574, 0.1398 0.0331, 0.0869 0.0283, 0.0579 
R1,
a
 wR2 (all data)
b
 0.1038, 0.2669 0.0802, 0.1510 0.0463, 0.0901 0.0463, 0.0598 
 
iibS-S Potential Hydrogen atoms on N5 and N8. However, attaching these to the parent 
atoms changed the R value from 9.93 to a higher 9.97 %. Initially all N-H hydrogen 
atoms were refined freely but a couple of them had too low temperature factors. For 
N5H5 and N8H8 however the temperature factor shot up to unrealistic numbers. 
 
LB. The asymmetric unit contains two independent molecules of the proligand. All N-H 









Table A.2.X-ray crystallography data of 2c, 3a, 3b and 3c. 
 2c 3a 3b 3c 
Empirical formula C34H34CuN6O2S2 C44H52Cl2Ga2N12O3S4 C18H18ClGaN6S2 C34H34ClGaN6O2S2 
Formula weight / 
g mol
-1 686.33 1135.56 487.69 727.96 
Crystal system Monoclinic Triclinic Triclinic Triclinic 
Space group P  21/c  P 1 P 1 P1 
a (Å) 9.1524(3) 10.4126(2) 9.5451(17) 10.2706(4) 
b (Å) 30.0870(13) 13.4257(3) 10.1534(13) 16.1315(5) 
c (Å) 11.5913(6) 19.4955(5) 11.2953(19) 21.9814(8) 
α (deg) 90 109.6470(10) 77.537(13) 69.885(2) 
β (deg) 105.227(2) 101.2810(10) 68.181(16) 78.060(2) 
γ (deg) 90 96.9310(10) 81.795(13) 75.348(3) 
V (Å
3
) 3079.8(2) 2465.32(10) 989.9(3) 3279.6(2) 
Z 4 2 2 4 
µ (mm
-1
) 0.888 1.424 5.260 1.090 
ρ (g cm-3) 1.480 1.530 1.636 1.474 
θ range (°) 3.25 to 25.14 4.12 to 27.61 
4.2780 to 
44.5780 
3.58 to 25.04 
Measured/independent 
reflections/ Rint 
41071 / 5418 
/ 0.2864 
41691 / 11236 / 
0.0713 
3077 / 1550 / 
0.0349 




 wR2 [I > 2σ(I)]
b
 0.0737, 0.1024 0.0480, 0.1076 0.0631, 0.0690 0.0564, 0.1055 
R1,
a
 wR2 (all data)
b
 0.1963, 0.1300 0.0739, 0.1205 0.0937, 0.0729 0.1211, 0.1278 
 
2c. The asymmetric unit contains two independent molecules of THF 
 
3a. The asymmetric unit contains two isomers of the gallium complex, 3a and one 
independent molecule of DMSO. 
 
3c. The asymmetric unit contains two independent molecules of the gallium complex, 
3c and four independent molecules of THF. 
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Table A.3. X-ray crystallography data of 4a, 4b, 4c and 4d. 
 4a 4b 4c 4d 
Empirical formula C16H14ClInN6S2 C18H18ClInN6S2 C30H26ClInN6OS2 C20H18ClInN6S2 
Formula weight / 
g mol
-1 
504.72 532.77 700.96 556.8 
Crystal system Orthorhombic Triclinic Triclinic Monoclinic 
Space group P n c a P 1 P 1 C 2/c 
a (Å) 13.7789(6) 7.8549(6) 10.3834(4) 32.4924(5) 
b (Å) 28.9035(17) 11.7751(7) 12.3013(5) 7.61040(10) 
c (Å) 17.8248(11) 12.0197(10) 12.3563(6) 23.5627(4) 
α (deg) 90 114.501(4) 96.575(2) 90 
β (deg) 90 93.823(4) 103.147(3) 116.7250(10) 
γ (deg) 90 94.215(5) 106.324(3) 90 
V (Å
3
) 7098.9(7) 1003.09(13) 1447.80(11) 5204.16(14) 
Z 16 2 2 8 
µ (mm
-1
) 1.732 1.537 1.089 1.199 
ρ (g cm-3) 1.889 1.764 1.608 1.570 
θ range (°) 2.96 to 25.04 5.77 to 25.12 3.08 to 25.09 3.55 to 27.48 
Measured/independent 
reflections/ Rint 
41697 / 5990 / 
0.1610 
11618 / 3510 / 
0.0616 
18028 / 5099 / 
0.1119 




 wR2 [I > 2σ(I)]
b
 0.1062, 0.1747 0.0408, 0.0870 0.0497, 0.1132 0.0348,0.0762 
R1,
a
 wR2 (all data)
b
 0.1868, 0.1982 0.0611, 0.0968 0.0755, 0.1271 0.0551,0.0846 
 
4a. The asymmetric unit contains two independent molecules of the indium complex, 4a. 
This was a very small, weak diffracting crystal. Hence the high R-(int) and high R 
factor. 
4 non H atoms had to be refined isotropically. 
 
4b. Hydrogen atoms attached to N have been located in the difference Fourier map and 
freely refine with idealised bond lengths. 
 
4c. The asymmetric unit contains one molecule of THF. 
 
4d. The asymmetrical unit consists of one In compound, 4d, one half molecule of THF 
which lies on a twofold axis and half a molecule of 1,4-Dioxane. The half molecule 
of 1,4-Dioxane is disordered over two sites with 25% occupancy. The O of the 
Dioxane are refined anisotropically and the C atoms of this solvent are refine 
Appendix A. 
 v 
isotropically. There is hydrogen bonding between N-H and the THF and Cl...H-N 
of the neighbouring molecule. 
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Appendix CIF Contents 
 
All CIFs are stored on the accompanying DVD 
 
1. Crystallographic Information File for iibS-S, sulphur-bridged ethyl-substituted 
bis(thiosemicarbazonato) proligand dimer. 
2. Crystallographic Information File for iid, allyl-substituted bis(thiosemicarbazone) 
proligand 
3. Crystallographic Information File for LB, bridged thiosemicarbazone proligand 
4. Crystallographic Information File for 1c, zinc phenyl-substituted 
bis(thiosemicarbazonato) complex 
5. Crystallographic Information File for 2c, copper phenyl-substituted 
bis(thiosemicarbazonato) complex 
6. Crystallographic Information File for 3a, gallium methyl-substituted 
bis(thiosemicarbazonato) complex 
7. Crystallographic Information File for 3b, gallium ethyl-substituted 
bis(thiosemicarbazonato) complex 
8. Crystallographic Information File for 3c, gallium phenyl-substituted 
bis(thiosemicarbazonato) complex 
9. Crystallographic Information File for 4a, indium methyl-substituted 
bis(thiosemicarbazonato) complex 
10. Crystallographic Information File for 4b, indium ethyl-substituted 
bis(thiosemicarbazonato) complex 
11. Crystallographic Information File for 4c, indium phenyl-substituted 
bis(thiosemicarbazonato) complex 








Appendix B. HPLC traces  
HPLC traces for compounds without elemental analysis and/or X-ray crystal structures, 




Figure B.1. HPLC traces of: bombesin analogue (left), of derivatised bombesin analogue (right), method 
E, obs = 280 nm. 
 
Figure B.2. HPLC traces of: complex 1aN (left), of complex 1bN bombesin analogue (right), method B, 
obs = 400 nm. 
 
Figure B.3. HPLC traces of: complex 1dN (left), method B, obs = 400 nm, complex 3bN (right), method 
D, obs = 400 nm. 
 







































 Derivatised bombesin analogue






















































































Figure B.4. HPLC of compound 1dB reaction mixture, obs = 400 nm, reference peaks to note under the 
same conditions – compound 3 Rt = 9.3 minutes and derivatised BBN Rt = 4.8 minutes (HPLC method E). 
 
  
Figure B.5. HPLC of purified compound from 1dB reaction mixture, obs = 400 nm (HPLC method E). 












































a)          b) 
Figure B.6. Overlay of UV-HPLC trace (black) of aromatic zinc bis(thiosemicarbazonato) precursor a) 
1a (R = methyl) and b) 1c (R = phenyl) with the radio-HPLC trace (blue) of aromatic 
68
GaCl 
bis(thiosemicarbazonato) complex.  
 
a)          b) 
Figure B.7. Overlay of UV-HPLC trace (black) of aromatic zinc bis(thiosemicarbazonato) precursor a) 
1d (R = allyl) and aromatic free ligand bis(thiosemicarbazonato) precursor b) iia (R = methyl) with the 
radio-HPLC trace (blue) of aromatic 
68
GaCl bis(thiosemicarbazonato) complex.  
 
 
Figure B.8. Overlay of UV-HPLC trace (black) of aromatic free ligand bis(thiosemicarbazonato) 











































































































































































































Figure B.9. Overlay of UV-HPLC trace (black) of aromatic zinc bis(thiosemicarbazonato) precursor with 
the radio-HPLC trace (blue) of aromatic 
111
InCl bis(thiosemicarbazonato) complex with a) 1a and b) 1d.  
 
 

















































































Appendix C. Fluorescence spectroscopy 
 
Figure C.1. 2D representation of the fluorescence of compound iia. 
 
a)      b) 
Figure C.2. 100 μM in DMSO where left represents a 2D plot of complexes a) 3a and b) 3d2 
 
 
Figure C.3. 100 μM in DMSO where left represents a 2D plot of complexes a) 4c and b) 4d 
 
                                                 
2
 Spectrum 3d was acquired with Brett Kennedy 
















































































































































































































Figure D.1. PBS challenges (50% DMSO, 50% PBS) for compound 1d at 100 µM, by fluorescence 
spectroscopy (left)  UV/Vis (right) monitored at time intervals up to 24h at room temperature. 
 
 
Figure D.2. EMEM SFM challenges (50% DMSO, 50% SFM) for compound 1d at 100 µM, by 
fluorescence spectroscopy (left)  UV/Vis (right) monitored at time intervals up to 24h at room 
temperature. 
   
Figure D.3. FCS assay (50% DMSO, 45% EMEM, 5% FCS) for compound 1d at 100 µM, by 




















 1d, PBS 15 mins
 1d, PBS 24 hours
 id, PBS 15 mins
 iid, PBS 15 mins






















 1d, PBS 15 mins
 1d, PBS  24 hours
 id, PBS 15 mins

















 1d SFM, 15 mins
 1d SFM, 24 hours
 id SFM, 15 mins
 iid SFM, 15 mins




















 1d SFM, 15 mins
 1d SFM, 24 hours
 id SFM, 15 mins
















 1d 5% FCS, 15 mins
 1d 5% FCS, 24 hours
 id 5% FCS, 15 mins
 iid 5% FCS, 15 mins




















 1d 5% FCS, 15 mins
 1d 5% FCS, 24 hours
 id 5% FCS, 15 mins





Figure D.4. Citric acid challenges (50% DMSO, 50% water, 2 eq of citric acid) for compound 1d at 100 





Figure D.5. L-methionine challenges (50% DMSO, 50% water, 2 eq of L-methionine) for compound 1d 





Figure D.6. L-methionine challenges (50% DMSO, 50% PBS, 2 eq of L-methionine) for compound 1d at 






















 1d, Citric Acid, in PBS, 15 mins
 1d, Citric Acid, in PBS, 24 hours
 id, Citric Acid, in PBS, 15 mins
 iid, Citric Acid, in PBS, 15 mins






















 1d, Citric Acid, in PBS, 15 mins
 1d, Citric Acid, in PBS, 24 hours
 id, Citric Acid, in PBS, 15 mins























 1d, L-Met, in MilliQ water, 15 mins
 1d, L-Met, in MilliQ water, 24 hours
 id, L-Met, in MilliQ water, 15 mins
 iid, L-Met, in MilliQ water, 15 mins




















 1d, L-Met, in MilliQ water, 15 mins
 1d, L-Met, in MilliQ water, 24 hours
 id, L-Met, in MilliQ water, 15 mins


















 1d, L-Met, in PBS, 15 mins
 1d, L-Met, in PBS, 24 hours
 id, L-Met, in PBS, 15 mins
 iid, L-Met, in PBS, 15 mins



















 1d, L-Met, in PBS, 15 mins
 1d, L-Met, in PBS, 24 hours
 id, L-Met, in PBS, 15 mins





Figure D.7. L-cysteine challenges (50% DMSO, 50% water, 2 eq of L-cysteine) for compound 1d at 100 




Figure D.8. L-histidine challenges (50% DMSO, 50% water, 2 eq of L- histidine) for compound 1d at 





Figure D.9. Glutathione challenges (50% DMSO, 50% water, 2 eq of Glutathione) for compound 1d at 






























 1d, L-Cys, in MilliQ water, 15 mins
 1d, L-Cys, in MilliQ water, 24 hours
 id, L-Cys, in MilliQ water, 15 mins
 iid, L-Cys, in MilliQ water, 15 mins



















 1d, L-Cys, in MilliQ water, 15 mins
 1d, L-Cys, in MilliQ water, 24 hours
 id, L-Cys, in MilliQ water, 15 mins




















 1d, L-His in MilliQ water, 15 mins
 1d, L-His in MilliQ water, 24 hours
 id, L-His in MilliQ water, 15 mins
 iid, L-His in MilliQ water, 15 mins




















 1d, L-His in MilliQ water, 15 mins
 1d, L-His in MilliQ water, 24 hours
 id, L-His in MilliQ water, 15 mins


















 1d, GSH challenge in MilliQ water, 15 mins
 1d, GSH challenge in MilliQ water, 24 hours
 id, GSH challenge in MilliQ water,15 mins
 iid, GSH challenge in MilliQ water, 15 mins






















 1d, GSH challenge in MilliQ water, 15 mins
 1d, GSH challenge in MilliQ water, 24 hours
 id, GSH challenge in MilliQ water,15 mins





Figure D.10. All Buffer challenges (50% DMSO, 50% water) for compound 1d at 100 µM by 
fluorescence spectroscopy (left)  and UV/Vis (right) monitored at 24 hours at room temperature. 
 
 
Figure D.11. Citric acid challenges (50% DMSO, 50% water, 2 eq of citric acid) for compound 3d at 100 





Figure D.12. L-methionine challenges (50% DMSO, 50% water, 2 eq of L-methionine) for compound 3d 




















 1d, pH 1.1 buffer, 24 hours
 1d, pH 2.0 buffer, 24 hours
 1d, pH 3.0 buffer, 24 hours
 1d, pH 5.0 buffer, 24 hours
 1d, pH 7.0 buffer, 24 hours
 1d, pH 9.0 buffer, 24 hours
 1d, pH 10.0 buffer, 24 hours





















 1d, pH 1.1 buffer, 24 hours
 1d, pH 2.0 buffer, 24 hours
 1d, pH 3.0 buffer, 24 hours
 1d, pH 5.0 buffer, 24 hours
 1d, pH 7.0 buffer, 24 hours
 1d, pH 9.0 buffer, 24 hours



















 3d, Citric Acid, in MilliQ water, 15 mins
 3d, Citric Acid, in MilliQ water, 24 hours
 id, Citric Acid, in MilliQ water, 15 mins
 iid, Citric Acid, in MilliQ water, 15 mins


















 3d, Citric Acid, in MilliQ water, 15 mins
 3d, Citric Acid, in MilliQ water, 24 hours
 id, Citric Acid, in MilliQ water, 15 mins





















 3d, L-Met, in MilliQ water, 15 mins
 3d, L-Met, in MilliQ water, 24 hours
 id, L-Met, in MilliQ water, 15 mins
 iid, L-Met, in MilliQ water, 15 mins





















 3d, L-Met, in MilliQ water, 15 mins
 3d, L-Met, in MilliQ water, 24 hours
 id, L-Met, in MilliQ water, 15 mins




Figure D.13. L-methionine challenges (50% DMSO, 50% PBS, 2 eq of L-methionine) for compound 3d 





Figure D.14. L-cysteine challenges (50% DMSO, 50% water, 2 eq of L-cysteine) for compound 3d at 




Figure D.15. L-histidine challenges (50% DMSO, 50% water, 2 eq of L- histidine) for compound 3d at 



















 3d, L-Met, in PBS, 15 mins
 3d, L-Met, in PBS, 24 hours
 id, L-Met, in PBS, 15 mins
 iid, L-Met, in PBS, 15 mins

















 3d, L-Met, in PBS, 15 mins
 3d, L-Met, in PBS, 24 hours
 id, L-Met, in PBS, 15 mins





















 3d, L-Cys, in MilliQ water, 15 mins
 3d, L-Cys, in MilliQ water, 24 hours
 id, L-Cys, in MilliQ water, 15 mins
 iid, L-Cys, in MilliQ water, 15 mins


















 3d, L-Cys, in MilliQ water, 15 mins
 3d, L-Cys, in MilliQ water, 24 hours
 id, L-Cys, in MilliQ water, 15 mins


















 3d, L-His in MilliQ water, 15 mins
 3d, L-His in MilliQ water, 24 hours
 id, L-His in MilliQ water, 15 mins
 iid, L-His in MilliQ water, 15 mins




















 3d, L-His in MilliQ water, 15 mins
 3d, L-His in MilliQ water, 24 hours
 id, L-His in MilliQ water, 15 mins




Figure D.16. Fluorescence spectroscopy buffer assay (a) 3a pH study Arbitrary Units pH 2 >> pH 5 > pH 
1.1 > pH 10 ≥ pH 9 > pH7 ≥ pH 9.4 > pH3. 0-40 and fluorescence intensity of complex with buffer. 3d 
pH study where pH 2 > pH1.1 > pH 3 ≥ pH 9 > pH 10 > pH 5 ≥  pH 7 ≥ pH 8. *3d pH study was carried 




a)      b) 
Figure D.17. (a)  Citric acid challenges (50% DMSO, 50% water, 2 eq of citric acid) (b) EDTA 
challenges (50% DMSO, 50% water, 2 eq of EDTA) for compound 3d at 10 µM by UV/Vis monitored at 
time intervals up to 24h at room temperature. 
 
a)      b) 
Figure D.18. (a)  Glutathione challenges (50% DMSO, 50% water, 2 eq of Glutathione) (b) L-cysteine 
challenges (50% DMSO, 50% water, 2 eq of L-cysteine) for compound 3d at 10 µM by UV/Vis 















































































 10 M 3d, EDTA, in MilliQ water, 15 mins
 10 M 3d, EDTA, in MilliQ water, 24 hours
 10 M id, EDTA, in MilliQ water, 15 mins
 10 M iid, EDTA, in MilliQ water, 15 mins



















 10 M 3d, Citric acid, in MilliQ water, 15 mins
 10 M 3d, Citric acid, in MilliQ water, 24 hours
 10 M id, Citric acid, in MilliQ water, 15 mins
 10 M iid, Citric acid, in MilliQ water, 15 mins



















 10 M 3d, GSH, in MilliQ water, 15 mins
 10 M 3d, GSH, in MilliQ water, 24 hours
 10 M id, GSH, in MilliQ water, 15 mins
 10 M iid, GSH, in MilliQ water, 15 mins


















 10 M 3d, L-Cys, in MilliQ water, 15 mins
 10 M 3d, L-Cys, in MilliQ water, 24 hours
 10 M id, L-Cys, in MilliQ water, 15 mins




Figure D.19. L-Histidine challenges (50% DMSO, 50% water, 2 eq of L-Histidine) for compound 3d at 
10 µM by UV/Vis monitored at time intervals up to 24h at room temperature. 
 
 
Figure D.20. Buffer challenges (50% DMSO, 50% water, pH 1.1 buffer, blank measured pH 1.6) for 
compound 3d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
Figure D.21. Buffer challenges (50% DMSO, 50% water, pH 2.0 buffer, blank measured pH 2.5) for 
compound 3d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 



















 10 M 3d, L-His, in MilliQ water, 15 mins
 10 M 3d, L-His, in MilliQ water, 24 hours
 10 M id, L-His, in MilliQ water, 15 mins




















 3d, pH 1.1 buffer, 15 mins
 3d, pH 1.1 buffer, 24 hours
 id, pH 1.1 buffer, 15 mins
 iid, pH 1.1 buffer, 15 mins




















 3d, pH 1.1 buffer, 15 mins
 3d, pH 1.1 buffer, 24 hours
 id, pH 1.1 buffer, 15 mins




















 3d, pH 2.0 buffer, 15 mins
 3d, pH 2.0 buffer, 24 hours
 id, pH 2.0 buffer, 15 mins
 iid, pH 2.0 buffer, 15 mins























 3d, pH 2.0 buffer, 15 mins
 3d, pH 2.0 buffer, 24 hours
 id, pH 2.0 buffer, 15 mins




Figure D.22. Buffer challenges (50% DMSO, 50% water, pH 3.0 buffer, blank measured pH 4.4) for 
compound 3d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
Figure D.23. Buffer challenges (50% DMSO, 50% water, pH 5.0 buffer, blank measured pH 6.9) for 
compound 3d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
  
Figure D.24. Buffer challenges (50% DMSO, 50% water, pH 7.0 buffer, blank measured pH 9.4) for 
compound 3d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 





















 3d, pH 3.0 buffer, 15 mins
 3d, pH 3.0 buffer, 24 hours
 id, pH 3.0 buffer, 15 mins



















 3d, pH 3.0 buffer, 15 mins
 3d, pH 3.0 buffer, 24 hours
 id, pH 3.0 buffer, 15 mins




















 3d, pH 5.0 buffer, 15 mins
 3d, pH 5.0 buffer, 24 hours
 id, pH 5.0 buffer, 15 mins
 iid, pH 5.0 buffer, 15 mins


















 3d, pH 5.0 buffer, 15 mins
 3d, pH 5.0 buffer, 24 hours
 id, pH 5.0 buffer, 15 mins

















 3d, pH 7.0 buffer, 15 mins
 3d, pH 7.0 buffer, 24 hours
 id, pH 7.0 buffer, 15 mins
 iid, pH 7.0 buffer, 15 mins















 3d, pH 7.0 buffer, 15 mins
 3d, pH 7.0 buffer, 24 hours




Figure D.25. Buffer challenges (50% DMSO, 50% water, pH 9.0 buffer, blank measured pH 9.35) for 
compound 3d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
Figure D.26. Buffer challenges (50% DMSO, 50% water, pH 10.0 buffer, blank measured pH 12.7) for 
compound 3d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
 
Figure D.27. All buffer challenges (50% DMSO, 50% water) for compound 3d at 100 µM by 
























 3d, pH 9.0 buffer, 15 mins
 3d, pH 9.0 buffer, 24 hours
 id, pH 9.0 buffer, 15 mins
 iid, pH 9.0 buffer, 15 mins
















 3d, pH 9.0 buffer, 15 mins
 3d, pH 9.0 buffer, 24 hours
 id, pH 9.0 buffer, 15 mins


















 3d, pH 10.0 buffer, 15 mins
 3d, pH 10.0 buffer, 24 hours
 id, pH 10.0 buffer, 15 mins


















 3d, pH 10.0 buffer, 15 mins
 3d, pH 10.0 buffer, 24 hours
 id, pH 10.0 buffer, 15 mins





















 3d, pH 1.1 buffer, 15 mins
 3d, pH 2.0 buffer, 15 mins
 3d, pH 3.0 buffer, 15 mins
 3d, pH 5.0 buffer, 15 mins
 3d, pH 7.0 buffer, 15 mins
 3d, pH 9.0 buffer, 15 mins
 3d, pH 10.0 buffer, 15 mins




















 3d, pH 1.1 buffer, 15 mins
 3d, pH 2.0 buffer, 15 mins
 3d, pH 3.0 buffer, 15 mins
 3d, pH 5.0 buffer, 15 mins
 3d, pH 7.0 buffer, 15 mins
 3d, pH 9.0 buffer, 15 mins




Figure D.28. DMSO challenges for compound 3d at 100 µM, by fluorescence spectroscopy (left)  
UV/Vis (right) monitored at time intervals up to 24h at room temperature. 
 
 
Figure D.29. Water challenges (50% DMSO, 50% water) for compound 3d at 100 µM, by fluorescence 
spectroscopy (left)  UV/Vis (right) monitored at time intervals up to 24h at room temperature. 
 
 






















 3d, DMSO, 15 mins
 3d, DMSO, 24 hours
 id, DMSO 15 mins
 iid, DMSO 15 mins



















 3d, DMSO 15 mins
 3d, DMSO 24 hours
 id, DMSO15 mins




























 3d, H2O MQ 15 mins  
 3d, H2O MQ 24 hours 
 id, H2O MQ 15 mins 
 iid, H2O MQ 15 mins 


















 3d, H2O MQ 15 mins
 3d, H2O MQ 24 hours
 id, H2O MQ 15 mins




















 t = 0
 t = 15 min
 t = 30 min
 t = 45 min
 t = 1 h
 t = 2 h
 t = 3 h
 t = 4 h
 t = 5 h
 t = 6 h
 t = 7 h




Figure D.31. DMSO challenges for compound 4d at 100 µM, by fluorescence spectroscopy (left)  




Figure D.32. Citric acid challenges (50% DMSO, 50% water, 2 eq of citric acid) for compound 4d at 100 
µM, by fluorescence spectroscopy (left)  UV/Vis (right) monitored at time intervals up to 24h at room 
temperature. 
 
Figure D.33. Citric acid challenges (50% DMSO, 50% PBS, 2 eq of citric acid) for compound 4d at 100 

























 4d, DMSO, 15 mins
 4d, DMSO, 24 hours
 id, DMSO 15 mins
 iid, DMSO 15 mins



















 4d,  DMSO 15 mins
 4d,  DMSO 24 hours
 id, DMSO 15 mins

























 4d, Citric Acid, in MilliQ water, 15 mins
 4d, Citric Acid, in MilliQ water, 24 hours
 id, Citric Acid, in MilliQ water, 15 mins
 iid, Citric Acid, in MilliQ water, 15 mins


















 4d, Citric Acid, in MilliQ water, 15 mins
 4d, Citric Acid, in MilliQ water, 24 hours
 id, Citric Acid, in MilliQ water, 15 mins


















 4d, Citric Acid, in PBS, 15 mins
 4d, Citric Acid, in PBS, 24 hours
 id, Citric Acid, in PBS, 15 mins
 iid, Citric Acid, in PBS, 15 mins






















 4d, Citric Acid, in PBS, 15 mins
 4d, Citric Acid, in PBS, 24 hours
 id, Citric Acid, in PBS, 15 mins




Figure D.34. L-methionine challenges (50% DMSO, 50% water, 2 eq of L-methionine) for compound 4d 





a)      b) 
Figure D.35. (a)  Citric acid challenges (50% DMSO, 50% water, 2 eq of citric acid) (b) EDTA 
challenges (50% DMSO, 50% water, 2 eq of EDTA) for compound 4d at 10 µM by UV/Vis monitored at 
time intervals up to 24h at room temperature. 
 
 
a)      b) 
Figure D.36. (a)  Glutathione challenges (50% DMSO, 50% water, 2 eq of Glutathione) (b) L-cysteine 
challenges (50% DMSO, 50% water, 2 eq of L-cysteine) for compound 3d at 10 µM by UV/Vis 



























 4d, L-Met, in MilliQ water, 15 mins
 4d, L-Met, in MilliQ water, 24 hours
 id, L-Met, in MilliQ water, 15 mins
 iid, L-Met, in MilliQ water, 15 mins


















 4d, L-Met, in MilliQ water, 15 mins
 4d, L-Met, in MilliQ water, 24 hours
 id, L-Met, in MilliQ water, 15 mins
 iid, L-Met, in MilliQ water, 15 mins




















 10 M 4d, Citric acid, in MilliQ water, 15 mins
 10 M 4d, Citric acid, in MilliQ water, 24 hours
 10 M id, Citric acid, in MilliQ water, 15 mins
 10 M iid, Citric acid, in MilliQ water, 15 mins




























 10 M 4d, EDTA, in MilliQ water, 15 mins
 10 M 4d, EDTA, in MilliQ water, 24 hours
 10 M id, EDTA, in MilliQ water, 15 mins
 10 M iid, EDTA, in MilliQ water, 15 mins




















 10 M 4d, GSH, in MilliQ water, 15 mins
 10 M 4d, GSH, in MilliQ water, 24 hours
 10 M id, GSH, in MilliQ water, 15 mins
 10 M iid, GSH, in MilliQ water, 15 mins



















 10 M 4d, L-Cys, in MilliQ water, 15 mins
 10 M 4d, L-Cys, in MilliQ water, 24 hours
 10 M id, L-Cys, in MilliQ water, 15 mins




Figure D.37. L-Histidine challenges (50% DMSO, 50% water, 2 eq of L-Histidine) for compound 4d at 
10 µM by UV/Vis monitored at time intervals up to 24h at room temperature. 
 
 
a)            b)  
Figure D.38. Fluorescence spectroscopy buffer assay a) 4a pH study where and fluorescence intensity of 
complex with buffer. pH 3 > pH 2 > pH 9 > pH 7 > pH 5 ≥ pH 9.4 ≈ pH 10 ≈ pH 1.1, b) 4b pH study 
where and fluorescence intensity of complex with buffer. pH 3 > pH 2 > pH 7 > pH  9 > pH 5 > pH 1.1 ≥ 




a)            b)  
Figure D.39. Fluorescence spectroscopy buffer assay a) 4a pH study where and fluorescence intensity of 
complex with buffer. pH 3 > pH 2 > pH 9 > pH 7 > pH 5 ≥ pH 9.4 ≈ pH 10 ≈ pH 1.1, b) 4b pH study 






















 10 M 4d, L-His, in MilliQ water, 15 mins
 10 M 4d, L-His, in MilliQ water, 24 hours
 10 M id, L-His, in MilliQ water, 15 mins

















































































































where and fluorescence intensity of complex with buffer. pH 3 > pH 2 > pH 7 > pH  9 > pH 5 > pH 1.1 ≥ 
pH 9.4 ≥ pH 10. 
 
 
Figure D.40. Buffer challenges (50% DMSO, 50% water, pH 1.1 buffer, blank measured pH 1.6) for 
compound 4d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
Figure D.41. Buffer challenges (50% DMSO, 50% water, pH 2.0 buffer, blank measured pH 2.5) for 
compound 4d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
Figure D.42. Buffer challenges (50% DMSO, 50% water, pH 3.0 buffer, blank measured pH 4.4) for 
compound 4d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 





















 4d, pH 1.1 buffer, 15 mins
 4d, pH 1.1 buffer, 24 hours
 id, pH 1.1 buffer, 15 mins
 iid, pH 1.1 buffer, 15 mins



















 4d, pH 1.1 buffer, 15 mins
 4d, pH 1.1 buffer, 24 hours
 id, pH 1.1 buffer, 15 mins






















 4d, pH 2.0 buffer, 15 mins
 4d, pH 2.0 buffer, 24 hours
 id, pH 2.0 buffer, 15 mins
 iid, pH 2.0 buffer, 15 mins























 4d, pH 2.0 buffer, 15 mins
 4d, pH 2.0 buffer, 24 hours
 id, pH 2.0 buffer, 15 mins






















 4d, pH 3.0 buffer, 15 mins
 4d, pH 3.0 buffer, 24 hours
 id, pH 3.0 buffer, 15 mins
 iid, pH 3.0 buffer, 15 mins





















 4d, pH 3.0 buffer, 15 mins
 4d, pH 3.0 buffer, 24 hours
 id, pH 3.0 buffer, 15 mins




Figure D.43. Buffer challenges (50% DMSO, 50% water, pH 5.0 buffer, blank measured pH 6.9) for 
compound 4d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
Figure D.44. Buffer challenges (50% DMSO, 50% water, pH 7.0 buffer, blank measured pH 9.4) for 
compound 4d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 
intervals up to 24h at room temperature. 
 
Figure D.45. Buffer challenges (50% DMSO, 50% water, pH 9.0 buffer, blank measured pH 9.35) for 
compound 4d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 





















 4d, pH 5.0 buffer, 15 mins
 4d, pH 5.0 buffer, 24 hours
 id, pH 5.0 buffer, 15 mins
 iid, pH 5.0 buffer, 15 mins























 4d, pH 5.0 buffer, 15 mins
 4d, pH 5.0 buffer, 24 hours
 id, pH 5.0 buffer, 15 mins























 4d, pH 7.0 buffer, 15 mins
 4d, pH 7.0 buffer, 24 hours
 id, pH 7.0 buffer, 15 mins
 iid, pH 7.0 buffer, 15 mins



















 4d, pH 7.0 buffer, 15 mins
 4d, pH 7.0 buffer, 24 hours
 id, pH 7.0 buffer, 15 mins






















 4d, pH 9.0 buffer, 15 mins
 4d, pH 9.0 buffer, 24 hours
 id, pH 9.0 buffer, 15 mins
 iid, pH 9.0 buffer, 15 mins


















 4d, pH 9.0 buffer, 15 mins
 4d, pH 9.0 buffer, 24 hours
 id, pH 9.0 buffer, 15 mins




Figure D.46. Buffer challenges (50% DMSO, 50% water, pH 10.0 buffer, blank measured pH 12.7) for 
compound 4d at 100 µM by fluorescence spectroscopy (left)  and UV/Vis (right) monitored at time 




Figure D.47. Water challenges (50% DMSO, 50% water) for compound 4d at 100 µM, by fluorescence 
spectroscopy (left)  UV/Vis (right) monitored at time intervals up to 24h at room temperature. 
 
 
























 4d, pH 10.0 buffer, 15 mins
 4d, pH 10.0 buffer, 24 hours
 id, pH 10.0 buffer, 15 mins
 iid, pH 10.0 buffer, 15 mins






















 4d, pH 10.0 buffer, 15 mins
 4d, pH 10.0 buffer, 24 hours
 id, pH 10.0 buffer, 15 mins




















 4d, H2O MQ 15 mins
 4d, H2O MQ 24 hours
 id, H2O MQ 15 mins 
 iid, H2O MQ 15 mins 



















 4d, H2O MQ 15 mins
 4d, H2O MQ 24 hours
  id, H2O MQ 15 mins




















 t = 0            t = 4 h
 t = 15 min   t = 5 h
 t = 30 min   t = 6 h
 t = 45 min   t = 7 h
 t = 1 h         t = 8 h
 t = 2 h         t = 24 h
























 t = 0            t = 8 h
 t = 15 min   t = 9 h
 t = 30 min   t = 10 h
 t = 45 min   t = 11 h
 t = 1 h         t = 12 h
 t = 2 h         t = 13 h
 t = 3 h         t = 14 h
 t = 4 h         t= 15 h
 t = 5 h         t = 16 h
 t = 6 h         t = 24 h


















 iid, pH 1.1 buffer, 15 minutes
 iid, pH 2.0, 15 minutes
 iid, pH 3.0, 15 minutes
 iid, pH 5.0, 15 minutes
 iid, pH 7.0, 15 minutes
 iid, pH 9.0, 15 minutes
 iid, pH 10.0, 15 minutes




















 iid, pH 1.1 buffer, 15 minutes
 iid, pH 2.0, 15 minutes
 iid, pH 3.0, 15 minutes
 iid, pH 5.0, 15 minutes
 iid, pH 7.0, 15 minutes
 iid, pH 9.0, 15 minutes
 iid, pH 10.0, 15 minutes
  
Figure D.50. All Buffer challenges (50% DMSO, 50% water) for compound iid at 100 µM by 


















 iid, pH 1.1 buffer, 24 hours
 iid, pH 2.0, 24 hours
 iid, pH 3.0, 24 hours
 iid, pH 5.0, 24 hours
 iid, pH 7.0, 24 hours
 iid, pH 9.0, 24 hours
 iid, pH 10.0, 24 hours




















 iid, pH 1.1 buffer, 24 hours
 iid, pH 2.0, 24 hours
 iid, pH 3.0, 24 hours
 iid, pH 5.0, 24 hours
 iid, pH 7.0, 24 hours
 iid, pH 9.0, 24 hours
 iid, pH 10.0, 24 hours
 
 
Figure D.51. All Buffer challenges (50% DMSO, 50% water) for compound iid at 100 µM by 
fluorescence spectroscopy (left) and UV/Vis (right) monitored at 24 hours at room temperature. 
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Appendix E. Two-photon Time Correlated Single Photon 
Counting data of DMSO solutions at 10 mM 
 
Table E.1. Two-photon Time Correlated Single Photon Counting data of solutions in DMSO of free 
ligands, nd = not done. 
 ia ib ic id 
10 mM 
ex  = 810 nm 
χ2 = 1.15 
0.568 ns 67.6% 
3.6706 ns 32.4% 
χ2 = 1.30 
0.468 ns 68.4% 
3.2237 ns 31.6% 
nd χ2 = 1.13 
4.1288 ns 64.6% 
0.583 ns 35.4% 
10 mM 
ex  = 910 nm 
χ2 = 1.38 
0.388 ns 63.9% 
4.236 ns 36.1% 
nd χ2 = 1.31 
0.413 ns 75.1% 
5.1734 ns 24.9% 
χ2 = 1.34 
0.339 ns 87.2% 
3.848 ns 12.8% 
 
 
Figure E.1. TCSPC decay curves for mono(substituted) proligands 810 nm (left) 910 nm (right) 
 
Table E.2. Two-photon Time Correlated Single Photon Counting data of solutions in DMSO of free 
ligands. 
 iia iib iic iid 
10 mM 
ex  = 810 nm 
χ2 = 1.88 
0.226 ns 95.7% 
2.576 ns 4.3% 
χ2 1.63 
0.183 ns 98% 
3.969 ns 2% 
χ2 = 1.71 
0.158 ns 98.7% 
2.380 ns 1.3% 
χ2 = 1.36 
0.243 ns 97.8% 
4.621 ns 2.2% 
10 mM 
ex  = 910 nm 
χ2 = 1.21 
0.231 ns 89.2 % 
2.117 ns 10.8 % 
χ2 = 1.14 
0.235 ns 90 % 
3.102 ns 10 % 
χ2 = 1.52 
0.169 ns 99.2% 
4.119 ns 0.8% 
χ2 = 1.25 
0.258 ns 94.1% 
6.488 ns 5.9% 
 





























Figure E.2. TCSPC decay curves for bis(substituted) proligands 810 nm (left) 910 nm (right) 
 




Table E.4. Two-photon Time Correlated Single Photon Counting data of solutions in DMSO of copper 
bis(thiosemicarbazonato)complexes ex  = 910 nm. 
 2a 2c 2d 
10 mM 
ex  = 910 nm 
χ2 = 1.70 
0.213 ns 90.5% 
1.826 ns 9.5% 
χ2 = 1.13 
0.294 ns 91.05% 
1.469 ns 9.76% 
χ2 = 1.24 
0.287 ns 91.4% 




































 1b 810 nm
 1b 910 nm





















ex  = 810 nm 
1b 
ex  = 910 nm 
1d 
ex  = 910 nm 
10 mM χ2 = 1.52 
0.261 ns 98.2% 
0.597 ns 1.8% 
χ2 = 1.25 
0.275 ns 100% 
 
χ2 = 1.56 
0.266 ns 99.7% 
1.201 ns 0.3% 
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Table E.5. Two-photon Time Correlated Single Photon Counting data of solutions in DMSO of gallium 
bis(thiosemicarbazonato) complexes, nd = not done. 
 
 

































































 3a 3b 3c 3d 
10 mM 
ex  = 810 nm 
χ2 = 1.08 
0.295 ns 58.3% 
0.744 ns 41.7% 
χ2 = 1.15 
0.250 ns 63.7% 
0.873 ns 36.3% 
χ2 = 1.67 
0.170 ns 97.4% 
0.603 ns 2.6% 
nd 
10 mM 
ex  = 910 nm 
χ2 = 1.22 
0.436 ns 57.8 % 
0.976 ns 42.2 % 
χ2 = 1.25 
0.362  ns 52.4% 
0.889 ns 47.6% 
χ2 = 1.32 
0.123 ns 85.9% 
4.099 ns 4.1% 
χ2 = 1.44 
0.306 ns 69.1% 
0.871 ns 30.9% 
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Table E.6. Two-photon Time Correlated Single Photon Counting data of 10 mM solutions in DMSO of 




Figure E.5. TCSPC decay curves for amine-functionalised zinc and gallium bis(thiosemicarbazonato) 
complexes 810 nm (left) 910 nm (right) 
 






























 1aN 1bN 1cN 1dN 3bN 
ex  = 810 nm χ
2
 = 1.83 
0.203 ns, 
98.7% 
1.479 ns. 1.3% 
χ2 = 1.40 
0.208 ns, 
99.1% 
1.502 ns, 0.9% 
χ2 = 1.46 
0.230 ns, 
95.1% 
1.173 ns, 4.9% 
χ2 = 1.84 
0.218 ns, 
97.8% 
1.499 ns, 2.2% 





ex  = 910 nm χ
2
 = 1.45 
0.226 ns, 
95.9% 
1.310 ns, 4.1% 
χ2 = 1.68 
0.195 ns, 
97.5% 
0.721 ns, 2.5% 
χ2 = 1.42 
0.210 ns, 
95.2% 
0.828 ns, 4.8% 
χ2 = 1.26 
0.244 ns, 
96.3% 
1.448 ns, 3.7% 







Appendix F. Two-photon Fluorescence lifetime imaging data of in 
cancer cells 
 
Table F.1. Two-photon fluorescence lifetime imaging data in HeLa and PC-3 cells of free ligands at 100 
µM concentration. 
Compound ia ia ic 
Cell line HeLa PC-3 HeLa 
χ2 1.43 1.22 1.16 
λ /nm 910 910 910 
τ1 / ns 0.176 0.199 0.12 
FWHM / ns 0.052 0.19 0.225 
τ1 % 51 80 91 
τ2 / ns 2.924 2.583 6.129 
FWHM / ns 1.507 1.114 1.048 
τ2 % 49 20 8 
 
 
Table F.2. Two-photon fluorescence lifetime imaging data in HeLa and PC-3 cells of ligand precursors, 
ex = 810 nm, at 100 µM concentration. 
Compound iia iib iic iic iid 
Cell line HeLa HeLa HeLa PC-3 HeLa 
χ2 1.50 1.26 1.15 1.13 1.23 
τ1 % 86 81 100 86 80 
τ1 / ns 0.903 0.868 1.803 0.233 0.725 
FWHM / ns 0.415 0.642 0.617 0.204 0.358 
τ2 % 14 19  14 20 
τ2 / ns 3.549 3.218  2.087 3.128 




Table F.3. Two-photon fluorescence lifetime imaging data in HeLa and PC-3 cells of ligand precursors, 
ex = 910 nm, at 100 µM concentration. 
Compound iia iib iic iid iia iib iic iid 
Cell line HeLa HeLa HeLa HeLa PC-3 PC-3 PC-3 PC-3 
χ2 1.54 1.05 1.38 1.33 1.48 1.21 1.47 1.21 
τ1 % 100 100 100 92 100 80 100 90 
τ1 / ns 3.062 2.522 0.344 0.307 2.469 0.081 0.531 0.164 
FWHM / 
ns 
0.42 0.303 0.9 0.575 1.293 0.202 0.506 0.544 
τ2 %    8  20  10 
τ2 / ns    0.436  0.434  0.418 
FWHM / 
ns 
   0.653  0.209  0.455 
 
Table F.4. Two-photon fluorescence lifetime imaging data in cancer cells of copper 
bis(thiosemicarbazonato) complexes, at 50 µM concentration. 
Compound 1b 1b 1c 1d 
Cell line MCF-7 HeLa HeLa HeLa 
χ2 1.67 1.77 1.15 1.30 
λ /nm 810 910 910 910 
τ 1 % 93.4 94.8 100 100 
τ 1 / ns 0.152 0.217 0.284 0.266 
FWHM / ns 0.093 0.098 0.087 0.146 
τ 2 % 6.6 5.2   
τ 2 / ns 0.433 0.505   
FWHM / ns 0.625 0.821   
 
Table F.5. Two-photon fluorescence lifetime imaging data in HeLa cells of copper 
bis(thiosemicarbazonato) complexes, at 50 µM concentration. 
Compound 2c 2d 
χ2 1.19 1.27  
τ 1 % 100 100 
τ 1 / ns 0.343 0.297 




Table F.6. Two-photon fluorescence lifetime imaging data in HeLa, ex = 810 nm, at 50 µM 
concentration. 
Compound 3b 3c 
χ2 1.58 1.18  
τ1 % 89 84 
τ1 / ns 0.309 0.308 
FWHM / ns 0.095 0.196 
τ2 % 11 16 
τ2 / ns 2.026 2.523 
FWHM / ns 0.865 1.562 
 
 
Table F.7. Two-photon fluorescence lifetime imaging data, ex = 910 nm in HeLa, PC-3 and MCF-7 cells 
of gallium bis(thiosemicarbazonato) complexes, at 50 µM concentration, where * and ** refer to before 
and after irradiation at 488 nm for 9 minutes. 
Compound 3a 3b 3c 3d 3b* 3b** 3c* 3c** 3b* 3b** 3c* 3c** 
Cell line HeLa PC-3 MCF-7 
χ2 1.19 1.19 1.17 1.47 1.27 1.18 1.16 1.01 1.21 1.27 1.12 1.37 
τ1 % 96 100 100 94 92 91 100 100 100 100 80 80 
τ1 / ns 0.166 0.348 0.32 0.125 0.291 0.364 0.674 0.281 0.65 2.001 1.155 1.113 
FWHM / 
ns 
0.124 0.161 0.142 0.078 0.116 0.187 0.772 0.035 0.449 1.118 0.029 0.148 
τ2 % 4   6 8 9     20 20 
τ2 / ns 0.588   0.361 0.475 0.475     0.567 0.575 
FWHM / 
ns 




Table F.8. Two-photon fluorescence lifetime imaging data in HeLa and PC-3 cells of indium 
bis(thiosemicarbazonato) complexes, at 50 µM concentration ex = 910 nm. 
 
Compound 4a 4b 4c 4d 4a 4b 4c 4d 
Cell line HeLa PC-3 
χ2 1.63 1.51 1.86 1.57 1.37 1.67 1.67 1.39 
τ1 % 100 100 100 100 100 100 100 83 
τ1 / ns 0.35 0.384 0.244 0.343 0.298 0.323 0.653 0.27 
FWHM / 
ns 
0.118 0.088 0.072 0.175 0.031 0.045 0.947 0.069 
τ2 %        17 
τ2 / ns        0.593 
FWHM / 
ns 
       0.347 
 
 
Table F.9. Two-photon fluorescence lifetime imaging data in HeLa and PC-3 cells of amine-
functionalised bis(thiosemicarbazonato) complexes, ex = 810 nm. 
 
Compound 1bN 1dN 3bN 3bN 3bN 
Conc. / μM 100 100 100 50 100 
χ2 1.31 1.43 1.43 1.31 1.18 
Cell line HeLa PC-3 HeLa PC-3 PC-3 
τ1 % 90 91 86 100 86 
τ1 / ns 0.283 0.230 0.465 0.629 0.442 
FWHM / ns 0.256 0.103 0.266 0.322 0.274 
τ2 % 10 9 14  14 
τ2 / ns 1.738 1.315 2.462  1.948 




Table F.10. Two-photon fluorescence lifetime imaging data in HeLa and PC-3 cells of amine-
functionalised bis(thiosemicarbazonato) complexes, ex = 910 nm. 
Compound 1bN 1cN 1cN 1dN 
Conc. / μM 100 100 100 100 
χ2 1.33 1.17 1.60 1.55 
Cell line MCF-7 MCF-7 HeLa PC-3 
τ1 % 100 100 80 100 
τ1 / ns 0.354 0.498 0.176 0.522 
FWHM / ns 0.218 0.165 0.177 0.331 
τ2 %   20  
τ2 / ns   0.468  






Appendix G. Fluorescence microscopy in biological cells 
 
 
a)                b)              c) 
Figure G.1. Single-photon confocal fluorescence microscopy of ia at 100 μM, 1% DMSO 30 mins, HeLa. 
a) DIC micrograph. b) Micrograph with excitation at 488 nm. c) Overlay image of a) and b). 
 
 
a)         b)              c)            d) 
Figure G.2. Single-photon confocal fluorescence microscopy of ia at 50 μM, 0.5% DMSO, 20 mins, 
HeLa, incubated with mitotracker. a) DIC micrograph. b) Micrograph with excitation at 488 nm. c) 




a)         b)              c)            d) 
Figure G.3. Single-photon confocal fluorescence microscopy of ia at 100 μM, 1% DMSO, 20 mins, PC-3, 
incubated with mitotracker . a) DIC micrograph. b) Micrograph with excitation at 405 nm, c) Micrograph 





a)    b)               c) 
Figure G.4. Single-photon confocal fluorescence microscopy of iid at 50 μM, 0.5% DMSO, 20 minutes, 
washed then 100 μM, 1% DMSO, incubated for 20 minutes, then washed in FEK-4. a) DIC micrograph. b) 
Micrograph with excitation at 488 nm. c) Overlay image of a) and b). Scalebar: 20 μm 
 
 
a)         b)              c)            d) 
Figure G.5. Single-photon confocal fluorescence microscopy of iib at 100 μM, 1% DMSO, 20 minutes, 
in PC-3. a) DIC micrograph. b) Micrograph with excitation at 488 nm. c) Micrograph with excitation at 
543 nm, d) Overlay image of a), b) and c). Scalebar: 20 μm  
 
 
a)         b)              c)            d) 
Figure G.6. Single-photon confocal fluorescence microscopy of iib at 100 μM, 1% DMSO, 20 minutes, 
in HeLa. a) DIC micrograph. b) Micrograph with excitation at 405 nm (green channel). c) Micrograph 
with excitation at 488 nm (green channel). d) Micrograph with excitation at 488 nm. (green channel). 





a)         b)              c)            d) 
Figure G.7. Single-photon confocal fluorescence microscopy of iid at 100 μM, 1% DMSO, 20 minutes, 
in HeLa. a) DIC micrograph. b) Micrograph with excitation at 405 nm (green channel). c) Micrograph 
with excitation at 488 nm (green channel). d) Micrograph with excitation at 488 nm. (green channel). 
Scalebar: 20 μm.  
 
 
a)         b)              c)            d) 
Figure G.8. Single-photon confocal fluorescence microscopy of iid at 100 μM, 1% DMSO, 20 minutes, 
in PC-3. a) DIC micrograph. b) Micrograph with excitation at 405 nm (green channel). c) Micrograph 
with excitation at 488 nm (green channel). d) Micrograph with excitation at 488 nm. (green channel). 
Scalebar: 20 μm.  
 
 
a)                b)              c) 
Figure G.9. Confocal microscopy of HeLa cells incubated with 1d at 50 μM, 0.5% DMSO, for 20 




a)       b)            c)       d)       e) 
Figure G.10. Confocal microscopy of HeLa cells incubated with 1b at 100 μM, 1% DMSO, for 20 
minutes, at 37. Where (e) Overlay of (a) the DIC image b) micrograph with excitation of 405 nm, (c) the 
micrograph with excitation of 488 nm and (d) the micrograph with excitation of 543 nm.  
 
 
a)                b)              c) 
Figure G.11. Confocal microscopy of HeLa cells incubated with 2d at 50 μM, 0.5% DMSO, for 60 






a)                b)              c) 
 
d)                e)                     f) 
Figure G.12. Complex 3b at 50 µM, 0.5% DMSO, irradiation experiment at 488 nm in PC-3 cells: (a – c) 
before irradiation and (d – f) after irradiation for ca. 10 minutes, DIC image (a, d), micrograph of cells 
after excitation at 488 nm (b, e, compound, green channel), micrograph of cells after excitation at 543 nm 
(d, i, compound, red channel). (c) Overlay of (a) and (b) images, whereas (f) Overlay of images (d) and 




a)         b)               c)             d) 
Figure G.13. Complex 3d at 50 μM, 0.5% DMSO, 20 minutes irradiation experiment at 488 nm in FEK-
4 cells: a) DIC image. b) Micrograph of cells after excitation at 405 nm. c) Micrograph of cells after 





a)         b)              c)             d) 
Figure G.14. Complex 3d irradiation experiment at 488 nm in FEK-4 cells, 100 μM, 1 % DMSO, ca. 3 
hours. (a, f) DIC image. (b, g) Micrograph of cells after excitation at 405 nm. (c, h) Micrograph of cells 




a)       b)            c)     d)       e) 
Figure G.15. Complex 3c irradiation experiment at 488 nm in HeLa cells: (a – e) with no added stain 
DIC image (a), micrograph of cells after excitation at 405 nm (b), micrograph of cells after excitation at 
488 nm (c, compound, green channel), micrograph of cells after excitation at 543 nm (d, compound, red 
channel). Image (d) Overlay of (a), (b) and (c) images. Scalebar: 20 μm. 
 
 
a)         b)              c)             d) 
Figure G.16. Complex 3a and Mitotracker in HeLa cells: DIC image (a), micrograph of cells after 
excitation at 488 nm (b, compound, green channel), micrograph of cells after excitation at 543 nm (c, red 






a)         b)              c)            d) 
Figure G.17. Complex 3a and Lysotracker in HeLa cells: DIC image (a), micrograph of cells after 
excitation at 488 nm (b, compound, green channel), micrograph of cells after excitation at 543 nm (c, 
compound, red channel). Image (d) Overlay of (a), (b) and (c) images suggesting some lysosome 
localisation. Scalebar: 20 μm 
 
 
a)         b)             c)             d) 
Figure G.18. Complex 3a and Lysotracker in PC-3 cells: DIC image (a), micrograph of cells after 
excitation at 488 nm (b, compound, green channel), micrograph of cells after excitation at 543 nm (c, 
compound, red channel). Image (d) Overlay of (a), (b) and (c) images suggesting lysosome localisation. 
Scalebar: 20 μm 
 
 
a)       b)            c)       d)       e) 
Figure G.19. Complex 3b and Hoechst (nuclear stain) in HeLa cells at 37°C: DIC image (a), micrograph 
of cells after excitation at 405 nm (b, Hoechst, blue channel), micrograph of cells after excitation at 488 
nm (c, compound, green channel), micrograph of cells after excitation at 543 nm (d, compound, red 
channel). Image (e) Overlay of (a), (b), (c) and (d) images suggesting some lysosome localisation. 





a)         b)              c)             d) 
Figure G.20. Single-photon confocal microscopy images of 3b in HeLa cells incubated at 4 
o
C, (a) DIC 
image, (b) excitation at 405 nm, emission 420-480 nm (c) excitation at 488 nm, emission >505 nm, (d) 




a)         b)             c)             d) 
Figure G.21. Single-photon confocal microscopy images of 4a in PC-3 cells,30 minute incubation (a) 




a)       b)            c)       d)       e) 
Figure G.22. Single-photon confocal microscopy images of 4b in PC-3 cells, 20 minute incubation, 50 
µM 0.5% DMSO (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) excitation at 488 nm, 
emission >505 nm, (d) micrograph of cells after excitation at 543 nm and (e) Overlay of (a), (b), (c) and 







a)       b)            c)       d)       e) 
Figure G.23. Single-photon confocal microscopy images of 4c in HeLa cells, 20 minute incubation, 50 
µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) excitation at 
488 nm, emission >505 nm, (d) micrograph of cells after excitation at 543 nm and (e) Overlay of (a), (b), 
(c) and (d) Scalebar: 20 μm 
 
 
a)         b)              c)             d) 
Figure G.24. Single-photon confocal microscopy images of 4a in HeLa cells (a) DIC image, (b) 
excitation at 488 nm, emission >505 nm, (c) micrograph of cells after excitation at 543 nm and (d) 




a)         b)             c)             d) 
 
e)         f)             g)   
Figure G.25. Single-photon confocal microscopy images of 4b in HeLa cells, 20 minute incubation, 50 
µM 0.5% DMSO at 4°C (a) excitation at 405 nm, emission 420-480 nm, (b) excitation at 488 nm, 
emission >505 nm, (c) micrograph of cells after excitation at 543 nm and (d) Overlay of (a), (b), (c) and 
(g), (e) is the DIC image from excitation at 405 nm, (f) is the DIC image from excitation at 488 nm, (g) is 




a)                b)              c) 
Figure G.26. Single-photon confocal microscopy images of 4c in PC-3 cells, before irradiation at 488 nm 
20 minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 
420-480 nm (c) excitation at 488 nm, emission >505 nm, (d) micrograph of cells after excitation at 543 





a)                b)              c) 
Figure G.27. Single-photon confocal microscopy images of 4c in PC-3 cells, after irradiation at 488 nm 
20 minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 
420-480 nm (c) excitation at 488 nm, emission >505 nm, (d) micrograph of cells after excitation at 543 
nm and (e) Overlay of (a), (b), (c) and (d) Scalebar: 20 μm. 
 
 
a)                b)              c) 
Figure G.28. Single-photon Epi-fluorescence microscopy images of 4d in HeLa cells, 3 hour incubation, 
100 μM, 1% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) Overlay of 
(a) and (b). Scalebar: 20 μm. 
 
 
a)                b)              c) 
Figure G.29. Single-photon Epi-fluorescence microscopy images of 4d in HeLa cells, 3 hour incubation, 
100 μM, 1% DMSO at 4°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) Overlay of (a) 






a)                b)              c) 
Figure G.30. Single-photon confocal microscopy images of 4b in FEK-4 cells, 3 hour incubation, 100 
μM, 1% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) Overlay of (a) 
and (b). Scalebar: 20 μm. 
 
 
a)                b)              c) 
Figure G.31. Single-photon confocal microscopy images of 4b in FEK-4 cells, 3 hour incubation, 100 
μM, 1% DMSO at 4°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) Overlay of (a) and 
(b). Scalebar: 20 μm. 
 
 
a)       b)            c)       d)       e) 
Figure G.32. Single-photon confocal microscopy images of 4d in PC-3 cells, 30 minute incubation, 50 
µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) Overlay of (a) 






a)                b)              c) 
Figure G.33. Single-photon confocal microscopy images of 4d in HeLa cells, 60 minute incubation, 50 
µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) Overlay of (a) 
and (b). Scalebar: 20 μm 
 
 
a)                b)              c) 
Figure G.34. Single-photon confocal microscopy images of 4d in, FEK-4 cells 100 μM, 1% DMSO 60 
minute incubation, at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) Overlay of (a) 
and (b). Scalebar: 20 μm 
 
 
a)         b)              c)            d) 
Figure G.35. Single-photon confocal microscopy images of 4a and Hoechst stain in HeLa cells after 20 
minutes, (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) micrograph of cells after 





a)         b)             c)            d) 
Figure G.36. Single-photon confocal microscopy images of 4c and Hoechst 6 hour in PC-3 cells, 20 
minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 
nm, (c) micrograph of cells after excitation at 543 nm, (d) Overlay of (a), (b) and (c). Scalebar: 20 μm. 
 
 
a)         b)             c)             d) 
Figure G.37. Single-photon confocal microscopy images of 4a and Hoechst stain in HeLa cells, 60 
minute incubation (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) excitation at 488 nm, 
emission >505 nm, (d) Overlay of (a), (b) and (c). Scalebar: 20 μm 
 
 
a)       b)            c)       d)       e) 
Figure G.38. Single-photon confocal microscopy images of 4a and Hoechst stain in PC-3 cells, 60 
minute incubation (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) excitation at 488 nm, 





a)         b)             c)            d) 
Figure G.39. Single-photon confocal microscopy images of 4d and Hoechst stain in PC-3 cells, 20 
minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 420-
480 nm (c) excitation at 488 nm, emission >505 nm, (d) Overlay of (a), (b) and (c). Scalebar: 20 μm 
 
 
a)         b)             c)            d) 
Figure G.40. Single-photon confocal microscopy images of 4d and Hoechst stain in PC-3 cells, 60 
minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 420-




a)         b)             c)            d) 
Figure G.41. Single-photon confocal microscopy images of 4a and Hoechst stain in PC-3 cells, 6 hour 
incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm 






a)               b)             c)           d) 
Figure G.42. Single-photon confocal microscopy images of 4d and Hoechst stain in FEK-4 cells, 50 μM, 
0.5% DMSO, 30 minutes at 37°C (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) 




a)       b)            c)       d)       e) 
Figure G.43. Single-photon confocal microscopy images of 4b in HeLa cells stained with Hoechst, 20 
minute incubation, 50 µM 0.5% DMSO (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) 
excitation at 488 nm, emission >505 nm, (d) micrograph of cells after excitation at 543 nm and (e) 
Overlay of (a), (b), (c) and (d) Scalebar: 20 μm. 
 
 
a)       b)            c)       d)       e) 
Figure G.44. Single-photon confocal microscopy images of 4b in PC-3 cells, 6 hour incubation, 50 µM 
0.5% DMSO (a) DIC image, (b) excitation at 405 nm, emission 420-480 nm (c) excitation at 488 nm, 
emission >505 nm, (d) micrograph of cells after excitation at 543 nm and (e) Overlay of (a), (b), (c) and 






a)         b)              c)            d) 
Figure G.45. Single-photon confocal microscopy images of 4c and Hoechst 1 hour in PC-3 cells, 20 
minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 
nm, (c) micrograph of cells after excitation at 543 nm, (d) Overlay of (a), (b) and (c). Scalebar: 20 μm. 
 
 
a)         b)              c)            d) 
Figure G.46. Single-photon confocal microscopy images of 4c in HeLa cells stained with ER tracker, 20 
minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, emission 420-
480 nm (c) excitation at 488 nm, emission >505 nm, (d) micrograph of cells after excitation at 543 nm 
and (e) Overlay of (a), (b), (c) and (d) Scalebar: 20 μm. 
 
 
a)         b)              c)            d) 
Figure G.47. Single-photon confocal microscopy images of 4a and Mitotracker Red in HeLa cells, 20 
minute incubation (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) micrograph of cells 






a)         b)              c)            d) 
Figure G.48. Single-photon confocal microscopy images of 4c and Mitotracker in PC-3 cells, 20 minute 
incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) 
micrograph of cells after excitation at 543 nm, (d) Overlay of (a), (b) and (c). Scalebar: 20 μm  
 
 
a)         b)              c)            d) 
Figure G.49. Single-photon confocal microscopy images of 4d and Mitotracker Red in HeLa cells, 20 
minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 




a)       b)            c)       d)       e) 
Figure G.50. Single-photon confocal microscopy images of 4c after a 20 minute incubation in HeLa cells, 
incubated with Lysotracker Red, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 405 nm, 
emission 420-480 nm (c) excitation at 488 nm, emission >505 nm, (d) micrograph of cells after excitation 






a)         b)              c)            d) 
Figure G.51. Single-photon confocal microscopy images of 4d and Lysotracker Red in HeLa cells, 20 
minute incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 




a)         b)              c)            d) 
Figure G.52. Single-photon confocal microscopy images of 4c and ER tracker in PC-3 cells, 20 minute 
incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) 




a)         b)              c)            d) 
Figure G.53. Single-photon confocal microscopy images of 4c and Mitotracker in PC-3 cells, 20 minute 
incubation, 50 µM 0.5% DMSO at 37°C (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) 





a)         b)              c)            d) 
Figure G.54. Single-photon confocal microscopy images of 4a and Lysotracker Red in HeLa cells, 20 
minute incubation (a) DIC image, (b) excitation at 488 nm, emission >505 nm, (c) micrograph of cells 
after excitation at 543 nm, (d) Overlay of (a), (b) and (c). Scalebar: 20 μm 
 
 
a)           b)      c) 
 
e)    f)         g) 
Figure G.55. (a – c) Single-photon confocal microscopy of complex 1bB reaction mixture, 100 M, 1% 
DMSO, incubated in HeLa cells for 20 minutes where a) DIC channel, b) excitation at 488 nm and c) 
overlay image of (a) and (b). Scalebar = 20 m. Two-photon fluorescence imaging of complex 2, 100 M, 
1% DMSO, λex = 910 nm, incubated in HeLa cells for 20 minutes where e) is the fluorescence intensity 
profile, f) is the fluorescence lifetime map of tm and g) is the corresponding lifetime distribution plot in 
ns of tm. 
 
 




















a)    b)    c) 
Figure G.56. Single-photon confocal microscopy of complex 1bB reaction mixture, 100 M, 1% DMSO, 
incubated in PC-3 cells for 20 minutes where a) DIC channel, b) excitation at 488 nm and c) overlay 
image of (a) and (b). Scalebar = 20 m 
 
 
a)    b)        c) 
Figure G.57. Two-photon fluorescence imaging of complex 1bB reaction mixture, 100 M, 1% DMSO, 
λex = 910 nm, incubated in PC-3 cells for 20 minutes where a) is the fluorescence intensity profile, b) is 





a)         b)              c)            d)  
Figure G.58. PC-3 cells stained with Alexa fluor plasma membrane dye, before (above) and after (below) 
addition of complex 1bB reaction mixture, final concentration after addition was 100 M, 1% DMSO. a) 
and e) represent the DIC channel, (b) and (f) correspond to excitation at 405 nm, (c) and (g) excitation at 
488 nm and (d) and (h) are an overlay of the three channels. 























a)         b)              c)            d) 
 
e)         f)              g)            h) 
Figure G.59. MCF-7 cells incubated with complex 1bB reaction mixture for 20 minutes at 100 M, 1% 
DMSO before (above) and after (below) addition of Alexa Fluor plasma membrane stain. a) and e) 
represent the DIC channel, (b) and (f) correspond to excitation at 405 nm, (c) and (g) excitation at 488 nm 
and (d) and (h) are an overlay of the three channels. (e) – (h) were acquired within 5 minutes of addition 
and (b) shows background emission before addition of the Alexa Fluor plasma membrane stain. 
(Precipitation was observable since no cell washing occurred to enable the image to be taken as soon as 
the compound was added.) Scalebar: 20 m. 
 
 
a)    b)        c) 
Figure G.60. Two-photon fluorescence imaging of complex 1bB reaction mixture, 100 M, 1% DMSO, 
λex = 910 nm, incubated in MCF-7 cells for 20 minutes where a) is the fluorescence intensity profile, b) is 
the fluorescence lifetime map and c) is the corresponding lifetime distribution plot in ns. 
 



















Figure G.61. Purified compound 1bB, 5% 500 μM in MCF-7 Overlay of DIC image and λex = 543 nm, 
scalebar = 20 µm. 
 
  
Figure G.62. Overlay image of purified compound 1dB in PC-3 cells, 5% DMSO 500 μM, DIC and λex = 




a)    b) 
Figure G.63. Purified compound 1bB, 1% 100 μM in MCF-7 a) FLIM colour map where lifetime τ1 = 
690 ns, 0.615 FWHM, τ2 = 0.984 ns, 0.944 ns FWHM, range of FLIM image is 0 to 5 ns, χ
2
 = 1.08 where 





a)    b) 
Figure G.64. Purified compound 1bB, 1% 100 μM in HeLa a) FLIM colour map where lifetime is 0.872 
ns ± 0.490 ns FWHM, range of FLIM image is 0 to 5 ns, χ2 = 1.15 where λex = 810 nm and b) Overlay of 





a)         b)              c)            d) 
Figure G.65. (a-d) Control experiments in HeLa incubation time 30 min: (a) DIC image, b) ex 488 
nm, emission 516-530 nm, c) Mitotracker stain: ex 543 nm, em 605-675 nm, d) overlay (a-c).  
 
 
a)         b)              c)            d) 
Figure G.66. (a-d) Control experiments in HeLa incubation time 60 min: (a) DIC image, b) ex 488 






a)         b)              c)            d) 
Figure G.67. Single-photon confocal microscopy images of Hoechst in HeLa, (a) DIC image, (b) 
excitation at 405 nm emission at 451 (c) excitation at 488 nm, emission 516 nm, (c) an overlay of the 
previous three images. 
 
 
a)         b)              c)            d) 
Figure G.68. Single-photon confocal microscopy images of Hoechst in PC-3, (a) DIC image, (b) 
excitation at 405 nm emission at 451 (c) excitation at 488 nm, emission 516 nm, (c) an overlay of the 
previous three images. 
 
 
a)         b)              c)            d) 
Figure G.69. Single-photon confocal microscopy images of DAPI in HeLa (fixed cells), (a) DIC image, 







a)         b)              c)            d) 
Figure G.70. Single-photon confocal microscopy images of PC-3 cells stained with Alexa fluor plasma 
membrane dye, a) represent the DIC channel, (b) correspond to excitation at 405 nm, (c) excitation at 488 





Appendix H. MTT MI50 cytotoxicity investigation 
 
  
a)      b) 
Figure H.1. Scatter graph representing MI50 in HeLa cells a) of Cis-Platin b) of Cu[ATSM] 
 
 
a)      b) 
Figure H.2. Scatter graph representing MI50 in HeLa cells a) of ia b) of id 
 
a)      b) 
Figure H.3. Scatter graph representing MI50 in HeLa cells a) of iib b) of iic 
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a)      b) 
Figure H.4. Scatter graph representing MI50 in HeLa cells a) of 1b b) of 1c 
 
a)      b) 
Figure H.5. Scatter graph representing MI50 in HeLa cells a) of 2b b) of 2c 
 
 
a)      b) 
Figure H.6. Scatter graph representing MI50 in HeLa cells a) of 3a b) of 3b 
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a)      b) 
Figure H.7. Scatter graph representing MI50 in HeLa cells a) of 3c b) of 3d 
 
 
a)      b) 
Figure H.8. Scatter graph representing MI50 in HeLa cells a) of 4a b) of 4b 
 
a)      b) 
Figure H.9. Scatter graph representing MI50 in HeLa cells a) of 4c b) of 4d 
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a)      b) 
Figure H.10. Scatter graph representing MI50 in FEK-4 cells a) of ia b) of id 
 
 
a)      b) 
Figure H.11. Scatter graph representing MI50 in FEK-4 cells a) of 3a b) of 3d 
 
 
a)      b) 
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a)      b) 
Figure H.13. Scatter graph representing MI50 in HeLa cells a) of 1aN b) of 1bN 
 
a)      b) 
Figure H.14 Scatter graph representing MI50 in HeLa cells a) of 1cN b) of 1dN 
 
 
Figure H.15. Scatter graph representing MI50 in HeLa cells of 3bN 





























 concentration / Log
10
 M






























 concentration / Log
10
M






























 Concentration / log
10
 M





























 Concentration / log
10
 M




































Appendix I. Miscellaneous 
 
Table I.1. Table representing the VT-NMR data of 3a. 
T 3a’ 3a K ln(K) 1/T 
299.9 1 1 1 0 0.003334 
258.8 1 1.26 1.26 0.231112 0.003864 
245.3 1 1.445 1.445 0.368109 0.004077 
232.1 1 1.5 1.5 0.405465 0.004308 
 
 
Figure I.1. Van’t Hoff analysis of 3a VT-NMR data. 
240 270 300 330 360 390
B/mT
 
Figure I.2. Continuous wave electron paramagnetic resonance (cwEPR) spectrum at the X-band (9.450 
GHz) of 2c. 
 






















Figure I.3. DFT optimisation of a symmetric zinc t-boc protected amine bis(thiosemicarbazonato 
complex in the gas phase by B3LYP 6-31G(d,p). Where grey = carbon, white = hydrogen, blue = nitrogen, 
red = oxygen, green = zinc. 
 
TD-DFT was calculated for the first 24 excited states using uB3LYP 6-31++ (d,p) methodology, of which 
excited state 13 had the most significant oscillator strength, f: 
 
Excited State   1:  2.419-B      1.3461 eV  921.04 nm  f=0.0001  <S**2>=1.212 
139A ->140A       -0.31840 
120B ->139B       -0.10709 
122B ->139B       -0.17645 
134B ->139B        0.11989 
137B ->139B        0.36601 
138B ->139B        0.80277 
138B ->140B        0.22422 
This state for optimization and/or second-order correction. 
"  Total Energy, E(TD-HF/TD-KS) =  -3766.95660896" 
Copying the excited state density for this state as the 1-particle  RhoCI density. 
 
Excited State   2:  3.190-B      1.4050 eV  882.46 nm  f=0.0000  <S**2>=2.294 
139A ->140A       -0.61794 
137B ->139B       -0.21181 
138B ->139B       -0.30491 




Excited State   3:  2.011-B      2.0065 eV  617.91 nm  f=0.0044  <S**2>=0.761 
139A ->140A       -0.13068 
120B ->139B       -0.12925 
122B ->139B       -0.18300 
126B ->139B        0.16620 
134B ->139B        0.13649 
137B ->139B        0.78692 
137B ->140B       -0.10186 
138B ->139B       -0.49426 
 
Excited State   4:  2.985-A      2.0290 eV  611.07 nm  f=0.0000  <S**2>=1.977 
134A ->141A        0.16587 
135A ->140A        0.12227 
136A ->140A        0.13565 
138A ->140A        0.65825 
139A ->141A       -0.42794 
134B ->141B       -0.16414 
135B ->140B       -0.12621 
136B ->140B       -0.16641 
138B ->141B        0.45109 
 
Excited State   5:  2.780-A      2.0489 eV  605.13 nm  f=0.0001  <S**2>=1.683 
134A ->141A       -0.14678 
135A ->140A       -0.11089 
136A ->140A       -0.19074 
138A ->140A        0.73136 
139A ->141A        0.38127 
134B ->141B        0.14886 
135B ->140B        0.10097 
136B ->140B        0.11897 





Excited State   6:  2.008-B      2.1182 eV  585.32 nm  f=0.1578  <S**2>=0.758 
137A ->140A        0.13205 
139A ->140A        0.63940 
129B ->139B       -0.24638 
137B ->139B        0.15213 
137B ->140B        0.14280 
138B ->140B        0.67095 
 
Excited State   7:  2.014-A      2.1446 eV  578.12 nm  f=0.0000  <S**2>=0.764 
121B ->139B        0.38639 
127B ->139B        0.29992 
135B ->139B       -0.54211 
136B ->139B        0.64503 
 
Excited State   8:  2.005-B      2.3985 eV  516.93 nm  f=0.0155  <S**2>=0.755 
114B ->139B       -0.29409 
124B ->139B        0.63691 
128B ->139B        0.59834 
129B ->139B       -0.30489 
 
Excited State   9:  3.455-B      2.5144 eV  493.09 nm  f=0.0004  <S**2>=2.734 
137A ->140A       -0.66339 
137B ->140B        0.70183 
 
Excited State  10:  3.387-A      2.5192 eV  492.15 nm  f=0.0001  <S**2>=2.619 
134A ->141A       -0.16621 
135A ->140A        0.11370 
136A ->140A        0.60944 
137A ->141A        0.11349 
139A ->141A        0.18211 
134B ->141B        0.16799 
135B ->139B       -0.20003 
136B ->139B       -0.24892 
136B ->140B       -0.55172 
137B ->141B       -0.10917 





Excited State  11:  2.134-A      2.6056 eV  475.84 nm  f=0.0008  <S**2>=0.889 
136A ->140A        0.21057 
121B ->139B       -0.14225 
135B ->139B        0.62814 
135B ->140B       -0.10025 
136B ->139B        0.66814 
136B ->140B       -0.22286 
 
Excited State  12:  2.012-B      2.6118 eV  474.71 nm  f=0.0732  <S**2>=0.762 
137A ->140A        0.13214 
139A ->140A        0.14621 
111B ->139B        0.17725 
114B ->139B        0.41816 
117B ->139B       -0.25326 
118B ->139B       -0.30034 
124B ->139B        0.50314 
129B ->139B        0.52414 
138B ->140B        0.13315 
 
Excited State  13:  2.009-B      2.7221 eV  455.48 nm  f=0.3843  <S**2>=0.759 
137A ->140A       -0.69617 
139A ->140A        0.17516 
137B ->140B       -0.65166 
138B ->140B        0.15402 
 
Excited State  14:  2.024-A      2.8421 eV  436.24 nm  f=0.1143  <S**2>=0.774 
136A ->140A        0.29657 
139A ->141A        0.62764 
136B ->140B        0.34796 





Excited State  15:  2.319-A      2.8883 eV  429.27 nm  f=0.0189  <S**2>=1.094 
135A ->140A        0.16389 
121B ->139B       -0.55446 
123B ->139B       -0.15587 
127B ->139B       -0.32730 
130B ->139B        0.11040 
131B ->139B       -0.20337 
133B ->139B       -0.16735 
135B ->139B       -0.45639 
135B ->140B       -0.28937 
136B ->139B        0.22114 
136B ->140B        0.18909 
138B ->141B       -0.14996 
 
Excited State  16:  2.130-A      2.9296 eV  423.21 nm  f=0.0812  <S**2>=0.884 
136A ->140A        0.47187 
139A ->141A       -0.27165 
121B ->139B        0.21841 
127B ->139B        0.11444 
130B ->139B       -0.12501 
131B ->139B        0.16854 
133B ->139B        0.15351 
135B ->139B        0.12231 
135B ->140B       -0.31493 
136B ->140B        0.59438 
138B ->141B       -0.29517 
 
Excited State  17:  3.171-A      2.9353 eV  422.39 nm  f=0.0106  <S**2>=2.264 
134A ->141A       -0.15688 
135A ->140A        0.63724 
136A ->140A       -0.37834 
139A ->141A        0.12868 
121B ->139B        0.20344 
127B ->139B        0.11085 
134B ->141B        0.13880 
135B ->139B        0.11120 




Excited State  18:  3.353-B      2.9412 eV  421.54 nm  f=0.0000  <S**2>=2.561 
134A ->140A        0.67766 
134B ->139B       -0.38705 
134B ->140B       -0.57894 
 
Excited State  19:  2.020-A      2.9685 eV  417.67 nm  f=0.0243  <S**2>=0.770 
135A ->140A        0.16639 
121B ->139B       -0.25131 
127B ->139B       -0.16191 
130B ->139B       -0.47586 
131B ->139B        0.51837 
133B ->139B        0.54790 
135B ->139B       -0.12508 
135B ->140B        0.11858 
 
Excited State  20:  2.248-B      3.0099 eV  411.92 nm  f=0.0000  <S**2>=1.014 
129A ->140A        0.17886 
134A ->140A        0.12314 
138A ->141A        0.89200 
134B ->139B        0.32223 
134B ->140B       -0.10067 
 
Excited State  21:  2.171-B      3.0340 eV  408.65 nm  f=0.0003  <S**2>=0.928 
134A ->140A        0.28532 
138A ->141A       -0.35699 
120B ->139B       -0.13108 
122B ->139B       -0.13091 
134B ->139B        0.79131 
134B ->140B       -0.20281 
137B ->139B       -0.25079 
 
Excited State  22:  2.015-B      3.1599 eV  392.36 nm  f=0.0012  <S**2>=0.765 
120B ->139B        0.45938 
122B ->139B        0.73800 
122B ->140B       -0.11023 
126B ->139B       -0.16282 
134B ->139B        0.26844 




Excited State  23:  3.461-A      3.2001 eV  387.44 nm  f=0.0014  <S**2>=2.744 
126A ->141A       -0.10820 
134A ->141A        0.52780 
135A ->140A        0.14162 
136A ->140A        0.10122 
137A ->141A       -0.20697 
139A ->141A        0.32499 
139A ->143A       -0.10461 
126B ->141B        0.10960 
134B ->141B       -0.52630 
137B ->141B        0.16666 
138B ->141B       -0.31435 
138B ->143B        0.10626 
 
Excited State  24:  2.017-B      3.2349 eV  383.27 nm  f=0.1058  <S**2>=0.768 
134A ->140A        0.62921 
134B ->140B        0.75113 
 
 












a)       b)   c)            d)  
Figure I.6. MicroPET images of in nude mice, 2c, where (a), (b), (c) and (d) are at timepoints 1h, 3h, 6h, 
and 24 h respectively.  
 
 
